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According to the World Health Organization (WHO), 17·3 million people died from 
cardiovascular disease worldwide in 2008 and more than 23 million people will die annually 
from cardiovascular disease by 2030. In the UK, the prevalence of cardiovascular disease is 
high—over 3 million people currently suffer from this disorder. There are a number of 
cardiovascular researchers in the UK population who access the National Health Services, but 
little evidence has been gathered from those who access the private medical insurance. 
According to figures from the Association of British Insurers, the number of people covered 
by private medical insurance rose to 6 million in 2008—about 10% of the UK’s population. 
Due to an increasing large number of this population, there is an urgent need to investigate 
their health, especially cardiovascular health in this affluent group. This PhD study used a 
retrospective cross-sectional design, and aimed to examine the modifiable cardiovascular risk 
factors—BMI, waist circumference, WHR, systolic blood pressure, diastolic blood pressure, 
total cholesterol, HDL cholesterol, and LDL cholesterol—in a population who attended 
Nuffield Health, a private medical insurance company. The dataset provided by Nuffield 
Health is one of the largest UK datasets specifically in a commercial setting. When examining 
the association of socioeconomic status and cardiovascular risk factors in this affluent 
population, the findings show that the likelihood of having high blood pressure was lower in 
the most deprived area than in the least deprived area. The likelihood of having low HDL 
cholesterol was not significantly different between groups, but the likelihood of having high 
total cholesterol and LDL cholesterol was statistically significantly lower in more deprived 
groups. In the study assessing the effect of geographical variations on cardiovascular risk 
factors, no North-South effect was detected in this relatively affluent population. This finding 
might be generalisable to affluent populations in other European countries. In order to see the 
difference between this affluent population and another population from an affluent region in 
England, data provided by Hampshire Health Record were analysed. Although the two datasets 
are comparable, people living in the south England region were more likely to develop obesity 
and hypertension, but less likely to have elevated cholesterol and LDL, as well as low HDL, 
compared with those from Nuffield Health on the basis of socioeconomic status. Evidence-
based population-wide policy interventions exist, and these interventions should now be 
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GLOSSARY OF TERMS 
 
Absolute risk reduction (risk difference) is the effect of a treatment can be expressed as the difference 
between relevant outcomes in treatment and control groups by subtracting one rate (given by the 
proportion who experienced the event of interests) from the other. The reciprocal is the number needed 
to treat (NNT). 
 
Analysis of variance (ANOVA) is a method of significance testing based on the ratio of between 
groups variance to within-groups variance. This method is used in statistical analysis if the dependent 
variable is continuous and the independent variable or variables are all categorical (i.e. nominal, 
dichotomous, or ordinal). If there is only one independent variable, the method is called one-way 
ANOVA. If there is more than one independent variable, the method is called N-way ANOVA, with N 
representing the number of independent variables. 
 
Bias is a systematic deviation of a measurement from the “true” value, leading to either an over- or 
underestimation of the treatment effect. Bias can originate from many different sources, such as 
allocation of patients, measurement, interpretation, publication and review of data. 
 
Bivariate statistics is descriptive statistics for the analysis of the association between two variables 
(e.g. contingency tables, correlations). 
 
A person's total body fat percentage is the total weight of the person's fat divided by the person's 
weight and reflects both essential fat and storage fat. Essential fat is that amount necessary for 
maintenance of life and reproductive functions. The percentage for women is greater than that for men, 
due to the demands of childbearing and other hormonal functions. Essential fat is 2–5% in men, and 
10–13% in women. Storage fat consists of fat accumulation in adipose tissue, part of which protects 
internal organs in the chest and abdomen. The minimum recommended total body fat percentage 




Patient with a certain outcome or disease are selected together with an appropriate group of controls 
without the outcome or disease. The groups are then compared with the populations which have been 




The intervention has been used in a series of patients (it may or may not be a consecutive series) and 
the results reported. There is no separate control group for comparison. 
 
Case study is a research method which focuses on the circumstances, dynamics and complexity of a 




Clinically important effect is an outcome that improves the clinical outlook for the patient. The 
recommendation made in clinical practice guidelines should be both highly statistical significant and 
clinically important (so that the 95% confidence interval includes clinically important effects).   
 
Clinical trial is an experiment where the participants are patients. 
 
Clinical outcome is an outcome for a study that is defined on the basis of the disease being studied 
(e.g. fracture in osteoporosis, peptic ulcer healing and relapse rates). 
 
Cluster is a sample unit which consists of a group of elements. 
 
Cluster sampling is probability sampling involving the selection of groupings (clusters) and selecting 




Groups who have been exposed, or not exposed, to a new technology or factor of interest are followed 
forward in time and their rates of developing disease (or achieving, etc.) are compared. 
 
Comparative study is a study including a comparison or control group. 
 
Concurrent controls are controls receive the alternative interventions and undergo assessment 
concurrently with the group receiving the new interventions. Allocation to the intervention or control 
is generally not random when this term is used. 
 
Confidence interval is an interval within which the population parameter (the true value) is expected 




The measure of a treatment effect is distorted because of differences in variables between the treatment 
and control groups that are also related to the outcome. For example, if the treatment (or new 
intervention) is trialled in younger patients then it may appear to be more effective than the comparator, 
not because it is better, but because the younger patients had better outcomes. 
 
Control group is the group in the experimental research that is not exposed to the independent variable 
(intervention). 
 
Control variable is a variable used to test the possibility that an empirically observed relationship 
between an independent and dependent variable is spurious. 
 
Cost-effectiveness analysis is the comparison of different programmes producing the same type of 
non-monetary benefit in relation to their monetary costs for an assessment of efficiency. 
 
The correlation coefficient is a measure of the degree of linear association between two continuous 
variables. A value of +1 indicates perfect positive association, a value of -1 indicates perfect negative 
xxi 
 
association, and a value of 0 indicates no linear association. The value is highly sensitive to a few 
abnormal data values. 
 
Cross-sectional study, also called prevalence study, where both exposure and outcomes are measured 




In a systematic review, the results of the relevant studies are ordered by some characteristic and 
sequential pooling of the trials is undertaken in increasing or decreasing order. 
 
Degrees of freedom (df) is the numbers of independent comparisons that can be made between the 
members of a sample.   
 
Descriptive statistics are used to describe the basic features of the data gathered from an experimental 
study in various ways. They provide simple summaries about the sample and the measures. Together 
with simple graphics analysis, they form the basis of virtually every quantitative analysis of data. It is 
necessary to be familiar with primary methods of describing data in order to understand phenomena 
and make intelligent decisions. 
 
Epidemiology is the study of factors affecting the health and illness of populations, and serves as the 
foundation and logic of interventions made in the interest of public health and preventive medicine. It 
is considered a cornerstone methodology of public health research, and is highly regarded in evidence-
based medicine for identifying risk factors for disease and determining optimal treatment approaches 
to clinical practice. In the work of communicable and non-communicable diseases, the work of 
epidemiologists range from outbreak investigation to study design, data collection and analysis 
including the development of statistical models to test hypotheses and the documentation of results for 
submission to peer-reviewed journals. Epidemiologists may draw on a number of other scientific 
disciplines such as biology in understanding disease processes and social science disciplines including 
sociology and philosophy in order to better understand proximate and distal risk factors. 
 
Evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in 




This refers to the extent to which a study’s results provide a correct basis for generalisation beyond the 
setting of the study and the particular people studied. It implies the application of the results of a study 
to another group or population.  
 
Gold standard is a method, procedure or measurement that is widely regarded or accepted as being the 
best available. Often used to compare with new methods.  
 
Haematology is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, 
and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. 
 




When time to the outcome of interest of interest is known, this is the ratio of the hazards in the treatment 
and control groups where the hazard is the probability of having the outcome at time t, given that the 
outcome has not occurred up to time t.  
 
Health risk assessments (HRAs) are the use of questionnaires or computer programs to elicit and 
evaluate information concerning individuals in a clinical or industrial medical practice. Each assessed 
person receives information concerning estimates of his or her life expectancy and the types of 
interventions that are likely to have a positive impact on health or longevity.  
 
Heart attacks happen when there is a blockage in one of the arteries in the heart. 
 
Hydration level: the process of providing an adequate amount of water to body tissues. (hydration 
reaction or mineral hydration) 
 
Incidence is the number of new events (new cases of a disease) in a defined population, within a 
specified period of time. 
 
An intervention will generally be a therapeutic procedure such as treatment with a pharmaceutical 
agent, surgery, a dietary supplement, a dietary change or psychotherapy. Some other interventions are 
less obvious, such as early detection (screening), patient educational materials or legislation. The key 
characteristic is that a person or his or her environment is manipulated in the hope of benefiting that 
person. 
 
Level of evidence 
 
Study designs are often grouped into a hierarchy according to their validity, or degree to which they are 
not susceptible to bias. The hierarchy indicates which studies should be given most weight in an 
evaluation. 
 
Lower Layer Super Output Areas (LSOAs) were first built using 2001 Census data from groups of 
Output Areas (typically four to six) and have been updated following the 2011 Census. They have an 
average of roughly 1,500 residents and 650 households. Measures of proximity (to give a reasonably 
compact shape) and social homogeneity (to encourage areas of similar social background) are also 
included. 
 
Meta-analysis is results from several studies, identified in a systematic review, are combined and 
summarised quantitatively. 
 
Meta-regression is the fitting of a linear regression model with an estimate of the treatment effect as 
the dependent variable and study level descriptors as the independent variables. 
 
Nonparametric data are data for which descriptive parameters such as the mean and standard deviation 





Nonrandomised cross-over design is participants in a trial are measured before and after introduction 
or withdrawal of the intervention and the order of introduction and withdrawal is not randomised. 
 
Null hypothesis is the hypothesis that there is no real (true) difference between means or proportions 
of the goups being compared or that there is no real association between two continuous variables. 
 
Number needed to harm (NNH) 
 
When the treatment increases the risk of the outcome, then the inverse of the absolute risk increase is 
called the number needed to harm (NNH).  
 
Number need to treat (NNT) is the number of patients with a particular condition who must receive a 
treatment for a prescribed period in order to prevent the occurrence of specified adverse outcomes of 
the condition. This number is the inverse of the absolute risk reduction. 
 
Observational studies are any nonrandomised, nonexperimental comparison. 
 
Outliers are extreme values that are widely deviant from the mean. 
 
Parametric data are data for which descriptive parameters (typically the mean and standard deviation) 
are known and define the underlying frequency distribution of the data. The underlying distribution is 
often assumed to be normal, as provided in the central limit theorem. 
 
Patient-relevant outcome is any health outcome that is meaningful to the patient. It can be the best 
surrogate outcome, resources provided as part of treatment, impact on productivity (indirect) or one that 
cannot be measured accurately (e.g. pain, suffering). Common examples include: primary clinical 
outcomes, quality of life and economic outcomes. 
 
Placebo is an inert substance, indistinguishable from the active drug, which is given to the control 
group. This enables both subjects and researchers to remain blinded to the treatment allocation. 
 
Prevalence is the measure of the proportion of people in a population who have some attribute or 
disease at a given point in time or during some time period. 
 
Publications bias is bias caused by the results of a trial being more likely to be published if a 




 The health status of the public (i.e., of a defined population). 
 The organised social efforts made to preserve and improve the health of a defined population. 
 
P value is the probability that the null hypothesis (that there is no treatment effect) is incorrectly 
rejected.  
 
Qualitative research is the social research which is carried out in the field (natural settings) and 




Quality of evidence is degree to which bias has been prevented through the design and conduct of 
research from which evidence is derived. 
 
Quality of life is the degree to which a person perceives him or herself able to function physically, 
emotionally and socially. In a more quantitative sense, an estimate of remaining life free of impairment, 
disability or handicap as captured by the concept of quality-adjusted life years (QALYs).  
 
Quantitative research is the measurement and analysis of observations in a numerical way. 
 
Random error is the portion of variation in a measurement that has no apparent connection to any 
other measurement or variable, generally regarded as due to chance. 
 
Random sampling gives each of the units in the target population a calculable and non-zero probability 
of being selected. 
 
Randomisation is a process of allocating participants to treatment or control groups within a controlled 
trial by using a random mechanism, such as coin toss, random number table or computer-generated 
random numbers. 
 
Randomised controlled trial is an experimental comparison study in which participants are allocated 
to treatment/intervention or control/placebo groups using a random mechanism. Participants have an 
equal chance of being allocated to an intervention or control group and therefore allocation bias is 
minimised (and virtually eliminated in very large studies). 
 
Randomised cross-over trial 
 
Patients are measured before and after exposure to different interventions (or placebo) which are 
administered in a random order (and usually blinded).  
 
Range is a measure of dispersion which is based on the lowest and highest values observed. 
 
Relative risk or risk ratio (RR) is ratio of the proportions in the treatment and control groups with the 
outcome. This expresses the risk of the outcome in the treatment group relative to that in the control 
group. 
 
Relative risk reduction (RRR) is the relative reduction in risk associated with an intervention. This 
measure is used when the outcome of interest is an adverse event and the intervention reduces the risk. 
It is calculated as one minus the relative risk, or: 
 
RRR = 1 – (event rate in treatment group/event rate in control group) 
 
Reliability, also called consistency or reproducibility, is the degree of stability that exists when a 
measurement is repeatedly made under different conditions or by different observers. 
 
Risk is calculated as the proportion of persons who are unaffected at the beginning of a study period 




Risk difference (RD) is the difference (absolute) in the proportions with the outcome between the 
treatment and control groups. If the outcome represents an adverse event (such as death) and the risk 
difference is negative (below 0) this suggests that the treatment reduced the risk – referred to as the 
absolute risk reduction.  
 
Risk factor is a characteristic that, if present and active, clearly increases the probability of a particular 
disease in a group of persons who have the factor compared with an otherwise similar group of persons 
who do not. A risk factor is neither a necessary cause nor a sufficient cause of the disease.  
 
Selection bias is error due to systematic differences in characteristics between those who are selected 
for study and those who are not. It invalidates conclusions that might otherwise be drawn from such 
studies. 
 
Standard deviation (SD) is the square root of the variance. 
 
Standard error (SE) is the standard deviation (SD) of a population of sample means, rather than of 
individual observations. The SE is calculated as the observed SD divided by the square root of N. 
 
Statistically significant effect is an outcome for which the difference between the intervention and 
control groups is statistically significant (i.e. the P value is ≤0.05). A statistically significant effect is 
not necessary clinically important. 
 
A systematic review is a literature review focused on a single question that tries to identify, appraise, 
select and synthesize all high quality research evidence relevant to that question. 
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1.1.1 Cardiovascular disease has been recognised as a global priority 
 
Cardiovascular diseases, conditions of the heart and blood vessels, are leading causes of 
morbidity and mortality throughout the world. Largely diseases of lifestyle and affluence, they 
account for about 50% of deaths in many developed countries (Gwatkin and Guillot 1999; 
WHO 2007). For example, in the United States and Western European countries, coronary 
heart disease is the leading cause of death, also accounting for approximately 50% of deaths. 
In the United States alone, the prevalence of cardiovascular disease in the total population was 
estimated to be over 71 million in 2003 (NHLBI 2006). Meanwhile, each year in Europe, more 
than 4·3 million people will die from cardiovascular disease; overall mortality due to 
cardiovascular disease is estimated to be 28% of deaths in men and 42% in women before the 
age of 75 years (Nichols et al. 2012).  
 
Cardiovascular disease has modifiable and non-modifiable risk factors. Non-modifiable risk 
factors such as age and sex are strongly associated with cardiovascular diseases. The rise of 
cardiovascular disease is also attributed to a number of modifiable risk factors. The leading 
global cardiovascular risk factors for cardiovascular disease mortality are high blood pressure 
(accountable for 13% of deaths globally), tobacco use (9%), high blood glucose (6%), physical 
inactivity (6%), and overweight and obesity (5%) (WHO 2008). These risk factors are 
responsible for raising the risk of cardiovascular diseases such as coronary heart disease, stroke, 
and ischaemic heart disease. The high prevalence of risk factors for heart diseases and stroke 
among young and middle-aged adults, combined with the ageing population worldwide, 
suggest that the prevention and management of cardiovascular diseases will continue to be a 
public health priority both in developing and developed countries. 
 
Because of high prevalence in the growing population, the UN held its first high-level Meeting 
of the General Assembly on chronic non-communicable diseases—mainly cardiovascular 
diseases, cancer, diabetes, and chronic respiratory disease—in New York in September, 2011 
(Beaglehole et al. 2010). This meeting made cardiovascular disease a global priority among 
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heads of states and governments and extended universal access to essential medicines and 
technologies for the secondary prevention of cardiovascular disease (Alleyne et al. 2010). The 
past declarations and recent global strategies provide a welcome sign that the international 
community is increasingly aware of the importance of cardiovascular disease. Moreover, the 
World Bank (2007) recently recognised the effects of cardiovascular disease in the most 
deprived areas of the world and acknowledged cardiovascular disease as a development 
priority. 
 
The vast majority of cardiovascular mortality might be prevented through simple interventions 
such as smoking cessation, improved diet, and increased exercise. In the INTERHEART case-
control study, Yusuf and colleagues (2004) identified nine modifiable cardiovascular risk 
factors that accounted for over 90% of the contribution to risk of an initial acute myocardial 
infarction for young men and women worldwide; cholesterol, smoking, blood pressure, 
diabetes, abdominal obesity (waist-to-hip ratio), psychosocial factors (including depression 
and stress), consumption of fruits and vegetables, consumption of alcohol, and physical 
activity. Chow and colleagues (2010) surveyed about 19 000 patients from 41 countries who 
had undergone percutaneous coronary intervention after myocardial infarction and who had 
answered questions about their lifestyle. They showed that patients who continued to smoke 
and did not adhere to diet and exercise regimens were 3·8 times more likely to suffer a 
myocardial infarction, stroke, or death within 6 months than were non-smokers who modified 
their diet and increased exercise, considering that both groups complied with their medications. 
Prevention and management of cardiovascular diseases will continue to be a public health 
priority both in developing and developed countries, but effective preventive care and a healthy 
lifestyle could lead to reduced prevalence of cardiovascular risk factors and, therefore, 
cardiovascular disease itself.  
 
Current evidence has identified modifiable cardiovascular risk factors, and we know how 
evidence has translated into population effects, such as sex, socioeconomic status, region and 
country. Taking obesity as an example, more than 1.4 billion adults, aged 20 and older, were 
overweight globally. Of these overweight adults, over 200 million men and nearly 300 million 
women were obese (WHO 2013). In all WHO regions women were more likely to be obese 
than men. In the WHO regions for Africa, Eastern Mediterranean and South East Asia, women 
had approximately twice as much the obesity prevalence as men. The prevalence of overweight 
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increases with income level of countries up to upper middle income levels. The prevalence of 
overweight in high income and upper middle income countries was more than twice as high as 
low and lower middle income countries. For obesity, the difference more than triples from 7% 
obesity in both sexes in lower middle income countries to 24% in upper middle income 
countries. Women's obesity was significantly higher than men's, with the exception of high 
income countries where it was similar. In low and lower middle income countries, obesity 
among women was approximately double that among men (Global Health Observatory 2013).  
 
1.1.2 Cardiovascular disease and associated risk factors in the UK population 
 
According to the British Heart Foundation (2009), cardiovascular disease contributed to more 
than 150,000 deaths in England in 2007, accounting for nearly 34% of all deaths. Furthermore, 
in a recent paper in The Lancet, Murray and colleagues (2013) assessed the UK’s health 
performance using the Global Burden of Diseases, Injuries, and Risk Factors (GBD) data and 
reported that the first ranked cause of years of life lost due to premature mortality in the UK in 
2010 was ischaemic heart disease and the third ranked was stroke. Hypertension has been 
identified as the major risk factor for this large burden, exceeding that for alcohol and high 
body-mass index (BMI). The design of GBD used in the assessment of the UK’s health 
performance is complex. GBD 2010 is the largest systematic effort to describe the 
epidemiology of a wide array of major diseases, injuries and risk factors ever undertaken. 
Millions of observations on mortality, causes of death, disease and injury prevalence and 
incidence, and risk factors have been collected, assessed, and collated (Murray et al. 2012). 
The advantage of the GBD approach is that consistent methods are applied to critically appraise 
available information on clinical conditions such as cardiovascular disease and associated risk 
factors, make this information comparable and systematic, estimate results from countries with 
incomplete data, and report on the burden of disease with the use of standardised metrics. 
However, it is not possible to access the raw data in the detail required to undertake a 
comparative analysis. Also, because of the GBD’s complexity and international focus (analysis 
in a country-level), it would be better to find a UK-focused database to assess its cardiovascular 




Two databases are commonly used in the UK— the Health Survey for England (HSE) and the 
General Practice Research Database (GPRD). HSE is an English statistical survey which is 
conducted annually to collect information on the basis of health and health-related behaviour 
of people aged 16 and above living in private households. It was originally set up in 1991 and 
conducted by the UK’s Office for National Statistics between 1991 and 1994. It was then 
changed in 1994 to be conducted by the Joint Survey Unit of the National Centre for Social 
Research (NatCen) and the Department of Epidemiology and Public Health at University 
College London. Since 1995, the surveys have also included children aged 2-15 and since 2001, 
infants aged under 2 years. The series of Health Surveys for England was designed to monitor 
trends in the nation’s health, to estimate the proportion of people in England who have specified 
health conditions, and to estimate the prevalence of certain risk factors and combinations of 
risk factors associated with these conditions (Health & Social Care Information Centre 2013). 
Each survey in the series includes core questions and measurements such as blood pressure, 
anthropometric measurements, etc. These data are not publicly accessible, therefore, the figures 
from the HSE could be used as a comparison but not for re-analysis for specific clinical 
outcomes. Additionally, several regional databases from the UK Public Health Observatories 
have appeared in publications, but these databases are not publicly accessible 
 
GPRD is also the world’s largest computerised database of anonymised longitudinal medical 
records from primary care. Containing comprehensive observational data from clinical 
practice, it is a valuable tool for academic research in a broad range of areas including clinical 
epidemiology, disease patterns, disease management, outcomes research, and drug utilisation. 
Data are collected through GP practice cross England. About 5% of the UK population is 
included in the GPRD, which is broadly representative of the general UK population in terms 
of age, sex, and geographic distributions. The database was operated by the Office for National 
Statistics until 1999, then took over by the Medicines and Healthcare Products Regulatory 
Agency (MHRA). In 2012, the new service, known as the Clinical Practice Research Datalink 
(CPRD), has been developed as the England-wide NHS observational and interventional 
research service. It has built on the research developments of the GPRD, and also the Health 
Research Support Service (HRSS) previously managed by the National Institute for Health 
Research (NIHR) Research Capability Programme. CPRD is now jointly funded by the NIHR 
and the MHRA. It is considered by many as the gold standard and its usage has resulted in over 
890 clinical reviews and papers (Currie et al. 2011; Grainge et al. 2011; Tannen et al. 2009). 
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It has simplified governance arrangements and access to data; however, due to its affordability, 
size and complexity. The GPRD database requires adequate computer hardware and software, 
and extensive experience in data management; it is not easy for small and medium-sized 
research groups to access this database, especially for a PhD project (GPRD 2011). Also, the 
database may not contain data on every patient characteristic or disease characteristic that may 
be required for a study (information on occupation, employment, and socioeconomic status is 
not available electronically).  
 
According to figures from the Association of British Insurers (2009), the number of people 
covered by private medical insurance rose to over 6 million in 2008—about 10% of the UK’s 
population—and included an increasing number of people employed in all sectors of the 
workforce from manual to management. Therefore, it is worth knowing the health outcomes, 
especially cardiovascular, of this emerging group. One would assume that people who are able 
to subscribe to private medical insurance should be relatively healthy. Is this in the reality? We 
do not know. Little evidence has been gathered in this potentially affluent population, because 
most research focuses on a representative population who access public-funded NHS service. 
One of the reasons for not considering GPRD in this research is that the population described 
in these publications are mainly public sector workers, as well as low and middle 
socioeconomic groups.   
 
Cardiovascular disease is linked to socioeconomic status with those in the least affluent 
populations showing much worse outcomes (Emberson et al. 2004). Improved understanding 
of the population effect of modifying cardiovascular risk factors may therefore be obtained by 
studying the behaviours of an affluent population group. After searching several databases, 
including PubMed/Medline, Embase, the Cochrane Library, and NHS Evidence Search, a few 
pieces of research have been found in the UK, focusing on one special group—commercial 
pilots. In their retrospective cross-sectional study involving 14 379 individuals (over 95% were 
men), Houston and colleagues (2011) examined the prevalence of cardiovascular risk factors 
among commercial aircrew and found that pilots had a significantly lower prevalence of obesity 
and smoking when compared with the highest income quintile of the general population and 
corrected for socioeconomic status. Would this evidence imply that people from a healthy sub 
group of an affluent group are healthier? If so, do we know any measurements such as 
hypertension, cholesterol, etc. in this relatively affluent population? If not, what is the 
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generalisability of this evidence? Although this piece of evidence could be a useful source of 
debate, public health policy cannot be made on the basis of one single study.  
 
1.1.3 Databases from Nuffield Health and Hampshire Health Record  
 
Nuffield Health’s dataset initiated an exciting opportunity in this field and established the 
foundation for my PhD project. Nuffield Health is a not-for-profit organisation offering 32 
private hospitals, 65 gyms, and hundreds of corporate fitness facilities. It conducts health 
assessments at over 40 Nuffield Health centres nationwide, including their hospitals, health 
clubs, and medical centres. During the health assessment, the participant has a one-on-one 
consultation with a physiologist or doctor, depending on the type of assessment. Individual 
data records are collected and recorded in a dataset. The population in their datasets are mainly 
from higher socioeconomic groups with over 60,000 patient records, and the dataset they 
provided for my PhD project included information about nine cardiovascular risk factors—
BMI, waist circumference, waist-to-hip ratio, systolic and diastolic blood pressure, total 
cholesterol, LDL, HDL, and smoking. This will be the first opportunity to assess the effect of 
socioeconomic status (by postcode) on a cluster of cardiovascular risk factors in a large affluent 
UK population.  
 
Postal code, which could be converted to deprivation score using the Index of Multiple 
Deprivation 2007 (IMD 2007, see more details in chapter 2), was provided in the dataset too. 
It has already known that socioeconomic status is strongly linked to cardiovascular risk factors 
(Emberson et al. 2004; Huisman et al. 2005; Kanjilal et al. 2006; Kivimaki et al. 2007). For 
example, there is a strong relationship between occupational social class, high blood pressure 
and cholesterol level (Rose et al. 1981; Woodward et al. 1992). However, mixed results were 
found between income and cardiovascular risk factors (Harald et al. 2008; Kanjilal et al. 2006; 
Lee et al. 2009). At present, several area-based indices have sought to measure socioeconomic 
deprivation as distinct from individual socioeconomic position (Payne et al. 2009; Stewart et 
al. 2009; Townsend 1987). Deprivation indices are easier to apply in clinical practice than most 
other measurement of socioeconomic status (Blakely et al. 2002), and have consequently 
become popular among public health researchers. This is because information about individual 
measures of socioeconomic status may be incomplete and potentially inaccurate. The 
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advantage of using IMD 2007 in this research is because it is made up of seven lower layer 
super output area (LSOA) level domain indices. The IMD 2007 combines a total of 38 
indicators, which is distributed across the seven domains, covering a range of social and 
economic issues to produce a deprivation score for each small area of England. The bigger the 
IMD 2007 score, the more deprived the LSOA. For example, the lowest IMD score is in 
E01016709 at Wokingham (0.37), while the highest score is in E01006755 at Liverpool 
(85.46). In the Nuffield Health’s dataset, the IMD 2007 score ranged from 0.37 – 77.67. 
Liverpool has an average IMD score of 46.97, in comparison, Oxford has an average score of 
18.80, and West Oxfordshire has an average score of 6.67. However, because of the exponential 
distribution, it is difficult to make direct comparison on the basis of IMD 2007 score itself. In 
order to make comparisons between LSOAs it is recommended that ranks should be used. A 
rank of 1 is assigned to the most deprived LSOA and a rank of 32 482 is assigned to the least 
deprived LSOA. On the basis of this recommendation, a comparison of the study population 
IMD rank (median & SD) from the Nuffield Health and National IMD rank was presented in 
table 1.1 below. As can be seen from the comparison below, the study population attending 
Nuffield Health are slightly affluent in the two least groups, and about twice as affluent than 
national IMD rank in the two most deprived groups (see more details of comparison in chapter 
5). 
 
Table 1.1 Comparison of the population in the Nuffield Health to the National representative 
population in terms of Index of Multiple Deprivation rank 





Group 3  
n=11051 
Group 4  
n=11033 

































It has been shown that the population who attended Nuffield Health is an affluent population. 
We would expect that the population in Nuffield Health is relatively healthy and shows better 
cardiovascular outcomes than the general population in the UK. However, we could also see 
that there are a lot of affluent areas in the UK on the basis of IMD 2007 score, and we would 
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expect these populations might have similar cardiovascular outcomes as the population in the 
Nuffield Health. Therefore, after obtaining Nuffield Health’s dataset, a contact was made with 
the Hampshire Health Record. The Hampshire Health Record is a joint project supported 
by Basingstoke and North Hampshire Foundation Trust, Hampshire Primary Care Trust, 
Portsmouth City Teaching Primary Care Trust, Portsmouth Hospitals NHS Trust, Southampton 
City Primary Care Trust, Southampton University Hospitals NHS Trust, and Winchester and 
Eastleigh Hospital NHS Trust. These trusts are located in the south central England region. The 
south central England region, where Hampshire Health Record collected the data, is relatively 
affluent compared with the national average. Local residents are typically very informed and 
influential and demand the very best from the NHS. In the Hampshire Health Record, seven 
cardiovascular risk factors were provided—BMI, waist circumference, systolic and diastolic 
blood pressure, total cholesterol, LDL, and HDL. Socioeconomic groups have been provided 
too in this dataset. However, postcodes were not provided, therefore, a direct comparison of 
socioeconomic status is not able to be compared with the general population in terms of IMD 
rank.  
 
This will be a unique opportunity to compare the effect of socioeconomic status (by postcode 
in an area-level) on cardiovascular risk factors between the population from a relatively affluent 
region in the UK who have access to public NHS services and those from an affluent 
socioeconomic group who attended private medical screening. Using data collected in the 
Nuffield Health dataset and the Hampshire Health Record, this study compares the prevalence 
of modifiable cardiac risk factors among two relatively affluent English populations. Both 
datasets made my PhD project possible, and my findings are concluded in the last chapter: 







The aim of this thesis is to investigate the prevalence of cardiovascular outcomes in people 
attending private medical screening, and to compare these figures with those figures from 
people accessing public-funded NHS services in the Hampshire Health Record, which is 




This thesis is structured in the modern style, with each chapter representing a discrete study. 
The central theme that links all chapters is the analysis of cardiovascular risk factors in a large 
UK population. 
 
Chapter 2 lays the fouondation for information that is needed to understand the series of studies 
analysed in the following chapters. Other fundamental principles of the underlying 
epistemology are also addressed in this chapter. 
 
Chapter 3 provides a literature review for socioeconomic status, cardiovascular disease, and its 
associated modifiable risk factors. It will also look at intervention strategies on how to prevent 
the cardiovascular disease. 
 
Chapter 4 aims to examine the prevalence of the different modifiable cardiovascular risk factors 
in the affluent population provided by the Nuffield Health dataset, and compares them to the 
general population represented in Health Survey for England 2006. 
 
Chapter 5 is the first retrospective cross-sectional study using the dataset provided by Nuffield 
Health to examine the effect of area-level socioeconomic status on cardiovascular risk factors 
in people attending private health screening. 
 
Chapter 6 further explore geographical variation in the prevalence of modifiable cardiovascular 
risk factors in people attending private health screenings in England; it compares the prevalence 
of modifiable cardiovascular risk factors from private medical screenings with the findings 
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from the HSE 2006; and estimates the risks of many modifiable cardiovascular risk factors at 
a regional level from dataset provided by the Nuffield Health. 
 
Chapter 7 aims to compare the prevalence of various modifiable cardiovascular risk factors 
between Nuffield Health (private health screening) and Hampshire Health Record (NHS Trust), 
and to identify the similarities and differences of the two datasets in relation to the 
cardiovascular risk factors. 
 
Chapter 8 aims to examine the association between area-level socioeconomic status and 
objectively measured, modifiable cardiovascular risk factors in a population from an affluent 
region in England who attended the public NHS, and to compare the effect of socioeconomic 
status on cardiovascular risk factors between people attending Nuffield Health and Hampshire 
Health Record. 
 
Chapter 9 summarises the thesis and its limitations, draws conclusions, and makes 
recommendations for the future research. 
 
1.4  NOTES FORMAT OF THE THESIS 
 
This thesis is written in the modern style. Each chapter represents a discreet piece of work 
which is linked to the other chapters by a common theme (Figure 1.1). The project is on the 
basis of two datasets, Nuffield Health and Hampshire Health Record. Therefore, in some cases 
(chapters three, four and six & chapters seven and eight) a common methodology and 
population were used. To avoid the reader having to read repeated methodology, these sections 




Figure 1.1: Outline of thesis 
Chapter 7: Comparison between prevalence of modifiable cardiovascular risk 
factors in people attending private medical screening and national health services 
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2.1 PRIMARY AND SECONDARY DATA  
 
Primary research entails the use of original primary data collected by the researcher. The 
popular ways to collect primary data consist of surveys, interviews and focus groups, which 
shows that direct relationship between the researchers and the researched Secondary research 
involves the summary, collation or synthesis of existing data or research findings, and is a 
means to reprocess and reuse information previously collected for another purpose..  
 
While primary research is a powerful method for acquiring information, it does pose several 
significant problems including high cost, time consuming, and it is not always feasible. 
Secondary data are useful for health research. Secondary data analysis can answer important 
questions and maximise opportunities provided by datasets through re-defining the way they 
are used. In health research, secondary data analysis is a legitimate approach to guide scientific 
inquiry and knowledge development. It can provide practical experience in data analysis, 
interpretation, and dissemination of findings. However, in secondary data, information relates 
to a past period and purpose, it lacks aptness and therefore, is not straightforward to use. . 
Secondary data analysis is conducted within an existing data set to answer research questions 
not posed in the original, or primary, study or purpose for collecting the data. Because many 
studies contain more data than the principal investigators can analyse, a variety of research 
projects can be conducted using pre-existing data (Kiecolt & Nathan, 1985). 
 
Although secondary data are old, it may be the only possible source on the subjects, where 
primary data are not available. The advantage of secondary data analysis is its potential for 
resource savings and cost-effectiveness. The database often took months or even longer to 
collect. Human resources are limited, and adequate computer storage and memory are needed 
(Mainous and Hueston 1997). Descriptive studies allow investigators to access datasets from 
large samples when representative samples are difficult to obtain directly. This type of study is 
helpful in the research design of subsequent primary research and can provide a baseline with 
which the collected primary data results can be compared . It also provides essential 
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groundwork for further studies seeking explanation, prediction, and control of health research 
phenomena, and might be useful for investigating health service utilisation and clinical 
outcome or effectiveness of treatment over lime (Burns and Groves 2001; Hearst et al. 
2001Rew et al. 2000). Hypothesis revision, or existing measures that need to be refined and 
improved, could use secondary data analysis (Hyman 1972; Nicoll and Beyea 1999). It could 
serve as a pilot study with aims to define a research question moreclearly. This pilot study 
could lead to hypotheses generation for a subsequent primary study (Mainous and Hueston 
1997; Nicoll and Beyea 1999).  
 
Secondary data analysis is not a casual approach to data analysis that requires less scientific 
rigour. A legitimate study using secondary data analysis requires a sound conceptualisation of 
the research question to be studied, including a theoretical or conceptual framework. The 
framework serves to define how the concepts are performed and how the research questions 
are described. Although actual data collection with secondary data analysis requires less time 
than primary data collection, identifying and obtaining appropriate data for the study could be 
time-consuming. . Before the actual analysis, some effort  must be made  to determine the 
reputation of the original investigators and any limitations inherent in the original database or 
study, and analyse the overall quality of the data (Nicoll and Beyea 1999). Secondary data 
analysis must be coded or compiled in a way that individual participants cannot be identified, 
as well as confidentiality must be maintained. If confidentiality could be ensured and the new 
questions are in agreement with the aims of the original study, or researchable through the 
database it is not necessary to contact the participants from the original sample again for 
consent (Rew et al. 2000).  
 
2.2. SOURCES OF DATASETS 
 
Secondary data analyses in the clinical settings exist in patient charts, surveys, quality 
improvement and administrative management systems (Nicoll and Beyea 1999). Survey 
research obtains data from persons about particular topics, including demographics and 
behavioral, attitudinal, and social responses. Representative surveys sponsored by state and 
national governments, as well as surveys conducted by large universities, are examples of 




Data in computerised databases are usually organised as individual or aggregate datasets 
(Hearst et al. 2001). The choice of dataset for the secondary data analysis depends on the 
research questions. Aggregate datasets contain information by groups or cohorts of 
participants. 
 
Analyses using aggregate data are referred to as ecologic studies. Ecologic studies enable the 
investigator to analyse associations between the cohorts (Hearst et al. 2001). Large datasets are 
available from a wide variety of institutions and organisations in the UK, not only in public 
NHS hospitals and general practitioner clinics, but also in private medical insurance 
companies. Two large datasets used for my PhD thesis are from Nuffield Health and Hampshire 
Health Record. 
 
2.2.1. Nuffield Health dataset 
 
Nuffield Health is a private health-care company. Data were extracted from the records of the 
Nuffield Health. Aggregate data provided by the Nuffield Health were anonymised. 
Identification of individuals is not possible from these data, because they are provided by a 
unique patient reference number in a dataset. The assessment programmes were delivered 
through a bespoke electronic patient-record system developed exclusively for Nuffield Health, 
the Vi System. This system offers greater accuracy and speedier and more comprehensive 
reports than other systems (e.g. paper-based systems). It has four interventions—Vi3, Vi4, Vi5, 
and Vi6, and details are provided below.  
 
Vi3, female-only assessment (1 hour). This assessment was designed to aid a proactive approach 
for women’s health and wellbeing. A tailored range of tests (height and weight measurement; 
body-mass index [BMI]; urine analysis; cholesterol; blood pressure; breast examination; pelvic 
examination and cervical smear; thyroid stimulating hormone blood test [for women aged 50 
years and over]; high vaginal swab; and mammography [for those aged 40 years and over]) 
gives a clear, in-depth picture of a woman’s current state of health. Participating women also 




Vi4, lifestyle health assessment for both men and women (1 hour). This assessment (medical 
history and lifestyle questionnaire; height and weight measurement; BMI; body fat percentage; 
waist-to-hip ratio [WHR]; urine analysis; blood glucose and cholesterol; blood pressure; 
hydration level; analysis of general nutritional status; computerised spinal assessment; stress 
levels; and fitness assessment) looks at how lifestyle might be affecting participants’ wellbeing 
and helps participants to find ways to make positive changes to their health and lifestyle. Highly 
trained health and wellbeing physiologists evaluate participants’ health status and provide tools 
for sustainable change. A coaching session by a trained physiologist to motivate behavioural 
change is included in the programme. Vi4M is for men and Vi4F is for women. Vi4M + GP and 
Vi4F + GP include additional general practitioner consultation for men and women, 
respectively. 
 
Vi5, so-called 360-degree health assessment for both men and women (2 hours).This 
assessment (full medical history and lifestyle questionnaire; height and weight measurement; 
BMI; body fat percentage; WHR; urine analysis; blood glucose and cholesterol; blood pressure; 
hydration level; analysis of general nutritional status; vision tests; lung function test; resting 
electrocardiography [ECG]; cardiovascular risk score; chest x-ray; bowel cancer test [for 
participants aged 50 years and over]; computerised spinal assessment; stress levels; and fitness 
assessment) includes access to the full range of the latest health evaluation technology. 
Participants have up to an hour with an experienced doctor to talk through concerns and health 
issues in detail, working out a management plan to improve health and meet lifestyle 
challenges. Vi5M is for men and Vi5F is for women.  
 
Vi6, so-called 360+ health assessment for both men and women (2 hours and 45 min).With 
access to the full range of the very latest health evaluation technology and ample time with an 
experienced health professional, this assessment (full medical history and lifestyle 
questionnaire; height and weight measurement; BMI; body fat percentage; WHR; urine 
analysis; blood glucose and cholesterol; blood pressure; hydration level; analysis of general 
nutritional status; dynamic cardiovascular assessment [both at rest and during exercise]; vision 
tests; lung function test; resting ECG; cardiovascular risk score; chest x-ray; bowel cancer [for 
participants aged 50 years and over]; computerised spinal assessment; stress levels; and fitness 
assessment) investigates participants’ health at every level. Participants have access to a 
dynamic test including ECG and measurement of blood pressure during activity and a 
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consultation with a physiologist to work out a plan to manage their health and lifestyle for 
optimum wellbeing and vitality. Vi6M is for men and Vi6F is for women. 
 
It provides instant comparison with previous test results and the ability for clients to use any 
of the Nuffield centres in the UK and immediately to access their records. At each of the 
company’s testing sites, data were collected by trained health professionals using protocols 
consistent with the British Hypertension Society (for blood pressure and blood analysis) and 
American College of Sports Medicine (for anthropometry). Protocol in assessing these 
measurements could be found in Appendix 2.1. 
 
To ensure patients are getting the best possible outcomes from their treatment and care, 
Nuffield Health collected patients’ health information during treatment and services through 
a network of over 200 facilities—private hospitals, health clinics, fitness and wellbeing 
centres, diagnostic units and a wide range of treatments into one complete healthcare 
service—across the UK.    
 
Data quality has been defined by dimensions or characteristics including accuracy, availability, 
completeness, relevance, reliability, timeliness and validity (Dancey et al. 2012). Nuffield 
Health embedded these criteria in all the stages of patients’ visits to improve the quality of data. 
However, Nuffield Health does have a relative fast staff turnover, but they are confident that 
the way data are collected—in-house training, adherence to protocols—are consistent no matter 
who collected the data or when the data were collected. Inter-rater reliability has also been 
performed to ensure the results are reliable or consistent in data collection. For example, when 
performing finger prick assessment for cholesterol level (in Appendix 2.1), test protocol are 
very detailed to instruct healthcare professionals in Nuffield Health to collect the blood for data 
record and further analysis, e.g. step 11—once strip is ready and client is ok switch on the 
machine and make sure the codes displayed match the strips will be using. If not, use supplied 
bar-coded strips within cholesterol pack and follow manufactures instructions to update code. 
Staff have opportunities to discuss why they chose the specific values they did. If there is any 
disagreement, they should discuss them and attempt to come up with rules for making decision. 
When collecting patients’ data, the standards of confidentiality will be applied in accordance 
with data protection law and confidentiality. Anonymous or aggregated data are provided by 




Using dataset provided by Nuffield Health, two chapters in this thesis will analyse 
cardiovascular health outcomes for participants registered in the private medical insurance 
company. Chapter 4 aims to examine the prevalence of the different modifiable cardiovascular 
risk factors in the affluent population, and compares them to the general population represented 
in Health Survey for England 2006. Chapter 5 is the first retrospective cross-sectional study to 
examine the effect of area-level socioeconomic status on cardiovascular risk factors in people 
attending private health screening. Chapter 6 further explore geographical variation in the 
prevalence of modifiable cardiovascular risk factors in people attending private health 
screenings in England; it compares the prevalence of modifiable cardiovascular risk factors 
from private medical screenings with the findings from the HSE 2006; and estimates the risks 
of many modifiable cardiovascular risk factors at a regional level from dataset provided by the 
Nuffield Health. 
 
2.2.2. Dataset from Hampshire Health Record 
 
The Hampshire Health Record (HHR) is a joint project supported by Basingstoke and North 
Hampshire Foundation Trust, Hampshire Primary Care Trust, Portsmouth City Teaching 
Primary Care Trust, Portsmouth Hospitals NHS Trust, Southampton City Primary Care 
Trust, Southampton University Hospitals NHS Trust, and Winchester and Eastleigh Hospital 
NHS Trust. HHR provides a detailed record of care which contains most of the information 
held in the GP’s record. It is stored by using a coding scheme (called READ Codes), which 
enables the data to be easily processed and displayed, whilst ensuring the quality and accuracy 
of the data is of a suitable level. Using this coding system means that only clinical data is shared 
and any comments GP may record for their own use are not shared. The amount of information 
will vary between patients, but will normally include information about allergies, medication, 
diagnosis, tests, and treatments. 
 
Hampshire Health Record is part of the National Health Services (NHS). Data collection from 
HHR will comply with the clinical guideline, Guide to Ensuring Data Quality in Clinical 
Audits, published by UK Healthcare Quality Improvement Partnership in 2011. In the 
following chapters, Chapter 7 aims to compare the prevalence of various modifiable 
cardiovascular risk factors between Nuffield Health (private health screening) and Hampshire 
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Health Record (public NHS data), and to identify the similarities and differences of the two 
datasets in relation to the cardiovascular risk factors. Chapter 8 aims to examine the association 
between area-level socioeconomic status and objectively measured, modifiable cardiovascular 
risk factors in a population from an affluent region in England who attended the public NHS, 
and to compare the effect of socioeconomic status on cardiovascular risk factors between 
people attending Nuffield Health and Hampshire Health Record. 
 
2.3. DATA SCREENING AND CLEANING 
 
Before proceeding to the data analysis, datasets from Nuffield Health and Hampshire Record 
are screened and cleaned carefully. This is helpful in dealing with errors and missing data. In 
addition to a manual inspection of the data or data samples, using the Descriptive, Explore, or 
Frequencies options in Statistical Package for the Social Sciences (SPSS) software could be 
very helpful in helping to spot unusual patterns of data properties and detect data quality 
problems. There are many available strategies for problems involved in dealing with the very 
important topic of missing data, for example, listwise deletion, pairwise deletion, etc. How to 
deal with missing data depends on the reasons why the data were missing, and different missing 
data techniques could be applied. Null items within the datasets were coded missing. Outliers 
also exist in two datasets, they are more extreme than the rest of the values. For example, in 
the dataset provided by Nuffield Health, there are values such as systolic blood pressure > 300 
mm Hg, but systolic >200 mm Hg, diastolic >130 mm Hg is a syndrome characterised by severe 
hypertension [Malignant (accelerated) hypertension]. It is not always appropriate to delete a 
value just because it is extreme. It is worth checking whether the outlier  differed from the 
others on other measures as well. If the outlier is different in other ways too, then it might worth 
considering excluding this value from the analysis.  
 
2.4. EPIDEMIOLOGICAL CONCEPTS USED IN THE THESIS 
 
Epidemiology represents a method of studying a health problem and can be applied to a wide 
range of problems, from transmission of an infectious disease agent to the design of a new 
strategy for healthcare delivery.  
 




Epidemiology is that field of medical science which is concerned with the relationship of 
various factors and conditions which determine the frequencies and distributions of infectious 
process, a disease, or a physiologic state in a human community (Lilienfeld 1978). 
 
John Last, in the Dictionary of Epidemiology, has defined epidemiology as follows: 
 
The study of the distribution and determinants of health-related states or events in specified 
population, and the application of this study to the control of health problems. 
 
Specific epidemiological study designs are used to achieve specific public health goals. These 
goals  range from identifying a suspected exposure-disease relationship to establishing that 
relationship, to designing an intervention to prevent it, and finally, to assessing the 
effectiveness of that intervention.  
 
In my PhD thesis, the studies mainly used retrospective design. Distinct advantages of such 
design are better for analysing multiple outcomes and helpful in addressing diseases of low 
incidence. However, significant biases may affect the selection of controls.  There are some 
similarities between two datasets, for example, both datasets are collected at population-level, 
and populations are relatively affluent, data collection are through healthcare professionals, 
both datasets have large sample size, and data quality are up to optimum use, but differences 
also exist, for instance, the geographical distribution of the practices participating in Nuffield 
Health is across the UK population, apart from small variations between regions. HHR data are 
collected from south central England region only. Dataset provided by Nuffield Health 
collected a broad range of data covering key health concerns such as diabetes, heart health, 
cancer risk and emotional wellbeing (Appendix 2.2).  and the dataset they provided for my PhD 
project included information about nine cardiovascular risk factors—BMI, waist 
circumference, waist-to-hip ratio, systolic and diastolic blood pressure, total cholesterol, LDL, 
HDL, and smoking. This will be the first opportunity to assess the effect of socioeconomic 
status (by postcode) on a cluster of cardiovascular risk factors in a large affluent UK population. 
In HHR dataset, seven cardiovascular risk factors were provided—BMI, waist circumference, 
systolic and diastolic blood pressure, total cholesterol, LDL, and HDL. Socioeconomic groups 
have been provided too in this dataset. However, postcodes were not provided. A number of 
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other variables would be welcome, such as smoking habit, weight, height, life style (diet, 
exercise). With retrospective studies, the temporal relationship is frequently difficult to assess. 
Retrospective studies also need very large sample sizes for health outcomes.  
 
Epidemiological methods are used throughout the thesis. The statistical concepts that are 
relevant to the following chapters are discussed below.  They lay the foundation for information 
that is needed to understand the series of studies. Hypothesis-testing paradigm started to use 
from Chapter 4, which aims to examine the prevalence of the different modifiable 
cardiovascular risk factors in the affluent population, and compares them to the general 
population represented in Health Survey for England 2006. The definition is introduced below.  
 
2.4.1. Hypothesis-testing paradigm 
 
According to Ajetunmobi (2002), a statistical hypothesis test is a method of statistical inference 
using data from a scientific study. In statistics, a result is called statistically significant if it has 
been predicted as unlikely to have occurred by chance alone, according to a pre-determined 
threshold probability, the significance level. 
 
Null hypothesis (H0): A simple hypothesis associated with a contradiction to a theory one 
would like to prove. 
 
Alternative hypothesis (H1): A hypothesis (often composite) associated with a theory one 
would like to prove. 
 
Type 1 error: Reject H0 when it is true 
 Significance level (α) or Type 1 error rate: is the probability of making this type of 
error.  
 This value is usually set to 0.05 for random reasons 
 
Type 2 error: Failing to reject H0 when it is false.  
 The value β is the probability of a type 2 error or type 2 error rate. 
 




Below, the discussion will be around the reasons why use effect size and analysis of variance 
(ANOVA), and odds ratio and logistic regression in the following chapters (Chapters 5, 6 and 
8), difference between statistical significance and clinical importance, as well as the 
introduction of regression and its application in my PhD chapters. 
 
2.4.2 Effect size and ANOVA  
 
In statistics, an effect size is a quantitative measure of the strength of a phenomenon. Reporting 
effect sizes is considered good practice when presenting empirical research findings in many 
fields. The reporting of effect sizes facilitates the interpretation of the substantive, as opposed 
to the statistical, significance of a research result. Effect sizes are particularly prominent in 
social and medical research. Relative and absolute measures of effect size convey different 
information, and can be used complementarily. 
 
Analysis of variance (ANOVA) is a method of significance testing based on the ratio of 
between groups variance to within-groups variance. This method is used in statistical analysis 
if the dependent variable is continuous and the independent variable or variables are all 
categorical (i.e. nominal, dichotomous, or ordinal). If there is only one independent variable, 
the method is called one-way ANOVA. If there is more than one independent variable, the 
method is called N-way ANOVA, with N representing the number of independent variables. 
 
2.4.3. Odds ratio and logistic regression 
 
An odds ratio (OR) is a measure of association between an exposure and an outcome. The OR 
represents the odds that an outcome will occur given a particular exposure, compared to the 
odds of the outcome occurring in the absence of that exposure. Odds ratios are most commonly 
used in case-control studies, however they can also be used in cross-sectional and cohort study 
designs as well (with some modifications and/or assumptions). 
 
Odds ratios are used to compare the relative odds of the occurrence of the outcome of interest 
(e.g. disease or disorder), given exposure to the variable of interest (e.g. health characteristic, 
aspect of medical history). The odds ratio can also be used to determine whether a particular 
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exposure is a risk factor for a particular outcome, and to compare the magnitude of various 
risk factors for that outcome.  
 OR=1 Exposure does not affect odds of outcome 
 OR>1 Exposure associated with higher odds of outcome 
 OR<1 Exposure associated with lower odds of outcome 
 
Confidence interval (CI) is an interval within which the population parameter (the true value) 
is expected to lie with a given degree of certainty (e.g. 95%). The 95% CI is used to estimate 
the precision of the OR. A large CI indicates a low level of precision of the OR, whereas a 
small CI indicates a higher precision of the OR. It is important to note however, that unlike the 
p value, the 95% CI does not report a measure’s statistical significance. In practice, the 95% 
CI is often used as a proxy for the presence of statistical significance if it does not overlap the 
null value (e.g. OR=1). Nevertheless, it would be inappropriate to interpret an OR with 95% 
CI that spans the null value as indicating evidence for lack of association between the exposure 
and outcome. 
 
When a logistic regression is calculated, the regression coefficient (b1) is the estimated 
increase in the log odds of the outcome per unit increase in the value of the exposure. In 
other words, the exponential function of the regression coefficient (eb1) is the odds ratio 
associated with a one-unit increase in the exposure. 
 
Statistically significant effect is an outcome for which the difference between the intervention 
and control groups is statistically significant (i.e. the P value is ≤0.05). A statistically 
significant effect is not necessary clinically important. Statistical significance is used in 
hypothesis testing, whereby the null hypothesis (that there is no relationship between variables) 
is tested. Statistical significance relates only to the likelihood that results obtained were not due 
to chance. Clinical significance answers the question, how effective is the intervention or 
treatment, or how much change does the treatment cause? In terms of testing clinical 
treatments, practical significance optimally yields quantified information about the importance 
of a finding. 
 




Binary logistic regression estimate the probability that a characteristic is present (e.g. estimate 
probability of ‘success’) given the values of explanatory variables, in this case a single 
categorical variable. Linear regression measures the relationship between a categorical 
dependent variable and one or more independent variables. 
 
Logistic regression is used to refer specifically to the problem in which the dependent variable 
is binary. For example, the number of available categories is two; and while problems with 
more than two categories that are referred to as multinomial logistic regression.  
 
2.4.3.2 Continuous variables vs ordinal grouping vs categorical variables 
 
Continuous variables are described as data that can take any value within a given range. For 
example, body weight, temperature, head circumference, etc.   
 
Ordinal variables are similar to continuous variables; they can be ordered sequentially. They 
are also similar to categorical variables because they (perhaps) cannot be differentiated from 
each other using a mathematical method. 
 
2.4.4. Chi-square test 
 
Chi-square is a statistical test commonly used to compare observed data with data we would 
expect to obtain according to a specific hypothesis. Chi-squared tests for variance are used to 
determine whether a normal population has a specified variance. The null hypothesis is that it 







Database research has many advantages—it is believed to be fast and not as expensive as 
experimental or other prospective studies, and it can analyse very large masses of data. It might 
be able to detect unexpected phenomena or demonstrate differences among subgroups that 
might not be included in a controlled experimental study. When it is not statistically definitive 
it can help refine questions, generate hypotheses, identify potential recruits for experimental 
studies, complement experimental studies, and generally inform the design of other research. 
And often it can proceed without the participants having to be involved or affected, especially 
if it uses anonymised data.  
 
Data quality is one of the common issues to ensure the robustness of secondary research. Data 
quality is important because accurate and timely information are needed to manage health 
services and improve quality of patient care; provide good information to manage health 
service effectiveness; prioritise and locate the health resources; and make judgements about 
the performance and governance in the organisation. Obtaining good-quality data is only a 
starting point, ultimately achieving data quality should be able to help to ensure that high-
quality evidence is used to guide the allocation of health-care resources efficiently and improve 
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Aneroid Blood Pressure monitor 
 
5.1 Prior to appointment 
 
The client should be as relaxed as possible.   
A full bladder may affect the blood pressure so the client should have been offered the 
opportunity to empty his/her bladder prior to this. (Ideally for urinalysis).  
No Caffeine for 4 hours prior to measurement. 
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No Nicotine for 30 min prior to measurement.  
Identify arm used for venepuncture and use the other one for measurement. 
 
5.2 Test Protocol using an Aneroid Manual Blood Pressure monitor 
 
1. Explain to the client that blood pressure is to be taken and discuss the procedure. 
Allow the client to rest for three to five minutes. Legs should not be crossed 
 
2. Select the appropriately sized cuff for the client’s arm.  The cuff should cover 80% of 
the circumference of the arm. 
 
3. Remove any restrictive clothing 
 
4. Ensure that the upper arm is supported and positioned with the mid point at heart level 
and with the palm of the hand facing upwards 
 
5. Apply the cuff of the sphygmomanometer snugly to the upper arm with the lower edge 
of the cuff approximately 2cm above the antecubital fossa ensuring that the centre of 
the bladder covers the brachial artery 
 
6. Palpate the brachial pulse and inflate the cuff until the pulse can no longer be felt and 
then increase the inflation by 20mmHg 
 
7. Deflate the cuff and note the level at which the pulse reappears – this is the 
approximate systolic pressure 
 
8. Deflate the cuff completely and wait for 15 – 30 seconds 
 
9. Re-inflate the cuff to 20 mmHg above the point at which the pulse disappears 
 
10. Place the bell of the stethoscope over the brachial artery.  It should not be placed over 
clothing 
 
11. Slowly deflate the cuff at 2-3 mmHg per second, listening for Phase one Korotkoff 
sounds 
 





13. Continue to deflate as above until no sounds are heard. Note the diastolic pressure 




14. The cuff should be deflated slowly for another 10mmHg to ensure that no further 
sounds are audible and then rapidly and completely deflated.  
 
 
5.3 Precautionary measures 
 
Do not apply more pressure with the stethoscope than necessary as this may distort the 
reading. 
 
Do not tuck the bell of the stethoscope under the cuff – this could exert additional pressure on 
the brachial artery. 
 





In 1904, Nicolai Korotkoff discovered that by using a stethoscope below the cuff over 
the artery at the elbow, characteristic sounds could be heard at systolic and diastolic 
pressure. 
 
‘Korotkoff’s Sounds’  
 
Phase one the appearance of faint, repetitive tapping sounds gradually 
increasing in intensity and lasting for at least two consecutive 
beats. 
Phase two A brief period where the sounds soften or swish. 
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Ausculatory gap in some clients the sound may disappear altogether. 
Phase three the return of sharper sounds becoming crisper but not with the 
intensity of phase one. 
Phase four the distinct abrupt muffling sounds becoming soft and blowing 
in quality 
















     
 
     
 










Record Phase one as Systolic  










Master skills – Finger prick assessment 
 
4.1 Prior to appointment 
 
Client should be fasted ideally for a period of two hours prior to the assessment. A non-
fasted test is still worthwhile performing although may need a re-test if it is above the 
recommended range. Fasting further helps ensure reproducibility. 
 
Dilution of capillary blood by tissue fluid can contribute to an inaccurate finger-prick result 
when compared against a venous sample. This should be explained to the client. 
 
Damage to blood cells from this method of collection can sometimes cause inaccurate test 
results (and the need to repeat the test with blood drawn from a vein). This should be 
explained to the client. 
 
Finally explain to the client the test is a gauge of total cholesterol and not cholesterol 
breakdown. Due to the increasingly important role of HDL cholesterol and heart risk we 
will not get the full picture from this test although it is an excellent marker of what the lipids 
levels are like within the bloodstream.  
 
Blood Safety  
 
Take care when dealing with blood and needles. 
 
When dealing with blood always ensure: 
 
- The physiologist works in a safe and clean manner. 
- That disposable gloves are worn by the physiologist whenever the physiologist may come into 
contact with blood performing the test. 
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- A sterile and clean working area is maintained for performing the test. 
- Any blood spillages are cleaned up immediately using alcohol wipes. 
- Needles are disposed of immediately and safely into a clinical sharps bin. 
- All consumables are disposed of in appropriate sanitary waste. 
 
In the unlikely event of you pricking yourself with a used needle / lancet, it is important that you 
understand the company policy and explain the procedure to the client involved. 
 
1) Thoroughly wash wound immediately and promote bleeding by opening the wound and 
squeezing.  
 
2)  First contact Oli Patrick Professional Head of Physiology, as soon as possible. Oli Patrick will 
be able to remind you of the company blood safety procedure and ensure appropriate 
measures for your safety are undertaken. 
 
3) You will also need to explain to the client that is our company policy that they will require a 
blood test for HIV and Hepatitis B. This test will be organised for them. 
 
4)  You will also require the same blood tests 
 
 
BE SAFE WITH NEEDLES – DISPOSE OF THEM WITH SAFETY AND CARE 
  
 
4.2 Test protocol  
 
TEST PROTOCOL  
 
1. Make sure you have a clean and sterile surface to perform the test. A clinical sharps 




2. Check client has fasted for 4 hours and only had a light breakfast/lunch prior to that. If 
client has not fasted explain results cannot be taken as valid although they may provide 
a useful biochemistry marker (see validity of results). 
 
3. Reassure client about what test you are about to perform and you must ask their 
permission to prick their finger with a finger prick device to attain 2 drops of their blood 
for Blood Cholesterol analysis. 
 
4. Seat the client next to a table and ask them to remove any item of clothing that may 
be making them uncomfortable.  
 
5. Load the Soft click finger prick device with a new lancet in front of the client (as per 
instructions on device) and explain to the client that a clean lancet / needle is being 
used. Set the appropriate depth of the device (For most adults this will be #3, however, 
a lower number may be more appropriate for children or slim clients).  
 
6. Remove one cholesterol strip (of the same codes) from air-tight sealed pots and 
replace lids afterwards. 
 
7. Place the strips next to the Blood Cholesterol Monitor on the sterile surface. 
 
8. Sitting next to the client and wearing rubber gloves ask the client to present you with a 
finger. It is usually recommended to use the second finger but clients may prefer to 
use another finger.  
 
9. Clean the end of the selected finger with an alcohol wipe and allow drying. Place some 
cotton wool to one side of the sterile surface. 
 
10. Gently palpate the finger in a milking fashion with the aim of drawing blood towards 
the tip of the finger. 
 
11. Once strip is ready and client is ok switch on the machine and make sure the codes 
displayed match the strips you will be using. If not, use supplied bar-coded strips within 
cholesterol pack and follow manufactures instructions to update code. 
 
12. Take the unused Cholesterol strip and slide it through the front of the machine. Wait 
for the beep to signal the machine is ready then open the top flap. The screen will 
display the test time (180 seconds for cholesterol, 12 seconds for glucose). The 
machine is now ready to analyze.  
 
13. With the clients palm facing upwards. Place the centre of the loaded finger prick device 
next to the most distal portion of the client’s finger, off the main finger pad and slightly 






15. Warn the client of the imminent small sharp pain and reassure if required. Then click 
the release button. 
 
16. Dispose of the lancet into the clinical sharps bin as soon as you have done this. 
 
17. Ask the client how they are feeling at this time and check for signs of dizziness or 
fainting. 
 
18. Gently palpate the finger in a milking fashion again pushing blood towards the end of 
the finger. If no blood arrives continue to do this for a few seconds whilst gently opening 
up the small wound with thumbs. You can also ask the client to lower their hand to 
increase the pressure in the region. 
 
19. Wipe away the first drop of blood with the cotton wool and place immediately in the 
clinical waste bin. Begin to milk the finger again to gain a fresh sample. 
 
20. Once you have got a drop of blood about the 2-3mm in size, place the testing strip 
close to the blood. It should be gently absorbed into the pad on the stick. Only apply 
blood outside of the meter. 
 
21. Take care not to press the pad of the stick directly onto to the skin so to avoid 
any moisture/skin cells from skin passing onto testing strip.  
 
22. Continue this process until you have enough blood on one strip. The underside of the 
strip has a circle that will change colour (red) to indicate enough blood has been 
collected. 
 
23. Throughout this process be very sensitive to the client and if they are in too much pain 
or are feeling unwell be ready to stop at any time. 
 
24. Give the client the small ball of cotton wool and ask them to push down on the small 
wound with the cotton wool. After a few minutes if the wound has not healed offer a 
plaster. The client should not suck their finger as this will prolong the bleeding. 
 
25. After the allotted time the machine will beep to indicate the result is ready. Record this 




26. Switch off the machine, dispose of all consumables into a sharps bin or clinical waste 
bin and clean machine internally with an alcohol wipe (70% alcohol). Prior to next client 
clean machine as detailed below. 
 
27. Warn client you will require another finger for the glucose test. You will also have to 
use a new lancet. 
 
28. Follow the same procedure for blood glucose. 
 
 






2.1 Prior to appointment 
 
Ideally: No food or drink, excluding water, 4 hours prior, complete evacuation of bowel, empty 
bladder, maximum 30 minutes prior to the test, no heavy exercise 12 hours prior, no alcohol 
48 hours prior. 
 
Realistic: well hydrated and no diuretics prior to test (unless prescribed by a doctor). 
 
Low Hydration levels do affect the accuracy of the result and clients should be reminded to 






Do not perform on those with pacemakers or with any implantable electronic device. 
Why? 
The affect of the single frequency Body Stat 1500 unit could cause interference with operation 
of electronic medical devices. 
 
Do not perform on pregnant ladies 
Why? 
The effects of an electrical current on a foetus are not known. 
 
 
Women experience more changes in hydration levels than men because of their menstrual 
cycle and this can affect body fat measuring, particularly using the BIA method. Retaining fluid 
may also cause weight to fluctuate day-to-day during this period causing additional variation 
in the body fat percentage 
 
2.2 Test Protocol 
 
 Explain Bioelectrical Impedance Analysis (BIA) to the client 
 
 
Based on the two-compartment method of body composition: – Fat component and 
Fat-Free component (lean), BIA is a rapid and non-invasive method of measuring body 
fat. 
 
Bioelectrical Impedance Analysis (BIA) measures the impedance or resistance  to the 
flow of an electric current through the body. 
Impedance is low in lean tissue, due to intracellular and extracelllular fluid. 
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Impedance is high in fat tissue.  
Impedance is also proportional to the total body water volume.  




1. Ask client to remove both their right shoe and right sock and lie down on the couch 
 
2. Place the proximal sensor on the dorsal surface of the wrist so the upper border of the 
electrode is placed against the most distal part of the ulna. 
 
3. Place the distal sensor at the base of the second or third metacarpal-phalangeal joint 
of the hand 
 
4. Place the proximal sensor on the dorsal surface of the ankle so that the lateral  border 
of the electrode  is placed against the medial part of the lateral malleolus 
 
5. Place the distal sensor at the base of the second or third metacarpal-phalangeal joint 
of the foot 
 
6. Attach the red electrode to the distal sensor and the black to the proximal on both hand 
and foot 
 
7. Make sure the client’s arms and legs are abducted at approximately 45 degrees  of 
each other. There should be no contact between legs or between arms and  body  
 
8. Double check for any contraindications to perform the test 
 
9. Explain this test will not cause any sensation.  and perform the test by sending the 
pulse. 
 
10. Disconnect the client and remove the electrodes. 
 
11. Inform  the client  of the results of their total body fat percentage.  Abstain from a full 
explanation at this stage if you are performing an assessment that will allow you more 







Using Biophotonic scanner 
 
 Master skills 
 
 
2.1 Procedures - Prior to the appointment 
 
1) The scanner should be warmed up and calibrated – allow at least 50 minutes prior to 
the first client scan 
a. Sufficient Scan Certificates available for all appointments booked  
b. Sufficient calibration putty – calibration is done twice a day when prompted. 
2) The questionnaire on lifestyle and nutrition should be completed by the client for better 
understanding of their habits and lifestyle  
 
2.2 Test Protocol 
 
1) Enter the first and last name fields as defined by Nuffield Proactive Health 
a. 1st Name = Nuffield 
b. Surname = Client ID 
 
2) Enter the Nuffield Hospital Location post code 
 
3) Tick box for NO EMAIL 
 
4) Place the right hand on the scanner in the preferred position 
If there is scarring or a physical handicap that will not allow the right hand to be 
scanned, use the left hand in the preferred position. 
 
5) Begin the scanning process – 3 minutes until a result is revealed 
 




7) Discuss client answers from the questionnaire in order to better understand the client 
lifestyle habits and risk factors associated with antioxidants/free radical sources 
 
a. Information Gathering – a flexible process 
b. Briefly explain -  The scanner and the scan 
c. Brief explanation of what the scanner is doing 
d. Manage any concerns about test – i.e., pregnant women is safe, Non-invasive, 
pain free 
e. Explain Anti-oxidants and Free Radicals 
f. The impact of lifestyle 
 
Prepare to show score 
 
g. Explain, using the score sheet, what the results mean will mean 
h. Ensure the client can see the laptop screen when revealing their score 
i. Emphasise this is their baseline score, and is influenced by their genes, 
lifestyle, diet, supplementation and other factors 
 
8) Press OK when prompted – this will reveal the individual’s scanner score. 
 
9) Explain the results 
 
10) Discuss the recommendations – all facets of lifestyle change inclusive of 
supplementation.   
 
a. How to manage score expectations / reactions 
i. No good or bad, it is their baseline 
ii. Any score can be increased from whatever baseline 
b. Go through positive and negative influences, using information gathered, and 
make recommendations 
c. How to manage very low score 
i. Which reflects lifestyle 
ii. Which does not reflect lifestyle 
iii.  
11) Score Validation 
 
a. If score less than 20,000 rescan to ensure hand was not moved during scan if 
score < 10,000 
i. Recommend serious increase in nutritional awareness (possible 
nutritionist) 
ii. May be absorption issue 
iii. May need more tests 
 
b. If score < 20,000 
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i. Does it reflect lifestyle? 
ii. Concern if significant difference between score and lifestyle 
iii. Big negative influences are smoking, overweight, stress and medication 
iv. If score much lower than expected – check nothing missed in dialogue 
v. If mismatch between score and lifestyle 
vi. Recommend serious increase in nutritional awareness (possible 
nutritionist) 
 
12) Lifestyle and Diet Guidance 
 




iv. Excessive exercise 
v. Environment 
 
b. Positive factors – increase anti-oxidants 
i. Type and quantity of fruit and vegetables 
ii. Cooking method 





a. Objective – as high a score as possible 
b. Reality – corporate life, time pressures, lifestyle 
c. Recommendations 
i. REALISTIC 
ii. Based on 
1. Client attitude to health 
2. Their priorities 
3. Start with easy goals 
4. More portions, change type of vegetables, cooking method 
5. Importance of stress and weight management, smoking 
d. Recognise for most clients impossible to get optimum score without 
supplementation 
 
14) Recommendation Process 
 
a. Common sense 
b. Address the concerns of the client 
c. Part of lifestyle change, not isolated or ignored or ‘end in itself’ 
d. Priority areas first 








Using Nerveexpress HRV technology. 
 
Prior to appointment 
Ensure limited caffeine and limited exercise for 4 hours.  




1. Debrief the client briefly regarding the purpose of the test and what we are hoping to 
achieve. Avoid using or referring to the word ‘stress’.  
 
2. Tell them that there will not be any talking throughout to ensure accurate results 
 
3. Ensure the client does not move substantially during the test other then the standing 
up action. 
 
4. Enter the client’s name.  DOB and ID number under additional information on the 
screen  
 
5. Take the heart rate monitor and moisten the sensors with an alcohol swab 
 
6. Assist the client with putting on the heart rate monitor – this should be approximately 
level with the sternum and underneath the client’s shirt 
 
7. Ask the client to lay down on the couch in the supine position and relax 
 
8. Attach the nerve express clip onto the patient’s shirt, ensuring that it is within 30 cm 
of the HR monitor 
 




10. When the words ‘Client stand up’ appear on the screen, ask the client to slowly stand 
and face the corner of the room, ensuring that the lead is still connected and a signal 
still being transmitted 
 
11. After the selected number of heart beats, the test will be complete and the screen will 
change showing the graphical analysis of the test 
 
12.  Remove the lead and HR monitor from the client 
 
13. Click on print – tick Nerve Express and Fitness Express icons only – then click ‘Ok’ to 





 1.7 Key problem solving 
 
 
Problem Possible solution 
No signal Is the belt wet enough? If not then use 
another swab on the receiver pads and 
try again. 
 
Does client have inverted sternum? If so 
try to move belt so side ‘pads’ have as 
much contact with ribs as possible. 
 
Are all leads connected at back of 





Loss of signal half way through test Has the receiver dropped off? If so there 
is a small window of opportunity <15 
seconds to re-connect receiver and 
continue test. If no signal returns then 
apologies and re-start test. If it happens 
again then the test may have to be re-
scheduled. 
 
Has the belt slipped when the client 
stood up? If so then ask the client to 
push the belt against their skin to provide 
a stronger signal. Tighten the belt if you 
have time. As above if not signal returns. 
 
Client gets bored during test and starts to 
talk 
Although this won’t stop the test it will 
make it less reproducible and less valid. 
Try to encourage them to be still and if 












Prior to appointment 
 
Ensure clients are informed of the test protocol and that appropriate clothing is available to 
allow a test to take place.  
 
If client has an existing back pain problem take note of this and only perform the upright 




Open spinal mouse program through Vi system on computer 
 
Ensure spinal mouse unit is ‘on’ within docking station 
 







Explain measurement process thoroughly to client explaining that to measure to S3 (aka 
Rima ani) effectively the mouse will have to roll into the top of the cleft of their buttocks. This 
process does not require taking pants off but will require exposure of this area. 
 
If the client is uncomfortable with this process then they may retain their pants and a degree 
of error should be factored in regarding lumbar spine results. 
 
Female clients should already be wearing the spinal mouse garment. At this point they 
should remove their bra and shoes. Men should remove shoes only.  
 
Females – open the rear panel of the spinal mouse to ensure access to C7 and S3. 
 
Males – request they remove their shirt and lower pants as appropriate against earlier 
discussion. 
 
Remove the spinal mouse unit from the holder and hold in one hand. Press the right hand 










Ask the client to stand with feet at shoulder width apart 
 
Arms should hand relaxed, laterally to the body 
 
Weight should be evenly distributed 
 
Focus should be horizontally – straight on  
 




To find C7 ask the client to bend forwards. C7 will be the most prominent. Place your 
finger on C7 and then ask the client to stand up straight again – it will disappear on 
standing in most cases 
 
 
Once C7 is identified place the spinal mouse on the clients back with C71 in-between the 
two measuring discs on the mouse unit 
 
Once the spinal mouse is in place press the left hand button to start the reading. The button 




Roll the spinal mouse down the spinal processes slowly putting a light pressure to keep a 
good contact with the skin 
 
The spinal mouse can take an accurate measure if it reads just to the side of the spinal 







Once the spinal mouse has reached S3 press the left hand button again to stop the reading. 
Ensure the result has been recorded on the computer program 
 
If the technique of measurement was not satisfactory then repeat the process. If happy then 




For flexion testing ask the client to bend forwards as far as is comfortable whilst keeping 
their knees locked and legs straight.  
 








Once flexion measurement has been completed press the right hand button to move onto 










Select the appropriate weight dumbbells based on the sex and weight of the client (see fig 7) 
 
Remember – Matthiass is not for use in clients with existing back pain. In these cases a 
simple upright measure is enough 
 
Ask the client to hold the dumbbells at a 90 degree angle to their body (shoulder height)  
 
Begin the stopwatch. Note – there is a stopwatch function available on the Spinal mouse 
program 
 
When the stopwatch reaches 20 seconds prepare to take the Matthias reading. The reading 
should be performed exactly as the upright protocol. 
 
Begin the measurement exactly on 30 seconds and once measurement has ceased instruct 
the client to lower their arms and return the dumbbells 
 
Allow the client to appropriately dress for the next test within their health assessment 
 
 
Matthiass master class 
 
The Matthiass test is designed to identify postural weakness by comparison of two 
standing postures. The first posture is normal and the second is with both arms in the 
horizontal position holding an appropriate weight (based on sex and weight). 
 
The patient is measured in the first position. Then, after 30 seconds with arms up, the 
measurement is repeated. Holding the arms horizontally moves the center of gravity 
forwards, and this stress is often compensated by shifting the whole body back. The 
pelvic girdle moves forwards and lordosis deepens.  
Patients with weak back-musculature show large differences between the two 
measurements: Shoulders shift back, hips forwards and lordosis is increased as in 







#6 : Good Posture, # 1: Weak Posture 
 
References further investigating the logic of the Matthiass test are shown at the end 
of this chapter. Matthiass test is a gauge of postural skill and serves to identify risk of 
future problems - based on the role of muscular strength and endurance in 
preventing lower back pain. 
 
Assumptions have always been made about importance of strength within both 
rectus abdominus and deeper abdominal muscles – most recently and notably 
transverses abdominus. Although significant volumes of studies have focused on the 
endurance ability of stabilising muscles rather than their dynamic power.  
 
Various studies conducted through the 1980’s (2, 3) repeatedly showed the muscular 
endurance capability of the erector spinae and other postural muscles had the largest 
influence on incidence of back pain – with increased endurance correlating to the 
lowest incidence of pain. Matthiass test is a combination of muscular strength and 
isometric endurance and as such offers vital insights into these proven areas. It also 
lends suggestion to the type of training that should be recommended to be both 










2.1 Prior to test 
 
Ensure the machine is calibrated – see maintenance 
 
The client should not have: 
 Smoked for 24 hours 
 Drunk alcohol for 4 hours 
 Eaten substantially for 2 hours 
 Exercised vigorously for the past 30 minutes  
 Taken bronchodilators for 4 hours 
 
None of the above are contraindications but a note should be made on the Vi system 
   
Ensure the client does not have any contra-indications   to taking the test 
 
2.1.1 Contra-Indications to Spirometry 
 
 Hypertension (B.P. exceeding 190/100) 
 Haemoptysis – coughing up blood 
 Pneumothorax – collapse lung tissue 
 Unstable cardiovascular status, unstable angina or recent heart complaint 
 Aneurysm – a local dilation / weakness in artery wall 
 Recent eye surgery / detached retina 
 Recently perforated ear drum 
 Recent thoracic (chest) or abdominal (stomach) surgery 
 Pregnancy – first three months or last three months 
 Current acute back problems – seek advice if unsure 
 
 




1. Switch on the Vitalograph machine  
 
2. Enter the correct date and temperature (check thermometer on face of machine) 
 
3. Enter accurate subject data, using the patient CIN number  as  the reference number 
 
4. After the client demographics have been entered, the printer starts, confirming the 
client as current user. 
 
5.  Inform the client that you are inserting a  new  mouthpiece into the machine 
 
6. Select FVC Test (Forced Exhalation Test) from the main menu 
 
7. Give visual demonstration of correct technique 
 
8. Commence FVC Test only when the READY prompt is displayed 
 
 Client  Instructions for Performing the Test: 
 
- Stand up 
- Take hold of the unit, keeping it in a vertical position and away from your mouth 
- Inhale as deeply as possible and insert the mouthpiece into your mouth, clamping 
it between your teeth 
- Seal your lips fully round the mouthpiece 
- Exhale as quickly as possible and try to keep exhaling for at least 6 seconds until 
the physiologist sees the FVC line obviously plateaux 
 
 
9. Encourage the client to keep exhaling as you monitor the exhalation volume 
 
10. After the test, ask the client if they are ok. Ensure you have a seat nearby in case they 
feel light-headed immediately after performing the test 
 
Minimum of 3 attempts and a maximum of 8 tests is recommended. Curves for each test will 
be displayed on the screen. The ‘best’ test (highest FVC + FEV1 sum) will be stored for output 
on the printed test report. It is imperative to monitor how the client is feeling and your 





11. Print out the report, which provides the client’s data, test results and graph. To stop 
the printer, press the enter key during printing. 
 








APPENDIX 2.2 Variables for extraction from the ViSystem 
 
Variable/Parameter Comment 









Blood Pressure  
Cholesterol  May be part of biochemistry blood results 
Bioimpedance  
Body Water May be part of bioimpedance results, but 
valuable to have this field separately  
Antioxidant score  
NBCIndex Calculated using body composition data 
within the Vi4, Vi5 and Vi6 
 
SNS/PSNS relationship Mirroring the corporate report formula put 
together by Richard Brennan. The formula 
records a positive result based on DSNS <=0 
and SNS >=0 and 
(DSNS < 1 or SNS > 1) 
All other results would be deemed negative 
Subjective stress score Taken from questionnaire page of Vi System 
– this will often be missing due to insufficient 
data entry. 
Behaviour scores break down Activity score (isolated) 
Exercise score (isolated) 
Nutrition score (isolated) 
Life balance score (isolated) 
Smoking score (isolated) 
Smoking Either/and/or Smoking score from behaviour 
page or selection of smoking from 
questionnaire page. 
Alcohol units per week From questionnaire page 
 
Alcohol units  how often Number of day drinking per week 
 
Spinal mouse score and breakdown of 
scores 
Eg Total score, Upright score, flexion score 
and postural competence score (4 results 
taken from the spinal mouse page) 
Fasting status To compare against glucose and cholesterol 
interrogations. Taken from physical 
measurements page 
Exercise, activity and relaxation section  Taken from Vi questionnaire including all 
options from motivation for exercise drop 
down box. 
Sleep health From Vi questionnaire 
 




Corporate account details 
 
From Samba? To allow reviews against 
sector. 
Lung function (absolute and % values) Results taken from physical measurements 
page 
Exercise ECG report from cardiologist Report received back from cardiologist team 
at Warwick. The code from the system will 
suffice. 
Cardiovascular risk score From the Framingham calculation within the 
clinical examination section of the health 
assessment.  
VO2 max score x 2 From the data entry in physical measurement 
in Vi4 and from the calculation from heart 
rates in the Vi6 
 
Biochemistry blood results Eg. Uric acid, ALP, ALT, GGT, Calcium etc. 
The full range. 
 
If possible (nice to have) 
 
Haematology blood results 
 
Eg FBC, WBC etc 







CHAPTER 3:  
 
SOCIOECONOMIC STATUS, CARDIOVASCULAR DISEASE, AND ASSOCIATED 




Globally, cardiovascular disease is the leading cause of death and is predicted to remain so. 
Understanding of the risks to health is the key to prevention of cardiovascular diseases and 
events. A cardiovascular event is often caused by more than one risk factor, which means that 
multiple interventions are needed to target each of these risks. The aim of this review was to 
undertake a comprehensive evaluation of available literature on cardiovascular diseases, 
several associated risk factors (provided in two databases—Nuffield Health and Hampshire 
Health Record), and evidence-based interventions to effectively improve the individual’s 
health and quality of life in the UK population. This review also aimed to compare the existing 
measurement of socioeconomic status and describe how the Indices of Deprivation 2007 were 




The databases were searched include the Cochrane Library, Medline, PubMed, and Embase 
between May 1980 and September 2012 with combinations of the terms: “cardiovascular 
disease”, “cardiovascular risk factors”, “risk factors”, “heart disease”, “coronary artery 
disease”, “CHD”, “CVD”, “body mass index”, “BMI”, “overweight”, “obesity”, “waist 
circumference”, “WC”, “waist-hip ratio”, “WHR”, “high blood pressure”, “blood pressure”, 
“elevated blood pressure”, “systolic blood pressure”, “diastolic blood pressure”, “elevated 
systolic blood pressure”, “elevated diastolic blood pressure”, “SBP”, “DBP”, “hypertension”, 
“cholesterol”, “total cholesterol”, “elevated total cholesterol”, “plasma cholesterol”, “lipids”, 
“low-density lipoproteins cholesterol”, “high-density lipoproteins cholesterol”, “LDL 
cholesterol”, “HDL cholesterol”, “elevated LDL cholesterol”, “elevated HDL cholesterol”, 
“socioeconomic group”, “socioeconomic status”, “education”, “income”, “occupation”, 
“profession”, “socioeconomic deprivation”, “area-level deprivation”, “area-level 
socioeconomic status”, “individual-level socioeconomic status”, and “neighbourhood 
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deprivation”. Publications from the last 10 years were largely selected, but it did not exclude 
commonly referenced and highly regarded older publications. The search was restricted to 
publications in English. Further search of reference lists of articles identified by this search 
strategy was also done and those relevant articles were selected. Reviews are cited to provide 
readers with further details and additional references. Abstracts and reports from meetings were 
included when they related directly to previously published work. 
 
There is a literature update between Sep 2012 and Dec 2013 with the same search strategy, 





In this Chapter, the following cardiovascular risk factors—BMI, waist circumference, WHR, 
systolic and diastolic blood pressure, total cholesterol, HDL, LDL—will be discussed in full 
details in this literature review, because data on these risk factors are provided in two datasets—
Nuffield Health and Hampshire Health Record, which will be analysed in the later chapters. 
Smoking, as an important risk factor contributed to cardiovascular disease and data are 
provided by the Nuffield Health’s dataset, will be reviewed in this Chapter and analysed in 
Chapter 4 later. The prevalence of smoking is estimated around 30% of the adult population 
worldwide, with up to 47% in men and 12% in women (Mackay et al. 2002). Tobacco 
accounted for 18% of deaths in high-income countries (WHO 2009). Chapter 7 aims to 
compare the prevalence of various modifiable cardiovascular risk factors between Nuffield 
Health (private health screening) and Hampshire Health Record (NHS Trust), and to identify 
the similarities and differences of the two datasets in relation to the cardiovascular risk factors. 
Finally, this thesis will look at the effect of socioeconomic status, at both an individual-level 
(e.g. education, income, occupation, etc.) and area-level (e.g. IMD 2007), on cardiovascular 
risk factors, which both Chapters 5 & 8 will examine the effect of area-level socioeconomic 
status on many cardiovascular risk factors in the large UK populations.  
 
3.2 RIST FACTORS FOR CARDIOVASCULAR DISEASE 
 
The risk factor concept is an important feature for an individual’s clinical assessment for initial 
or recurrent cardiovascular events. A risk factor is something that increases the chance of 
developing cardiovascular disease. The greater the combination of risk factors, the higher the 
probability of developing cardiovascular disease. The risk of a recurrent event is usually subject 
to indicators of the severity of the first event, but other influencing risk factors continue to play 
an essential part. On the basis of risk assessment, risk factors could be divided into modifiable 
or non-modifiable risk factors. Modifiable risk factors include diabetes, high cholesterol, 
hypertension (high blood pressure), obesity, sedentary lifestyle (physical inactivity), smoking, 
or exposure to environmental tobacco smoke. Non-modifiable risk factors (such as strong 
family history of cardiovascular disease) could nevertheless offer support for risk assessment, 




Worldwide, the two most important modifiable cardiovascular risk factors are high cholesterol 
and smoking (Emberson et al. 2003; Zipes et al. 2007). Obesity, diabetes, hypertension, and 
psychosocial factors are the next most important in the general population; however, their 
relative effects vary in different regions of the world (Yusuf et al. 2003). Excessive alcohol 
consumption is an additional important risk factor for a smoker. Many of these risk factors are 
unequally distributed across society, with the most deprived groups often exposed to the 
highest risks (Emberson et al. 2003; Yusuf et al. 2003). 
 
Non-modifiable risk factors include age, especially for people older than 50 years, gender, 
genetic factors or family history of cardiovascular disease, and ethnicity. In the UK, South 
Asians have a particularly higher risk than do other ethnic groups. Also, people from Afro-
Caribbean backgrounds have a higher than average risk of developing high blood pressure. 
 
Cardiovascular risk factors could also be classified as major independent risk factors—age, 
cigarette smoking, diabetes, blood pressure>140/90 mm Hg, high-density lipoprotein (HDL) 
less than 1 mmol/l, raised low-density lipoprotein (LDL) concentrations, family history of 
premature coronary artery disease (first-degree male relative <55 years or first-degree female 
relative <65 years), and renal impairment; and lifestyle risk factors—obesity, physical activity 
and atherogenic diet (Yusuf et al. 2003).  
 
3.3 HISTORICAL CONTEXT 
 
Cardiovascular disease is a general term used to describe disorders that can affect the heart 
(cardio) and the body’s system of arteries and veins (vascular), or both of them. This can lead 
to increased risk of heart attack, heart failure, sudden death, and even stroke, hence reducing 
quality of life and shortening life expectancy (Zipes et al. 2007; Durstine et al. 2008).  
 
Globally, cardiovascular disease is the leading cause of death and is predicted to remain so 
(WHO 2011). Cardiovascular disease has a major effect on both developed and developing 
countries. About 17·3 million people died of cardiovascular disease in 2008 (WHO 2011), 
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accounting for 30% of overall global mortality, with other cardiovascular system diseases 
causing further mortality and disability.  
 
During the last several decades, much progress has been made in establishing the determinants 
of cardiovascular disease and how to reduce the incidence and mortality. On the basis of this 
knowledge and the emerging evidence of the rising burden of cardiovascular disease 
worldwide, there has been a steady acceleration of international reports, declarations, and 
resolutions calling attention to the rising global epidemic of cardiovascular disease. The recent 
historical context is summarised in Appendix 3.1. 
 
One of the first publications to highlight the global burden of cardiovascular disease was the 
1993 World Development Report by the World Bank (1993). This report focused on the critical 
part that investments in health play in international development. The report also introduced 
the Global Burden of Disease study (1990), which definitively established that cardiovascular 
disease is responsible for more deaths worldwide than other cause.  
 
As the realisation of the true global burden of cardiovascular disease began to grow among the 
international public health community, several major reports examined national capacities to 
implement prevention and treatment programmes for cardiovascular disease. These reports, 
most notably the 1999 World Heart Federation White Book, The Impending Global Pandemic 
of Cardiovascular Diseases (Achutti et al. 1999), and the 2001 WHO Assessment of National 
Capacity for Non-Communicable Disease Prevention and Control (Alwan et al. 2001), found 
that the majority of countries did not have cardiovascular disease and other chronic disease 
control policies, programmes, funding, or the will to take action. As a result, there was little 
prevention or control underway. 
 
A series of reports from multilateral organisations further explored the growing burden of 
cardiovascular disease and other chronic diseases, which are shown in Appendix 2.1, including 
the 2000, 2002, and 2005 WHO Reports (WHO 2000a; WHO 2002a; WHO 2005b) and the 
Global Burden of Disease Reports in 2000, 2006, and 2008 (Jamison et al. 2006; WHO 2000b; 
WHO 2008b). Additionally, the Earth Institute/IC Health Report (2004) examined the social 
and macroeconomic effect of the growing epidemic of cardiovascular disease. Overall, these 
reports established that cardiovascular disease is the number one cause of death worldwide, 
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that the disease burden will only increase in the coming decades, and that control efforts are 
not sufficient to address the disease burden. These reports also recognised that cardiovascular 
disease is a complex issue, influenced by interdependent factors that involve many sectors and 
stakeholders extending far beyond the realm of health and public health systems. 
 
Death rates from cardiovascular disease in England have been decreasing, but the disease still 
remains the main cause of mortality—up to 184,000 deaths—along with cancer and other 
chronic diseases in England and Wales in 2005 (National Statistics 2006). In 2003, around one 
per 300 people was newly diagnosed with some form of coronary heart disease in Scotland 
(SIGN 2007). Cardiovascular disease led to 28% of premature deaths (deaths in people younger 
than 75 years) in 2005 in England (National Statistics 2006). The government target is to reduce 
the mortality rate of cardiovascular disease in people younger than 75 years by a minimum of 
40% from the 1995–97 baseline by 2010 (to 83·8 deaths per 100,000 population; DoH 1999). 
Although significant achievements in the prevention and treatment of cardiovascular disease 
in England in the last two decades, cardiovascular disease mortality was still up to 200,000 
annually in the UK, there is much more to be done (DoH 2013), and one of many ways is to 
investigate the risk factors for cardiovascular disease and identify some outcomes strategies to 




Obesity can be defined as an excess of body fat accumulation or adiposity, with specific 
multiple organ adaptive or maladaptive consequences. Energy imbalance or a chronic state of 
positive caloric balance is implicated as the cause of obesity. Obesity can be associated with 
enhanced risk of morbidity and mortality.  
 
Assessment of anthropometric indices is an essential part of obesity management in clinical 
practice. These indices are helpful in defining the degree of obesity and reflecting regional fat 
distribution. The most commonly used anthropometric indices of obesity are: 1) body mass 






BMI is defined as weight in kilograms divided by the square of the height in metres (Sabia et 







The current thresholds are: a BMI of 18·5–25 kg/m2 may indicate optimum adiposity; a BMI 
lower than 18·5 kg/m2 suggests that the person is underweight; a number above 25 kg/m2 may 
indicate the person is overweight; a number above 30 kg/m2 suggests the person is obese; and 
over 40 kg/m2, morbidly obese (WHO 2005; NICE 2006b). A WHO expert consultation 
discussed the BMI cutoff points for determining overweight and obesity in the Asian 
population, and made recommendations for population-specific thresholds for BMI (Barba et 
al. 2004). The research reviewed existing evidence that Asian populations have different 
associations between BMI, percentage of body fat, and health risks than do their European 
counterparts. It concluded that some Asian people have a high risk of type 2 diabetes and 
cardiovascular disease at BMIs lower than the recommended WHO cutoff point for overweight 
(≥25 kg/m2). However, available data do not indicate a clear BMI cutoff point for all Asians 
who are overweight and obese. The cutoff point for observed risk varies from 22 to 25 kg/m2 
in different Asian populations; for high risk it varies from 26 to 31 kg/m2.  
 
Globally, it was estimated by WHO (2008) that more than 1 billion adults 20 years or older 
were overweight (body-mass index [BMI] ≥25 kg/m2) and more than 500 million were obese 
in 2008 (BMI ≥30 kg/m2). The International Obesity Task Force estimates that at present at 
least 1·1 billion adults are overweight, including 312 million who are obese (James et al. 
2004b). Figure 3.1 shows the average regional prevalence of obesity (not including overweight) 
by age and sex in the subregions of the world. These estimates, based on measured BMI in 
appropriate population samples, show that the only region in which obesity is not common is 
sub-Saharan Africa as a whole (Ezzati et al. 2005; James et al. 2004a). Excess bodyweight is 
now the sixth most important risk factor contributing to the global disease burden (Ezzati et al. 
2002). At all ages and throughout the world, women are generally found to have a higher mean 




According to WHO’s (2009) estimation, average BMI is highest in the Americas, Europe, and 
the Eastern Mediterranean. In the USA, more than 70% of men and 60% of women were 
overweight or obese in 2003–04 (Ogden et al. 2006). In women, obesity is more common than 
overweight, demonstrating a marked skewness in the distribution of body-mass index (BMI). 
Ethnic differences in the prevalence of obesity showed that about 3% of non-Hispanic Whites 
are severe obese, as well as more than 5% of non-Hispanic blacks and about 2% of Mexican 
Americans (Ogden et al. 2006). Pleis et al. (2010) showed that the prevalence rate of obesity 
was 26.8% for women and 27.6% for men in 2009 in the USA. The prevalence of obesity in 
Canada is much lower than in the USA. A study showed an increase in the prevalence of obesity 
from 9% in 1981 to 14% in men in 1996, and in women, the figures were 8% in 1981 increasing 
to 12% in 1996 (Tremblay et al. 2002).  
 
 
Figure 3.1. Prevalence of obesity worldwide, by age and sex (derived from Haslam and 
James [2005]) 
Doak et al. (2012) investigated the recent prevalence of overweight and obesity in Europe. This 
research was conducted on adults aged between 25 and 64 years in the period 1985–2005 in 
the 53 countries of the WHO European Region. In England, the proportion of men who were 
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overweight increased from 62·4% in 1991–95 to 70·9% in 2001–05, and the obesity rate 
increased from 15·6% in 1991–95 to 24·4% in 2001–05. In women, the figures for overweight 
were 50·0% in 1991–95, increasing to 57·2% in 2001–05, and obesity increased from 17·9% 
in 1991–95 to 24·3% in 2001–05. The increase in risk of death with each unit increase in BMI 
declines progressively with age but remains substantial until the age-group of 75 years and 
older (Stevens et al. 1998). Thus, the UK Government now estimates that a BM'I of 25.0 kg/m2 
decreases the life expectancy of English men by two years and, given the progressive epidemic 
of obesity, the effect will increase to five years by 2050 (DoH 2004).  
 
Romero-Corral et al. (2006) conducted an analysis of 40 studies including 250,000 people. 
Patients with BMI in the normal range were at higher mortality risk from cardiovascular disease 
than were people whose BMIs put them in the overweight range (BMI 25–29·9 kg/m2). 
Moreover, high cardiovascular mortality in patients in the study who were underweight (BMI 
<20 kg/m2) or severely obese (BMI >35 kg/m2) is growing. However, this finding is subject to 
confounding factors including many chronic diseases—for example, diabetes, which caused 
weight loss before eventual death. In view of this factor, higher mortality rates among slimmer 
people would be the expected result (Khalangot et al. 2009). 
 
The simplicity of this method makes it ideal because the calculation requires only height and 
weight and it is inexpensive and easy to use for clinicians and for the general public. The use 
of BMI allows a person to compare their own adiposity status to that of the general population. 
Also, BMI correlates well with morbidity and mortality (Iacobellis 2009). However, the 
correlation between BMI and adiposity varies with sex, race, and age (Gallagher et al. 1996). 
BMI does have limitations in that, chiefly, it does not calculate the percentage of body fat. The 
NICE guideline (2006b) has generally acknowledged some limitations of the BMI model. BMI 
is dependent on weight and height, on the basis of distribution of muscle and bone mass, it 
could thus overestimate adiposity on individuals with more lean body mass such as athletes, 
while underestimating adiposity on those with less lean body mass such as the elderly people. 
In conclusion, BMI is merely an indicator of body fatness. It is simple to measure BMI. Also, 
the measurement of BMI is accurate and helpful in population surveillance and monitoring of 
trends in the prevalence of obesity. However, it needs to be remembered that BMI cannot 
distinguish between individuals who have a similar build but significant differences in regional 
body fat distribution and fat content.  
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3.4.2 Waist measurement 
 
BMI does not distinguish between mass due to body fat and mass due to muscular physique. It 
also does not consider the distribution of fat. Therefore, it has been postulated that waist 
circumference could be a better measure than BMI to identify those with a health risk from 
being overweight (HSE 2008). Waist circumference provides an estimate of body girth at the 
level of the abdomen.  
 
In accordance with the definition of abdominal obesity used by the US National Institutes of 
Health (NIH 2001) Adult Treatment Panel (ATP) III, a raised waist circumference is greater 
than 102 cm in men and greater than 88 cm in women. These levels identify people at risk of 
metabolic syndrome, a disorder characterised by increased risk of developing diabetes and 
cardiovascular disease. Given the fact that cardiovascular risk varies significantly with 
ethnicity, waist circumference is a helpful index of visceral adiposity among different racial 
groups. However, because of the significant differences in body size among different ethnic 
groups, specific high-risk waist circumference values have been proposed for each ethnic 
group, as summarised in Table 3.1. 
 
Table 3.1: Ethnic-specific values for waist circumference 
Country or ethnic group Men Women 
European ≥94 cm ≥80 cm 
South Asian, Chinese ≥90 cm ≥80 cm 
Japanese ≥85 cm ≥90 cm 
South and Central American Use South Asian cutoff points until more 
specific data is available 
Sub-Saharan African Use European cutoff points until more 
specific data is available 
Eastern Mediterranean and Middle East 
(Arab) 
Use European cutoff points until more 
specific data is available 
 
In conclusion, waist circumference is a surrogate marker of visceral adiposity. It is a helpful 
tool in the clinical management of patients with increased visceral fat and increased 
cardiovascular risk who do not necessarily fit into the obese categories as defined by BMI. It 
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might be subject to operator variability and might lose sensitivity in severely obese patients. In 
some ethnic groups, such as Chinese and South-Asians, waist circumference is a better 
indicator of relative disease risk than BMI (Iacobellis 2009). Ethnic and age-related differences 
in body fat distribution can modify the predictive validity of waist circumference. 
 
3.4.3 Waist-hip-ratio (WHR) 
 
A WHR of 0·95 or higher in men or 0·8 or higher in women indicates increased cardiovascular 
risk. WHR is a powerful independent predictor of hypertension, diabetes, and coronary heart 
disease.  
 
In Japanese-American men aged 71–93 years, Kalmijn et al (1999) found a positive association 
between quintiles of WHR and all-cause mortality, whereas quintiles of BMI were negatively 
related to all-cause mortality. Larsson and colleagues (1984) found that in men aged 54 years, 
mean WHR was higher in those who died than in those who survived a period of 4.5 years 
follow-up. However, a large WHR might not only reflect a large waist circumference, but also 
a small muscle area in the thigh measured, as shown by computed tomography (Seidell et al. 
1989). Seidell et al (2000) also found that lean body mass was associated with decline of age 
in elderly population. The waist circumference is easier to interpret than WHR, especially in 
the elderly (Allison et al. 1995). Hip circumference reflects femoral and gluteal subcutaneous 
fat. Hip circumference in women can be explained mostly by variations in gluteal fat mass and 
pelvic width, whereas in men, muscle mass can be the main determinant of hip circumference. 
 
3.4.4 Combined assessment of health risk from obesity 
 
BMI is widely used in epidemiological studies to assess the risks of health outcomes associated 
with different levels of body weight. However, it does not measure body composition directly. 
Obesity refers to an excess of body fat. The underlying assumption of using BMI to define 
obesity is that at a given height, higher weight is associated with increased fatness (Benn 1971). 
However, BMI is an imperfect measure of body fatness, as it does not directly measure fat mass 
(Roche et al. 1981; Wellens et al. 1996). Some studies suggested that waist circumference, 
either alone or in combination with BMI, may have a stronger relation to smoking, obesity and 
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mortality, than BMI alone (Bigaard et al. 2003; Bigaard et al. 2005; Janssen et al. 2004; 
Visscher et al. 2001).  
 
In the National Health and Nutrition Examination Survey (NHANES) data, Flegal and 
colleagues (2009) conducted a study of comparison of percentage body fat, body mass index 
and waist circumference in adults over 20 years old. They found that both BMI and waist 
circumference has a similar relation to percentage body fat and both were more highly 
correlated with each other than with percentage body fat. However, limitations were that 
percentage fat was based only on dual-energy X-ray absorptiometry (DXA) measurements, 
which was normally requires specialised DXA systems and X-ray exposure, and not on more 
complex body-composition models; waist circumference was measured just above the iliac 
crest, which might limit the comparability of the results with waist circumference measured in 
other anatomic locations. Also, there is question about the validity of the assumptions on the 
missing data. Finally, they concluded that BMI, waist circumference, and percentage body fat 
were all closely related, and, as percentage body fat increases, BMI and waist circumference 
increase. For men, waist circumference agreed slightly better than did BMI with categories of 
percentage fat. For women, BMI was associated with categories of percentage fat better than 
did waist circumference. 
 
The UK guidelines issued by NICE (2006b) currently state that it is important to use both BMI 
and waist circumference in adults with a BMI less than 35 kg/m2 when assessing health risks 
associated with overweight and obesity, which is shown below in Table 3.2. 
 
Table 3.2: BMI classification (HSE 2008) 
BMI classification  
Waist circumference 
Men 94 cm (37 
in) or less 
Women 80 cm 
(31.5 in) or less 
Men 102 cm (40 
in) or less 
Women 88 cm 
(35 in) or less 
Men > 102 cm 
(40 in) 
Women > 88 
cm (35 in) 
Underweight (<18·5 kg/m2) No increased risk No increased risk No increased risk 
Normal BMI (18·5 to less than 25 kg/m2) No increased risk  No increased risk Increased risk 
Overweight (25 to less than 30 kg/m2) No increased risk Increased risk High risk 
Obesity I (30 to less than 35 kg/m2) Increased risk High risk Very high risk 
Obesity II (35 to less than 40 kg/m2) High risk Very high risk Very high risk 









Blood pressure is a result of the pumping action of the heart and the resistance of the vessels, 
through which the blood flows. Blood pressure varies during the day. It is normally highest 
around lunchtime or after exercise and lowest when people are resting or sleeping. Blood 
pressure is quoted as two numbers, the first number known as systolic blood pressure (SBP), 
the second as diastolic blood pressure (DBP). SBP is defined as the peak pressure in the arteries, 
which occurs near the beginning of the cardiac cycle when the ventricles are contracting; DBP 
is the lowest pressure during the resting phase of the cardiac cycle. 
 
In Hutton’s study, patients were classified (Table 3.3) into one of five groups on the basis of 
their SBP and DBP readings. The last three categories together are considered as 
hypertensive.  
 
Table 3.3: Classification of blood pressure for adults (Hutton et al. 2008) 
Classification of blood pressure for adults 
Category SBP (mm Hg) DBP (mm Hg) 
Hypotension <90 <60    
Normal  90–119 60–79    
Pre-hypertension 120–139 80–89 
Stage 1 hypertension 140–159 90–99 





Since the late 1970s, the minimum blood pressure reduction for most patients with 
hypertension has been less than 140/90 mm Hg. The US National Heart, Lung and Blood 
Institute has issued several reports on high blood pressure (Chobanian et al. 2003; JNC 5 1993; 
JNC 6 1997). In its 7th report on the Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (Chobanian et al. 2003), the panel recommended an even lower rate for higher-
risk patients, including those with diabetes or chronic renal impairment, to less than 130/80 
mm Hg. The previous guideline (JNC 6 1997) recommended a target blood pressure of less 
than 125/75 mm Hg for patients with renal impairment and no more than a gram per day of 
urinary protein, which is no longer recommended. The American Heart Association guidelines 
(Rosendorff et al. 2007) have added patients with known coronary artery disease, carotid 
disease, peripheral arterial disease, or an abdominal aortic aneurysm and those with a calculated 
10-year Framingham Risk Score of 10% or more to the group of high-risk patients with a blood 
pressure target of less than 130/80 mm Hg.  
 
If an individual’s blood pressure reading is consistently 140/90 mm Hg or above, this is 
considered high blood pressure and treatment is required. The high blood pressure reading can 
be either a systolic reading of 140 mm Hg or above, a diastolic reading of 90 mm Hg or above, 
or both. The target for the general population is to have a controlled blood pressure below 
140/85 mm Hg. The latest guidelines from the British Hypertension Society (Williams et al. 
2004) define blood pressure of 130/85 mm Hg or below as normal but say that 120/80 mm Hg 
is optimum. A blood pressure of 140/90 mm Hg is the typical level used to classify high blood 
pressure. Several European guidelines have been developed, and are mostly consistent with the 
requirements set by WHO/International Society for Hypertension, who set 150/95 mmHg as 
the threshold for treating low-risk patients, but lower this threshold to 130/85 mmHg for those 







Hypertension is the second most important preventable cause of premature death in developed 
countries (WHO 2002a). Most hypertension patients have a blood pressure above the treatment 
goal of less than 140/90 mm Hg. Hence, uncontrolled hypertension can be regarded as a 
rampant but treatable risk factor. Although hypertension is common, its prevalence has not 
changed significantly in recent years. However, in the past 20 years, detection, treatment, and 
control of high blood pressure has progressively improved (Table 3.4). In the 1990s, however, 
there was an apparent levelling of effect in the USA, with many still unaware and ineffectively 
treated (Chobanian et al. 2003; Luepker et al. 2006). The estimation from National Institute 
for Health and Clinical Excellence (NICE) in the UK noted that 40% of adults in England and 
Wales have hypertension, using the threshold of 140/90 mm Hg (NICE 2006).  
 
Table 3.4: Trends in awareness, treatment, and control of high blood pressure in adults with 
hypertension aged 18–74 years* (Chobanian et al. 2003) 
 National Health and Nutrition Examination Surveys, 
weighted % 
 1976–80 1988–91 1991–94 1999–2000 
Awareness 51 73 68 70 
Treatment 31 55 54 59 
Control† 10 29 27 34 
*Data from the National Heart, Lung, and Blood Institute and date for National Health and Nutrition 
Examination Surveys 
†Systolic blood pressure less than 140 mm Hg and diastolic blood pressure less than 90 mm Hg 
 
The origins of high blood pressure are not well understood, however, associations with obesity, 
physical inactivity, salt intake, and alcohol intake suggest that behavioural factors play an 
important part. For example, overconsumption of salt causes up to 30% of all cases of 
hypertension (Joffres et al. 2007). Genetic factors are also apparent, but the high prevalence of 
hypertension suggests that any hereditary characteristics are very common in most populations. 
Also, in view of increasing life expectancy of the ageing population, it is expected that 




3.5.3 Measuring blood pressure 
 
An accurate reading requires that a participant not drink coffee, smoke cigarettes, or engage in 
exercise for about 2–3 hours before measuring their blood pressure. It also requires emptying 
of the bladder before the reading, since there might be an effect on blood pressure 
measurement. A systematic review compared trials of using BP lowering strategies conducted 
by Lv and colleagues (2012) has shown that the more intensive strategies reduced the BP of 
participants by 7.5/4.5 mmHg more than the less intensive strategies on average; more intensive 
BP lowering strategies reduced the risk of major cardiovascular events (a composite endpoint 
comprising heart attack, stroke, heart failure, and cardiovascular death) by 11%, the risk of 
heart attack by 13%, the risk of stroke by 24%, but did not have any clear impact on the risk of 
death or serious adverse events. 
 
3.5.4 Causes of high blood pressure 
 
Anyone can develop high blood pressure and its causes might be idiopathic and therefore 
unknown. Hypertension is the diagnosis for patients with persistent high blood pressure. A 
family history of high blood pressure plays a very large part in who does and does not develop 
high blood pressure. Generally speaking, at least half of the variance in blood pressure within 
large groups of people can be predicted from knowledge of blood pressure in parents, brothers, 
and sisters (Hart et al. 2000).  
 
Stress can cause a large rise in blood pressure, lasting minutes or even hours (Rainforth et al. 
2007). Such rises are normal and occur in everyone. They are brief additions to the usual 
average pressure, whether this pressure is high or low. The factors can also cause hypertension 
if being of Afro-Caribbean or South Asian origin, being obese, lacking of exercise, smoking, 
having excessive alcohol or salt consumption, and having high fat diet (Chaturvedi et al. 2012; 




3.5.5 Prevention of hypertension  
 
Lifestyle modifications including weight, exercise, and diet have the potential to prevent 
hypertension. They have also been found to be effective at lowering moderate hypertension 
with little risk and minimum cost. Although modification of lifestyle factors alone might not 
control high blood pressure, it could help to reduce the amount of antihypertensive drugs taken 
by the patient (Neaton et al. 1993). Excess bodyweight is associated with raised blood pressure. 
Weight reduction can reduce blood pressure in obese individuals with hypertension (Neaton et 
al. 1993); therefore, weight reduction is an important part of hypertension control. Recent 
research suggests that a diet lower in fat and higher in fruits and vegetables also results in lower 
blood pressure among people with mild hypertension (Krauss et al. 1998). Dietary fats, 
especially saturated fats, induce a rise in systolic and diastolic blood pressures as well as 
hypercholesterolaemia, as shown in the Dietary Approaches to Stop Hypertension (DASH) 
trials (Appel et al. 1997). Energy-dense diets rich in fats and refined sugars promote weight 
gain, and high sugar intakes also induce increases in blood pressure of 6·9 mm Hg (systolic) 
and 5·3 mm Hg (diastolic) (Drewnowski 1998; Raben et al. 2002; Stubbs et al. 1995). Energy 
density is reduced by higher intake of fruit and vegetables, which the DASH trial also showed 
lowered blood pressure.  
 
Salt intake is particularly relevant to hypertension. Population surveys demonstrate strong 
association between population blood pressure and salt intake (INTERSALT Cooperative 
Research Group 1988). Migration studies where salt intake is greatly increased among people 
who migrate from low to high salt cultures is associated with increasing prevalence of 
hypertension (Joseph et al. 1983). Despite widespread information about the role of salt, 
considerable debate remains. The US National Dietary Goals recommend no more than 6 g of 
sodium chloride daily (Chobanian et al. 2003), but still well below the average intake. As the 
consumption of processed food increases, salt will play an increasing part in hypertension. The 
challenge, therefore, is to assess the contribution of weight gain as distinct from that 
attributable to dietary factors including salt (Sacks et al. 2001). 
 
Physical inactivity also plays an important part in hypertension, with overweight individuals 
having up to 50% increased risk of developing high blood pressure. Moderate physical activity 
could control weight and potentially lower blood pressure (NIH 1996). Dietary factors also 
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have a role in precipitating or reducing hypertension. Alcohol consumption raises blood 
pressure. The National High Blood Pressure Education Programme recommends consumption 
of no more than 30 ml of ethanol as beer, wine, or whisky per day for men and 15 ml per day 
for women (Chobanian et al. 2003). 
 
There was debate over the generalisability of hypertension trials to older adults and other 
groups; it is generally believed that the whole population will benefit from blood pressure 
lowering. Many medications are currently available for hypertension treatment; however, 
diuretics are recommended for initiating treatment because they have the longest clinical trial 
experience and a proven record of reducing morbidity and mortality in clinical trials 
(Chobanian et al. 2003; Furberg 2002).  
 
3.5.6 Treatment of hypertension 
 
An individual is unlikely to require treatment if he or she has a naturally low blood pressure. 
If an individual has postural hypotension, his or her treatment will depend on the underlying 
cause. For example, if a patient is on a drug that lowers blood pressure that had too strong 
effect, the doctor might switch the patient to a different type of drug to control the blood 
pressure. Diuretics and α blockers are examples of drugs that cause a dramatic drop in blood 
pressure. Most blood pressure drugs only lower the pressure back to normal. A slight reduction 
of SBP in adults of 2 mm Hg would save more than 14,000 lives per year in the UK (Critchley 
et al. 2003). 
 




Cholesterol is an essential component of cell membranes, steroid-based hormones, and the bile 
acid that is produced by the liver. It is the main constituent of atheroma, which is deposited 
inside arterial walls and forms plaques. Cholesterol is required by the body to maintain health, 
and is found in the daily diet in meat, poultry, fish and other seafood, and dairy products, 




Cholesterol is a lipid and cannot travel around the body unchaperoned, and thus it is carried 
around the body by proteins. These combinations of cholesterol and proteins are called 
lipoproteins. They are classified according to their density, and there are five components: 
 
 Chylomicrons: these are the largest, and they contain the highest concentration of lipid. 
 Very-low-density lipoproteins (VLDL): made in the liver. 
 Intermediate-density lipoproteins (IDL) 
 Low-density lipoproteins (LDL; commonly known as LDL-cholesterol): made in the 
plasma   
 High-density lipoproteins (HDL; sometimes called HDL-cholesterol): these are the 
smallest, and they contain the lowest concentration of lipid; HDL maintains 
cardiovascular health, preventing the narrowing of the arteries (atherosclerosis) 
deposited by removing cholesterol from arteries to be disposed by the liver 
 
The results from the Health Survey for England (HSE) 2006 showed that, although the 
prevalence of raised cholesterol concentrations is falling, cholesterol concentrations are still 





Keys and colleagues (1984) found that individuals with high cholesterol concentrations have 
increased risk of suffering from atherosclerosis and coronary heart disease compared with 
individuals with low cholesterol. Moreover, Stamler and colleagues (1986) found that the 
higher the level of cholesterol, the greater the risk of a coronary event. Furthermore, the 
principal determinants of blood lipid concentrations are dietary intake of cholesterol, 
polyunsaturated fat, and saturated fat (Clarke et al. 1997; Hegsted et al. 1993; Keys et al. 1957), 
although cholesterol concentrations are also affected by reduced energy intakes resulting in 
weight loss and genetic and other factors (Dattilo and Kris-Etherton 1992; Goldstein and 
Brown 1977). Much of the international variation in cardiovascular disease rates is therefore 
dietary in origin. Metabolic ward studies suggest that, in a typical western diet, replacing 60% 
of saturated fat intake by monounsaturated or polyunsaturated and avoiding 60% of dietary 
cholesterol would reduce blood total cholesterol (mainly LDL cholesterol) by about 10–15% 
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(typically about 0·8 mmol/L; Clarke et al. 1997). At a population level, this difference would 
be associated with about a 40% reduction in coronary disease in middle-aged patients 
(Lewington et al. 2007). Individualised intensive dietary advice has a more modest effect in 
free-living participants with typical reductions of about 6% in blood cholesterol, which tend to 
decrease over time (Tang et al. 1998). Moreover, reduction of LDL is the primary target for 
cardiovascular prevention, and statin-induced lowering of LDL has been shown to reduce the 
cardiovascular disease risk by about 30%. 
 
3.6.3 Causes of high cholesterol  
 
Saturated fat encourages the body to make more cholesterol than it needs or can eliminate. A 
cigarette smoker has about twice the risk of having a heart attack compared with a non-smoker. 
A smoker with high blood pressure and high cholesterol increases the chances of suffering a 
heart attack by more than eight times.  
 
Other health conditions—for example, unsuccessfully controlled diabetes, certain kidney and 
liver diseases, and an underactive thyroid gland—could also cause high cholesterol. Some 
medicines such as β blockers, steroids, or thiazides (a type of diuretic) could also affect 
cholesterol levels (Indian Polycap Study [TIPS] 2009; Maron et al. 2010; Rosenstock et al. 
2008; Rucker et al. 2007; Van Gaal et al. 2008). 
 
3.6.4 Measuring lipid levels 
 
LDL-cholesterol can be calculated indirectly by measuring total cholesterol, HDL-cholesterol, 
and triglycerides from a fasting venous blood sample and applying the Friedewald equation: 
LDL (mmol/l) = total cholesterol – HDL – (triglycerides/2·2) (Friedewald et al. 1972). This 
method is not suitable for individuals with triglyceride levels higher than 5mmol/L. It is 
desirable to have a total cholesterol level less than 5mmol/l and an LDL level under 3 mmol/l 
on the basis of current UK guidelines (HSE 2008). 
 
With respect to estimation of the risk of developing cardiovascular disease, the best indicator 
is the ratio of total cholesterol to HDL. A lower ratio is desirable, because this indicates that a 
person has high levels of HDL. For greatest accuracy, 12-hour fasting samples are required as 
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HDL-cholesterol and triglycerides levels vary between fasting and non-fasting states. HDL-
cholesterol is lower by 5-10% in the non-fasting state than in the fasting state and triglyceride 




High cholesterol is a major risk factor for cardiovascular disease, but it can be better controlled 
by a good diet and being physical active. The first approach in lowering cholesterol levels is to 
adopt an alternative diet. Most people can reduce their cholesterol level by 15–20% by reducing 
their intake of foods that are high in cholesterol and fat, especially saturated fat. The recognition 
that usual food intake is a behaviour strongly related to culture and food availability has 
resulted in community-based public health strategies to improve dietary intake. The North 
Karelia and Stanford Three Town Studies were among the first to use public and health 
professional education about dietary fat to reduce cholesterol level (Farquhar et al. 1977; Puska 
et al. 1995). In both studies, an improved eating pattern with reduced saturated fats resulted in 
reduced average cholesterol levels in these small communities. Larger studies in medium-sized 
cities in Europe and the USA showed similar results. Strong favourable secular trends in control 
communities resulted in modest differences in cholesterol levels (GCP Research Group 1998; 
Farquhar et al. 1990; Luepker et al. 1994; Carleton et al. 1995).  
 
Blood cholesterol levels continue to be predictive in adults older than 65 years, although the 
relative risk is reduced (Abbott et al. 1997). Blood cholesterol can be lowered in adults with 
moderate changes in diet and loss of weight. A progressive fall reported in blood cholesterol 
levels in the USA was associated with changes in the habitual diet during the past 25 years 
(Carroll et al. 2005; Arnett et al. 2005). 
 
Evidence from a meta-analysis including 90,056 participants in 14 randomised trials of statin 
therapy showed that a 1·0 mmol/L reduction in LDL cholesterol reduced the 5-year relative 
risk of a major vascular event by 21%, irrespective of sex, age, blood pressure, pre-existing 
diabetes, or history of a previous vascular event (relative risk 0·79, 95% CI 0·77–0·81; 
p<0·0001; absolute risk reduction 3·7%; Baigent et al. 2005). A number of large secondary 
prevention trials using statin therapy to lower cholesterol have also been completed, including 
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the Scandinavian Simvastatin Survival Study (Scandinavian Simvastatin Survival Study 1994). 
It demonstrated a significant reduction in all-cause mortality, coronary heart disease mortality, 
coronary events, and revascularisation procedures in patients with known coronary heart 
disease. The Cholesterol and Recurrent Events trial and the Long-Term Intervention with 
Fibrostatin in Ischaemic Disease trial also demonstrated cholesterol reductions associated with 
fewer major coronary events (Sacks et al. 1996; LIPID Study Group 1998). The MRC/BHF 
Heart Protection Study resulted in a 25% reduction in cardiovascular events with simvastatin 
in 20,536 high-risk patients (Collins et al. 2002) 
 
3.6.6 The benefits of lowering cholesterol for cardiovascular risk 
 
There is consistent evidence from clinical trials of the benefits of reduced total cholesterol and 
LDL cholesterol. There is also a suggestion that raising HDL cholesterol adds to these 
beneficial effects. A Finnish trial in men with known coronary heart disease resulted in a 
significant reduction of coronary events associated with increased HDL cholesterol and 
decreased triglycerides. Total cholesterol results were variable (Frick et al. 1987). A more 
recent treatment study of men with average total cholesterol but high LDL cholesterol with 
gemfibrozil also produced positive results. HDL cholesterol increased in the treatment group 
compared with placebo. Coronary events were reduced. Serum triglycerides also fell 
significantly, raising questions about the relative importance of the two lipid effects (Rubins et 
al. 1999). 
 
Several trials have showed that reducing cholesterol levels decreases fatal and non-fatal 
myocardial infarction without increasing death from other causes. An 11% reduction in total 
cholesterol is associated with a 23% decrease in cardiovascular events. However, even a strict 
low-fat diet might result in only a 5% reduction in total cholesterol levels (Aron 2004; Handler 
2004). 
 
In more recent randomised control trials of lipid lowering, LDL has been targeted for therapy. 
In patients with and without cardiovascular disease, trials have specified the degree of relative 
risk reduction for major coronary events using statin therapy. The risk reduction could be 
achieved from a given lowering of LDL. Evidence showed that relative risk for major coronary 
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events is reduced by approximately 1% for every 1% reduction in LDL cholesterol levels 
(ALLHAT Offices and Coordinators for the ALLHAT Collaborative Research Group 2002; 
Heart Protection Study Collaborative Group 2002; Shepherd et al. 2002; Sever et al. 2003). 
 
The National Service Framework (NSF 2000) published guidelines for those with, or at high 
risk of developing, cardiovascular disease, giving a treatment threshold for total cholesterol at 
5·0 mmol/l, The Joint British Societies produced their second national treatment guidelines 
(JBS 2) for those at risk of cardiovascular disease in December 2005 (JBS2 2006). High risk 
individuals were recommended a lower cholesterol level threshold of 4·0 mmol/l. In January 
2006, NICE published its Health Technology Appraisal of statins, which found that they were 
both clinically and cost effective for patients at risk of developing cardiovascular disease 
(NICE 2007). NICE is currently developing Clinical Guidance for the primary and secondary 






Smoking is defined as a practice where a substance, most commonly tobacco, is burned and 
the smoke tasted or inhaled. The most common method of smoking today is through cigarettes. 
It is primarily manufactured by industries, but also hand-rolled from loose tobacco and rolling 
paper. Other forms, though not as common, are pipes, cigars, hookahs, and bongs (Slovic 2001; 
WHO 2002a). 
 
Smoking is one of the most common forms of recreational drug use. Tobacco smoking is the 
most popular form of smoking and is practised by over 1 billion people across the world 
(Neovius et al. 2009). Every day more than 1 billion people smoke or chew tobacco because 
of their addiction to nicotine, and about 15 000 die from tobacco-related diseases; tobacco use 
accounts for half the health inequalities, as assessed by education, in male mortality (Jha et al. 
2006). Tobacco use has fallen in many high-income countries, at least in men, but is now rising 
rapidly in many low-income and middle-income countries with a prevalence of more than 25% 
in adolescents in some countries. This rise is due to the tobacco industry's uncontrolled 
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activities and persistent efforts to influence and weaken tobacco control policies (Freeman and 




The World Health Organization (WHO) states that much of the disease burden and premature 
mortality contributed to tobacco use excessively affect low-income individuals. Of the 1·22 
billion smokers, 1 billion of them live in low-income and middle-income countries (Mackay et 
al. 2002). While up to 30% of men are former smokers in industrial countries, only 2% of men 
from China have quit, and 10% in Vietnam (WHO/WPRO-Tobacco 2007). Rates of smoking 
have stabilised or declined in high-income countries; the rate in the USA lowered by half from 
1965 to 2006, from 42% to 20·8%, in adults (Rock et al. 2007). From 2002, the consumption 
of tobacco has risen at a rate of 3·4% per year in high-income countries (WHO 2008b). 
 
The prevalence of smoking is estimated around 30% of the adult population worldwide (47% 
in men and 12% in women; Mackay et al. 2002). If the growth dropped from the current rate 
by 1% per year, there is a net growth of 2%, which would lead to an estimated number of 
smokers of 1·3 billion between 2010 and 2025 (Guindon et al. 2003). 
 
Smoking was generally five times higher among men than women in the 1990s (Guindon et al. 
2003), however the gender gap is smaller at younger ages (CDC 2001; WHO 2002b). As of 
2002 in China, 67% of men smoke and 4% of women; however, among teens the gap closes to 
33% among men and 8% in women (WHO 2002b). In developed countries, smoking rates for 
men have peaked and have begun to decline; however, for women they continue to climb (Peto 
et al. 2006). 
 
An estimated 13 million people smoke in the UK, with an equal proportion of males and 
females. In 2006, it is reported that 24% of men and 21% of women smoked smoking cigarettes. 
Prevalence of cigarette smoking differs by sex and by age, and is highest among men aged 25–
34 years, which accounts for 34%, and among females aged 16–24 years, which accounts for 
28% (HSE 2008). It is becoming more and more common in younger generations, so it is 
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important to start education at school-age, with particular focus on prevention programmes 
(Kmietowicz 2008), because it can become an addiction shortly after developing the habit. 
 
Research has showed that middle-aged men who smoke more than 20 cigarettes a day have a 
two to three times higher risk of a major cardiac event compared with non-smokers of the same 
age (Byberg et al. 2009). The risk of developing coronary heart disease (CHD) is dose related. 
Smoking raises blood pressure, which can cause hypertension – a major risk factor for heart 
attacks and stroke. The cardiovascular morbidity and mortality risks for women are similar to 
those for men, but the risk of fatal myocardial infarction is 13 times higher if they use the oral 
contraceptive pill (Wilson et al. 2000). 
 
It is estimated that 114,000 deaths in England per year are directly attributable to smoking and 
30,600 die from cardiovascular disease (HSE 2008). The government is committed to reducing 
the number of people smoking; the target set for smoking rates among adults should be 21% 
or less by 2010, with a reduction in prevalence among manual group to 26% or less (HSE 
2008). It is widely recognised that levels of smoking vary between different socioeconomic 
groups; it is more prevalent in those of lower socioeconomic class and lower educational status 
(Townsend et al. 1998). In 2004, the government set out its strategy to tackle smoking, its 
effects other people in the white paper, Choosing Health (DoH 2004). The report contained a 
number of initiatives to reduce smoking prevalence and announced a commitment to 
establishing smoking-free public places. 
 
Smoking is the single largest cause of death, disability, preventable illness and unnecessary 
health expense in the UK (Handler 2004). It is approximately caused 17-30% of all 
cardiovascular deaths (Lyratzopoulos et al. 2006). It has showed that the lifespan would be 
shortened by the smoking to an estimated 10 years. About 50% of smokers die of a smoking-
related illness (Lyratzopoulos et al. 2006; HSE 2008). 
 
The risk of CHD falls by 50% one year after cessation, and after four years it is similar to that 
for a person who has never smoked (Peto et al. 2000). This benefit also applies to smokers 
aged over 60 years (Aveyard et al. 2007). Smoking cessation should be the main focus of risk 
reduction for patients with vascular disease, and should be managed like heroin and cocaine 
addiction. Stopping smoking reduces the 10-year risk of deaths by over half (from 54% to 18%) 
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(Aveyard et al. 2007). It is the single most important intervention conferring the greatest 
symptomatic and prognostic benefit. Table 3.5 below shows the timeline of health benefits 
after stopping smoking. 
 
Table 3.5: Timeline of health benefits after stopping smoking (WHO 2002b; WHO/WPRO 
2007) 
After... Health Benefit... 
72 hours 
Breathing becomes easier. Bronchial tubes begin to relax and energy levels 
increase 
1 month Skin appearance improves owing to improved skin perfusion 
3–9 
months 
Cough, wheezing, and breathing problems improve and lung function increases 
by up to 10% 
1 year Risk of a heart attack falls to about half that of a smoker 
10 years Risk of lung cancer falls to about half that of a smoker 
15 years Risk of heart attack falls to the same level as someone who has never smoked 
 
3.8 SHARED RISK FACTORS AND THEIR CAUSES 
 
The main risk factors for cardiovascular disease for individuals are well known and are similar 
in all countries. Tobacco use, foods high in saturated and trans fats, salt, and sugar (especially 
in sweetened drinks), physical inactivity, and the harmful consumption of alcohol contribute 
to more than one-thirds of all new cases of cardiovascular disease and increase the risk of 
complications in people with cardiovascular disease (Yusuf et al. 2004).  
 
Changes in the social and economic environment have resulted in the risk factors for 
cardiovascular disease becoming widespread (Geneau et al. 2010). Socioeconomic factors have 
been recognised as playing a major role in both developed and developing countries.   
 
In conclusion, the prevalence of cardiovascular disease is high in the UK—over 3 million 
people currently suffer from this disorder. Although the burden of cardiovascular disease is 
large, 80–90% of premature cardiovascular mortality is preventable. At the same time, dietary 
risk factors for high blood pressure, cholesterol and obesity, coupled with insufficient physical 
activity, are responsible for an increasing proportion of the cardiovascular disease burden. In 
the chapters 3 & 7, it will examine the prevalence of these cardiovascular risk factors (above 
mentioned) in affluent UK populations both from the private medical insurance company and 
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NHS Trust. In the following section, we will look at the prevention of cardiovascular disease 
and associated risk factors. 
 
3.9 INTERVENTION STRATEGIES  
 
3.9.1 Tobacco control 
 
Cardiovascular disease is the most common smoking-related cause of death, especially in the 
age range between 35 and 69 years, in which 25% of deaths are attributable to tobacco (Doll et 
al. 2004). Mortality after myocardial infarction is lower in patients who stop smoking 
compared with those who continue smoking (CDC 2009). Furthermore, it declines dramatically 
after stopping smoking when assessing the risk of coronary events. The risk of such events is 
similar to that for individuals who have never smoked after 2–3 years of abstinence (Unal et 
al. 2005). 
 
In a health policy paper published by The Lancet, Beaglehole et al. (2011) suggested that the 
priority for immediate action is to achieve by 2040 of a world essentially free from tobacco 
where less than 5% of the population use tobacco. 5·5 million deaths over 10 years in 23 low-
income and middle-income countries with a high burden of cardiovascular disease and other 
non-communicable diseases could be saved if four of the Framework on Tobacco Control 
strategies are fully implemented (Asaria et al. 2007). This strategy will have immediate health 
and economic benefits as reduction in exposure to tobacco smoke, both direct and second hand, 
will reduce the burden of cardiovascular disease within one year and thus health expenditures 
(Lightwood and Glantz 1997; Sims et al. 2010)   
 
2.9.2 Salt reduction 
 
Reduction in salt consumption is the other top priority intervention strategy for cardiovascular 
disease because it will cause lower blood pressure, one of the main risk factors for stroke and 
heart disease. Reduction of population-wide salt consumption by only 15%—through mass-
media campaigns and reformulation of food products by industry—would avert up to 8·5 
million deaths in 23 high-burden countries over 10 years (Asaria et al. 2007). In the long term, 
the reduction in salt consumption will have a greater effect since reduced intake will decrease 
the age-associated higher blood pressure, and any small risk of iodine deficiency can be 
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addressed by other means (Verkaik-Kloosterman et al. 2010). Salt substitution in countries 
such as China, where much of the salt is added during cooking and eating, will be a useful 
strategy (CSSC Group 2007). As the consumption of processed foods rises in many countries, 
a change in the industry norms to reduce the addition of salt now will have important benefits 
in the future, although government regulation might be needed. Suggestion is to reduce 
worldwide salt intake to less than 5 g (or 2000 mg sodium) per person per day by 2025 (Cobiac 
et al. 2010; WHO 2007). 
 
3.9.3 Promotion of healthy diets and physical activity 
 
Physical inactivity is epidemic in most industrialised societies and is becoming more so in the 
developing world. There is considerable debate over public health recommendations for 
physical activity, including the amount, type, and duration of physical activity needed to obtain 
beneficial cardiovascular effects, as well as the issue of fitness. Finally, the association of 
vigorous physical activity with sudden death has increased concerns regarding advice. 
Considering these factors, several recommendations have emerged in recent years, however, 
only moderate cardiovascular gains accrue from this addition (NIH 1996). People need 
sufficient activity to increase the heart rate and breathing rate. Regular physical activity will 
lead to increased fitness; however, much of the association with fitness might be genetically 
determined rather than the result of training alone (Sofi et al. 2008). Nonetheless, observational 
study did show that physical fitness is associated with reduced rates of cardiovascular disease 
(Sofi et al. 2008).  Also important is that people have five portions of fruit and vegetables daily 
can protect against heart disease and stroke (Lancet 2010). 
 
Health policies in promoting physical activity and the consumption of foods low in saturated 
and trans fats, salt, and sugar—particularly sugar-sweetened drinks—will lead to wide-ranging 
health gains, including preventing overweight (especially in children), cardiovascular disease 
(Lock et al. 2005). The main interventions is to increase the price of high saturated food, 
industrially produced trans fats and sugar; food labelling; and marketing restrictions of 
unhealthy food products, specifically in children and young people (WHO 2004). All countries’ 
governments should make compulsory regulatory and fiscal measures for food industry to 
reformulate processed foods and stop the promotion of unhealthy products to children. 
Agricultural subsidies, and trade and capital market liberalisation have contributed to reduced 
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prices and increased availability of unhealthy products, and to the increasing rates of risks now 
noted among young people, leading to a rapid rise in the proportion who are overweight 
(Rayner et al. 2006). Modification of the built environment to promote physical activity also 
has the potential to prevent obesity, and although it would be more challenging initially, could 
rapidly advance as a co-benefit of climate control methods (Chow et al. 2009; Younger et al. 
2008). 
3.9.4 Reduction of harmful alcohol consumption 
 
Policies that affect the price, promotion, and availability of alcohol reduce alcohol-related 
harms (Anderson et al. 2009). Enforced legislation that reduces drink-driving, and 
interventions for at-risk drinkers are also effective. In countries with high amounts of 
unrecorded production and consumption, an important strategy is to increase the proportion of 
alcohol that is taxed; it requires effective policing of illegal and informally produced alcohol. 
The imposition of a tax based on alcohol content is an essential complement to increased taxes. 
In most countries, and globally, alcohol marketing and sponsorship are widespread and, as with 
tobacco, legislative responses are needed to reduce harmful consumption of alcohol. 
 
3.9.5 Access to essential drugs and technologies 
 
Universal access to affordable and good-quality drugs for cardiovascular disease is an 
important issue for all countries, and especially low-income and middle-income countries. This 
issue also arises in the treatment of HIV infection and AIDS; an integrated approach is needed 
for the treatment of all priority diseases with special attention to reducing inequalities 
(Beaglehole et al. 2011). 
 
The best evidence-based clinical approach in low-income and middle-income countries is a 
multidrug combination for people identified opportunistically in primary care as being at high 
risk of cardiovascular disease, or for patients who have already had a clinical event (Lim et al. 
2007). WHO has produced risk assessment charts that can be further simplified by removal of 
the need for a blood sample (Gaziano 2008; WHO 2010). Scale-up of this intervention would, 
over 10 years, avert 18 million deaths from cardiovascular disease in 23 high-burden low-
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income and middle-income countries at a cost of about US$1·08 per person per year (Lim et 
al. 2007).  
 
3.10 SOCIOECONOMIC STATUS 
 
3.10.1 Measurement of socioeconomic positions 
 
Socioeconomics is the study of the relationship between economic activity and social life (van 
Jaarsveld et al. 2007; Myint et al. 2009). It has emerged as a separate field of study in the late 
twentieth century (Rask et al. 2009). Socioeconomic status has been defined as a descriptive 
term for a person’s position in society, which may be expressed on an ordinal scale using such 
criteria as income, educational level obtained, occupation, value of dwelling place, etc.  
 
3.10.1.1 Occupation  
 
Occupational measures have been widely applied to research in public health. Occupation is 
categorised into defined ranks such as professional, managerial, clerical, non-manual and 
manual (Singh-Manoux et al. 2008). The use of occupational measures is limited by their lack 
of applicability to "economically inactive" people such as "home-keepers" (particularly 
women) and beneficiaries. The classification (Nordstrom et al. 2007; Rask et al. 2009) which 
is popularly used has been divided into the following grades: A (upper middle class) – 
professional or at director level; B (middle class) – senior management; C1 (lower middle 
class) – junior management and clerical; C2 (working class) – skilled; D (working class) – 
unskilled, manual labour; and E – those reliant on the state, such as pensioners and the long-
term unemployed. Occupation is one of the social determinants that is independently associated 
with cardiovascular risk factors (Gregory et al. 2007; McFadden et al. 2008). 
 
Although occupation as a measure of social class has been widely used in the public health 
research, it has several disadvantages (Kaplan and Keli 1993). First, considerable information 
should be collected about individual’s occupational history, it would be useful to reflect more 
than current occupation by classification, and easily identify the effect of disease. Moreover, 
although the same occupation, but in different organisations, it meant different social status. 
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For example, a chief executive officer of a large multinational corporation and a proprietor of 
a small family business would be the same rank in some systems, or a skilled manual worker 
might have an income that considerable exceeds a university professor’s income. Therefore, a 
classification on the basis of characteristics such as decision latitude, time pressure, intellectual 
discretion, and other job-related characteristics provided a better way of grouping occupations 
with respect to socioeconomic status. Second, there is a need for accurate rankings including 
rapid changes in the existence and status of new occupations, as well as those who do not work 
or who are housekeepers. Finally, socioeconomic status scales on the basis of prestige rankings 
could be faulted for their inherent subjectivity. 
   
3.10.1.2 Income  
 
Income-based measures exhibit consistently strong associations with health status (Nagpal et 
al. 2008; Schulz et al. 2008; Shaw et al. 2008). Measuring income is, however, “a complex 
process and these measures are unable to capture the socioeconomic circumstances of some 
population subgroups whose taxable incomes are prone to miscalculation”. Examples would 
include self-employed and retired people. Findings in a US survey by the National Health and 
Nutrition Examination showed that the prevalence of hypertension decreasing from the lowest 
to highest income groups. Similar findings were also found in Finnish men from three regions 




Educational measures are relatively less complex and tend to be fixed after young adulthood 
(Sainio et al. 2007). Roohafza and colleagues (2005) found a negative association between 
educational level and some cardiovascular risk factors such as cholesterol, blood pressure, and 
BMI, but no statistically significance was shown between smoking and educational level. A 
cross-sectional study assessed hypertension in an urban working population in Ghana showed 
negative association between the level of education and hypertension after controlling for the 
other measures of social indicators (Addo et al. 2009). Although educational measures can be 
used in most people, they do not discriminate adequately between population subgroups 
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(Reddy et al. 2007), e.g. the link between a given level of education and its "economic return" 




Using professional classification, Emberson et al. (2004) found that BMI was higher in manual 
than non-manual UK workers. Puslaw (2008) found that higher BMI values with decreasing 
professional classifications. Dragano et al. (2005) found that people having the least education 
were twice as likely to be obese than the most educated in Czech. This ratio was 1.6 in 
Germany. Stafford and colleagues (2010) found that residence in a more deprived 
neighbourhood contributed to a higher initial BMI when the study started. There was also a 
note that in this longitudinal, multilevel Whitehall II study of 13 years follow-up using the 
Townsend index of multiple deprivation at census-ward level, participants from the most-
deprived neighbourhoods experienced relatively greater weight gain over time, an increase of 
1.5kg/m2 in men and 1.4kg/m2 in women. Wang et al. (2007) gathered five cross-sectional 
surveys conducted by the Stanford Heart Disease Prevention Programme between 1979 and 
1990 and found that participants from low socioeconomic neighbourhoods had a higher mean 
BMI than those from high socioeconomic neighbourhoods, after adjusting for age, gender, 
ethnicity, individual-level socioeconomic status, smoking, physical activity and nutrition 
knowledge. Similar finding has also been assured in GLOBE study (van Lenthe and 
Mackenbach 2002) that odds ratios of BMI increased significantly with increasing 
neighbourhood deprivation, after adjusting sex. 
 
3.10.1.5 Area-level measures 
 
Chen and Tunstall-Pedoe (2005) conducted the Scottish MONICA survey in 2,233 men and 
2,516 women aged 25-64 years to investigate the relationship of waist circumference to 
socioeconomic deprivation, measured by Carstairs Index. In the cross-sectional survey, they 
also compared the relationship of waist circumference to WHR and BMI and found that large 
waist circumference has a closer relationship than WHR and BMI to the socioeconomic 
deprivation in men and women, although waist circumference, WHR and BMI increased with 
level of deprivation significantly in both sexes. The Kuopio Ischemic Heart Disease Risk 
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Factor Study found that after adjustment for smoking, hypertension, dyslipidemia, and diabetes 
resulted in a modest (24%) attenuation of the relative socioeconomic gradient of CHD risk, the 
most deprived groups are still have higher risks compared with those in the least deprived 
groups. These risk factors accounted for most (72%) of the absolute socioeconomic gradient 
(Lynch et al. 2006).  
 
3.10.2 Rational for using English Indices of Deprivation 2007 
 
Deprivation indices are defined as a measurement for a group of individual residing in a 
specific geographic area having similar environmental conditions (Abu-Kharmeh et al. 2009). 
Deprivation indices are referenced as low or high weights for living and service needs 
indicated, or both of them (Morris et al. 1991). Deprivation measurements often refer to 
geographic areas rather than individuals, they are indicative for the whole society that lives in 
a specific area (Lee et al. 1995). 
 
Deprivation indices are easier to be used in practice than most other measures of socioeconomic 
status (Galobardes et al. 2006), and have subsequently become accepted among researchers 
into public health, especially when personal data are not able to access. 
 
It is usually a debate in social sciences among scholars and researchers about the issue of 
poverty studies and construction of their analysis on expenditure and income, while analysis 
of deprivation studies are built on many other important socioeconomic issues, namely 
deprivation of income, health, education and the deprivation from adequate access to services 
(Townsend et al. 1988). Deprivation issues have heavily been discussed in the developed 
world. There are numerous examples of use of indices of deprivation in health research, 
particularly in the UK (Adams et al. 2005). 
 
The English Indices of Deprivation (ID) 2007 (Noble 2007) are the Government’s official 
measure of multiple deprivation on a small area scale. Their purpose is to identify priority 
areas, inform resource allocation, to help assess the impact of regeneration policies and to 
measure progress in implementing the National Strategy for Neighbourhood Renewal. These 
aim to narrow the gap between the most affluent and deprived neighbourhoods in the country. 
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The ID 2007 is the third set of indicators to be published in seven years; the first being 
published in 2000 (Noble 2000) and then again in 2004 (Noble 2004). The Indices are used 
widely to analyse patterns of deprivation, as well as identifying areas that would benefit from 
special Government initiatives or programmes. The ID 2007 provides a relative ranking of 
areas across England according to their level of deprivation.  
 
The new Index of Multiple Deprivation 2007 (IMD 2007) is a lower layer super output area 
(LSOA) level measure of multiple deprivation, and is made up of seven LSOA level domain 
indices. The IMD 2007 combines a total of 38 indicators, which is distributed across the seven 
domains, covering a range of social and economic issues to produce a deprivation score for 
each small area of England. The IMD 2007 score is termed “the combined sum of the weighted, 
exponentially transformed domain rank of the domain score”. There are 32,482 of these small 
areas – known as lower level super output areas, or LSOAs – in England, each containing 
between 1,000 and 3,000 people, an average population of 1,500 people. The bigger the IMD 
2007 score, the more deprived the LSOA. However, because of the exponential distribution, it 
does not mean that a LSOA with a score of 40 is twice as deprived as a LSOA with a score of 
20. In order to make direct comparisons between LSOAs it is recommended to use ranks. Each 
area is then ranked nationally from 1 (most deprived) to 32,482 (least deprived). By producing 
a score for each of these it is possible to compare relative levels of deprivation between areas.  
 
It is important to remember that the Index of Multiple Deprivation 2007 is a relative not an 
absolute measure of deprivation. The purpose of the Indices is to identify small areas of 
England which are experiencing multiple aspects of deprivation. The Indices of Deprivation is 
a comparator indication; it measures how much we have improved in comparison with other 
areas, not absolute improvements. Being a relative measure, there will always be, for example, 
10% of areas that are defined as the most deprived 10%, even if significant improvements are 
made to the absolute levels of deprivation in the country. When examining the most deprived 
10% of areas it is therefore important to remember that the absolute level of deprivation 
experienced by people living in these areas may vary between years. 
 
When considering the various domain indices, the overall rank of an LSOA may not change, 
but this does not mean there have been no changes to the level of deprivation. Conversely, an 
area may increase or decrease in rank without any actual change in levels of deprivation 
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occurring. This reflects the fact that all change is relative. For example, if an area sees no 
change in the rate of income deprivation between two Indices but other LSOAs do improve 
their figures, the LSOA in question may have a lower domain rank because it has been 
‘overtaken’ by other LSOAs, even if its score is the same in both years. 
 
Equally, when comparing the overall Index of Multiple Deprivation, if improvements in one 
domain are offset by a decline on another domain, the overall Index of Multiple Deprivation 
position may be the same even if significant changes have occurred to the domains. 
 
3.10.3 Explanation of calculating Index of Multiple Deprivation 2007 score 
 
The IMD, in general, is defined as a weighted area level aggregation of these specific 
dimensions of deprivation. The IMD2007 is subdivided into seven different “domains” of 
deprivation (Noble 2007). Every domain is given a specific weight, according to its importance, 
totalling 100%. Table 3.6 summarised domain weights for the IMD 2007. 
 
Table 3.6: Domain Weights for the IMD 2007 (Department for Communities and Local 
Government 2008) 
 Domain Weight 
Income Deprivation Domain  22.5% 
Employment Deprivation Domain 22.5% 
Health Deprivation and Disability Domain 13.5% 
Education, Skills and Training Domain 13.5% 
Barriers to Housing and Services Domain 9.3% 
Crime Domain 9.3% 
Living Environment Domain 9.3% 
 
3.10.4 Data limitations 
 
 The ID 2007 cannot be used to determine ‘how much’ more deprived one LSOA is than 
another as it is a relative measure of deprivation 
 The ID 2007 scores and ranks are not able to be used as absolute measures of deprivation 
or to identify absolute change over time. 
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 The ID 2007 identifies concentrations of deprivation, which means not all deprived people 
live in deprived areas, vice versa, not everyone living in a deprived area is deprived. 
 The ID 2007 is not a measure of affluence. The indicators which have been used have been 
chosen because they represent different aspects of deprivation. A lack of deprivation does 
not necessarily mean to affluence. Therefore, the LSOAs with the highest ranks (i.e. close 
to 32,482) are not necessarily affluent, just less deprived. 
 The Index scores from 2004 cannot be compared with those from 2007. Although the two 
Indices are very similar, it is not valid to compare the scores between the two time points 
they are relative to each other but not comparable. An area’s score is affected by the scores 
of every other area; so it is impossible to tell whether a change in score is a real change in 
the level of deprivation in an area or whether it is due to the scores of other areas going up 
or down. 
 The Indices are for England only.  
 
3.10.5 Establishing deprivation index from postcode 
 
The National Statistics Postcode Directory (NSPD) (National Statistics 2007) is a list of all the 
current and terminated postcodes that have ever existed in the UK, together with geographical 
links or matches for each postcode to a variety of different administrative, health, electoral and 
other geographies that are, or have been, used within the UK. 
 
The information contained within the NSPD has a wide range of potential uses across a broad 
range of disciplines wherever postcode data is used, or where information on the relationships 
between different geographies, or changes in a single geography over time is required. 
 
GeoConvert (GeoConvert 2007) is an online service available from the Census Dissemination 
Unit (CDU). It uses information originated from the NSPD which is used to work with the 
dataset directly to supply functions to perform a range of the tasks. Functions provided by 
Geoconvert allow users to convert postcodes to deprivation scores. 
 
Socioeconomic status is one of the strongest predictors of morbidity and premature mortality 
of cardiovascular disease (Winkleby et al. 1992). In Chapters 4, data on postcode were 
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provided by the Nuffield Health, and it would be used to transfer to IMD 2007 score. This will 
help to measure socioeconomic status in an area-level, which is distinct from individual 
socioeconomic position. It will also assess the effect of this area-level socioeconomic status on 
modifiable cardiovascular risk factors in this affluent population who attended the Nuffield 
Health. The advantage of using IMD 2007 in this research is because it is made up of seven 
lower layer super output area level domain indices. The IMD 2007 combines a total of 38 
indicators, which is distributed across the seven domains, covering a range of social and 
economic issues to produce a deprivation score for each small area of England. This method 
does not apply to Chapter 8, because the socioeconomic groups were provided (groups 1-10, 
and then merged to 5 groups) by the Hampshire Health Record. Chapter 8 will also compare 




Cardiovascular disease and other non-communicable diseases have been categorised as a top 
priority against premature death and preventable morbidity and disability worldwide, and the 
UN High-Level Meeting on Non-Communicable Diseases has been held at New York in 
September 2011 to discuss the strategy of tackling these diseases. Six objectives has been 
addressed in a published report, 2008-2013 Action Plan for the Global Strategy for the 
Prevention and Control of Non-communicable Diseases—raising the priority accorded to non-
communicable disease in development work at global and national levels, and integrating 
prevention and control of such diseases into policies across all government department; 
establishing and strengthening national policies and plans for the prevention and control of 
non-communicable disease; promoting interventions to reduce the main shared modifiable risk 
factors for non-communicable diseases including tobacco use, unhealthy diets, physical 
inactivity and harmful use of alcohol; promoting research for the prevention and control of 
non-communicable disease; promoting partnerships for the prevention and control of non-
communicable disease; monitoring non-communicable diseases and their determinants and 
evaluate progress at the national, regional and global level. 
 
Beaglehole et al. (2011) suggested that the top priority action for the cardiovascular disease 
and other non-communicable diseases is tobacco control, and proposed a goal to achieve a 
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world essentially free from tobacco by 2040—ie, a prevalence of less than 5%. Large countries, 
such as China, begin to take tobacco control seriously, rapid progress will be achieved. Some 
countries will set an earlier date for achievement of this goal. The other top priority intervention 
is salt reduction with a goal of 5 g per person per year by 2025. The Pan American Health 
Organization has already established a goal of 5 g by 2020. However, research data on smoking 
data are limited, and on salt intake are scarce. Therefore, research on cardiovascular diseases 
and associated research data on smoking and salt intake are needed, especially from the 
population in the UK. 
 
Health risks are in transition: populations are ageing owing to successes against infectious 
diseases; at the same time, patterns of physical activity and food, alcohol and tobacco 
consumption are changing. Low-income and middle-income countries now face a double 
burden of increasing chronic, non-communicable conditions, as well as the communicable 
diseases that traditionally affect the most deprived communities. Understanding the role of 
these risk factors is important for developing clear and effective strategies for improving global 
health. Therefore, research focus on the cardiovascular health of an ageing population and 
different socioeconomic groups in the UK are also needed. Given that not much research has 
been done in people who pay for private medical insurance, priority should be given to this 
neglected area. Also, research data are limited on serum lipids specifically on LDL in the UK 
population, so more research should be needed. 
 
Chapters 4-8 have been introduced in this literature review, except Chapter 6, which will assess 
the geographical variation of cardiovascular risk factors in the study population provided by 
the Nuffield Health. Although the prevalence of cardiovascular risk factors will be investigated 
at an area-level by socioeconomic status in Chapter 5, there is still a need to investigate how 
cardiovascular risk factors are distributed at a national geographical level, since the occurrence 
of cardiovascular disease does vary geographically. Other established cohort studies—The 
Whitehall II, Renfrew-Paisley, Scottish Heart Health, and Glasgow Students studies (Hart et 
al. 1997; Hart et al. 1997; Marmot et al. 1991; McCarron et al. 1999)—which conducted about 
two decades ago, have provided valuable aetiological insights and comparisons between 
women and men, but have limited national representativeness, and are unable to assess 
geographical variations because of their single locations. Also, although several studies have 
been conducted in the NHS and by public survey (Lawlor et al. 2003; HSE 2008; Shelton et 
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al. 2007; Shelton 2009), no study has previously been undertaken in a population of people 
with private medical insurance. An explanation for the regional variation remains unknown. 
Therefore, Chapter 6 is planned to answer this question. Therefore, the purpose of this study 
was to: (1) explore regional disparities in the prevalence of modifiable cardiovascular risk 
factors in people attending private health screenings in England; (2) compare the prevalence of 
modifiable cardiovascular risk factors from private medical screenings with the findings from 
the HSE 2006; and (3) estimate the risks of various modifiable cardiovascular risk factors at a 
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Appendix 3.1: Historical context for global cardiovascular disease (CVD) development (the 
following table is adopted from the US Institute of Medicine [IOM] 2010 report) 
1992 Victoria Declaration on Heart Health 
This declaration, which was issued following the First International Heart 
Health Conference, was intended to give a sense of urgency to the prevention 
and control of CVD. It focused on exploring methods of applying existing 
knowledge about CVD prevention on a global scale, urging government, 
research institutions, scientists, the media, and civil society to join forces in 
eliminating the CVD epidemic by adopting new policies, making regulatory 
changes, and implementing new population-level health promotion and CVD 
prevention programmes. It further specified that the policy implementation 
should consist of the adoption of a public health approach for the prevention 
and control of CVD that was inclusive of all population groups and promoted 
“four cornerstones” of heart health (healthy dietary habits, a tobacco-free 
lifestyle, regular physical activity, and a supportive psychosocial environment) 
(Advisory Board of the International Heart Health Conference 1992) 
1993 The World Bank World Development Report: Investing in Health 
This report examined the interplay between human health, health policy, and 
economic development. Like its predecessors, this report included the World 
Development Indicators, which offer selected social and economic statistics on 
127 countries. This report advocated a three-pronged approach to government 
policies for improving health in developing countries. First, governments need 
to foster an economic environment that enables households to improve their 
own health. Second, government spending on health should be redirected to 
more cost-effective programmes that do more to help the poor. Third, 
governments need to promote increased diversity and competition in the 
financing and delivery of health services. The report also highlighted the need 
to promote tobacco control and acknowledged the rising burden of chronic 
diseases in low-income and middle-income countries. It recommended that 
basic public health interventions including chronic disease prevention be part 
of the essential clinical package in countries with low and middle incomes (The 
World Bank 1993) 
1993 Disease Control Priorities in Developing Countries (DCP) 
A comparison document to the 1993 World Development Report, this book 
introduced an important new metric for measurement of disease outcomes: the 
disability-adjusted life year (DALY). The introduction of DALYs dramatically 
altered the way researchers measured disease burden because it quantified the 
toll of disabilities associated with diseases. This development helped 
researchers to fully realise the tremendous burden of chronic diseases, which 
cause years of disability and impair an individual’s ability to lead a healthy life. 
The report also provided quantitative evidence on demographic transition and 
the resulting growth in CVD in developing countries. It also generated initial 
estimates of the cost-effectiveness of primary prevention, of secondary 
prevention (using low-cost drugs) and of treatment of angina, diabetes, and 
acute myocardial infarction (Jamison et al. 1993). 
1995 Catalonia Declaration: Investing in Heart Health (40 case studies) 
Issued after the Second International Heart Health Conference, this declaration 
sought to support efforts of the Victoria Declaration by examining the economic 
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realities of implementing CVD prevention on a global scale. It provided 
concrete examples of policies and programmes for CVD prevention that 
succeeded in saving both lives and money in an effort to prove that investment 
in heart health now will save money in the long term. It also provided a list of 
14 recommendations for promotion of heart health, presented resources for and 
barriers to implementing CVD prevention programmes, and highlighted 41 
successful projects that have been implemented around the world (Advisory 
Board of the Second International Heart Health Conference 1995). 
1997 Catalonia Declaration Follow-up 
This companion document, World Efforts to Improve Heart Health: A Follow-
up to the Catalonia Declaration—Selected Programme Descriptions, was 
developed to further explore case studies presented in the Catalonia Declaration 
and to discuss many other programmes that promote heart health. The resulting 
collection, which described projects in six continents and more than 30 
countries, gathered diverse information under the central theme of CVD 
prevention. It also highlighted worldwide efforts to improve heart health and 
contained 83 programme descriptions, citing numerous publications and other 
resources (Grabowsky et al. 1997). 
1998 The Singapore Declaration: Forging the Will for Heart Health in the Next 
Millennium  
This declaration, built on the Victoria and Catalonia declarations, focused on 
the need to build capacity to create heart health. It provided guidance on how to 
build capacity by developing a heart health infrastructure at international, 
national, and local levels; identifying leadership, policy, economic, scientific, 
technical, and physical aspects of this infrastructure at each level; and creating 
individual, organisational, and political will to carry out the implementation of 
an appropriate infrastructure for heart health (Pearson et al. 1998) 
1998 IOM Report: Control of Cardiovascular Diseases in Developing Countries 
This report established priorities for research and development (R&D) 
investment to control CVD in developing countries and offered 
recommendations for R&D investment in several broad areas for the control of 
CVD. These areas included determining the magnitude of CVD burden in low-
income and middle-income countries; developing targeted and effective 
prevention strategies using case-control studies; reducing tobacco use; detecting 
and treating hypertension; starting pilot studies to evaluate essential vascular 
packages of effective and low-cost drugs; developing algorithms for affordable 
clinical CVD care; building R&D capacity; and developing institutional 
mechanisms that facilitate CVD prevention and control (IOM 1998). 
1999 World Heart Federation White Book 
This book was designed to define the problems posed by the present and 
projected burden of CVD, to document the resources available to combat these 
diseases, to formulate appropriate strategies for international action, and to 
provide a framework of action for the World Heart Federation to pursue in 
galvanising the energies of all the appropriate players at the global level. The 
book urges a global approach to CVD, emphasising coordination among global, 
regional, and local programmes. It also emphasised that prevention programmes 
must be designed to address risk factors across the entire lifespan, starting in 




1999 Global Strategy for the Prevention and Control of Non-Communicable 
Diseases: Report by the Director-General 
This report by World Health Organization (WHO) Director-General Gro 
Harlem Brundtland called attention to the growing burden of non-
communicable diseases in low-income and middle-income countries and cited 
the increasingly strong epidemiological evidence linking these diseases to 
common risk factors. It briefly reviewed lessons learned in chronic disease 
prevention and control and, on the basis of these lessons, called for improved 
surveillance of emerging non-communicable disease epidemics and their 
determinants of CVD, and continued emphasis on strengthening of primary care 
capacity. The report became the basis for future WHO strategies for chronic 
disease control such as the Global Strategy on Diet, Physical Activity, and 
Health and the 2008 Action Plan for the Global Strategy for the Prevention and 
Control of Non-Communicable Diseases (Brudtland 1999) 
2000 The 2000 Victoria Declaration 
This declaration highlighted the high burden of CVD among women worldwide, 
calling upon governments, research institutions, non-governmental 
organisations, multinational organisations, and civil society to invest resources 
and develop targeted CVD prevention and treatment programmes for women. 
While describing the policies, community action programmes, and services 
required to support heart disease and stroke prevention and management, the 
declaration emphasised using the values of “health as a human right, equity, 
solidarity, participation and accountability”. The declaration also emphasised 
the importance of the psychosocial and socioeconomic determinants of 
women’s heart disease and stroke (Advisory Board of the Third International 
Heart Health Conference 2000) 
2000 2000 World Health Report 
The 2000 World Health Report focused on strengthening health systems. It 
emphasised that health systems (and their supporting governments) have four 
vital functions: service provision, resource generation, financing, and, most 
importantly, stewardship. The report stressed that it is the responsibility of 
national governments to ensure that health systems are providing both fair and 
good health care to the entire population—standards that require governments 
to devise essential care packages that ensure high-quality care for all. The report 
is significant for CVD because it is evidence of the shifting priorities of the 
international health community from vertical, disease-specific initiatives to a 
more horizontal, health-system strengthening emphasis. Furthermore, the report 
estimated that non-communicable diseases together contributed to almost 60% 
of global mortality (31·7 million deaths) and 43% of the global burden of 
disease in 1999 (WHO 2000a). 
2001 The Osaka Declaration: Health Economics and Political Action: Stemming 
the Global Tide of Cardiovascular Disease 
This declaration furthered the process started by previous heart health 
declarations by reviewing the factors outside of the health sector, specifically 
social, economic, and political factors, that have contributed to the lack of 
progress in CVD prevention and promotion globally. It also argued for the 
crucial role that health professionals and their organisations must play in 
advocacy and political action to influence the governance of health systems and 
mitigate systemic barriers to achieving health. The declaration also went beyond 
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the health system to examine global forces that condition the awareness, 
understanding, and commitment to take global action on CVD prevention 
(Advisory Board of the Fourth International Heart Health Conference 2001) 
2001 WHO Assessment of National Capacity for Non-Communicable Disease 
Prevention and Control 
This report described the national capacity for non-communicable disease 
prevention and control in WHO member states based on a survey done in 2001. 
The survey found that fewer than half the WHO member states had chronic 
disease policies and that only about two-thirds of the countries had a chronic 
disease unit in their ministries of health and fewer than 40% had a specific 
budget line for chronic diseases. The report highlights the traditional lack of 
attention that chronic diseases receive in many countries around the world 
despite their increasing prevalence and contribution to morbidity and mortality. 
The report identifies several areas in which WHO could provide technical 
support and emphasised the need for countries and the international community 
to strengthen their capacity to prevent and treat chronic disease (Alwan et al. 
2001)  
2002 2002 World Health Report 
The 2002 World Health Report focused on reducing risks and promoting 
healthy lives. The report highlighted the world’s ten leading risk factors that 
account for more than one-third of deaths worldwide. It went on to suggest 
effective and efficient strategies that governments and the international 
community can employ to reduce the prevalence of these risk factors, thus 
saving millions of lives. Five of the risk factors highlighted in the report—
hypertension, tobacco consumption, alcohol consumption, high cholesterol, and 
obesity—are key cardiovascular risk factors. The report emphasised the 
increasing global burden of CVD, especially its rise in low-income and middle-
income countries, citing the dual epidemics of infectious and non-
communicable diseases that many developing countries are now facing. The 
report’s focus on risk factor reduction and its prominent use of key CVD risk 
factors provides further validation of the gravity of the world CVD epidemic 
and signals the growing recognition from the global health community of the 
importance of addressing CVD in developing countries (WHO 2002a). 
2003 Framework Convention on Tobacco Control 
This treaty, adopted by the World Health Assembly on May 21, 2003, was the 
first negotiated under the auspices of WHO and has since become one of the 
most rapidly adopted international treaties in history, having been ratified by 
nearly 170 countries. The treaty was developed in response to the global tobacco 
epidemic and represents a shift in the way the world addresses regulation of 
addictive substances by stressing the importance of reducing demand for 
tobacco. The treaty encourages countries to strengthen their tobacco control 
policies by enacting price, tax, regulatory, and social measures to reduce 
demand. The treaty represents a major milestone in the global fight to reduce 
chronic disease risk factors and has prompted previously unseen international 
collaboration around tobacco control (WHO 2003a). 
2003 Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure 
The JNC7 report summarised the available scientific evidence on hypertension 
and offers guidance to primary care clinicians. The report specified 
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hypertensive risk thresholds for adults and offered guidelines for appropriate 
treatment with antihypertensive medication. The report cited the significant 
success in awareness and reduction of hypertension in the USA, with awareness 
increasing by 19–70% by 1999–2000. It also reported that since 1972, age-
adjusted death rates from stroke and coronary heart disease had fallen by 
roughly 60% and 50%, respectively. This provides evidence that CVD mortality 
can be significantly reduced with comprehensive treatment and prevention 
programmes (Chobanian et al. 2003) 
2004 Towards a WHO Long-Term Strategy for Prevention and Control of 
Leading Chronic Diseases 
This report recommended seven strategic initiatives for action by WHO. It 
described the health and economic effects of chronic diseases and the long-term 
drivers underlying their spread, and analysed the deeply entrenched policy 
responses to the epidemic of chronic diseases. The resulting strategy takes a 
long-term, strategic global view and builds on existing research, programmes, 
and approaches already taken by the WHO non-communicable disease cluster 
(Yach and Hawkes 2004) 
2004 WHO Global Strategy on Diet, Physical Activity, and Health 
The overall goal of this report was to promote and protect health by guiding the 
development of an enabling environment for substantial actions at individual, 
community, national, and global levels that, when taken together, will lead to 
reduced disease and death rates related to unhealthy diet and physical inactivity. 
These actions would support UN Millennium Development Goals (MDGs) and 
have immense potential for public health gains worldwide. The Global Strategy 
sought to help to reduce chronic disease risk factors stemming from poor diet 
and lack of physical activity through essential health action; increase overall 
awareness of the influences of diet and physical activity on health; encourage 
the development, strengthening, and implementation of policies and action 
plans to improve diets and increase physical activity; and monitor scientific data 
and support research on diet and physical activity (WHO 2004). 
2004 The Milan Declaration: Positioning Technology to Serve Global Heart 
Health 
This declaration followed up on the previous International Heart Health 
Declarations by calling for the international community to mobilise new and 
existing technologies to improve heart health. The declaration examined a range 
of technologies—including health promotion and disease prevention, 
information and communication technology, food technology, medical 
technology, and biotechnology—and their potential to reduce the burden of 
CVD. Key considerations for all governments, especially those of low-income 
and middle-income countries, included choosing the right mix of highly 
technical and expensive technologies that benefit a small number of individuals 
and equally or less expensive population-level strategies that enhance the health 
status of the entire population. The declaration stressed that a comprehensive 
range of treatment and prevention strategies is essential to control the global 
CVD epidemic and that treatment technology options need to be effective but 
also substantial and affordable (Advisory Board of the Fifth International Heart 




2004 Earth Institute/IC Health Report 
This report examined the social and economic effect of CVD in one low-income 
and four middle-income countries, now and for the next 40 years. It also 
reviewed strategies for the prevention of CVD in terms of their costs and 
benefits, where such data exist. The report offered six conclusions emphasising 
the need to put CVD in low-income and middle-income countries on 
international health and development agendas, more accurately document the 
prevalence and costs of CVD worldwide, develop partnerships at the 
macroeconomic level with national governments in key developing countries, 
establish health worker training programmes about CVD, undertake trial 
treatment and prevention interventions, and establish a long-term research base 
for CVD interventions (Leeder et al. 2004) 
2005 WHO Preventing Chronic Disease: A Vital Investment 
This report made the case for urgent action to halt and reverse the course of the 
growing chronic disease epidemic worldwide. It sought to dispel the 
misperception that chronic diseases are diseases of the affluent and do not affect 
those in low-income and middle-income countries. It estimated 80% of chronic 
disease-related deaths in 2005 to be in low-income and middle-income 
countries, and in younger people than in high-income countries. The report 
stressed that the growing threat of chronic diseases can be overcome using 
existing knowledge and highly cost-effective interventions and provided 
suggestions for how countries can implement interventions to reduce and 
prevent chronic diseases (WHO 2005a) 
2005 2005 World Health Report  
This report highlighted maternal and child health issues. One of the major foci 
of the report was achieving universal access to health services, which the report 
stressed could be achieved through health systems strengthening. The report 
emphasised that this strengthening needed to occur at the infrastructure, 
workforce, and health system funding levels. The report also tied maternal and 
child health efforts to chronic diseases by recognising that the antecedents of 
many of these diseases occur in early life and, as such, improving health early 
in life is an important component of preventing the early onset of chronic 
diseases (WHO 2005b).  
2005  Lancet Series on Chronic Diseases 
The first of two Lancet series on chronic diseases, this set of articles called 
attention to the major gap in the global health discourse regarding chronic 
diseases. The series noted that chronic diseases were not listed in the MDGs and 
warned that if they continue to be ignored by the global health community, the 
progress gained from reducing the burden of infectious disease would be 
eclipsed by a rising burden of chronic diseases in developing countries (Epping-
Jordan et al. 2005; Fuster and Voute 2005; Horton 2005; Reddy et al. 2005; 
Strong et al. 2005; Wang et al. 2005). 
2006  Disease Control Priorities in Developing Countries 2nd Edition (DDCP2) 
This follow-up to the original Disease Control Priorities in Developing 
Countries brought together 350 specialists from diverse fields and proposed 
context-sensitive policy recommendations to significantly reduce the burden of 
disease in developing countries. The book included a chapter that specifically 
discussed CVD and further called into focus the sizable burden of the disease 
in developing countries. It estimated the economic burden of CVD in low-
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income and middle-income countries and updated and expanded the cost-
effectiveness estimates for primary prevention, secondary prevention, and 
treatment interventions from the 1993 report (Jamison et al. 2006). 
2007 Lancet Series on Chronic Diseases  
The second Lancet series on chronic diseases noted the increasing recognition 
of the importance of chronic diseases within the global health community. It 
also provided a deeper, more complicated examination of the burden of chronic 
diseases and predicted the reductions in burden at the population and individual 
level that could be achieved through prevention and treatment interventions 
(Abegunde et al. 2007; Asaria et al. 2007; Beaglehole et al. 2007; Gaziano et 
al. 2007; Horton, 2007; Lim et al. 2007). 
2007 United Nations (UN) Resolution on Diabetes 
In January, 2007, the UN established November 14 as World Diabetes Day, an 
official UN day. The resolution recognised diabetes as a widespread and serious 
chronic disease that threatens international development and the achievement 
of the MDGs. It also recognised that diabetes prevention and control should be 
included in health systems strengthening efforts. The resolution is important 
because it was an additional sign that the international health community was 
increasingly recognising the threat posed by non-communicable diseases and 
the necessity to invest in their prevention and control (UN General Assembly 
2006). 
2007 Grand Challenge in Chronic Non-Communicable Diseases 
This article identified the top 20 policy and research priorities for chronic non-
communicable diseases. These grand challenges are intended to reduce the 
global epidemic of these diseases by making the case for worldwide debate, 
support, and funding and by guiding policy and research in an evidence-based 
manner. The authors asserted that with concerted action following the blueprint 
outlined in the article, 36 million premature deaths from chronic non-
communicable diseases can be averted by 2015 (Daar et al. 2007). 
2008 Closing the Gap in a Generation: Health Equity through Action on the 
Social Determinants of Health. Final Report of the WHO Commission on 
Social Determinants of Health 
This report of the Commission on Social Determinants of Health examined how 
health-damaging experiences are unequally distributed within and across 
societies as a result of unfair economic arrangements, poor social policies, and 
discriminatory politics. The report calls on the international community to close 
the health gap in a generation, setting out key areas—daily living conditions, 
social and cultural inequalities, and the need for governments committed to 
equity—in which action is needed. Those social policies proven effective in 
improving health and health equity in countries at all levels of socioeconomic 
development (CSDH 2008). 
2008 Oxford Health Alliance Sydney Resolution and Sydney Challenge (The 
Sydney Resolution) 
The Sydney Resolution and Challenges were the outcomes of the 2008 Oxford 
Health Alliance Summit and served as a call to action for the international 
community to make healthier choices to turn back the rising tide of preventable 
chronic diseases. The resolution explained that 50% of the world’s deaths are 
caused by four preventable chronic diseases: CVD, diabetes, chronic lung 
disease, and cancer. The resolution stressed that these four diseases place 
136 
 
immense costs on society, threaten economic stability, and push individuals 
further into poverty. The resolution challenged the international community to 
take urgent action and prioritise health-promoting decisions in urban planning, 
food manufacturing and policy, business decisions, and public policy (The 
Sydney Resolution 2008).  
2008 The Global Burden of Disease: 2004 Update 
This update to the Global Burden of Disease report, based on 2004 data, revised 
previous estimates of the burden of ischaemic heart disease (IHD) and diabetes 
on the basis of more accurate data, resulting in a significantly increased estimate 
of the global burden of these chronic diseases. These revisions increased 
estimated DALYs attributed to IHD by 7%. The report also used new data to 
recalibrate the long-term case fatality rates for cerebrovascular disease, 
decreasing the prevalence of stroke survivors and, as a result, decreasing the 
estimate of global years lost to cerebrovascular disease by 30%. The report 
stressed that of every ten deaths globally, six are caused by chronic diseases and 
that CVD was the foremost cause of death in the world. CVD was responsible 
for 32% of global deaths in men and 27% in women in 2004. The report also 
affirmed that cerebrovascular disease and IHD were the number one and two 
causes of death in high-income and middle-income countries, and that IHD was 
the number two cause of death in low-income countries. Furthermore, the 
update projected that CVD burden would continue to increase in low-income 
and middle-income countries (WHO 2008b). 
2008 WHO 2008-2013 Action Plan for the Global Strategy for the Prevention 
and Control of Non-Communicable Diseases 
This action plan, directed at the international development community as well 
as government and civil society, makes the case for urgent action to enact 
chronic disease prevention and control programmes. The document provides a 
policy framework for action, outlining a series of objectives and action items 
for key stakeholder groups at varying levels of the global health system. It 
further urges WHO Member States to develop national policy frameworks, 
establish prevention and control programmes, and share their experiences and 
build capacity internationally to address chronic diseases. Recognising that 80% 
of the chronic disease burden is in developing countries and that the greatest 
increase in disease burden over the next 10 years is projected to occur in these 
countries, the plan places particular focus on low-income and middle-income 
countries. The action plan was endorsed by all 192 Member States during the 
World Health Assembly in May, 2008 (WHO 2008a).  
2009 IOM Report: The US Commitment to Global Health 
This report examined the US commitment to global health and articulated a 
vision for future US investments and activities. Coinciding with the US 
presidential transition, the report outlined how the US global health enterprise, 
which includes both government agencies and non-governmental organisations, 
can improve global health under the leadership of a new administration. The 
report identified five key areas for action by the US global health enterprise: 
scaling up existing interventions; generating and sharing knowledge to address 
health problems endemic to the global audience; investing in people, 
institutions, and capacity building with global partners; increasing the US 
financial commitments to global health; and setting an example of engaging in 
partnerships. The report also included an emphasis on the rising tide of non-
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communicable diseases in low-income and middle-income countries, 
specifically recommending that the USA increase attention to chronic diseases 
and adopt a leadership role in reducing death from chronic diseases and tobacco-
related illnesses (IOM 2009). 
2009 Kampala Statement 
This statement was a product of a summit, Preparing Communities: Chronic 
Disease in the Developing Regions of Africa and Asia, hosted by the Aga Khan 
Development Network, in Kampala, Uganda. In the Statement the Assembly of 
Kampala agreed: 1) to implement the WHO Action Plan and create the basis for 
a multisectoral chronic disease alliance in Asia and Africa, and to accelerate 
progress by sharing resources, expertise, and experiences to promote an 
integrated and evidence-based approach to reducing the health and economic 
burdens of chronic diseases; 2) that governments and multisectoral partners at 
all levels will provide the leadership vital to further refine and advance the 
directions developed during this summit; and 3) to build upon and expand the 
momentum generated at this summit and monitor and report back on progress 
in 2011 in New Delhi, India (Chronic Diseases Summit 2009). 
2010 IOM Report: Promoting Cardiovascular Health in the Developing World: 
A Critical Challenge to Achieve Global Health 
The report described the parts that governments, international agencies, 
industries, and non-profit organisations can play in tackling the burden of heart 
disease in low-income and middle-income nations. Given that many developing 
nations have limited economic and political capacity to quickly gear up 
comprehensive disease reduction plans, they should in the near term prioritise 
steps to be effective at reducing heart disease in industrialised nations. It draws 
attention to strategies such as reducing tobacco use and salt in the food supply 






CHAPTER 4:  
 
PREVALENCE OF MODIFIABLE CARDIOVASCULAR RISK FACTORS BY AGE 




Aim: This chapter aimed to examine the prevalence of various modifiable cardiovascular risk 
factors by age and sex for participants who accessed private health care across the UK. 
 
Methods: A retrospective study of 65,536 participants across the UK was achieved with the 
use of a dataset provided by a private health-care company. Eight risk factors were analysed: 
body-mass index (BMI), waist size, waist-to-hip ratio (WHR), systolic and diastolic blood 
pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, and low-density 
lipoprotein (LDL) cholesterol. Age was divided into six groups: 18–24 years, 25–34 years, 35–
44 years, 45–54 years, 55–64 years, and 65–75 years. 
 
Results: For different age groups, participants aged 65–75 years had the highest prevalence of 
overweight and those aged 55–64 years had the highest prevalence of obesity. Participants aged 
55–64 years had the second highest prevalence of overweight and those aged 45–54 years had 
the second highest prevalence of obesity. Participants aged 25–34 years had the highest 
prevalence of underweight. Participants aged 55–75 years had higher prevalence of high blood 
pressure.. The highest prevalences of high total cholesterol and high LDL concentrations were 
found in the group aged 55–64 years; and the highest prevalences of low HDL was found in 
the group aged 45-54 years. Women aged 65–75 years had the highest prevalence of 
overweight and obese. Women aged 65–75 years had the highest prevalence of high blood 
pressure, but women aged 18–24 years had the highest prevalence of low HDL cholesterol. 
 
Discussion: Our data showed that male participants registered with the private medical 
company were likely to be overweight. Men were almost twice as likely as women to be 
overweight, and one in two men were overweight (as measured by BMI). Compared with 
prevalences previously reported in the scientific literature, participants in our study had a lower 
prevalence of hypertension and high total cholesterol. Men were about five times more likely 
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to have lower HDL than were women. Not much research evidence is available about the 
prevalences of LDL and WHR, with most available evidence about LDL focusing on 
therapeutic coverage. Our findings showed some similarity with existing studies, especially in 
the UK population. Our dataset is one of the largest UK datasets, especially from a commercial 
setting. 
 
Conclusion: Participants aged 55–75 who attend private medical insurance need more 
attention paid to their cardiovascular health. They might need to care more about their lifestyle 






In 1991, the British Government set new targets for the health of the nation, particularly for 
coronary heart disease and stroke, and the risk factors associated with these diseases (Secretary 
of State for Health 1991). After 3 years, the Health Survey for England (1994) was established 
to monitor trends in cardiovascular risk factors. Most cardiovascular research has focused on 
the general population. There has been very little research into the prevalence of cardiovascular 
risk factors in patients covered by private health insurance. This chapter will examine the 
prevalence of various cardiovascular risk factors in the population using the Nuffield Health 
dataset (a private medical insurance company, which provided information about nine 
cardiovascular risk factors): body-mass index (BMI), waist circumference, waist-to-hip ratio 
(WHR), systolic and diastolic blood pressure, total cholesterol, low-density lipoprotein (LDL) 
cholesterol, high-density lipoprotein (HDL) cholesterol, and smoking. Post codes, which can 
be converted to deprivation score with use of the Index of Multiple Deprivation 2007, were 
also provided in the dataset. 
 
Across the UK, the prevalence of obesity has rapidly increased in recent decades (DoH 2006). 
The number of deaths per year attributable to obesity is roughly 30,000 in the UK (Allison et 
al. 1999; Haslam and James 2005; Mokdad et al. 2004; National Audit Office 2001). According 
to Diabetes UK (2010), the number of people older than 16 years registered as obese has risen 
to more than 5·5 million in 2010—an increase of more than 265,000 compared with the 
previous year. One in ten of the population is being treated for obesity. The condition costs the 
National Health Service (NHS) an estimated £4·2 billion annually, which will more than 
double by 2050 (QOF 2010).  
 
High blood pressure is the leading cause of cardiovascular death in all regions, contributing to 
37% of cardiovascular deaths in regions of southeast Asia (eg, India), and to 54% of 
cardiovascular deaths in middle-income European countries (Danaei et al. 2006). Average 
blood pressure levels are particularly high in middle-income European countries and African 
countries, mainly due to poor diet, alcohol consumption, lack of exercise, and obesity; these 




The first nationwide survey of the management of hypertension in England, using data from 
the Health Survey for England 1994, of adults aged 16 years and older, reported that 19·5% 
were hypertensive (defined as systolic blood pressure ≥160  mm Hg, diastolic blood pressure 
≥95  mm Hg, or anti‐hypertensive treatment). Among patients with hypertension, only 66% of 
women and 60% of men had been told they had high blood pressure previously. Approximately 
half of all patients with hypertension were receiving treatment (54·4% of women vs. 44·8% of 
men), and of these patients, 59% of patients achieved adequate control of blood pressure 
(defined as blood pressure <160/95  mm Hg). On the basis of a more stringent definition of 
hypertension (systolic blood pressure ≥140  mm Hg, or diastolic blood pressure ≥90  mm Hg) 
(Kaplan et al. 2003), the analogous rates for awareness, treatment, and control were 40%, 26%, 
and 6%, respectively (Colhoun et al. 1998). However, although rates of awareness, treatment, 
and control have improved, most patients with hypertension still achieve inadequate control of 
blood pressure or receive no anti‐hypertensive treatment at all (Burt et al. 1995; Colhoun et al. 
1998). 
 
Trends in hypertension prevalence in the USA have, in general, been obtained from the 
National Health and Nutrition Examination Survey (NHANES). NHANES is a sequential 
stratified multistage probability sample of adults and children in the USA. The first survey was 
conducted in 1960–1962 and the latest in 1999–2002. The age-adjusted prevalence of 
hypertension fell between 1960–1962 and 1988–1991, from 29·7% to 20·4% (Burt et al. 1995). 
On the basis of NHANES data, in 1991–1994, the age-adjusted prevalence of hypertension was 
25%, and in 1999–2002 was 28·6% (Hajjar and Kotchen 2003). Hypertension affects 
approximately one in three adults in the USA. Every year, hypertension contributes to one of 
every seven deaths in the USA and to nearly half of all cardiovascular-disease-related 
mortality, including stroke (Chobanian et al. 2003). Data from the Framingham Heart Study 
suggest that cardiovascular disease risk is increased by 2·5 times in women and 1·6 times in 
men with systolic blood pressure between 130–139 mm Hg and diastolic blood pressure 85–
89 mm Hg (Kannel 1996; Vasan et al. 2001). The UK Public Health Observatory’s modelling 
study estimated that the number of people with high blood pressure increased by 2·7% per year 
from 332,767 in 2004/2005 to more than 12 million in 2007/2008. During the same period, 
figures from the Quality Framework statistics showed that general practitioners discovered and 
diagnosed 934,993 people with high blood pressure. This finding increased the number of 
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people diagnosed with high blood pressure to about 7 million. 5·7 million people in the UK are 
at risk without knowing it.  
 
Overall, raised total cholesterol is estimated to cause 2·6 million deaths and 29·7 million 
disability-adjusted life-years (WHO 2009) worldwide. In 2008, the global prevalence of raised 
total cholesterol among adults was 39% (37% in men and 40% in women). According to the 
WHO report on non-communicable diseases (2011), the prevalence of elevated total 
cholesterol was highest in the WHO Region of Europe (54% for both sexes), followed by the 
WHO Region of the Americas, which the prevalence was 48% for both sexes. The WHO 
African Region and the South East Asian Region showed the lowest rate, which were 22·6% 
and 29·0%. The prevalence of raised total cholesterol increased substantially on the basis of 
country’s income level. In low-income countries, about 15% of adults had raised total 
cholesterol, increasing to more than 30% in low-income and middle-income countries. In high-
income countries, more than 50% of adults had raised total cholesterol, more than three times 
as many as in low-income countries (WHO 2011).  
 
Cholesterol increases the risks of heart disease, stroke, and other vascular diseases. Recent 
research shows that concentrations of LDL and HDL cholesterol are more important for health 
than is total cholesterol (ALLHAT Collaborative Research Group 2002; Lewington et al. 
2007). Findings from some randomised controlled trials also suggested that larger reductions 
in LDL cholesterol would produce larger reductions in the risk of cardiovascular events (Chen 
et al. 1991; Cholesterol Treatment Trialists' Collaboration 2005; Heart Protection Study 
Collaborative Group 2002; Stamler et al. 1993). The evidence-based recommendations for 
management of lipid disorders in clinical practice in the USA are specified by the National 
Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) (Grundy 2001). 
The NCEP ATP III places a primary focus for cholesterol management on high concentrations 
of LDL cholesterol. The guidelines set LDL target concentrations that are based on history of 
coronary heart disease (CHD) or risk for developing CHD in the next 10 years. Kuklina and 
colleagues (2009), using the National Health and Nutrition Examination Survey (NHANES) 
data, investigated trends of LDL prevalence across 4 study cycles (1999–2000, 2001–2002, 
2003–2004, and 2005–2006), reported that, among the NHANES population aged 20 years or 
older, the prevalence of high LDL concentrations decreased from 1999–2000 to 2005–2006, 




Much research about risk factors for cardiovascular disease has been undertaken in the NHS in 
the UK (Marmot 1985; Lyratzopoulos et al. 2006; Purslow et al. 2008). However, according 
to figures from the Association of British Insurers (2009), the number of people covered by 
private medical insurance rose to more than 6 million in 2008—about 10% of the UK’s 
population—and included an increasing number of people employed in all sectors of the 
workforce from manual to management. However, little evidence has been gathered in this 
affluent population. In Chapter 1 (Introduction), I have explained the reason why this research 
is urgently needed. Therefore, this chapter aims to examine the prevalence by age of various 
modifiable cardiovascular risk factors in this affluent population, and compare the results with 
the general population represented in Health Survey for England 2006.  
 
4.2 DESIGN AND METHODS 
 
4.2.1 Study setting and data collection 
 
Data were provided by a private health-care company, Nuffield Health. Identification of 
individuals is not possible from these data, because they are provided by a unique patient 
reference number in a dataset. The assessment programmes were delivered through a bespoke 
electronic patient-record system developed exclusively for Nuffield Health, the Vi System. 
This system offers greater accuracy and speedier and more comprehensive reports than other 
systems (eg, paper-based systems). It has four interventions—Vi3, Vi4, Vi5, and Vi6. It provides 
instant comparison with previous test results and the ability for clients to use any of their centres 
in the UK and immediately access the records. Data were extracted from the records of the 
Nuffield Health. Aggregate data provided by the Nuffield Health were anonymised, in line with 
the Information Commissioner Office’s (2013) anonymisation code; it can be freely processed 
and publicly disclosed. Data were recorded for participants during screening for provision of 
employment-related medical care. At each of the company’s testing sites, data were collected 
by trained health professionals using protocols consistent with the British Hypertension Society 





4.2.2 Cardiovascular risk factors 
 
Several established cardiovascular risk factors represent the risk profile of the participants: (1) 
anthropometric characteristics; (2) blood pressure; and (3) plasma serum. BMI, WHR, and 
waist circumference were examined. BMI is defined as: (1) underweight (<18·5 kg/m2); (2) 
normal (18·5–<25 kg/m2); (3) overweight (25–<30 kg/m2); (4) obese (30–<40 kg/m2); or (5) 
morbidly obese (>40 kg/m2; HSE 2008). Waist circumference was measured at the anatomical 
waist. For men, low waist circumference was defined as less than 94 cm, high as 94–102 cm, 
and very high as greater than 102 cm; for women, low waist circumference was less than 80 
cm, high was 80–88 cm, and very high was greater than 88 cm (NICE 2006a). WHR was 
calculated and defined as high if values were greater than 0·95 in men and greater than 0·80 in 
women (Croft et al. 1995). Blood pressure included systolic blood pressure and diastolic blood 
pressure. All blood pressure measurements were taken after the participant completed a 
Nuffield Health questionnaire, which typically took 10–12 min. Blood pressure was measured 
after a further 5 min of quiet, seated rest. Trained staff fitted an appropriately sized inflatable 
cuff around the upper left arm of each participant. Participants were instructed to sit still in 
their chair with their left arm resting on a table at the same level as the heart. One measure of 
systolic blood pressure and diastolic blood pressure was made with an aneroid 
sphygmomanometer (Welch Allyn DS45; Skaneateles Falls, New York, NY, USA). 
Hypertension was classified as greater than 90 mm Hg (diastolic) and greater than 140 mm Hg 
(systolic; NICE 2006b). Plasma serum included total, HDL, and LDL cholesterol. For Vi4, the 
finger prick method was used (Accutrend GC; Roche Diagnostics, Mannheim, Germany); for 
Vi3, Vi5, and Vi6, the venous method was used, and the blood sample was drawn and analysed 
(pocH100i; Sysmex, Kobe, Japan). Total cholesterol was classified as raised if higher than 6 
mmol/L. HDL was classified as low if less than 1·0 mmol/L; LDL was defined as raised if 
greater than 3·36 mmol/L (Contois et al. 1996). Age was divided into six groups: 18–24, 25–
34, 35–44, 45–54, 55–64, and 65–75 years. 
 
4.2.3 Statistical analysis 
 
Data from this study were analysed with SPSS version 17.0 (SPSS Inc, Chicago, IL, USA). 
The dependent measures were modifiable risk factors—eg, BMI, WHR, waist circumference, 
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blood pressure, plasma cholesterol, etc. Prevalence was calculated for each modifiable risk 
factor proportionately.  
 
4.3 RESULTS  
 
Table 4.1 shows the prevalence of modifiable cardiovascular risk factors in different age groups 
of the overall population. Tables 4.2 and 4.3 show the prevalence of modifiable cardiovascular 
risk factors in different age groups for men and women, respectively. The data show a normal 
distribution pattern, with the mean about age group 35–44 years old.  
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Table 4.1: Prevalence of modifiable cardiovascular risk factors in different age groups  



















Body-mass index (n) 1427 11154 18628 17600 9424 1583 59816 
Underweight (n) 49 229 124 92 46 8 548 
% 3·4% 2·1% 0·7% 0·5% 0·5% 0·5% 1·0% 
Normal (n) 983 6485 7814 6223 2905 524 24934 
% 68·9% 58·0% 41·9% 35·4% 30·8% 33·1% 41·7% 
Overweight (n) 305 3478 7765 7908 4532 808 24796 
% 21·4% 31·2% 41·7% 44·9% 48·1% 51·0% 41·4% 
Obese (n) 80 917 2785 3216 1859 234 9091 
% 5·6% 8·2% 15·0% 18·3% 19·7% 14·8% 15·2% 
Morbidly obese (n) 10 45 140 161 82 9 447 
% 0·7% 0·4% 0·8% 0·9% 0·9% 0·6% 0·7% 
Waist circumference 
(n) 
1182 9879 17455 16612 8985 1512 55625 
High (n) 135 1483 4053 4316 2631 459 13077 
% 11·4% 15·0% 23·2% 26·0% 29·3% 30·4% 23·5% 
Very high (n) 87 1011 3119 3946 2514 436 11113 
% 7·4% 10·2% 17·9% 23·8% 28·0% 28·8% 20·0% 
Waist-to-hip ratio 
(n) 
1182 9879 17455 16610 8985 1512 55623 
n 159 1440 3973 5135 3542 702 14951 
% 13·5% 14·6% 22·8% 30·9% 39·4% 46·4% 26·9% 
Systolic blood 
pressure (n) 
1426 11153 18623 17598 9423 1583 59806 
n 31 325 1198 2132 2090 515 6291 
% 2·2% 2·9% 6·4% 12·1% 22·2% 32·5% 13.1% 
Diastolic blood 
pressure (n) 
1426 11153 18625 17598 9423 1583 59808 
n 25 345 1485 2179 1420 205 5659 
% 1·8% 3·1% 8·0% 12·4% 15·1% 13·0% 9·5% 
Total cholesterol (n) 668 6400 14880 16333 8979 1539 48799 
n 132 2046 7583 10749 6287 993 27790 
% 19·8% 32·0% 51·0% 65·8% 70·0% 64·5% 57·0% 
High-density 
lipoprotein (n) 
668 6400 14875 16329 8978 1539 48789 
n 43 482 1588 1775 954 138 4980 
% 6·4% 7·5% 10·7% 10·9% 10·6% 9·0% 10·2% 
Low-density 
lipoprotein (n) 
669 6351 14619 16024 8860 1525 48048 
n 66 1118 5077 7538 4534 742 19075 
% 9·9% 17·6% 34·7% 47·0% 51·2% 48·7% 40·0% 
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Table 4.2: Prevalence of modifiable cardiovascular risk factors in different age groups in men 



















Body-mass index (n) 633 5592 11381 11423 6525 1048 36602 
Underweight (n) 12 34 22 10 6 2 86 
% 1·9% 0·6% 0·2% 0·1% 0·1% 0·2% 0·2% 
Normal (n) 398 2666 3583 2995 1575 292 11509 
% 62·8% 47·7% 31·5% 26·2% 24·1% 27·9% 31·4% 
Overweight (n) 179 2353 5722 6060 3513 604 18431 
% 28·3% 42·1% 50·3% 53·1% 53·8% 57·6% 50·3% 
Obese (n) 40 520 1984 2285 1389 144 6362 
% 6·3% 9·3% 17·4% 20·0% 21·3% 13·7% 17·4% 
Morbidly obese (n) 4 19 70 73 42 6 214 
% 0·6% 0·3% 0·6% 0·6% 0·6% 0·6% 0·6% 
Waist circumference (n) 633 5595 11376 11425 6522 1047 36598 
High (n) 58 838 2704 3210 2021 327 9158 
% 9·2% 15·0% 23·8% 28·1% 30·1% 31·2% 25·0% 
Very high (n) 35 470 1862 2487 1706 268 6828 
% 5·5% 8·4% 16·4% 21·8% 26·2% 25·6% 18·6% 
Waist-to-hip ratio (n) 633 5595 11376 11425 6522 1047 36598 
n 18 338 1593 2661 2160 392 7162 
% 2·8% 6·0% 14·0% 23·3% 33·1% 37·4% 19·6% 
Systolic blood pressure (n) 632 5593 11377 11422 6523 1048 36595 
n 24 276 986 1604 1580 325 4795 
% 3·8% 4·9% 8·7% 14·0% 39·6% 33·9% 13·1% 
Diastolic blood pressure 
(n) 
632 5593 11377 11422 6523 1048 36595 
n 18 280 1229 1738 1148 141 4554 
% 2·8% 5·0% 10·8% 15·2% 17·6% 13·5% 12·4% 
Total cholesterol (n) 180 2784 8840 10526 6211 1018 29559 
n 33 1091 5276 7230 4097 597 18324 
% 18·3% 39·2% 59·7% 68·7% 66·0% 58·6% 62·0% 
High-density lipoprotein 
(n) 
180 2784 8836 10522 6210 1018 29550 
n 25 377 1395 1594 894 124 4409 
% 13·9% 13·5% 15·8% 24·7% 14·4% 12·2% 15·0% 
Low-density lipoprotein 
(n) 
181 2740 8594 10245 6101 1004 28865 
n 26 736 3911 5469 3078 452 13672 
























Body-mass index (n) 794 5562 7247 6177 2899 535 23214 
Underweight (n) 37 195 102 82 40 6 462 
% 4·7% 3·5% 1·4% 1·3% 1·4% 1·3% 2·0% 
Normal (n) 585 3819 4231 3228 1330 232 13425 
% 73·7% 68·7% 58·4% 52·3% 45·9% 43·4% 57·8% 
Overweight (n) 126 1125 2043 1848 1019 204 6365 
% 15·9% 20·2% 28·2% 29·9% 35·2% 38·1% 27·4% 
Obese (n) 40 397 801 931 470 90 2729 
% 5·0% 14·5% 11·1% 15·1% 16·2% 16·8% 11·7% 
Morbidly obese (n) 6 26 70 88 40 3 233 
% 0·8% 0·5% 1·0% 1·4% 1·4% 0·6% 1·0% 
Waist circumference (n) 549 4284 6079 5187 2463 465 19027 
High (n) 77 645 1349 1106 610 132 3919 
% 14·0% 15·1% 22·2% 21·3% 24·8% 28·4% 20·6% 
Very high (n) 52 541 1257 1459 808 168 4285 
% 9·0% 12·6% 20·7% 28·1% 32·8% 36·1% 22·5% 
Waist-to-hip ratio (n) 549 4284 6079 5185 2463 465 19025 
n 141 1102 2380 2474 1382 310 7789 
% 25·7% 25·7% 39·2% 47·7% 56·1% 66·7% 41·0% 
Systolic blood pressure (n) 794 5560 7246 6176 2900 535 23211 
n 7 49 212 528 510 190 1496 
% 0·9% 0·9% 2·9% 8·5% 17·6% 35·5% 6·4% 
Diastolic blood pressure 
(n) 
794 5560 7248 6176 2900 535 23213 
n 7 65 256 441 272 64 1105 
% 0·9% 1·2% 3·7% 7·1% 9·4% 12·0% 4·8% 
Total cholesterol (n) 488 3616 6040 5807 2768 521 19240 
n 99 955 2307 3519 2190 396 9466 
% 20·3% 26·4% 38·2% 60·6% 82·7% 76·0% 49·2% 
High-density lipoprotein 
(n) 
488 3616 6039 5807 2768 521 19239 
n 18 105 193 181 60 14 571 
% 3·7% 2·9% 3·2% 3·2% 2·2% 2·7% 3·0% 
Low-density lipoprotein 
(n) 
488 3611 6025 5779 2759 521 19183 
n 40 382 1166 2069 1456 290 5403 
% 8·2% 10·6% 19·4% 35·8% 52·8% 55·7% 28·2% 





4.3.1.1 Body-mass index 
 
In the overall population (table 4.1), participants aged 65-75 years (group 6) had the highest 
prevalence of overweight. The highest prevalence of obesity occurred in group 5 (ages 55-64 
years) and of morbid obesity in both group 5 and 4 (ages 55-64 and 45-54) The second highest 
prevalence of overweight, obesity, and morbid obesity occurred in group 5 (ages 55-64), 4 
(ages 45-54) and 3 (35-44), respectively. Participants aged 25–34 years (group 2) had the 
highest prevalence of underweight. 
 
For men (table 4.2), group 6 (ages 65-75 years) had the largest number of participants that were 
overweight (n=604). Men aged 55-64 years (group 5) had the highest prevalence of obesity 
(n=1389).  Morbid obesity occurred in the same percentage (0·6%) in all groups except group 
2 (ages 25-34 years) where it was the lowest and equaled 0·3%. Group 2 (ages 25–34 years) 
had the largest number of participants that were underweight (n=34). Men shared similar 
pattern as the overall population; the highest prevalence of overweight and obesity was found 
in group 6 (ages 65-75 years) and 5 (ages 55-64 years) and equaled 57·6% and 21·3%, 
respectively. Men aged 18–24 years (group 1) had the highest prevalence of underweight 
(1·9%) and the lowest prevalence of overweight (28·3%) and obesity (6·3%). The second-
lowest prevalence of overweight and obesity was found in group 2 (ages 25-34 years) and 
equaled 42·1% and 9·3%, respecively. For women (table 4.3), group 5 (ages 55-64 years) had 
the largest number of participants that were overweight (n=2043); group 4 (ages 45–54 years) 
had the largest number of participants that were obese and morbidly obese (n=931 and 88, 
respectively). The highest prevalence of overweight and obesity was found in group 6 (ages 
65-75 years) and equaled 38·1% and 16·8%, respectively. The highest prevalence of morbid 
obesity occurred in both group 4 (ages 45-54 years) and 5 (ages 55-64 years) and equaled 1·4%. 
The highest prevalence of underwieght was found in group 1 (ages 18-24) and equaled 4·7%. 
Women shared the same pattern as men in the lowest prevalence of overweight, obesity, and 
morbid obesity between 18–24 years and 65–75 years. The second-lowest prevalence of 
overweight was found in group 2 (ages 25-34 years) and the second-lowest prevalence of 




4.3.1.2 Waist circumference 
 
In the overall population (table 4.1), participants aged 65-75 (group 6) had the highest 
prevalence of high and very high waist circumference (30·4% and 28·8%, respectively).  
 
For men (table 4.2), group 4 had the largest number of participants that were centrally obese 
(high: n=3210; very high: n=2487). The highest prevalence of high waist circumference 
(31·2%) was found in group 6 (ages 65-75 years). The highest prevalence of very high waist 
circumference (26·2%) was found in group 5 (ages 55-64 years). The lowest prevalence of 
central obesity (both high and very high) was found in group 1 (ages 18–24 years); the figures 
were 9·2% and 5·5%, respectively. For women (table 4.3), group 3 had the largest number of 
participants that had high waist circumference (n=1349), and group 4 had the largest number 
of participants that had very high waist circumference (n=1459). The prevalences in these two 
groups were 22·4% (high) and 28·1% (very high), respectively. The highest prevalence of both 
high and very high waist circumference occurred in group 6 and equaled 28·4% and 36·1%, 
respectively. The lowest prevalence of high and very high waist circumference were also found 
in group 1, and the figures were 14·0% and 9·0%, respectively.  
 
4.3.1.3 Waist-to-hip ratio (WHR) 
 
In the overall population (table 4.1), participants aged 65-75 (group 6) had the highest 
prevalence of higher WHR (46·4%).  
 
Women (table 4.3) were more than twice as likely as men (table 4.2) to have a higher 
prevalence of higher WHR; the rate was 19·6% in men and 41·0% in women. For both men 
and women, the highest prevalence of higher WHR was found in group 6 (37·4% and 66·7%, 
respectively); the lowest prevalence was found in group 1 (ages 18–24 years; 2·8% and 25·7%, 
respectively). The prevalence of WHR equaled 25·7% in women aged 25-34 years as well. The 
second highest prevalence of higher WHR was found in group 5 (ages 55–64 years) for both 




4.3.2 Blood pressure 
 
4.3.2.1 Systolic blood pressure 
 
In the overall population (table 4.1), participants aged 65-75 years (group 6) had the highest 
prevalence of high systolic blood pressure; those aged 55–64 (group 5) years had the second 
highest prevalence of high systolic blood pressure. Participants aged 18–24 years (group 1) had 
the lowest prevalence of high systolic blood pressure. 
 
Men (table 4.2) were about twice as likely to a have higher prevalence of higher systolic blood 
pressure as were women (table 4.3). The figures were 13·1% in men and 6·4% in women. In 
men, the highest prevalence of higher systolic blood pressure equaled 39·6% and was found in 
group 5 (ages 55-64 years). In women, it eqaled 35.5% and occurred in group 6 (ages 65-75 
years). The second highest prevalence of higher systolic blood pressure was found in group 6 
in men (33.9%) and in group 5 in women (17.6%). The lowest prevalence in men was 3·8% 
and was found in group 1 (ages 18-24). In women, both group 1 and group 2 had the lowest 
prevalence of 0·9%. 
 
4.3.2.2 Diastolic blood pressure 
 
In the overall population (table 4.1), participants aged 55-64 years (group 5) had the highest 
prevalence of high diastolic blood pressure; those aged 65-75 years (group 6) had the second 
highest prevalence of high diastolic blood pressure. Participants aged 18–24 years (group 1) 
had the lowest prevalence of high diastolic blood pressure. 
 
The prevalence of high diastolic blood pressure shared similar pattern as did systolic blood 
pressure in men (table 4.2) and women (table 4.3). The figures were 12·4% in men and 4·8% 
in women, respectively. In men, the highest prevalence of 17·6% was found in group 5 (ages 
55-64 years) and the second highest prevalence of 15·2% was found in group 4 (ages 45-54 
years). In women, the highest prevalence was 35·5% and occurred in group 6 (ages 65-75 
years) and the second highest prevalence was 17·6% and was found in group 5 (ages 55-64 
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years). The lowest prevalence occurred in group 1 in men and group 1 and 2 in women and 
equaled 2·8% and 0·9%, respectively.  
 
4.3.3 Serum lipids 
 
4.3.3.1 Total cholesterol 
 
Highest prevalence of high total cholesterol was found in group 5 (ages 55-64 years); and the 
second highest prevalence was found in group 4 (ages 45-54 years). The lowest prevalence was 
found in group 1 (ages 18–24 years) (table 4.1). 
 
The prevalence of high total cholesterol in men (table 4.2) and women (table 4.3) was 62·0% 
and 49·2%, respectivly. For men, the highest prevalence was 68.7% and was found in group 4 
(ages 45-54 years) and the second highest preavalence equaled 66·0% and occurred in group 5 
(ages 55-64 years). For women, the highest prevalence was 82·7% and was found in group 5 
and the second highest prevalence equaled 76·0% and was found in group 6 (ages 65-75 years). 
The lowest prevalence of high total cholesterol in both men and women was found in group 1 
(ages 18-24) and equaled 18·3% and 20·3%, respectively. 
 
4.3.3.2 High-density lipoprotein cholesterol 
 
The highest prevalence of low HDL was found in group 4 (ages 45–54 years); and the second 
highest prevalence was found in group 5 (ages 55-64 years). The lowest prevalence of low 
HDL was found in group 1 (ages 18–24 years) (table 4.1). 
 
Men were about five times more likely to have higher prevalence of lower HDL than in women. 
The prevalence of low HDL was 15·0% and 3·0% in men and women, respectively (tables 4.2 
and 4.3). For men, the highest prevalence of 24·7% was found in group 4 (ages 45-54 years) 
and the second highest prevalence of 15·8% in group 3 (ages 35-44 years). For women, the 
highest prevalence of 3·7% occurred in group 1 (ages 18-24 years) and the second highest 
prevalence of 3·2% was found in both gourp 3 and 4. The lowest prevalence in men was found 




4.3.3.3 Low-density lipoprotein cholesterol 
 
Highest prevalence of high LDL was found in group 5 (ages 55-64 years); and the second 
highest prevalence was found in group 6 (ages 65-75 years). The lowest prevalence was found 
in group 1 (ages 18–24 years) (table 4.1). 
 
The prevalence of high LDL in men (table 4.2) and women (table 4.3) was 47·4% and 28·2%, 
respectively. For men, the highest prevalence of high LDL was found in group 4 and equaled 
53·4%. The second highest prevalence of 50·5% occurred in gourp 5 (ages 55-64 years). For 
women, the highest prevalence was 55·7% and was found in group 6 (ages 65-75 years) and 
the second highest prevalence was 52·8% and occurred in group 5. The lowest prevalence for 





4.4.1 Overall findings of this study 
 
The prevalence of various modifiable cardiovascular risk factors—BMI, WHR, waist 
circumference, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL, and 
LDL—for clients who attended health centres across the UK were analysed from a substantial 
dataset. Overall, participants in group 6 (ages 65–75 years) had the highest prevalence of 
overweight, participants in group 5 (ages 55–64 years) had the highest prevalence of obesity. 
Participants in group 6 had the highest prevalence of high systolic blood pressure and 
participants in group 5 had the highest prevalence of high diastolic blood pressure. Participants 
in group 5 had the highest prevalence of high total cholesterol and LDL; participants in group 
4 (ages 45-54 years) had the highest prevalence of low HDL. Men in group 6 had the highest 
prevalence of overweight, but men in group 5 had the highest prevalence of obesity; women in 
group 6 had the highest prevalence of both overweight and obesity. Men in group 5 and women 
in group 6 had the highest prevalence of high systolic and diastolic blood pressures. Men in 
group 4 had the highest prevalence of high total cholesterol and LDL, as well as low HDL; 
154 
 
whereas women in group 5 had the highest prevalence of high total cholesterol, group 6 had 
the highest prevalence of high LDL, and group 1 (ages 18-24 years) had the highest prevalence 




WHO describes obesity as one of the most neglected public health problems in both developing 
and developed countries. Globally, it was estimated by WHO (2008a) that more than 1 billion 
adults 20 years or older were overweight (BMI ≥25 kg/m2) and more than 500 million were 
obese in 2008 (BMI ≥30 kg/m2). Overweight and obesity are increasing worldwide with 
changes in lifestyle such as diet and physical inactivity (Bull et al. 2004; Lock et al. 2004). In 
my study, BMI, waist circumference, and WHR will be considered together because patterns 
are similar, but individual variables will be discussed and compared with the Health Survey for 
England 2006 separately.  
 
The recent European Health Interview Survey (EHIS 2011) published by Eurostat—the 
statistical office of the European Union, aims to measure the health status, life style and health 
care of citizens across the European Union Member States on a harmonised basis. Obesity and 
overweight was measured using BMI. Among the 19 member states, the proportion of obese 
people in the adult population varied in 2008/2009 between 8·0% and 23·9% for women and 
between 7·6% and 24·7% for men. According to the report, the UK’s prevalence of obesity 
was highest in men aged 45–64 years, and in women aged 65–74 years; the figures were 31·1% 
and 33·2%, respectively. Men aged 45–64 had higher prevalence of obesity in this study, and 
the figure was 41·3%. This finding is higher than that of the EHIS study. Meanwhile, women 
aged 65–74 had the second lowest prevalence of obesity in this study, with a figure of 16·8%. 
However, women who had the highest prevalence of obesity was aged 55–64 years, with a 
figure of 46·1%. The prevalence of obesity in both men and women aged 18–24 years was the 
lowest, but was almost three times higher for women than for men (5·9% vs. 16·6%). This 
finding is very similar to my finding, which showed that the prevalence of obesity in both men 




In Canada, obesity has emerged as a critical public health issue during the past few decades. 
The Canadian Community Health Survey 2004 (CIHI 2006) showed that about 36% of 
Canadian adults were overweight, and almost 23% could be recognised as obese. In the USA, 
the prevalence of obesity was 26·8% for women and 27·6% for men in 2009 (Pleis et al. 2010). 
A study of the prevalence of obesity in urban Delhi has been completed by the Nutrition 
Foundation of India. It has reported that the prevalences of overweight (BMI ≥25 kg/m2) and 
obesity (BMI >30 kg/m2) were 50% and 14%, respectively (Gopalan 1998). However, this was 
in contrast to my findings—the prevalences of overweight and obesity in the overall population 
were 41·4% and 15·2%. The prevalence of obesity was 11·7% for women and 17·4% for men. 
It seems that the rate of overweight in my study is higher than in other developed countries 
such as Canada, but lower than in developing countries such as India. The rate of obesity is 
lower in my study than other developed countries such as the USA, but higher than other 
developing countries such as India. This finding could result from the fact that the population 
in my study was more affluent than the general UK population and could afford private medical 
insurance; the prevalence of obesity in men and women in the general UK population is 22·1% 
and 23·9%, respectively (EHIS 2011).  
 
Our findings were different from Health Survey for England 2006 (2008). In this survey, the 
prevalences of overweight and obesity, which was measured by BMI, were 43% and 24% in 
men, and 32% and 24% in women. The current research showed that the prevalences of 
overweight and obesity were 50·3% and 17·4% in men, and 27·4% and 11·7% in women. In 
the present research, men seemed more likely to be overweight but less likely to be obese than 
were those in Health Survey for England; women were less likely to be overweight and obese. 
Also, in the Health Survey for England 2006, men were more likely to be overweight than were 
women in all age groups, and were more likely to be obese than were women aged less than 65 
years. However, they were less likely to be obese than were women aged 65 years and older. 
There were some similarities between this research and the Health Survey for England 2006—
men were more likely to be overweight than were women aged 18 years and older, but results 
were not consistent in men and women who were obese. Also, in a systematic review of the 
evidence for diagnosis and treatment of obesity in older adults, McTigue et al. (2006) found 
that obesity could be diagnosed easily and inexpensively using an anthropometric measure. 
BMI might have the greatest clinical utility because it is linked with the widest range of health 
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states, and waist circumference and WHR might be useful adjuncts for assessing cardiovascular 
risk in adults who were aged 60 years and older.  
 
In the Health Survey for England 2006 (2008), the prevalence of raised waist circumference, 
which was defined as to be greater than 102 cm in men and greater than 88 cm in women, was 
32% in men and 41% in women. In the current research, the figures for men and women were 
18·6% and 22·5%, respectively. Compared with the population in the Health Survey for 
England 2006, men and women were shown to be less obese in the current research findings. 
According to the data from Health Survey for England 2006, women were more likely to have 
raised waist circumference than men. Men and women shared the same pattern in all age 
groups, in which their raised waist circumference went up with the increase of their age up to 
75 years, but suddenly going lower aged 75 years and older. In the current research, women 
were also more likely to have a raised circumference than men aged less than 35 years, but less 
likely aged 35 years and older. The similar pattern of prevalence in men and women which 
showed the raised waist circumference was going up with the increase of age less than 45 years, 
and going down with the decrease of age at 45 years and older. 
 
Overall, men and women in the current research were shown to be healthier in terms of 
adiposity than the population from the Health Survey for England 2006. One reason could be 
because people who attended private medical screening were from least deprived groups, and 
they were wealthier and healthier. In a recent report of eating habits in 19 European Union 
countries published by the European Food Information Council (2011), it was suggested that 
the British were not eating enough fruit and vegetables. The analysis showed that the British 
ate 258g (9·1oz) of fruit and vegetables a day, compared with a European average of 386g 
(13·6oz), and even lower than 400g (14·1oz) minimum consumption recommended by WHO. 
People from the most deprived groups may not be able to afford enough fruit and vegetables 
compared with those from the least deprived groups (Dibsdall et al. 2003). High costs might 
negatively affect intake on fruit and vegetables, especially in the most deprived groups. Thus, 
affordability, availability, and accessibility are likely to be several factors mediating the effect 
of socioeconomic groups on fruit and vegetable consumption (Kamphuis et al. 2007; WHO 
2005b). Therefore, further research into the association between socioeconomic groups and 




Many dietary interventions encourage participants to eat less fat and more fruit and vegetables, 
restrict their dietary sodium intake to less than 6 g per day, avoid processed food with high salt 
content, add less salt to food or substitute low-sodium salt, and take regular aerobic exercise 
for at least 30 min three to five times a week. Overweight patients should be encouraged to 
lose weight through a low-calorie diet and exercise. Clinicians should ascertain their patients’ 
alcohol consumption and recommend reduced intake if patients drink excessively. It might be 
more appropriate to recommend inclusion of oily fish in a healthy diet rather than fish oil 
supplements (Kris-Etherton et al. 2002).  
 
BMI has been routinely used in clinical and public health practice for decades to identify 
individuals and populations at risk of future cardiovascular disease. However, in recent years, 
BMI has been criticised as a measure of risk because it reflects both fat and lean mass and 
because it does not identify fat distribution (Mason et al. 2008). A growing body of evidence 
suggests that abdominal adiposity is a more important risk factor for cardiovascular disease 
than is general adiposity (Janssen et al. 2004). The mechanisms through which abdominal fat 
contributes to the risk of these diseases are not fully understood, although one of the 
components of abdominal fat—visceral adipose tissue, which is highly metabolically active—
is believed to play a key part (Despres 2006).  
 
Several studies have recommended the use of anthropometric measures that capture abdominal 
adiposity, such as waist circumference and WHR, as alternatives to, or in addition to, BMI in 
assessment of disease prediction in clinical practice and public health surveillance 
(Dobbelsteyn et al. 2001; Pischon et al. 2008; Yusuf et al. 2005). There are, however, concerns 
about the reliability of these measurements (Sebo et al. 2008), because waist and hip 
circumference can differ depending on the precise site at which they are measured (Wang et 
al. 2003). Results from published studies to date that have tried to compare different 
measurements of general and regional adiposity have not been consistent. BMI has been 
compared separately with different anthropometric measures, and different outcome measures 
have been assessed (Canoy et al. 2006; Pischon et al. 2008; Vazquez et al. 2007; Wannamethee 
et al. 2005). This is why several measures were used including BMI, WHR and waist 




4.4.3 Blood pressure 
 
Men in group 5 (ages 55–64 years) and women in group 6 (ages 65–75 years) had the highest 
prevalence of raised systolic and diastolic blood pressures. The figures in men were 39·6% of 
systolic blood pressure and 17·6% of diastolic blood pressure, and in women were 35·5% of 
systolic blood pressure and 12·0% of diastolic blood pressure.  
 
In the current research, the prevalence of raised systolic and diastolic blood pressures in men 
were 13·1% and 12·4%, respectively; whearas the prevalence of raised systolic and diastolic 
blood pressures in women were 6·4% and 4·8%, respectively. These figures are lower than 
those in the Health Survey for England 2006 (2008), in which the prevalence of hypertension 
was 34% in men, and 32% in women. These figures are also lower comparable to the USA. In 
the US NHANES 1999–2002, hypertension prevalence was much lower, 29·0% in women 
versus 27·8% in men (CDC 2005). As mentioned earlier for the obesity issue, wealth might be 
a factor to explain the difference. This could be applied to hypertension. In terms of treatment, 
a diet rich in fruits, vegetables, and low-fat dairy foods with reduced saturated and total fat can 
substantially lower blood pressure, concluded the findings in the DASH trial (Appel et al. 
1997). However, it is important to emphasise that DASH trial was an 11-week feeding study. 
It was not designed to identify the effective or ineffective components of the diets. Adherence 
to the diets among people selecting their own food or the long-term effects of the diets on blood 
pressure and clinical cardiovascular events. But several clinical and public health benefits—
eg, an effective nutritional approach to preventing hypertension, effective alternative to drug 
therapy, and potentially shift the population distribution of blood pressure downward, reducing 
the occurrence of blood pressure-related cardiovascular disease—are also implied. Such a diet 
offers an additional nutritional approach to the prevention and treatment of hypertension.  
 
The difference between my study and other studies could be explained by the different 
techniques or under certain conditions used for measurement. Any definition of hypertension 
should be based on the assumption that appropriate techniques are used for the measurement 
and that the conditions under which the measurement is obtained are described. Guidelines for 
defining hypertension have been modified by expert panels over time to lower blood pressure 
levels as more information has become available. JNC VII, published in 2003, defines normal 
blood pressure as <120/80 mm Hg (Chobanian et al. 2003). This definition is based primarily 
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on epidemiologic data rather than on outcomes of clinical trials. Individuals with systolic blood 
pressure 120–139 mm Hg or diastolic blood pressure 80–89 mm Hg are considered 
prehypertensive, and individuals with systolic blood pressure ≥140 mm Hg and/or diastolic 
blood pressure ≥90 mm Hg are considered to have hypertension. These guidelines are based 
on the average of two or more seated blood pressure readings during each of two or more office 
visits. Home blood pressures and average 24 h ambulatory blood pressures are generally lower 
than clinic blood pressures. A blood pressure of 135/85 mm Hg has been recommended as the 
upper limit of normal for home and average awake ambulatory blood pressures (Pickering et 
al. 2005). White-coat hypertension, also associated with increased cardiovascular disease risk, 
has been defined as a blood pressure persistently ≥140/90 mm Hg in the office or clinic and an 
average awake ambulatory reading <135/85 mm Hg (Verdecchia et al. 2003).  
 
The prevalence of hypertension was increasing with the increase of age in women, but in men 
before age 65 years old. This finding is in line with many studies which documented an increase 
in hypertension prevalence with age (Burt et al. 1995; CDC 2005; Hajjar and Kotchen 2003; 
Vasan et al. 2002; Whelton et al. 2004; Wolf et al. 1997; Wolf et al. 2003). In the current study, 
the prevalence of raised systolic blood pressure in women was higher than in men aged 65–75 
years (35·5% vs 33·9%). This is similar to other research which documented individuals aged 
60 or older, in which mean systolic blood pressure for women was higher than that for men 
(Hajjar et al. 2001). This is because most clinical trials, to ensure adequate events, limit 
recruitment to patients older than 55 years and have usually reported a mean age of the study 
populations of more than 65 years. Thus, younger patients are poorly represented in outcome 
trials. This is a concern because modern prevention strategies for cardiovascular diseases 
increasingly advocate the importance of primary prevention and treatment of increasing 
numbers of younger patients. It is conceivable that in younger patients, subtle differences in 
drug effects on various surrogate or “intermediate” disease markers could have an important 
beneficial effect over the long term (Williams 2005). However, many developing countries do 
not experience increases in prevalence of high blood pressure and hypertension with age 
(Kaminer and Lutz 1960; Oliver et al. 1975; Pavan et al. 1997; Sever et al. 1980; Stamler et 
al. 1976; Truswell et al. 1972). A common characteristic of these populations is a low dietary 
salt intake (Elliott et al. 1996). When these populations migrate to a more developed society, 




4.4.4 Plasma cholesterol 
 
Men in group 4 had the highest prevalence of high total cholesterol and LDL, as well as low 
HDL; whereas women in group 5 had the highest prevalence of high total cholesterol, group 6 
had the highest prevalence of high LDL, and group 1 (ages 18-24 years) had the highest 
prevalence of low HDL. 
 
In the Health Survey for England 2006, the prevalence of high total cholesterol was 57% in 
men and 61% in women. In men, the prevalence of high total cholesterol increased in those 
aged less than 55 years, but decrease aged 55 years and older. It is a slightly different in women, 
in which the prevalence was going up with the increase of age at less than 65 years, and 
decreased aged 65 years and older. Women are more likely to have higher total cholesterol than 
men aged 16–24 years, but less likely aged 25–44 years. The absolute difference between men 
and women aged 45–54 years is 4%, which is the smallest gap in all age groups, but women 
are more likely to have higher total cholesterol than men aged 45 years and older. 
 
Our findings were in agreement with Health Survey for England 2006. In that survey, men 
were about five times more likely to have lower HDL than women. The prevalence of low HDL 
was 1·8% in women, and 9·4% in men. In the current research, although the rates were higher, 
the prevalence of low HDL was 3·0% in women, and 15·0% in men. The prevalence of low 
HDL in men was going down with the decrease of the age less than 55 years, and was much 
the same between age groups of 45–54 years and 55–64 years, then increase aged 65–74 years. 
It then decreased again aged 75 years and older. In women, the prevalence of low HDL was 
much the same in age groups 16–24 years, 25–34 years and 65–74 years, which was 2·2%. The 
prevalence was going down with the increase of the age less than 65 years, and the lowest 
prevalence of low HDL was found in women aged 75 years and older, which was 0·2%.  
 
4.4.5 Strengths and limitations 
 
There are some similarities between European Health Interview Survey and my study. 
European Health Interview Survey used Health Survey for England 2009 as the data source for 
United Kingdom. In the survey, adults were asked questions about the general health, alcohol 
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consumption, smoking, fruit and vegetable consumptions. The core sample of Health Survey 
for England 2009 comprised 4680 addresses selected at random in 360 postcode sectors. 
Although this was a short period of survey with a small sample size, which showed the strength 
of the present study having a larger sample size, the population in Health Survey for England 
2009 should be representable because my study population is more affluent. Most of the 
participants were employees and could afford private medical insurance. Blood pressure in the 
Health Survey for England 2009 used Omron HEM 907, but the investigators consider systolic 
and diastolic blood pressure of 180/115 mm Hg as raised, which is different from the cut-off 
point in my study (140/90 mm Hg), so there is a possibility for the prevalence of hypertension 
is much higher in my study. Blood sample was non-fasting, and was analysed by Olympus 640 
analyser; this analyser is operated by a professional staff, so the errors should be reduced to 
minimum and higher precision than finger prick. The data difference between Health Survey 
for England 2009 and my study could also be due to the period of data collection. There is also 
a difference in the design of the study, which HSE 2009 was a cross-sectional survey, and my 
study is a retrospective study.  
 
Differences between ethnic groups in various modifiable cardiovascular risk factors were not 
analysed in this study because ethnic group was not recorded by the company. However, 
several population-based studies in the UK have investigated ethnic differences in order to 
explain the variability in cardiovascular disease mortality and morbidity. Some authors 
reported a raised prevalence of hypertension in Afro-Caribbean populations and in south 
Asians. Additionally, most of these studies have also reported significantly higher mean blood 
pressure levels in both Afro-Caribbean populations and south Asian men compared with white 
Caucasian populations (Cappuccio et al. 1997; Chaturvedi et al. 1993; Primatesta et al. 2000).  
 
The medication of the participants in the dataset was also not recorded. However, Roth and 
colleagues (2010) conducted an analysis of medication coverage and therapeutic control in total 
cholesterol from eight countries including England. Their findings suggested that effective 
delivery of cholesterol lowering medication has increased three times in England and five times 
in the USA during the past two decades. This was associated with the increase use of 
medication among the diagnosed population rather than an increase in the fraction of the 
population that is diagnosed. Therefore, efforts to screen more people and make them aware of 
their high total cholesterol concentrations have been less successful than efforts to deliver 
162 
 
treatment to those who know they are hypercholesterolaemic. The assessment of diagnosis and 
medication use was based on a self-reported response. There were therefore concerns about the 
data validity, reliability and comparability. Also, the available data often came from different 
time periods, so, comparisons across countries may be confounded. In this study, investigators 
defined high total cholesterol as ≥6·2 mmol/l, which is now considered to be higher than 
optimal.  
 
Our data showed that participants registered in the private medical company were more likely 
to be overweight, especially men who were almost twice as likely as were women. One in two 
men were overweight when using BMI as a measurement. Compared with participants in 
Health Survey for England 2006, our findings showed that participants had much a lower 
prevalence of hypertension and raised total cholesterol. Men and women had a similar pattern 
on the prevalence of low HDL, which in men was five times higher than in women. There is 
little research evidence about the prevalence of LDL and WHR, with the most available 
evidence on LDL having a focus on therapeutic coverage. Because participants are registered 
in a private medical insurance company, it is likely that socioeconomic status in this research 
is significantly different from those in the Health Survey for England 2006. Socioeconomic 
status has a strong effect on cardiovascular disease and associated risk factors, therefore, 
research is needed to evaluate socioeconomic status on cardiovascular risk factors in those 
people who attend private medical screening. Finally, our findings showed some similarity 
with existing studies, especially in the UK population. Most importantly, our dataset is one of 
the largest UK from a commercial setting. More research in the private sector is needed because 





The findings are mixed when compared this affluent population to the general population in 
the Health Survey for England. Using BMI as a measurement, men attended the Nuffield 
Health seemed more likely to be overweight but less likely to be obese than were those in 
Health Survey for England; women were less likely to be overweight and obese. However, 
when using waist circumference as a measurement for overweight and obese, compared with 
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the population in the Health Survey for England 2006, men and women were shown to be less 
obese in the current research findings. Men and women attended the Nuffield Health seemed 
less likely to have higher total cholesterol than were those in Health Survey for England. Men 
were about five times more likely to have lower HDL than women, but the prevalence was 
lower in Health Survey for England than were those in the Nuffield Health both in men and 
women. As can be seen, these differences about prevalence of cardiovascular risk factors in the 
two populations, it is therefore important to compare the populations from similar 
socioeconomic groups or regions because they might have much the same cardiovascular 
outcomes.  
 
In Chapter 7, a public-funded NHS dataset was provided by the Hampshire Health Record. 
South England region, where the Hampshire Health Record collected its data, is a more affluent 
region in the UK compared with other regions in terms of the Indices of Multiple Deprivation 
(IMD) 2007 score. Nuffield Health is a private medical insurance company, so people who 
attended Nuffield Health were more likely to be from a higher socioeconomic class. Therefore, 
Chapter 7 aims to compare the prevalence of various modifiable cardiovascular risk factors 
between Nuffield Health (private health screening) and Hampshire Health Record (NHS Trust), 
and to identify the similarities and differences of the two datasets in relation to the 
cardiovascular risk factors. 
 
People aged 55–75 signed up the private medical insurance are more likely to have more than 
one cardiovascular risk factor. Although they are generally healthy and wealthy, there is a 
possibility to develop cardiovascular disease due to the high prevalence of cardiovascular risk 
factors in this age group. Compared to the other age groups, this special age group deserves 
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SOCIOECONOMIC STATUS AND MODIFIABLE CARDIOVASCULAR RISK 





Aim: Many modifiable cardiovascular risk factors are strongly related to socioeconomic 
position. This chapter aims to examine the influence of socioeconomic status and other 
covariates on modifiable cardiovascular risk factors in people attended private health 
screening. 
 
Methods: A retrospective study of 60,334 participants aged between 18 and 75 across the UK 
was conducted using a dataset provided by a private healthcare company. Eight risk factors 
were analysed: body mass index (BMI), waist size, waist-to-hip ratio (WHR), systolic and 
diastolic blood pressure, total cholesterol (TC), HDL-C and LDL-C. The English Indices of 
Deprivation 2007 scale was used to allocate deprivation scores, and the cohort was divided by 
quintile (group 1 being the least deprived and group 5 the most deprived). 
 
Results: After adjusting for age, sex and smoking, obesity (BMI) were significantly higher in 
the two most deprived quintiles (Group 4: odds ratio=1.14, 95% CI 1.05, 1.25, p=0.002 and 
Group 5: odds ratio=1.24, 95% CI 1.13, 1.36, p<0.001). Waist circumference was significantly 
higher in the three most deprived quintiles (Group 3: odds ratio=1.15, 95% CI 1.06, 1.24, 
p=0.001; Group 4: odds ratio=1.17, 95% CI 1.07, 1.27, p<0.001 and Group 5: odds ratio=1.23, 
95% CI 1.13, 1.34, p<0.001) and, compared with the least deprived group, all other groups had 
a greater likelihood of age-, sex- and smoking- adjusted waist-to-hip ratio. Adjusted odds ratio 
for systolic blood pressure was the highest in participants from group 4 (odds ratio=1.07, 95% 
CI 0.97, 1.18), and lowest in groups 2 (odds ratio=0.95, 95% CI 0.86, 1.05) and 5 (odds 
ratio=0.95, 95% CI 0.85, 1.06), but no statistically significance was shown among five groups. 
Adjusted odds ratio for diastolic blood pressure was significant lower in participants from the 
least deprived group (odds ratio=0.83, 95% CI 0.74, 0.94, p=0.002). Compared with the least 
deprived group, the three most deprived groups were significantly less likely to have raised 
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total cholesterol, and statistical significance was shown in the most deprived group (odds 
ratio=0.84, 95% CI 0.78, 0.91, p<0.001) Compared with the least deprived group, the 
likelihood of elevated low density lipoprotein was decreased in the two most deprived groups, 
and statistical significance was shown in the most deprived group (odds ratio=0.84, 95% CI 
0.77, 0.91, p<0.001). There was a general trend towards a lower likelihood in more deprived 
groups, but overall there were no significant between-group differences in the likelihood of 
having a low HDL subfraction between these groups.  
 
Discussion: The present data concur with previous findings, showing a positive association 
between anthropometric indices of adiposity and deprivation. This was evident for BMI in the 
most deprived groups, but much more so, for waist circumference and WHR where all groups 
were more likely to be centrally obese compared with the least deprived. The prevalence of all 
anthropometric measures indicating obesity was high in women. It appears from the present 
data, that being within the most deprived group was a significant predictor of having a more 
healthy blood pressure reading. Like blood pressure, plasma cholesterol is a risk factor often 
associated with increased adiposity. In this study, participants from the least deprived areas had 
less favourable serum lipids compared with those individuals from the most deprived areas. 
However, both total cholesterol and low-density lipoprotein cholesterol measures were 
significantly lower in the most deprived groups. Indeed it appears from the present data, being 
in the most deprived group (only) was a significant predictor of having a more healthy plasma 
lipid reading.  
 
Conclusion: Our study indicated that the mechanisms underlying the association between 
socioeconomic status and modifiable cardiovascular risk factors are complex. In conclusion, in 
this retrospective study of 55,217 participants attending private medical screening, we have 
shown that people are more likely to be obese, but less likely to have hypertension, raised total 
cholesterol and LDL in the most deprived areas compared with the least deprived areas. Hence, 





5.1 INTRODUCTION  
 
Cardiovascular disease accounts for around 30% of global deaths each year, and it is still 
growing, from 17.1 million in 2004 to an anticipated 23.4 million in 2030 (Chockalingam et al. 
2000; Mathers et al. 2006; WHO 2008). The landmark INTERHEART case-control study 
across 52 countries identified nine modifiable cardiovascular risk factors which accounted for 
over 90% of the contribution to risk of an initial acute myocardial infarction for young men 
and women worldwide. These are: cholesterol, smoking, blood pressure, diabetes, abdominal 
obesity (waist-to-hip ratio), psychosocial factors (including depression and stress), 
consumption of fruits and vegetables, consumption of alcohol, and physical activity (Yusuf et 
al. 2004).  
 
A recent report published by the Institute of Medicine (2010) noted that cardiovascular disease 
is not only a foremost cause of death in high income countries, but has also become a major 
impact in low and middle income countries. The increased prevalence of risk factors for 
cardiovascular disease including tobacco use, poor nutrition, low physical activity, elevated 
blood lipids, and hypertension. These reflect significant global changes in behaviour and 
lifestyle in both high and low middle income countries (Daar et al. 2007; IOM 2010; Marmot 
and Wikinson 1999). These risk factors were associated with social determinants such as 
income, wealth, and educational attainment.  
 
Socioeconomic status is a measurement of individual characteristics such as occupation, 
income and educational level, or characteristics of the area in which individuals live. In terms 
of educational levels, Roohafza et al. (2005) found an inverse association with several 
cardiovascular risk factors such as serum cholesterol, blood pressure and BMI, but no 
significant association with smoking. Occupation is a social determinant which is 
independently associated with cardiovascular risk factors (Gregory et al. 2007; McFadden et 
al. 2008). If the behaviours impacting on energy imbalance do not change, this imbalance may 
accumulate over time, resulting in an accelerated rate of weight gain among low socioeconomic 
groups (Ball and Crawford 2004). There is a strong relationship between occupational social 
class, high blood pressure and cholesterol level. Manual workers are at higher risk of 
cardiovascular disease than non-manual workers (Rose et al. 1981; Woodward et al. 1992). 
The association between income and cardiovascular risk factors are found in the US National 
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Health and Nutrition Examination Survey (NHANES)—prevalence of hypertension decreased 
from the lowest to highest income groups. This was also found in Finnish men from three 
regions (Harald et al. 2008; Kanjilal et al. 2006). However, a different pattern was found in a 
Canadian cross-sectional study examining the trends of modifiable cardiovascular risk factors 
from the perspective of socio-demographic correlates. Regional variations and temporary 
trends that hypertension was detected in all income groups. (Lee et al. 2009).  
 
Using professional classification, Emberson et al. (2004) found that BMI was higher in manual 
than non-manual UK workers. Puslaw (2008) found that higher BMI values were found with a 
decrease in professional classification. Dragano et al. (2005) found that people having the least 
education were twice as likely to be obese than the most educated in Czech Republic. This ratio 
was 1.6 in Germany. Stafford and colleagues (2010) found that residence in a more deprived 
neighbourhood contributed to a higher initial BMI when the study started. There was also a 
note that in the longitudinal, multilevel Whitehall II study over 13 years follow-up using 
Townsend index of multiple deprivation at census-ward level, participants from the most-
deprived neighbourhoods experienced relatively greater weight gain over time, an increase of 
1.5kg/m2 in men and 1.4kg/m2 in women. Wang et al. (2007) gathered five cross-sectional 
surveys conducted by the Stanford Heart Disease Prevention Programme between 1979 and 
1990 and found that participants from low socioeconomic neighbourhoods had a higher mean 
BMI than those from high socioeconomic neighbourhoods, after adjusting for age, gender, 
ethnicity, individual-level socioeconomic status, smoking, physical activity and nutrition 
knowledge. A similar finding has also been established in the GLOBE study (van Lenthe and 
Mackenbach 2002); the odds ratios of BMI increased significantly with increasing 
neighbourhood deprivation, after adjusting for sex. 
 
Chen and Tunstall-Pedoe (2005) conducted the Scottish MONICA survey in 2,233 men and 
2,516 women aged 25-64 years to investigate the relationship of waist circumference to 
socioeconomic deprivation, measured by the Carstairs Index. In this cross-sectional survey, 
they also compared the relationship of waist circumference to WHR and BMI and found that a 
large waist circumference has a closer relationship than WHR and BMI to the socioeconomic 
deprivation in men and women, although waist circumference, WHR and BMI increased with 
level of deprivation significantly in both sexes. The situation between the highest and lowest 
income groups in terms of the prevalence of hypertension in developed countries such as USA 
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and European countries are different from the developing countries. In the developed countries, 
the Kuopio Ischemic Heart Disease Risk Factor Study found that, after adjustment for smoking, 
hypertension, dyslipidemia, and diabetes, it resulted in a modest (24%) attenuation of the 
relative socioeconomic gradient of CHD risk. The most deprived groups still had higher risks 
compared with those in the least deprived groups. These risk factors accounted for most (72%) 
of the absolute socioeconomic gradient (Lynch et al. 2006). In developing countries, a study 
of low-income rural women in Mexico similarly observed an inverse association between 
educational attainment and systolic blood pressure and a positive association with income, 
housing and asset index (Fernald et al. 2008). A cross-sectional study assessed hypertension in 
an urban working population in Ghana. It showed a lower prevalence of hypertension in 
participants of the most deprived groups and highest prevalence in those of the least deprived 
groups with an inconsistent pattern among participants in the intermediate deprived groups. 
There was a suggested negative association between the level of education and hypertension 
after controlling for the other measures of social indicators, such as employment and current 
wealth (Addo et al. 2009).  
 
Socioeconomic status is one of the strongest predictors of morbidity and premature mortality 
(Winkleby et al. 1992). Many cardiovascular risk factors are strongly related to socioeconomic 
status (Emberson et al. 2004; Huisman et al. 2005; Kanjilal et al. 2006; Kivimaki et al. 2007), 
Ellaway et al.  (1997) found an increasing mean BMI with an increasing level of deprivation. 
Reijneveld (1998) noted a statistically significantly increased risk of obesity (BMI >27kg·m2) 
in the most, compared with the least deprived areas. This remained significant after adjustment 
for three indicators of social status. Cardiovascular risk is determined by the area of residence, 
independently and in addition to the effect of individually measured socioeconomic status 
(Ashworth et al. 2008; Sundquist et al. 2004). Kerr et al. (2008) showed that a high burden of 
modifiable cardiovascular risk factors, particularly in younger people among Maori and Pacific 
people from areas of high deprivation in New Zealand.  
 
At present, several area-based indices have sought to measure socioeconomic status as distinct 
from individual socioeconomic position (Payne et al. 2009; Stewart et al. 2009; Townsend 
1987). Deprivation indices are easier to apply in clinical practice than most other measurement 
of socioeconomic status (Blakely et al. 2002), and have consequently become popular among 
public health researchers. This is because information about individual measures of 
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socioeconomic status may be incomplete and potentially inaccurate. When employed as a 
dependent measure, deprivation indices provide a way by which routine population-based 
primary care data can be used to examine the effects of socioeconomic deprivation in 
determining cardiovascular risk factors.  
 
Cardiovascular risk factors and the prevalence of cardiovascular disease itself are both 
associated with deprivation or analogous measures such as socioeconomic status, but few data 
from private medical companies are available in the UK. The aim of this chapter is, therefore, 
to examine the association between area-level status and objectively-measured, modifiable 
cardiovascular risk factors in a non-clinical UK population who attended private health 
screening. 
 
5.2 MATERIAL AND METHODS  
 
5.2.1 Study setting and data collection 
 
Data were provided by a private health-care company, Nuffield Health. Identification of 
individuals is not possible from these data, because they are provided by a unique patient 
reference number in a dataset. The assessment programmes were delivered through a bespoke 
electronic patient-record system developed exclusively for Nuffield Health, the Vi System. This 
system offers greater accuracy and speedier and more comprehensive reports than other 
systems (eg, paper-based systems). It has four interventions—Vi3, Vi4, Vi5, and Vi6. It provides 
instant comparison with previous test results and the ability for clients to use any of their 
centres in the UK and immediately access the records. Data were extracted from the records 
of the Nuffield Health. Aggregate data provided by the Nuffield Health were anonymised, in 
line with the Information Commissioner Office’s (2013) anonymisation code, it can be freely 
processed and publicly disclosed. Data were recorded for participants during screening for 
provision of employment-related medical care. At each of the company’s testing sites, data 
were collected by trained health professionals using protocols consistent with the British 
Hypertension Society (for blood pressure and blood analysis) and American College of Sports 




5.2.2 Individual level cardiovascular risk factors 
 
Several established cardiovascular risk factors represent the risk profile of the participants:  (1) 
anthropometric characteristics; (2) blood pressure; and (3) plasma serum. We examined BMI, 
WHR, and waist circumference. Obesity was examined by BMI, waist-to-hip ratio (WHR), 
waist circumference, separately. BMI was classified as obese if over 30 kg/m2. Waist 
circumference was measured at the anatomical waist, central obesity was defined as greater 
than 102cm in men and greater than 88 cm in women. The waist-to-hip ratio was calculated 
and defined as high if values were greater than 0.95 in men and  greater than 0.80 in women 
(Croft et, al. 1995). Hypertension was classified as greater than 90 mm Hg (diastolic) and 
greater than 140 mm Hg (systolic; NICE 2006b). Plasma serum includes total, HDL, and LDL 
cholesterol. Arterial blood was drawn and analysed. Total cholesterol, LDL subfraction, and 
HDL subfraction were measured. Total cholesterol was classified as raised if higher than 6.0 
mmol/L. HDL was classified as low if less than 1·0 mmol/L; LDL was defined as raised if 
greater than 3·36 mmol/L (Contois et al. 1996). 
 
5.2.3 Individual level covariates 
 
Age and sex were adjusted in all multivariate analyses. Age was defined as a continuous 
variable. On the basis of current evidence (Purslow et al. 2008; Stafford et al. 2010) and 
available data collection, smoking was defined as covariates and it has been divided into three 
categories – none (never smoked and given up), light smoker (no more than 10 per day) and 
heavy smoker (above 10 per day). 
 
5.2.4 Area level socioeconomic status 
 
The English Indices of Deprivation (Noble et al. 2008) were calculated from each clients’ home 
postcode. This was used to compare the different risk factors from the least deprived to the 
most deprived areas. These area level indices can be used to contrast disadvantaged areas or 
populations (Carstairs et al. 1995; DETR Indices of Deprivation 2000; Morris et al. 1991). The 
Indices were established to capture the multidimensional concept of socioeconomic deprivation 
and are based on various indicators within seven distinct domains—income, employment, 
182 
 
health and disability, living environment, crime, barriers to housing and services, and 
education, skills and training. A total of 38 indicators are distributed across these seven 
domains, with the aim of measuring both financial resources and consequent outcomes. The 
English Indices of Deprivation 2007 scale was used to allocate deprivation scores on the basis 
of postcode, and the cohort was divided by quintile (group one being the least deprived and 
group five being the most deprived). This was used to compare the different risk factors from 
the least deprived to the most deprived areas.  
 
5.2.5 Statistical Analysis 
 
Descriptive statistics were generated. Binary logistic regressions were performed to investigate 
the impact of socioeconomic status on different modifiable cardiovascular risk factors, as 
measured in people attending private healthcare screening. The association between groups and 
cardiovascular risk factors was evaluated by the odds ratios after adjustment for age, sex, 
smoking and deprivation. Both results are compared in the statistical analysis. Data from this 
study were analysed by using SPSS Version 17.0 (SPSS, Inc., Chicago, IL). All baseline data 




5.3.1 Descriptive statistics for Nuffield dataset in different measures 
 
A retrospective study of 55 217 participants aged between 18-75 years old across the UK was 
selected for analysis. Demographic and clinical characteristics of the population in different 
socioeconomic groups in the format of mean and standard deviation (SD) values are shown in 
Table 5.1. As we could see from the comparison below, the study population attended the 
Nuffield Health are slightly affluent in the two least groups, and about twice as affluent than 
national IMD rank in the two most deprived groups 
 
Table 5.1: Demographic and clinical characteristics of the population in different 
socioeconomic groups (mean and SD) in private dataset 










Age (years) 46.6 (10) 46.2 (10) 45.7 (11) 43.6 (11) 40.0 (11) 





























BMI (kg/m2) 26.31 (4.04) 26.28 (4.10) 26.26 (4.13) 26.13 (4.31) 25.83 (4.44) 
Waist 89.6 (12.53) 89.7 (12.58) 89.5 (12.86) 88.7 (13.11) 87.2 (13.13) 




SBP 125 (15.13) 124 (14.90) 124 (15.26) 123 (15.18) 121 (14.53) 
DBP 80 (9.75) 80 (9.67) 80 (9.83) 79 (9.91) 77 (9.72) 
Cholesterol 
(mmol/l) 
     
Total 5.4 (0.98) 5.3 (0.99) 5.3 (1.01) 5.3 (1.00) 5.1 (1.00) 
HDL 1.5 (0.42) 1.5 (0.41) 1.5 (0.42) 1.5 (0.42) 1.5 (0.40) 
LDL 3.2 (0.89) 3.2 (0.90) 3.2 (0.92) 3.1 (0.89) 3.0 (0.86) 
 
5.3.2 Anthropometric characteristics 
 
Mean BMI was the highest in participants from the least deprived areas and the lowest in those 
from the most deprived areas. Socioeconomic status has a very limited influence on BMI, as 
there was no statistical significance was shown between groups. Multiple logistic regression 
models were constructed to assess the effects of socioeconomic status on the impact of BMI. 





Risk factors Number of 
people 
Model 




Body mass index 
(Obese) 
55032   
Deprivation groups    
Group 1 (least deprived) 11148 1.00  
Group 2 10900 1.00 (0.92-1.09) 0.91 
Group 3 10988 1.03 (0.94-1.12) 0.52 
Group 4 11018 1.14 (1.05-1.25) 0.002 
Group 5 (most deprived) 10978 1.24 (1.13-1.36) 0.000 
Sex    
Male  1.00  
Female  0.69 (0.65-0.77) 0.000 
Age  1.02 (1.016–1.022) 0.000 
Smoking    
0 (non-smoker)  1.00  
1 (light smoker)  0.89 (0.78-1.02) 0.09 
2 (heavy smoker)  1.19 (1.03-1.38) 0.017 
Waist circumference 
(Obese) 
51042   
Deprivation groups    
Group 1 (least deprived) 10529 1.00  
Group 2 10237 1.07 (0.99-1.16) 0.09 
Group 3 10269 1.15 (1.06-1.24) 0.001 
Group 4 10105 1.17 (1.07-1.27) 0.000 
Group 5 (most deprived) 9902 1.23 (1.13-1.34) 0.000 
Sex    
Male  1.00  
Female  1.31 (1.24-1.38) 0.000 
Age  1.035 (1.033–1.038) 0.000 
Smoking    
0 (non-smoker)  1.00  
1 (light smoker)  1.05 (0.93-1.19) 0.40 
2 (heavy smoker)  1.40 (1.23-1.60) 0.000 
Waist-hip-ratio (WHR) 
(Obese) 
51049   
Deprivation groups    
Group 1 (least deprived) 10530 1.00  
Group 2 10238 1.15 (1.07-1.23) 0.000 
Group 3 10270 1.16 (1.08-1.25) 0.000 
Group 4 10107 1.23 (1.14-1.33) 0.000 
Group 5 (most deprived) 9904 1.29 (1.19-1.39) 0.000 
Sex    
Male  1.00  
Female  2.96 (2.82-3.11) 0.000 
Age  1.055 (1.052–1.057) 0.000 
Smoking    
Table 5.2: Anthropometric characteristics (BMI, waist circumference and WHR) after adjusted 








In multivariate models, females were less likely to be obese (odds ratio=0.69, 95% CI 0.65, 
0.77, p<0.001), but more likely to be centrally obese (odds ratio=1.31, 95% CI 1.24, 1.38, 
p<0.001) and to have an elevated waist-to-hip ratio (odds ratio=2.96, 95% CI 2.82, 3.11, 
p<0.001). Age-, sex- and smoking- corrected odds for obesity (BMI) were significantly higher 
in the two most deprived quintiles (Group 4: odds ratio=1.14, 95% CI 1.05, 1.25, p=0.002 and 
Group 5: odds ratio=1.24, 95% CI 1.13, 1.36, p<0.001). Waist circumference was significantly 
higher in the three most deprived quintiles (Group 3: odds ratio=1.15, 95% CI 1.06, 1.24, 
p=0.001; Group 4: odds ratio=1.17, 95% CI 1.07, 1.27, p<0.001 and Group 5: odds ratio=1.23, 
95% CI 1.13, 1.34, p<0.001) and, compared with the least deprived group, all other groups had 
a greater likelihood of age, sex and smoking adjusted waist-to-hip ratio. 
 
5.3.3 Blood pressure measurements 
 
Mean value of systolic and diastolic blood pressure is higher in the participants from the least 
deprived areas than those from the most deprived areas (Table 5.1). Table 5.3 shows the odds 
for hypertension after adjusting for age, sex, smoking and deprivation. Adjusted odds ratio for 
systolic blood pressure was the highest in participants from group 4 (odds ratio=1.07, 95% CI 
0.97, 1.18), and lowest in groups 2 (odds ratio=0.95, 95% CI 0.86, 1.05) and 5 (odds ratio=0.95, 
95% CI 0.85, 1.06), but no statistically significance was shown among five groups. Adjusted 
odds ratio for diastolic blood pressure was significant lower in participants from the least 
deprived group (odds ratio=0.83, 95% CI 0.74, 0.94, p=0.002) 
 
  
0 (non-smoker)  1.00  
1 (light smoker)  1.30 (0.17-1.45) 0.000 
2 (heavy smoker)  1.87 (1.65-2.12) 0.000 
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Table 5.3: Blood pressure (systolic and diastolic) after adjusted for age-, sex- smoking-, and 
deprivation groups (odds ratio and 95%CI) in private dataset 
 
 
Risk factors Number of 
people 
Model 




Systolic blood pressure 55005   
Deprivation groups    
Group 1 (least deprived) 11142 1.00  
Group 2 10890 0.95 (0.86-1.05) 0.30 
Group 3 10983 0.97 (0.88-1.07) 0.59 
Group 4 11008 1.07 (0.97-1.18) 0.19 
Group 5 (most deprived) 10982 0.95 (0.85-1.06) 0.35 
Sex    
Male  1.00  
Female  0.57 (0.53-0.61) 0.000 
Age  1.071 (1.068–1.075) 0.000 
Smoking    
0 (non-smoker)  1.00  
1 (light smoker)  0.89 (0.75-1.07) 0.215 
2 (heavy smoker)  1.31 (1.10-1.56) 0.002 
Diastolic blood pressure 55019   
Deprivation groups    
Group 1 (least deprived) 11148 1.00  
Group 2 10894 0.90 (0.81-0.99) 0.30 
Group 3 10984 0.98 (0.89-1.08) 0.66 
Group 4 11011 0.96 (0.86-1.06) 0.41 
Group 5 (most deprived) 10982 0.83 (0.74-0.94) 0.002 
Sex    
Male  1.00  
Female  0.44 (0.40-0.47) 0.000 
Age  1.036 (1.033–1.039) 0.000 
Smoking    
0 (non-smoker)  1.00  
1 (light smoker)  0.91 (0.76-1.09) 0.315 
2 (heavy smoker)  1.37 (1.15-1.63) 0.000 
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In multivariate models, females were less likely than male to have elevated systolic and 
diastolic blood pressure (odds ratio=0.57, 95% CI 0.53, 0.61, p<0.001 vs odds ratio=0.44, 95% 
CI 0.40, 0.47, p<0.001). 
 
5.3.4 Plasma cholesterol measurements 
 
Mean value of total cholesterol is higher in the participants from the least deprived areas than 
those from the most deprived areas (Table 5.1). Very similar mean values of HDL and slightly 
difference on mean values of LDL between groups (Table 5.1). Table 5.4 shows the odds ratio 
for raised total and LDL cholesterol or low HDL cholesterol after adjusting for age, sex, 
smoking and deprivation. Compared with the least deprived group, the three most deprived 
groups were significantly less likely to have raised total cholesterol, and statistical significance 
was shown in the most deprived group (odds ratio=0.84, 95% CI 0.78, 0.91, p<0.001) 
Compared with the least deprived group, the likelihood of elevated low density lipoprotein was 
decreased in the two most deprived groups, and statistical significance was shown in the most 
deprived group (odds ratio=0.84, 95% CI 0.77, 0.91, p<0.001). There was a general trend 
towards a lower likelihood in more deprived groups, but overall there were no significant 
between-group differences in the likelihood of having a low HDL subfraction between 





Table 5.4: Plasma cholesterol (total cholesterol, HDL and LDL) after adjusted for age-, sex-, 
smoking- and deprivation groups (odds ratio and 95%CI) in private dataset 
Risk factors Number of 
people 
Model  




Total Cholesterol 45108   
Deprivation groups    
Group 1 (least deprived) 9550 1.00  
Group 2 9437 0.96 (0.90-1.03) 0.27 
Group 3 9339 0.94 (0.88-1.01) 0.09 
Group 4 8870 0.94 (0.88-1.01) 0.11 
Group 5 (most deprived) 8002 0.84 (0.78-0.91) 0.000 
Sex    
Male  1.00  
Female  0.71 (0.68-0.75) 0.000 
Age  1.042 (1.040–1.045) 0.000 
Smoking    
0 (non-smoker)  1.00  
1 (light smoker)  1.16 (1.04-1.30) 0.01 
2 (heavy smoker)  1.26 (1.10-1.44) 0.001 
HDL 45108   
Deprivation groups    
Group 1 (least deprived) 9549 1.00  
Group 2 9349 0.97 (0.87-1.08) 0.61 
Group 3 9340 1.06 (0.95-1.17) 0.32 
Group 4 8868 1.00 (0.89-1.12) 0.96 
Group 5 (most deprived) 8002 0.98 (0.87-1.11) 0.81 
Sex    
Male  1.00  
Female  0.16 (0.14-0.18) 0.000 
Age  0.994 (0.990–0.997) 0.001 
Smoking    
0 (non-smoker)  1.00  
1 (light smoker)  1.38 (1.17-1.63) 0.000 
2 (heavy smoker)  2.10 (1.78-2.48) 0.000 
LDL 44421   
Deprivation groups    
Group 1 (least deprived) 9407 1.00  
Group 2 9222 1.05 (0.98-1.13) 0.13 
Group 3 9214 1.02 (0.96-1.10) 0.49 
Group 4 8707 0.95 (0.88-1.02) 0.14 
Group 5 (most deprived) 7871 0.84 (0.77-0.91) 0.000 
Sex    
Male  1.00  
Female  0.51 (0.48-0.53) 0.000 
Age  1.034 (1.032–1.036) 0.000 
Smoking    
0 (non-smoker)  1.00  
1 (light smoker)  1.15 (1.02-1.29) 0.02 
2 (heavy smoker)  1.24 (1.08-1.41) 0.002 
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In multivariate models, females were less likely than males to have raised total cholesterol and 
LDL (odds ratio=0.71, 95% CI 0.68, 0.75, p<0.001 vs odds ratio=0.51, 95% CI 0.48, 0.53, 




5.4.1 Overall findings of this study 
 
The aim of this study was to determine the association between socioeconomic deprivation and 
three groups of objectively measured, modifiable cardiovascular risk factors; adiposity, blood 
pressure, and plasma cholesterol. Measures, such as BMI, can be collected with relative ease 
in large, population-based samples such as NHANES and the HSE. Cholesterol measures from 
blood are more difficult to obtain and, until recently, routine screening has not been in place. 
Clinical samples, from GP surgeries have an inherent bias, as individuals giving these samples 
typically have health problems, necessitating the GP visit. 
 
The published literature, in which risk factors were usually clustered, the outcome showed 
contrasting or paradoxical findings compared with this research—greater adiposity was found 
in people from more deprived groups estimated by all three measures: BMI, waist 
circumference and WHR. The findings also showed that the likelihood of having high blood 
pressure, however, was lower in the most deprived area than in the least deprived area. The 
likelihood of having low HDL was similar between groups, but the likelihood of having high 




BMI is a widely used method for the definition of obesity. However, Sönmez et al. (2003) 
found that the rate of obesity diagnosed by BMI was lower than those diagnosed by waist 
circumference and WHR. Some authors considered that waist circumference could be a more 
accurate method for the definition of obesity and prediction of cardiovascular diseases (Han et 
al. 1995; Ho et al. 2001; Lean et al. 1995; Lean et al. 1998; Pouliot et al. 1994). Moreover, in 
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the current NICE guidance (2006a), assessment of the health risk associated with overweight 
and obesity should be based on both BMI and waist circumference was also suggested. In 
addition to the available data collection, we analysed obesity on the basis of these three 
measurements. Because of the similarity patterns, the following sections will discuss BMI, 
waist circumference and WHR together. It is of note, however, that there were slight 
differences between the three adiposity measures. BMI was higher in the two most deprived 
groups, whereas waist circumference is likely to be more significantly larger in the three most 
deprived groups, and WHR is only lower in the least deprived group.  
 
The findings of the current study agree with the existing studies in that people in the most 
deprived area are more likely to be obese by using measurement of BMI. Using professional 
classification, Emberson et al. (2004) found that BMI was higher in manual than non-manual 
UK workers. Puslaw (2008) found that higher BMI values with decreasing professional 
classifications. Stafford and colleagues (2010) found that residence in a more deprived 
neighbourhood contributed to a higher initial BMI when the study started. There was also a 
note that in this longitudinal, multilevel Whitehall II study of 13 years follow-up using 
Townsend index of multiple deprivation at census-ward level, participants from the most-
deprived neighbourhoods experienced relatively greater weight gain over time, an increase of 
1.5kg/m2 in men and 1.4kg/m2 in women.  
 
Wang et al. (2007) gathered five cross-sectional surveys conducted by the Stanford Heart 
Disease Prevention Programme between 1979 and 1990 and found that participants from low 
socioeconomic neighbourhoods had a higher mean BMI than those from high socioeconomic 
neighbourhoods, after adjusting for age, sex, ethnicity, individual-level socioeconomic status, 
smoking, physical activity and nutrition knowledge. Similar finding has also been 
demonstrated in the GLOBE study (van Lenthe and Mackenbach 2002) with odds ratios of 
BMI increasing significantly with increasing neighbourhood deprivation, after adjusting for 
sex. Dragano et al. (2005) found that people having the least education were twice as likely to 
be obese than the most educated in Czech Republic and that this ratio was 1.6 in Germany. A 
Dutch study conducted by Han et al. (1998) suggested that large waist circumference was 




The same pattern was observed as in most other national and international studies. This study 
is confirmatory, but may not explain fully why such an association exists. Some studies have 
found that there are more fast-food outlets per capita and fewer healthy food stores per capita 
in the most deprived compared with least deprived areas, although the evidence is not 
consistent across all countries (Cummins and Macintyre 2002; Li et al. 2008; Li et al. 2009; Li 
et al. 2009; Mehta et al. 2008; Mhjahid et al. 2008; Rundle et al. 2009). Deprived areas often 
offered fewer opportunities for physical activity in the community (Boehmer et al. 2007; Frank 
et al. 2004; Frank et al. 2009; Hoehner et al. 2005; Li et al. 2008; Mhjahid et al. 2008; Rundle 
et al. 2009; Santos et al. 2008). There may also be socialisation effects stemming from the 
transmission of norms and behaviors associated with overweight and obesity that may differ 
between most deprived and least deprived areas (McLaren and Gauvin 2002). 
 
5.4.3 Blood pressure 
 
Given the confirmatory nature of the present data regarding the association between obesity 
and deprivation, it was expected that the related risk factor of blood pressure would be elevated 
in a similar, graded manner with deprivation. The data did not support this hypothesis, 
however, and despite elevated adiposity, neither blood pressure measures were significantly 
more likely to suggest hypertension in the most deprived groups. Paradoxically, it appears from 
the present data, being in the most deprived group was a significant predictor of having a more 
healthy blood pressure reading.  
 
This association is more in line with the direction seen in the developing countries. Fernald and 
Adler (2008) conducted a house-to-house cross sectional survey in women aged 18-65 years 
old in Mexico. They found that two indicators of socioeconomic deprivation—educational 
attainment and working outside the home—showed an inverse association with systolic blood 
pressure. Similar findings have also been found in a multicentre collaborative study of risk 
factors for cardiovascular disease in the International Clinical Epidemiology Network 
(INCLEN). Nogueira et al. (1994) examined the relationship between cardiovascular risk 
factors and socio-economic variables in 12 centres in 7 countries—three in Thailand, two each 
in China, Chile and Brazil and one each in the Philippines, Indonesia and Colombia. They 
investigated approximately 200 men aged 35-65 drawn at random from a population within 
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their locality and found that among five Latin America countries, three showed a negative 
association between socioeconomic status and systolic blood pressure, and others showed no 
association. In a study of hypertension in an urban working population in Ghana the results 
showed a prevalence of hypertension in participants of lower socioeconomic status and a 
highest prevalence in those of the highest socioeconomic status (Addo 2009). There were 
suggestions of a negative association between the level of education and hypertension after 
adjusting for the other measures of socioeconomic status.  
 
Our data are in contrast with much of the previous work conducted in developed countries. In 
a review of published literature to assess the association between socioeconomic status and 
blood pressure, high mean blood pressure or prevalence of hypertension was associated with 
low socioeconomic status in almost all studies from North America and most from Europe, 
regardless of the measure of socioeconomic status used (Colhoun et al. 1998). In the Whitehall 
study of London-based civil servants, mean BP and prevalence of hypertension were higher 
among men in the lower grades of employment (Marmot 1985). Hart and colleagues (2000) 
also found that the hazard ratio of higher risk of blood pressure in adults in the most deprived 
areas compared with those in the least deprived areas. In a study from developing countries, 
Cubbin et al. (2001) noted that blood pressure was higher in the most deprived areas than the 
least deprived areas among African women.  
 
It is difficult to explain why the findings were different from other developed countries, but 
consistent with the findings from developing countries. The explanations could be the use of 
small non-representative samples, a variety of design flaws, the use of different measures of 
health outcomes and the measurement of socioeconomic status. A recent study (Perova et al. 
2001) has shown mixed results, which may be due to methodological differences, heterogeneity 
of samples or differences in the degree of economic development.  
 
5.4.4 Plasma cholesterol 
 
Like blood pressure, plasma cholesterol is a risk factor often associated with increased 
adiposity.  In this study, participants from the least deprived areas had less favourable serum 
lipids compared with those individuals from the most deprived areas. However, both total 
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cholesterol and low-density lipoprotein cholesterol measures were significantly lower in the 
most deprived groups. Indeed it appears from the present data, being in the most deprived group 
was a significant predictor of having a more healthy plasma lipid reading.  
 
For total cholesterol, our data agreed with a study of 2682 Finnish men in the Kuopio ischaemic 
heart disease risk factor study (KIHD). Using educational levels as a measure of socioeconomic 
status, Lynch et al. (2006) found that total cholesterol were significantly higher for those who 
only attended primary school than those who are high school graduates in Finland. In the Puerto 
Rico Heart Programme, Sorlie and Garcia-Palmieri (1990) found that the mean values for 
serum cholesterol increased steadily with education indicating a cholesterol level of 
approximately 29 mg/dl (0.75mmol/l) lower for those with no education compared to those at 
the highest level in the urban area. This is in contrast to a study conducted in a Chinese urban 
population of 4,506 by Yu et al. (2001), who found that men in higher socioeconomic status 
had significantly higher total cholesterol compared with men in low socioeconomic status. This 
contrasting finding is consistent with previous Chinese studies (Siegrist et al. 1990; Tian et al. 
1995) and other studies carried out in developing countries (Bunker et al. 1996; Pereira et al. 
1998; Sorlie et al. 1990).  
 
The contrasting findings were also found in other developed countries. Choiniere et al. (2000) 
used the Canadian Heart Health Surveys Database to analyse a probability sample of 29855 
men and women aged 18-74 years old. Using educational level as a measure of socioeconomic 
status, they found that men and women with a university degree were less likely to have an 
elevated cholesterol level than those with no university degree. This situation appeared to be 
in contrast to those reported in the developing countries (Bennett 1995; Kaplan and Keil 1993; 
Winkleby et al. 1992). However, Lyratzopoulos and colleague (2007) found that deprivation 
status did not influence change in total cholesterol. 
 
For HDL, our findings did not agree with existing literature. In two Chinese studies however, 
the authors found that men in the lower socioeconomic status had significantly higher HDL 
compared with men in higher socioeconomic status (Siegrist et al. 1990; Yu et al. 2001). The 
similar findings of Winkleby et al. (1992), showed that higher HDL was found in the highest 
socioeconomic groups. But Lynch et al. (2006) found that HDL was higher in the people who 
had only primary education compared with those who were high school graduate. Pereira et al. 
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(1998) also conducted a study in a population who are 25-74 years old in Mauritius. Using 
occupation as a measure of socioeconomic status, they found that HDL was higher in unskilled 
workers than professional/skilled workers. Also to note that females were five times less likely 
than males to have lower HDL.  
 
LDL cholesterol had a similar pattern to total cholesterol. Our findings agree with several 
Chinese studies (Siegrist et al. 1990; Tian et al. 1995; Yu et al. 2001), which found that men 
in higher socioeconomic status had significantly higher LDL compared with men in low 
socioeconomic status. Pereira et al. (1998) also reported that LDL was lower in unskilled 
workers than professional/skilled workers. Using educational levels as a measure of 
socioeconomic status, Lynch et al. (2006) found that LDL were significantly higher for those 
only attending primary school compared with those who are high school graduate. In contrast, 
Larranaga et al. (2005) found that adults of lower socioeconomic status attending primary care 
clinics in the Basque region of Spain were found to have higher LDL compared with those of 
higher socioeconomic status. Moreover, females were two times less likely than males to have 
higher LDL.  
 
A few studies have also reported that cholesterol increases as the level of socioeconomic 
deprivation level increases due to the reduction of intake of saturated fats, lower alcohol 
consumption, and consumption of more fruit, vegetables and whole grains (Briefel and Johnson 
2004; Kanjilal et al. 2006; Marmot et al. 1991; McFadden et al. 2009; Popkin et al. 1996). 
 
5.4.5 Strengths and limitations of the current study 
 
The study is one of the first largest datasets on deprivation indices with this number of risk 
factors in the private medical care setting. As the dataset was obtained from a private healthcare 
company, it means that most participants were employed and able to afford private health 
screening. Therefore, our results might be different from other studies that used samples 
obtained from the National Health Services (NHS) in the UK. As NHS is free at the point of 
access, poorer economic circumstances should not in themselves be barriers to obtaining 
specialist care. Patients who attend the NHS primary care clinics may not be typical of the 
socioeconomic profile of its specific area because of variations in healthcare-seeking behaviour 
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or general practitioner referral patterns (Stewart et al. 2009). People who attended Nuffield 
Health are more likely to be of higher socioeconomic class due to the requirement to pay for 
this service. However, it is possible to compare the population who attended Nuffield Health 
with those located in a relatively affluent England region in terms of socioeconomic status, and 
validate these findings. The south central England region is relatively affluent compared with 
the national average. Therefore, in Chapter 8,  we aim to examine the association between area-
level deprivation and objectively measured, modifiable cardiovascular risk factors in a 
socioeconomic affluent population who attended the public NHS (dataset provided by the 
Hampshire Health Record), and then to compare the findings with those of this Chapter. 
 
The number of people covered by private medical insurance rose to over six million in 2008, 
according to figures from the Association of British Insurers (2009), and an increasing number 
of those included in our dataset will be those employed in all sectors of the workforce from 
manual to management. Our results may be generalisable to other commercially insured 
populations. The benefit of this study is that the data were collected from different areas across 
the UK, and the study is larger than published work on deprivation indices with this number of 
risk factors in the primary care setting. Although many studies have assessed the association 
between socioeconomic status and cardiovascular risk factors, those studies were on the basis 
of much smaller sample size than was used in this study. This means that the results are not as 
valid and generalisable as this study.  
 
There are many ways to measure deprivation, affluence or socioeconomic status within 
populations including: levels of education (Bhopal et al. 2002; Dragano et al. 2005), social 
class (Embason et al. 2004; Purslow et al. 2008; Starr and Deary 2010), income (Harrington 
and Elliott 2008; Lawlor et al. 2005), multiple indicators (Addo et al. 2009; Khan et al. 2006; 
Yu et al. 2002), area-level indices including multiple indices (Chen and Tunstall-Pedoe 2005; 
Lyratzopoulos et al. 2006; Stewart et al. 2009; Sundquist et al. 2004; van Lenthe and 
Mackenbach 2002). Previous work using area-level deprivation indices from the UK has 
demonstrated an association between deprivation and poor health outcomes at an individual 
level (Carstairs 1995; Woodward 1996). Area of residence is a determinant of cardiovascular 
risk, independently and additional to the effect of individually measured socioeconomic status 




The present study used the English Indices of Deprivation 2007 because the advantages of 
postcode estimates served various epidemiological purposes. This was particularly when it was 
not feasible to collect detailed information on socioeconomic status due to large sample size. 
The smaller area level displays greater variation in many characteristics and provides a more 
sensitive basis for the identification of need and delivery of care than the health district. 
Therefore, an area measure of socioeconomic position could be used to help standardise for the 
health effects, which is important when the occurrence of a disease and associated risk factors 
are both related to poverty (Danesh et al. 1999). It has been used not only by health researchers 
to make more detailed measurements of socioeconomic status in a subset of participants, but 
also by the government for the last 10 years to identify and target areas of concentrated 
deprivation—important in directing significant levels of government funding and resources, 
both for regeneration and other programmes. Although the data used in this analysis are derived 
from a large and generally well maintained database, incomplete ascertainment of certain risk 
factors and the potential for errors in risk measurement arising from the non-research design of 
the database are acknowledged.  
 
Another limitation of this study is the dataset does not include a history of medication. Use of 
lipid lowering drugs, primarily statin therapy, is recommended for patients with clinical 
evidence of cardiovascular disease. However, as this is a private medical insurance company, 
it only has limited data resources, because participants will still see their general practitioners 
(GP) to prescribe medication. Therefore, it is hard to know if participants’ blood pressure and 
cholesterol level were drug controlled. Also, the present study did not measure habitual 
physical activity but it may be that more deprived participants were more active than those in 




In conclusion, in this retrospective study of 55,217 participants attending Nuffield Health, 
findings showed that there is an association between socioeconomic deprivation and 
cardiovascular risk factors, especially strong links in obesity and lipids. People from the most 
deprived areas in this affluent population are more likely to be obese than those from the least 
deprived areas, but less likely to have higher total cholesterol and LDL. In this affluent 
population, individuals in the most deprived areas remain to be a target population for 
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prevention of obesity, but people from the least deprived areas should be targeted for total and 
LDL cholesterol check. The distribution of the pattern on cardiovascular risk factors in this 
affluent population is consistent with the distribution of cardiovascular risk factors in the 
general population. Regional preventive policy should focus on these higher prevalent 
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GEOGRAPHICAL VARIATIONS IN MODIFIABLE CARDIOVASCULAR RISK 





Aim: Modifiable cardiovascular risk factors vary in prevalence across the UK. This chapter 
investigates geographical variations in modifiable cardiovascular risk factors in people 
attending private health screenings. 
 
Methods: A retrospective study of over 50 000 participants from all regions in England was 
conducted using a dataset provided by a private healthcare company. Seven risk factors were 
analysed: body-mass index (BMI), waist circumference, waist-to-hip ratio (WHR), 
hypertension, total cholesterol, high-density lipoprotein (HDL) cholesterol, and low-density 
lipoprotein (LDL) cholesterol, selected from an extensive dataset including over 50 health 
variables. The English Indices of Deprivation 2007 scale was used to assign deprivation values 
to nine English regions. 
 
Results: The absolute differences in various cardiovascular risk factors between regions were 
small, but some interesting statistically significant regional differences were apparent. Both 
men and women in Southern England were less likely to be obese than those in other regions 
in England. Participants in the South East (odds ratio [OR] 1·84, 95% CI 1·73–1·97, p=0·000), 
the West Midlands (OR 1·69, 95% CI 1·55–1·85, p=0·000), and the North West (OR 1·63, 
95% CI 1·49–1·79, p=0·000) were much more likely to have high blood pressure than those 
from other regions. Men were twice as likely as women to be hypertensive across all regions 
in England (OR 2·18, 95% CI 2·08-2·29, p=0·000). Plasma cholesterol levels varied by 
region—participants in the North East had the highest risk of elevated total cholesterol, and 
those in the North West had the lowest risk; both men and women in the Midlands were less 
likely to have low HDL cholesterol than those in other regions in England; and participants in 
the North were less likely to have low LDL cholesterol than those in other regions. Because 
the primary focus of the Health Survey England (HSE) 2006 was cardiovascular disease, and 
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the prevalence of several modifiable risk factors—BMI, waist circumference, total cholesterol, 
HDL cholesterol, and hypertension—were investigated in this survey. Therefore, a comparison 
between the data from HSE 2006 and Nuffield Health dataset was conducted. Overall, the 
prevalence of most modifiable cardiovascular risk factors was higher in HSE 2006 data than in 
Nuffield Health data for both men and women across all regions in England. For men, the 
prevalence of overweight, raised waist circumference, and raised total cholesterol were higher 
in Nuffield Health data than in HSE data. Men in London were generally healthier than in other 
regions in England. Differences in prevalence of several risk factors were wide between 
regions, such as raised waist circumference (up to two times), low HDL (over three times), and 
hypertension (about two times). For women, the prevalence of obesity, raised waist 
circumference, and hypertension were much lower in the Nuffield Health data than in HSE 
2006 data. Only the difference in prevalence of hypertension was wide between regions (more 
than two times). 
 
Discussion: Geographical variations in the prevalence of modifiable cardiovascular risk factors 
have been reported both between and within countries. In general, participants from London 
were much healthier than those from other regions. Men from the Midlands, and especially 
those from the East Midlands, had relatively worse health conditions than those from other 
regions, so did women from the Midlands. Interestingly, women from South England had 
similar health conditions to those from the Midlands. Participants in the East Midlands and 
North West regions had a much higher risk of obesity than those from most other regions. 
Participants in the South East had the highest risk, and those in York & The Humber the lowest 
risk, of being hypertensive. In terms of plasma cholesterol measures, the distribution among 
regions seemed variable—participants in the North East had the highest risk of elevated total 
cholesterol, and those in the North West had the lowest risk; both men and women in the 
Midlands were less likely to have low HDL cholesterol than those in other regions in England; 
and participants in North England were less likely to have high LDL cholesterol than those in 
other regions in England. The variation in cardiovascular risk factors can be explained by 
difference in dietary consumption of fats, sugars, and green, leafy vegetables. However, a 
North-South (Scottish) effect was not seen in the current study. The reason could be the study 
population in the present study, which was an affluent group. We could speculate that this 




Conclusion: Clear regional differences exist for cardiovascular risk factors: participants from 
London had the lowest cardiovascular risks compared with those from all other regions in the 
analysis. This is one of the first studies to show regional differences in cardiovascular risk 
factors across England with such a high number of risk factors and other variables in a primary 





Geographical variations in cardiovascular disease and associated risk factors have been 
identified and reported in a range of European countries on the basis of both prevalence and 
incidence. Sans and colleagues (1997) analysed regional data for European countries submitted 
to the World Health Organization (WHO), and reported a clear north–east to south–west 
gradient in cardiovascular disease mortality. They noted that the lowest rates of mortality from 
cardiovascular disease for both men and women were in France, Spain, Switzerland, and Italy 
and the highest rates were observed in Central and Eastern European countries such as Ukraine, 
Bulgaria, and the Russian Federation. The effect of regional variation within countries varied. 
In Germany, 10 years after reunification, Müller-Nordhorn and colleagues (2004) concluded 
that mortality from ischaemic heart disease was still about 50% higher in East compared with 
West Germany. In the West, mortality from ischaemic heart disease continuously decreased 
throughout the 1990s, whereas in the East, mortality peaked during the early 1990s, and is now 
declining gradually. In France, mortality from ischaemic heart disease showed a north–south 
gradient (Lang et al. 1999).  
 
The current European Guidelines on Cardiovascular Disease Prevention in Clinical Practice 
take national variation in cardiovascular mortality into consideration (De Backer et al. 2003). 
In the primary prevention setting, the overall 10-year cardiovascular risk is estimated for 
different combinations of risk factors. The assessment of cardiovascular risk takes the 
following risk factors into consideration: age, sex, smoking, systolic blood pressure (SBP), and 
cholesterol. An increased risk greater than 5% of a fatal cardiovascular event in the next 10 
years should lead to increased preventive efforts including lifestyle changes and medication. 
In the guidelines, the use of two different risk assessment charts is recommended: one for 
countries with high risk and one for countries with low risk. On the basis of several cohort 
studies assessing cardiovascular risk, countries with a low risk are Belgium, France, Greece, 
Italy, Luxembourg, Spain, Switzerland, and Portugal, with all other European countries 
classified as high risk.  
 
In the UK, many studies have shown that mortality and morbidity vary across both small and 
larger geographical areas (Boyle et al. 1999; Cliff et al. 1981; Shelton et al. 2007). Specifically, 
modifiable cardiovascular risk factors vary in prevalence across the UK. In England, for 
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example, this is exemplified at a regional level by a North–South gradient in prevalence of 
cardiovascular risk factors and health outcomes, with higher prevalence in the North (Doran et 
al. 2006). Furthermore, several studies have investigated the relationship between geographical 
variation and cardiovascular risk factors. The British Regional Heart Study (BRHS) showed 
that the North–South differences in cardiovascular disease incidence in men could be explained 
by classical risk factors such as smoking, physical activity, body-mass index (BMI), alcohol 
consumption, SBP, serum total cholesterol, occupational social class, and height. In women, 
differences in prevalence of cardiovascular disease across four broad regions of the UK 
(Scotland, North England, Midlands/Wales, and South England) were examined in the baseline 
survey of the British Women's Heart and Health Study (BWHHS). The highest prevalence of 
cardiovascular disease was reported in Scotland, and the lowest in South England. By contrast 
with findings in men drawn from the same geographical areas, this variation by region 
remained after adjustment for several cofactors such as age, SBP, diastolic blood pressure 
(DBP), total cholesterol, high-density-lipoprotein (HDL) cholesterol, smoking, physical 
activity, fruit consumption, social class, and use of aspirin or statins.  
 
The Health Survey for England (HSE) is an annual health examination survey of a nationally-
representative sample of the English population living in private households. It provides 
representative data on a broad range of health topics. Participants are visited by interviewers, 
who measure height and weight and collect household-level and individual-level data using 
computer-assisted personal interviews. Participants who agree to additional assessments are 
visited on a separate occasion by nurses, who obtain further measurements and biological 
samples. The interviewer’s visit includes a short self-completion booklet, which includes 
questions about perceived social support and the General Health Questionnaire (GHQ12, a 
measure of psychological health) questions (DeLeeuw et al. 2003). The HSE 2006 report 
focused on cardiovascular disease and associated risk factors, which covered health-status risk 
factors including total cholesterol, HDL cholesterol, blood pressure, diabetes, and 
anthropometric measurements such as BMI and waist circumference. 
 
Chapter 5 examined the association between area-level socioeconomic deprivation and 
objectively-measured, modifiable cardiovascular risk factors in a non-clinical UK population 
who attended private health screenings. The results showed that there is an association between 
socioeconomic deprivation and cardiovascular risk factors, with especially strong associations 
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for obesity and lipids. People from the most deprived areas are more likely to be obese than 
those from the least deprived areas, but are less likely to have raised total and LDL cholesterol. 
Although the prevalence of cardiovascular risk factors has been investigated at an area-level 
by socioeconomic status, there is still a need to investigate how cardiovascular risk factors are 
distributed at a national geographical level, since the occurrence of cardiovascular disease does 
vary geographically. Other established cohort studies—The Whitehall II, Renfrew-Paisley, 
Scottish Heart Health, and Glasgow Students studies (Hart et al. 1997; Hart et al. 1997; Marmot 
et al. 1991; McCarron et al. 1999)—have provided valuable aetiological insights and 
comparisons between women and men, but have limited national representativeness, and are 
unable to assess geographical variations because of their single locations. Also, although 
several studies have been conducted in the NHS and by public survey (Lawlor et al. 2003; HSE 
2008; Shelton et al. 2007; Shelton 2009), no study has previously been done in a population of 
people with private medical insurance. An explanation for the regional variation remains 
unknown.  
 
Better knowledge about regional variation of cardiovascular disease could lead to improved 
understanding disease aetiology, more appropriate for allocation of treatment resources in the 
health system. Therefore, the purpose of this study was to: (1) explore geographical variations in 
the prevalence of modifiable cardiovascular risk factors in people attending private health 
screenings in England; (2) compare the prevalence of modifiable cardiovascular risk factors 
from private medical screenings with the findings from the HSE 2006; and (3) estimate the 
risks of various modifiable cardiovascular risk factors at a regional level from dataset provided 




6.2.1 Study setting and data collection 
 
Data were provided by a private healthcare company, Nuffield Health. The assessment 
programmes were delivered using a bespoke electronic patient record system developed 
exclusively for Nuffield Health—the Vi System. This system offered greater accuracy, and 
faster and more comprehensive reports than other systems, e.g. paper-based systems. It 
215 
 
provides instant comparison with previous test results and the ability for clients to use any of 
their centres in the UK to immediately access their records. Data were extracted from the 
records of the Nuffield Health. Aggregate data provided by the Nuffield Health were 
anonymised, in line with the Information Commissioner Office’s (2013) anonymisation code, 
it can be freely processed and publicly disclosed. Data were recorded for participants during 
screenings for provision of employment-related medical care. At each of the company’s testing 
sites, data were collected by trained health professionals using protocols consistent with the 
British Hypertension Society for blood pressure and blood analysis, and the American College 
of Sports Medicine for anthropometry. 
 
6.2.2 Individual-level cardiovascular risk factors 
 
Several established cardiovascular risk factors represented the risk profile of the participants: 
(1) anthropometric characteristics—BMI, waist-to-hip ratio (WHR), and waist circumference. 
Obesity was examined by BMI, WHR, and waist circumference, separately. Normal weight 
was defined as a BMI between 18·5 and 25 kg/m2; overweight was defined as a BMI between 
25 and 30 kg/m2; obesity was defined as a BMI between 30 and 40 kg/m2; and morbid obesity 
was defined as a BMI over 40 kg/m2 (WHO 2005; NICE 2006). Waist circumference was 
measured at the anatomical waist; central obesity was defined as greater than 102cm in men 
and greater than 88 cm in women. The waist-to-hip ratio was defined as high if values were 
greater than 0·95 in men and greater than 0·80 in women (Croft et al. 1995). (2) Blood pressure. 
Hypertension was classified as DBP greater than 90 mm Hg (DBP) or SBP greater than 140 
mm Hg (NICE 2006). (3) Plasma serum. Plasma serum measures include total, HDL, and LDL 
cholesterol. Arterial blood was drawn and analysed, with measurements of total cholesterol, 
LDL subfraction, and HDL subfraction. Total cholesterol was classified as raised if higher than 
6·0 mmol/L. HDL was classified as low if less than 1·0 mmol/L; LDL was classified as raised 
if greater than 3·36 mmol/L (Contois et al. 1996). 
 
Age and sex were adjusted for in multinomial and binary logistic regression analyses. Age was 
defined as a continuous variable. 




The National Statistics Postcode Directory (NSPD) (National Statistics 2007) is a list of all the 
current and terminated postcodes that have ever existed in the UK, together with geographical 
links or matches for each postcode to a variety of different administrative, health, electoral, and 
other areas that are, or have been, used within the UK. The information contained within the 
NSPD has a wide range of potential uses across a broad range of disciplines wherever postcode 
data are used, or where information on the relationships between different geographies, or 
changes in a single geography over time, is required. GeoConvert (GeoConvert 2007) is an 
online service available from the Census Dissemination Unit. It uses information from the 
NSPD to perform a variety of functions. Geoconvert was used to convert postcodes to different 
geographical regions—North East, North West, Yorkshire & The Humber, East Midlands, 
West Midlands, East of England, London, South East, South West, Scotland, Wales, Northern 
Ireland, Isle of Man, and Isle of Wight.  
 
6.2.4 Statistical Analysis 
 
Descriptive statistics were generated. ANOVA was performed for mean values of each 
cardiovascular risk factor. Multinomial logistic regressions and binary logistic regression were 
both performed to investigate the effect of regional variation on various modifiable 
cardiovascular risk factors. The association between geographical variation and cardiovascular 
risk factors was evaluated by the ORs for regions alone (model 1), and after adjustment for age 
and sex (model 2). Both of adjusted and unadjusted results are compared in the statistical 
analysis. Data from this study were analysed with SPSS Version 17.0 (SPSS Inc., Chicago, IL, 







6.3.1 Geographical descriptive statistics for the Nuffield dataset in different measures 
 
A retrospective population of 60,334 participants aged between 18 and 75 years across the UK 
was selected for analysis. Demographic and clinical characteristics of men and women in 
different geographical regions in the format of mean values with standard deviations are shown 
in Tables 6.1 and 6.2, respectively. 
 
Table 6.1: Demographic and clinical characteristics of men in different geographical regions 
(mean and SD) 
 




SBP DBP Total 
cholesterol 
HDL LDL 
 (n=33552) (n=33550) (n=33550) (n=33548) (n=33548) (n=27107) (n=27099) (n=26477) 




81.5 (8.8) 5.49 (1.03) 1.44 (0.39) 3.33 
(0.95) 






































81.0 (9.3) 5.42 (1.00) 1.35 (0.34) 3.39 
(0.89) 
London 




79.5 (8.9) 5.23 (0.98) 1.44 (0.33) 3.15 
(0.83) 




83.1 (9.6) 5.43 (1.01) 1.39 (0.36) 3.39 
(0.90) 




81.2 (9.1) 5.46 (1.00) 1.39 (0.34) 3.39 
(0.89) 











Table 6.2: Demographic and clinical characteristics of women in different geographical 
regions (mean and SD) 
 




SBP DBP Total 
cholesterol 
HDL LDL 
 (n=21551) (n=17582) (n=17582) (n=21548) (n=21550) (n=18066) (n=18065) (n=18012) 

































































































Men in London had the lowest mean BMI, and those in Yorkshire & The Humber the highest 
(26·21 vs 27·66, p<0·001). The lowest prevalence of overweight in men was in London, and 
the highest was in the East Midlands (47% vs 54%). Men in London also had the lowest 
prevalence of obesity, with the prevalence in Yorkshire & The Humber almost twice that in 







Women in London had the lowest mean BMI, and those in Yorkshire & The Humber the 
highest (24·20 vs 25·79, p<0·001). The lowest prevalence of overweight was in London, and 
the highest was in Yorkshire & The Humber (23% vs 33%). Women in London also had the 
lowest prevalence of obesity, with the highest prevalence seen in two regions—Yorkshire & 
The Humber and the North East (10% vs 17%). 
 




Men in London had the lowest mean waist circumference, and those in the East Midlands the 
highest (90·7 vs 96·6, p<0·001). The lowest prevalence of raised waist circumference for men 
was in London, and the highest was in the East Midlands, where the prevalence was twice that 




Women in London had the lowest mean waist circumference; and those in the South West the 
highest (78·5 vs 90·5, p<0·001). The lowest prevalence of raised waist circumference was in 
London, and the highest was in the North West (20% vs 30%). 
 




Men in London had the lowest mean WHR, and the highest mean WHRs were in three 
regions—the North East, the East Midlands, and the South West (0·88 vs 0·92, p<0·001). The 
lowest prevalence of raised WHR was in London, and the highest were in the North East and 






Women in Yorkshire & The Humber, the East of England, and London had the lowest mean 
WHR, and the East Midlands had the highest mean WHR (0·79 vs 0·81, p<0·001). The lowest 
prevalence of raised WHR was in Yorkshire & The Humber, and the highest was in East 






Men in London had the lowest mean SBP and DBP; the highest mean SBP was in the South 
West and the highest mean DBP was in the South East (SBP 122·7 vs 129·6, p<0·001; DBP 
79·5 vs 83·1, p<0·001). The lowest prevalence of hypertension was in London, and the highest 




Women in London had the lowest mean SBP and DBP; the highest mean SBP was in the South 
West and the highest mean DBP was in the West Midlands (SBP 114·1 vs 122·7, p<0·001; 
DBP 73·7 vs 77·6, p<0·001). The lowest prevalence of hypertension was in London, and the 
highest were in the South East and South West (7% vs 17%). 
 




Men in London had the lowest mean total cholesterol, and those in the North East the highest 
(5·23 vs 5·49, p<0·001). The lowest prevalence of raised cholesterol was in London, and the 







Women in London had the lowest mean total cholesterol, and those in the South West the 
highest (4·93 vs 5·33, p<0·001). The lowest prevalence of raised cholesterol was in London, 
and the highest was in the South West (46% vs 62%).  
 




Men in London had the highest mean HDL cholesterol, and those in the East Midlands the 
lowest (1·44 vs 1·31, p<0·001). The lowest prevalence of low HDL cholesterol was in London, 




Women in London had the highest mean HDL cholesterol, and those in the East Midlands the 
lowest (1·77 vs 1·65, p<0·001). The lowest prevalence of low HDL cholesterol was in London, 
and the highest was in the West Midlands (0·8% vs 2·1%).  
 




Men in London had the lowest mean LDL cholesterol, and those in the East Midlands the 
highest (3·15 vs 3·45, p<0·001). The lowest prevalence of raised LDL cholesterol was in 








Women in London had the lowest mean LDL cholesterol, and those in the East Midlands the 
highest (2·72 vs 3·13, p<0·001). The lowest prevalence of raised LDL cholesterol was in 
London, and the highest was in the East Midlands (19% vs 38%).  
 
Overall, both men and women from London were much healthier than those from other regions. 
Men from the Midlands, especially the East Midlands, had relatively worse health conditions. 
Women from the Midlands also had relatively worse health conditions. Interestingly, women 
from South England had similar health conditions to those from the Midlands (with more than 
five risk factors up to high likelihood of risk). 
 
6.3.2 Risk estimates for the modifiable cardiovascular risk factors in the Nuffield 
dataset 
 
Age and sex are non-modifiable risk factors. They have, therefore been adjusted for, with the 






Risk factors Number of 
people 
Model 






   
Government Office Regions    
London 5669 1.00  
North East 572 0.81 (0.66-0.99) 0.04 
North West 1827 1.06 (0.84-1.35) 0.60 
Yorkshire & The Humber 1313 1.14 (0.92-1.40) 0.23 
East Midlands 1126 1.29 (1.04-1.60) 0.019 
West Midlands 1880 1.11 (0.89-1.38) 0.34 
East of England 2739 1.15 (0.93-1.42) 0.19 
South East 5639 1.02 (0.83-1.26) 0.81 
South West 2089 0.92 (0.75-1.13) 0.42 
Sex    
Male  3.27 (3.15-3.40) 0.000 
Female  1.00  
Age  1.029 (1.027–1.031) 0.000 
Body mass index (obese)    
Government Office Regions    
London 1746 1.00  
North East 236 0.59 (0.46-0.76) 0.000 
North West 765 1.01 (0.75-1.35) 0.96 
Yorkshire & The Humber 605 1.10 (0.85-1.44) 0.46 
East Midlands 461 1.38 (1.05-1.80) 0.02 
West Midlands 792 1.04 (0.88-1.51) 0.29 
East of England 1167 1.10 (0.85-1.44) 0.46 
South East 2155 1.00 (0.77-1.30) 0.99 
South West 812 0.80 (0.62-1.03) 0.09 
Sex    
Male  2.50 (2.37-2.62) 0.000 
Female  1.00  
Age  1.036 (1.034–1.038) 0.000 
Waist circumference 
(obese) 
   
Government Office Regions    
London 2283 1.00  
North East 298 1.39 (1.20-1.60) 0.000 
North West 1097 1.78 (1.64-1.94) 0.000 
Yorkshire & The Humber 632 1.32 (1.20-1.47) 0.000 
East Midlands 645 1.67 (1.51-1.85) 0.000 
West Midlands 997 1.45 (1.33-1.48) 0.000 
East of England 1271 1.19 (1.10-1.29) 0.000 
South East 2800 1.24 (1.17-1.32) 0.000 
South West 1114 1.28 (1.18-1.39) 0.000 
Table 6.3: Anthropometric characteristics (BMI, waist circumference, and WHR) after adjusted 







Sex    
Male  0.73 (0.70-0.76) 0.000 
Female  1.00  
Age  1.035 (1.034–1.037) 0.000 
 
Waist-to-hip ratio (WHR) 
(obese) 
   
Government Office Regions    
London 3418 1.00  
North East 411 1.35 (1.18-1.54) 0.000 
North West 1338 1.45 (1.34-1.57) 0.000 
Yorkshire & The Humber 746 0.99 (0.90-1.09) 0.81 
East Midlands 826 1.50 (1.36-1.66) 0.000 
West Midlands 1310 1.27 (1.17-1.38) 0.000 
East of England 1788 1.14 (1.06-1.22) 0.001 
South East 3786 1.11 (1.05-1.17) 0.001 
South West 1604 1.24 (1.14-1.34) 0.000 
Sex    
Male  0.30 (0.29-0.31) 0.000 
Female  1.00  






Risk factors Number of 
people 
Model  
  Odds ratio  
(95% CI) 
p value 
Hypertension (SBP>90 mm 
Hg or DBP>140 mm Hg) 
   
Government Office Regions    
London 1809 1.00  
North East 273 1.32 (1.14-1.53) 0.000 
North West 875 1.63 (1.49-1.79) 0.000 
Yorkshire & The Humber 526 1.20 (1.07-1.34) 0.001 
East Midlands 543 1.39 (1.24-1.56) 0.000 
West Midlands 1016 1.69 (1.55-1.85) 0.000 
East of England 1270 1.33 (1.23-1.45) 0.000 
South East  3407 1.84 (1.73-1.97) 0.000 
South West 1140 1.45 (1.33-1.59) 0.000 
Sex    
Male  2.18 (2.08-2.29) 0.000 
Female  1.00  
Age  1.057 (1.055–1.059) 0.000 
Table 6.4: Hypertension (SBP >140 mm Hg or DBP >90 mm Hg) after adjusted for age, sex and 





Risk factors Number of 
people 
Model 




Elevated total cholesterol    
Government Office Regions    
London 6133 1.00  
North East 731 1.32 (1.15-1.51) 0.000 
North West 1786 1.08 (0.99-1.18) 0.07 
Yorkshire & The Humber 1601 1.28 (1.16-1.40) 0.000 
East Midlands 1449 1.23 (1.12-1.36) 0.000 
West Midlands 2335 1.17 (1.08-1.26) 0.000 
East of England 3389 1.18 (1.10-1.26) 0.000 
South East  7194 1.19 (1.13-1.26) 0.000 
South West 2899 1.23 (1.14-1.33) 0.000 
Sex    
Male  1.43 (1.38-1.49) 0.000 
Female  1.00  
Age  1.046 (1.044-1.048) 0.000 
Low HDL cholesterol    
Government Office Regions    
London 326 1.00  
North East 60 0.56 (0.42-0.74) 0.000 
North West 88 0.95 (0.75-1.21) 0.69 
Yorkshire & The Humber 158 0.47 (0.39-0.58) 0.000 
East Midlands 208 0.31 (0.26-0.37) 0.000 
West Midlands 276 0.38 (0.32-0.45) 0.000 
East of England 376 0.41 (0.35-0.48) 0.000 
South East  619 0.53 (0.46-0.61) 0.000 
South West 218 0.59 (0.49-0.70) 0.000 
Sex    
Male  0.14 (0.12-0.16) 0.000 
Female  1.00  
Age  1.007 (1.003-1.011) 0.001 
High LDL  cholesterol 
 
   
Government Office Regions    
London 3375 1.00  
North East 446 1.26 (1.10-1.44) 0.001 
North West 1067 1.14 (1.04-1.24) 0.004 
Yorkshire & The Humber 1075 1.52 (1.38-1.66) 0.000 
East Midlands 1039 1.67 (1.52-1.84) 0.000 
West Midlands 1576 1.46 (1.35-1.59) 0.000 
East of England 2291 1.47 (1.37-1.58) 0.000 
South East  8055 1.44 (1.36-1.53) 0.000 
Table 6.5: Plasma cholesterol (total cholesterol, HDL cholesterol, and LDL cholesterol) after 









After adjustment for age and sex, the risk of being overweight (as defined by BMI) for 
participants in the North East was significantly lower than for those in London (OR 0·81, 95% 
CI 0·66–0·99 p=0·04). However, participants in the East Midlands had a significantly higher 
prospect of being overweight than those in London (OR 1·29, 95% CI 1·04–1·60, p=0·019). 
Across England, men were over three times more likely than women to be overweight (OR 
3·27, 95% CI 3·15–3·40, p<0·001).  
 
The pattern for BMI-defined obesity was similar to that for overweight. After adjustment for 
age and sex, the risk of being obese for participants in the North East was significantly lower 
than for those in London (OR 0·59, 95% CI 0·46–0·76 p<0·001). However, participants in the 
East Midlands had a significantly higher chance of being obese than those in London (OR 1·38, 
95% CI 1·05–1·80, p=0·02). Across the whole of England, men were 2·5 times more likely 
than women to be overweight (OR 2·50, 95% CI 2·37–2·62, p<0·001). 
 
6.3.2.2 Waist circumference 
 
Compared with participants in London, those in all other regions were significantly more likely 
to be obese (as defined by waist circumference), after adjustment for age and sex. Participants 
from the North West (OR 1·78, 95% CI 1·64–1·94, p<0·001) and the East Midlands (OR 1·67, 
95% CI 1·51–1·85, p<0·001) were much likely to be obese (defined by waist circumference) 
than those from other regions. Men were less likely than women to be defined as obese on the 
basis of waist circumference (OR 0·73, 95% CI 0·70–0·76, p p<0·001). 
 
  
South West 1960 1.48 (1.38-1.60) 0.000 
Sex    
Male  2.05 (1.97-2.13) 0.000 
Female  1.00  
Age  1.036 (1.034-1.038) 0.000 
228 
 
6.3.2.3 Waist-to-hip ratio 
 
Compared with participants in London, those in other regions were more likely to be obese (as 
defined by WHR), and these differences were statistically significant for all regions apart from 
Yorkshire & The Humber (OR 0·99, 95% CI 0·90–1·09, p=0·81), after adjustment for age and 
sex. Participants in the East Midlands were most likely to have the highest WHR, with an OR 
of 1·50 (95% CI 1·36–1·66, p<0·001). Men were less likely than women to be obese on the 




Compared with participants in London, those in other regions were significantly more likely to 
be hypertensive after adjustment for age and sex. Participants in the South East (1·84, 95% CI 
1·73–1·97, p<0·001), the West Midlands (1·69, 95% CI 1·55–1·85, p<0·001), and the North 
West (1·63, 95% CI 1·49–1·79, p<0·001) were much likely to have high blood pressure than 
those from other regions. Men were twice as likely as women to be hypertensive (2·18, 95% 
CI 2·08–2·29, p<0·001). 
 
6.3.2.5 Total cholesterol 
 
Compared with participants in London, those in other regions were more likely to have elevated 
total cholesterol, and these differences were statistically significant for all regions apart from 
the North West (OR 1·08, 95% CI 0·99–1·18, p=0·07), after adjusting for age and sex. 
Participants in the North East were most likely to have the highest total cholesterol, with an 
OR of 1·32 (95% CI 1·15–1·51, p<0·001). Men were more likely than women to have elevated 
total cholesterol (OR 1·43, 95% CI 1·38–1·49, p<0·001). 
 
6.3.2.6 HDL cholesterol 
 
Compared with participants in London, those in other regions were more likely to have low 
HDL cholesterol, and the increased odds were statistically significant for all regions apart from 
the North West (OR 0·95, 95% CI 0·75–1·21, p=0·69), after adjustment for age and sex. 
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Participants in the East Midlands were the least likely to have low HDL cholesterol, with an 
OR of 0·31 (95% CI 0·26–0·37, p<0·001). Participants in the West Midlands (OR 0·38, 95% 
CI 0·32–0·45, p<0·001) and the East of England (OR 0·41, 95% CI 0·35–0·48, p<0·001) were 
the next least likely to have low HDL cholesterol. Men were much less likely than women to 
have low HDL cholesterol (OR 0·14, 95% CI 0·12–0·16, p<0·001). 
 
6.3.2.7 LDL cholesterol 
 
Compared with participants in London, those in all other regions were significantly more likely 
to have raised LDL cholesterol, after adjustment for age and sex. Participants from the East 
Midlands (OR 1·67, 95% CI 1·52–1·84, p<0·001) and Yorkshire & The Humber (OR 1·52, 
95% CI 1·38–1·66, p<0·001) were the most likely to have raised LDL cholesterol. Men were 
twice as likely as women to have raised LDL cholesterol (OR 2·05, 95% CI 1·97–2·13, 
p<0·001). 
 
6.3.3 Comparison of prevalence of modifiable cardiovascular risk factors between the 
Nuffield dataset and the Health Survey for England 2006 
 
There were two reasons to compare the results from Nuffield Health with HSE 2006. First, the 
primary focus of HSE 2006 was cardiovascular disease, and the prevalence of several 
modifiable risk factors in different regions in England included in this survey—BMI, waist 
circumference, total cholesterol, HDL cholesterol, and hypertension—were also investigated 
in Nuffield Health dataset. Second, HSE 2006 provided data from nationally representative 
samples to monitor trends in England—a total of 14,142 adults from 14,400 addresses (data for 
3491 children were reported separately) were selected, and households were sampled 
proportionately across the nine Government Office regions of England. The differences 
between the results of data from HSE 2006 and the Nuffield Health dataset are shown in tables 





Table 6.6: Comparison of a list of modifiable cardiovascular risk factors between HSE 2006 
and the Nuffield data in men by Government Office Regions  
 
 Overweight (%) Obese (%) Raised waist 
circumference (%) 
Total cholesterol 
≥ 5·0 mmol/l (%) 








































North East 35 53 28 20 32 24 59 72 9.4 7.9 35 26 
North 
West 




41 53 26 23 30 23 62 68 10.4 9.3 31 22 
East 
Midlands 
42 54 26 21 31 28 54 67 9.9 13.4 32 26 
West 
Midlands 
47 53 28 22 34 24 60 68 14.1 10.8 32 29 
East of 
England 
48 51 22 20 31 20 58 67 10.0 10.3 28 24 
London 42 47 19 13 30 14 52 60 7.5 4.6 31 16 
South East 46 50 20 20 31 21 59 68 8.7 8.2 26 31 
South 
West 
41 53 27 18 37 25 56 69 6.5 7.4 31 28 
 
 
Table 6.7: Comparison of a list of modifiable cardiovascular risk factors between HSE 2006 
and the Nuffield data in women by Government Office Regions  
 
 




≥ 5·0 mmol/l (%) 
HDL cholesterol 











































North East 32 28 28 17 41 27 61 58 2.0 0.8 28 12 




32 33 25 17 39 24 61 58 1.3 1.0 30 11 
East 
Midlands 
34 29 26 15 41 28 60 61 0.6 1.4 29 14 
West 
Midlands 
33 32 30 15 42 28 60 54 1.8 2.1 25 15 
East of 
England 
36 28 23 16 44 24 61 56 2.0 1.6 23 13 
London 28 23 21 10 40 20 58 46 2.6 0.8 24 7 
South East 30 28 24 13 40 26 63 57 1.7 1.2 26 17 














Compared with data collected from HSE 2006, the prevalence of BMI-defined overweight in 
men in the Nuffield Health dataset was higher in all regions. In the HSE 2006 data, the highest 
prevalence of overweight was in the East of England (48%), and lowest was in the North East 
(35%). In the Nuffield dataset, the highest prevalence was in the East Midlands (54%), and the 
lowest in London (47%). 
 
The prevalence of obesity in men was much higher in HSE 2006 data than in the Nuffield 
Health data in all regions apart from the South East, where the prevalence was the same (19%). 
In the HSE 2006 data, the highest prevalence of obesity was in the North East and West 
Midlands (28%), and lowest was in London and North West (19%). In the Nuffield Health 





Compared with data collected from HSE 2006, the prevalence of BMI-defined overweight in 
women in the Nuffield Health dataset was lower in all regions apart from Yorkshire & The 
Humber, which was higher in Nuffield Health data (33% v3233%). In the HSE 2006 data, the 
highest prevalence of overweight was in the East of England (36%), and lowest was in London 
(28%). In the Nuffield dataset, the highest prevalence of overweight was in Yorkshire & The 
Humber (33%), and the lowest was in London (23%). 
 
The prevalence of obesity in women was much higher in the HSE 2006 data than in the Nuffield 
Health data in all regions. In the HSE 2006 data, the highest prevalence of obesity was in the 
West Midlands (30%), and the lowest was in London and North West (21%). In the Nuffield 
Health dataset, the highest prevalence of obesity was in the North East and Yorkshire & The 








The prevalence of raised waist circumference in men was higher in the HSE 2006 data than in 
the Nuffield Health data across all regions. In the HSE 2006 data, the highest prevalence of 
raised waist circumference was in the South West (37%), and lowest was in London and 
Yorkshire & The Humber (30%). In Nuffield Health data, the highest prevalence of raised waist 




Compared with data collected from HSE 2006, the prevalence of raised waist circumference in 
women in the Nuffield Health dataset was much lower in all regions. In the HSE 2006 data, 
the highest prevalence of overweight was in the South West (45%), and the lowest was in the 
North West (37%). In the Nuffield dataset, the highest prevalence of overweight was in the 
North West (30%), and the lowest was in London (20%). 
 




The prevalence of raised total cholesterol in men was higher than 50% in both datasets. The 
prevalence of raised total cholesterol in men was lower in the HSE 2006 data than in the 
Nuffield Health data across all regions. In the HSE 2006 data, the highest prevalence of raised 
total cholesterol was in Yorkshire & The Humber (62%), and lowest prevalence was in London 
(52%). In the Nuffield Health dataset, the highest prevalence of raised total cholesterol in men 






The prevalence of raised total cholesterol in women was higher than 50% in both datasets. The 
prevalence of raised total cholesterol in women was higher in the HSE 2006 data than in the 
Nuffield Health data across all regions apart from the East Midlands, where it was similar in 
both datasets (60% vs 61%). In the HSE 2006 data, the highest prevalence of raised total 
cholesterol was in the South West (66%), and lowest was in London (58%). The pattern was 
similar in the Nuffield Health data, with the highest prevalence also in South West (62%), and 
the lowest also in London (46%). 
 




The prevalence of low HDL cholesterol in men was higher in the HSE 2006 data than in the 
Nuffield Health data in most of the regions. In the HSE 2006 data, the highest prevalence of 
low HDL cholesterol was in the West Midlands (14·1%), and lowest was in the South West 
(6·5%). In the Nuffield Health data, the highest prevalence was in the East Midlands (13·4%), 




The prevalence of low HDL cholesterol in women was generally very low in both datasets—
under 3% of the population in all regions. The prevalence was slightly higher in the HSE 2006 
data than in the Nuffield Health data for all of the regions apart from the East Midlands (where 
it was slightly higher in the Nuffield Health data [1·4% vs 0·6%]) and the West Midlands 
(where it was similar in the HSE and Nuffield datasets [1·8% vs 2·1%]). In the HSE 2006 data, 
the lowest prevalence of low HDL cholesterol was in the East Midlands (0·6%), and highest 
was in London (2·6%). In the Nuffield Health data, the lowest prevalence was in the North 









The prevalence of hypertension in men was higher in the HSE 2006 data than in the Nuffield 
Health data in all the regions apart from the South East, where it was much higher in Nuffield 
Health data (31% vs 26%). In the HSE 2006 data, the highest prevalence of hypertension was 
in the North East (35%), and the lowest was in the South East (26%). In the Nuffield Health 




The prevalence of hypertension in women was much higher in the HSE 2006 data than in the 
Nuffield Health data in all regions. In the HSE 2006 data, the lowest prevalence of hypertension 
was in the East of England (23%), and highest was in Yorkshire & The Humber (30%). In 
Nuffield Health data, the lowest prevalence was in London (7%), and the highest was in the 
South West (17%). 
 
No comparison was produced for WHR or LDL cholesterol because HSE 2006 did not include 




Data for diet, tobacco use, and alcohol intake are available at the regional level for England, 
Scotland, and Wales (DoE 1970-4; Ministry of Agriculture, Fisheries and Food 1971-5). The 
evidence has shown that geographical variations have an effect on cardiovascular mortality 
related to diet or smoking (Armstrong et al. 1975; Chilvers and Adelstein 1981; Knox 1974). 
However, little is known about geographical variations in the distribution of cardiovascular 
risk factors such as obesity, hypertension, and hyperlipidaemia, in a population with access to 
private medical insurance. The results of the present study showed that participants from 
London were much healthier than those from other regions. Men from the Midlands, and 
especially those from the East Midlands, had relatively worse health conditions than those from 
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other regions, so did women from the Midlands. Interestingly, women from South England had 
similar health conditions to those from the Midlands.  
 
Participants in the East Midlands and North West regions had a much higher risk of obesity 
than those from most other regions on the basis of three measures—BMI, waist circumference, 
and WHR. Participants in the South East had the highest risk, and those in York & The Humber 
the lowest risk, of being hypertensive. In terms of plasma cholesterol measures, the distribution 
among regions seemed variable—participants in the North East had the highest risk of elevated 
total cholesterol, and those in the North West had the lowest risk; both men and women in the 
Midlands were less likely to have low HDL cholesterol than those in other regions in England; 
and participants in North England were less likely to have high LDL cholesterol than those in 
other regions in England.  
 
A few previous studies have detected a North–South effect, or a Scottish effect on prevalence 
of cardiovascular disease and associated risk factors (Lawlor et al. 2003; Shelton 2009). Similar 
effect has also been observed in France (Lang et al. 1999), Germany (Muller-Nordhorn et al. 
2004) and Europe (Muller-Nordhorn et al. 2008). Shelton (2009) showed that there were 
significant geographic variations in cardiovascular risk factors between and within England 
and Scotland. At the national level, consumption of five or more portions of fruit and vegetables 
a day was significantly higher in England than Scotland in both men and women, smoking 
prevalence was significantly higher in Scotland than in England. However, this effect was not 
seen in the current study. This could be the study population in the present study, which is an 
affluent population in the UK. We could speculate that this effect might be able to be seen in 
the same population in other countries in Europe. 
 
Some, but not all, of these findings were consistent with previous evidence. Lawlor and 
colleagues (2003), in the British Women’s Heart and Health Study of women aged 60–79 years 
from 23 towns in England, Scotland, and Wales, showed that the age-adjusted prevalence of 
obesity was highest in the Midlands & Wales, and lowest in South England (30·8% vs 24·9%). 
Women in North England had the lowest age-adjusted prevalence of hypertension, and those 
in the Midlands & Wales the highest (32·6% vs 34·3%). With respect to raised total cholesterol, 
women in North England and the Midlands & Wales had the lowest age-adjusted prevalence 
(16·2% and 16·4%, respectively), and the highest prevalence was in South England (17·9%). 
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The lowest prevalence of raised LDL cholesterol was found in North England (2·1%), and 
highest in the Midlands & Wales (4·2%). However, this study was in older women only, and 
only had four regions in about 7,000 participants. Shelton (2009) used two sets of public survey 
data, the 2003 Scottish Health Survey and the 2003 HSE, to detect regional difference in four 
risk factors—eating fruit and vegetables (5+ per day), smoking, obesity, and type 2 diabetes—
in order to investigate health inequalities in Scotland and England. The results showed that men 
in London had the lowest prevalence of obesity (18%), with the highest prevalence in men 
from Yorkshire & The Humber (25%). The results were different for women, with those in the 
South East having the lowest prevalence of obesity (19%), and those in the West Midlands the 
highest (29%).  
 
This geographical variation could be partly explained by large numbers of participants in the 
different regions in the present study. Another possible explanation could be geographical 
variations in health service access or quality, or in the use of aspirin and statins, which could 
be a proxy indicator of health service utilisation (Ebrahim et al. 1998; Lawlor et al. 2003; Perry 
et al. 2000). In some areas, deprivation could be a good marker on cardiovascular risks. This 
could vary by region and thus alter the strength of the relation between deprivation and 
cardiovascular risks (Eames et al. 1993). A few studies have reported that cholesterol decreased 
in lower socioeconomic groups due to the reduction of intake of saturated fats, lower alcohol 
consumption, and consumption of more fruit, vegetables, and whole grains (Briefel and 
Johnson 2004; Kanjilal et al. 2006; Marmot et al. 1991; McFadden et al. 2009; Popkin et al. 
1996). 
 
Individual regions are a complex mixture of smaller areas, which differ considerably in the 
prevalence of cardiovascular risk factors, and will certainly differ substantially with respect to 
smoking, alcohol consumption, and dietary patterns. In general, the cardiovascular risk factor 
profile of a region tends to be worse in the North of England than in the South of England, due 
to climatic factors such as rainfall and temperature (Roberts and Lloyd 1972; West et al. 1973), 
water hardness (Morris et al. 1961), and social deprivation (Carstairs and Morris 1989; Eames 
et al. 1993). This is a pattern that part of the current study’s findings is in agreement with—




Several environmental factors—water hardness, rainfall, and temperature—and certain social 
factors substantially explain the geographical variations in cardiovascular mortality in the UK. 
The broader definition of social factors covers a wide range of behavioural variables and 
phenomena associated with living standards and conditions. Climatic factors can even have an 
effect on lifestyle on the basis of physical activity in leisure times, smoking and drinking habits, 
and dietary preferences. Evidence has shown the ways in which social factors might be 
reflected in behaviours such as smoking and drinking, and in physiological measurements such 
as overweight, blood pressure, and blood lipids (Shaper et al. 1981).  
 
More affluent areas might be greater beneficiaries of health promotion than less favoured areas. 
The traditional focus on individual risk-factor modification has broadened to take in areas such 
as the social environment with, for example, the “Healthy Cities” project (Ashton 1992). 
Social-directed policies such as improvement of child benefits and pensions, and provision of 
employment opportunities and good-quality housing could also have a major effect (Lancet 
1990).  
 
6.4.1 Comparison of prevalence of modifiable cardiovascular risk factors between the 
Nuffield dataset and the Health Survey for England 2006 
 
Overall, the prevalence of various modifiable cardiovascular risk factors was higher in HSE 
2006 data than in the Nuffield Health data for both men and women across all regions in 
England. In men, the prevalence of overweight, raised waist circumference, and raised total 
cholesterol was higher in the Nuffield Health data than in HSE data. Men in London were 
generally healthier than those in other regions in England. Differences in prevalence of several 
risk factors were wide between regions, such as raised waist circumference (up to two times), 
low HDL cholesterol (over three times), and hypertension (about two times). In women, the 
prevalence of obesity, raised waist circumference, and hypertension was much lower in the 
Nuffield Health data than in the HSE 2006 data. Only the difference in the prevalence of 
hypertension was wide between regions (more than two times). The distribution of 
cardiovascular risk factors in the affluent population did not mirror the distribution of 
cardiovascular risk factors in the general population on regional variation. These findings could 
be because the participants who attended Nuffield Health were much wealthier than those in 
the HSE 2006 data. However, HSE 2006 was not designed to provide local area data—the 
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sample sizes (16,000 adults and 7,300 children in 2006) were too small to provide reliable 
estimates below the regional level. 
 
This study provided a unique opportunity to show how geographical region affects modifiable 
cardiovascular risk factors in a large UK population from private medical screenings. These 
risk factors could have led to subsequent risk of cardiovascular disease. This is the only study 
reported to date that includes such a large number of cardiovascular risk factors in a primary 
care setting. However, the fact that the population was made up exclusively of participants 
registered in private medical insurance might be considered a limitation of this study. The 
participants all had access to private health care either through their employer or from self-
funding, meaning that the sample reflected the more affluent sectors of the population. This 
might have an effect on the geographical variations, but not for the purpose of this research. 
Shelton (2009) found that significant geographical variation remained once individual 
socioeconomic status was taken into consideration, but the relationship was complex and 
further research is needed. Another limitation of this study is that the dataset does not include 
a history of medication use. Use of lipid-lowering drugs, primarily statin therapy, is 
recommended for patients with clinical evidence of cardiovascular disease. However, data from 
a private medical insurance company is limited—participants still see their general 
practitioners (GPs) to prescribe medication. Therefore, it was impossible to identify whether a 
participant’s blood pressure and cholesterol level was drug-controlled. Other limitations 
include the complexity and heterogeneity of the data, which might introduce some bias into the 
analyses.  
 
Geographical variations in the prevalence of modifiable cardiovascular risk factors have been 
reported both between and within countries (Crombie et al. 1990; Eames et al. 1993; Morris et 
al. 2001; Nebrand et al. 1991; WHO MONICA Project Principle Investigators 1988). Lawlor 
and colleagues (2003) measured the geographical variation in prevalence of cardiovascular 
disease and associated risk factors, as well as their control in a national sample of 7,173 women 
aged 60–79 from 23 towns in England, Scotland, and Wales. Their findings for the prevalence 
of major risk factors by geographical region are partly in agreement with results of the present 
study. The variation in cardiovascular risk factors can be explained by differences in dietary 
consumption of fats, sugars, and green, leafy vegetables and the prevalence of obesity. The 
Seven Countries Study was the first to make systematic comparisons of cardiovascular disease 
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rates and characteristics of risk in different cultures (Keys 1980; Kromhout et al. 1989; 
Toshima et al. 1994). Keys and collaborators (1980) hypothesised that differences in 
population-level cardiovascular disease and individual-level risks were related to lifestyle risks 
including diet. Formal cross-sectional surveys were conducted starting in 1958 among men 
aged 40–59 years in different cultures in Yugoslavia, Italy, Greece, Holland, Finland, Japan, 
and the USA. The Seven Countries Study was the first to carry out both cross-sectional and 
summarise of a 35-year collaborative experience of epidemiology research in populations 
contrasting in cardiovascular disease rate, lifestyle, and diet (Toshima et al. 1994). This study 
also demonstrated that the major cardiovascular risk factors were common in importance and 
that the penetrance of risk factors differed between contrasting populations and between 
populations and individuals. The 2003 WHO MONICA study evaluated cardiovascular events 
and trends in mortality and risk factors in 21 countries across Europe, North America, Asia, 
and Australasia. The objective of this study was to measure trends in cardiovascular mortality, 
and coronary heart disease (CHD) and stroke morbidity, and to assess to extent to which these 
trends were related to changes in risk factors, daily living habits, health care, or major 
socioeconomic features. A large difference in cardiovascular disease event rates and mortality 
was observed in different countries, with high rates in Finland, Scotland, Iceland, and Denmark 
and low rates in Italy, Spain, and China. The cardiovascular disease mortality rates correlated 
with lifestyle and associated risk factors. 
 
Differences in cardiovascular mortality, especially a higher mortality have been noted in 
southeastern states, as compared with other states in the USA. This is related to a higher 
prevalence of hypertension and other lifestyle risk factors in these regions (Asplund 2004). In 
the Ni-Hon-San study, Abraham Kagan and colleagues (1973) examined physical 
characteristics, dietary intake, and biochemical markers among three groups of Japanese men 
living in Japan, Hawaii, and California. Consumption of dietary saturated fat in the three 
populations was reported to be 7%, 12%, and 14%, respectively. Evidence for regional 
difference in cardiovascular mortality that is related to major cardiovascular risk factors exists 
in many other countries of the world including Sweden, France, and Italy (Artauld-Wild et al. 
1993; Criqui and Ringel 1994; Nerbrand et al. 1992). In Europe the national differences can be 
explained on the basis of high-fat diets in the countries of the north and a high intake of green, 
leafy vegetables, monounsaturated fats, and wine in the southern countries (WHO and WHO 
MONICA Project Investigators 2003). Artaud-Wild et al. (1993) examined coronary mortality 
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in 40 countries in Europe and correlated it with cholesterol, saturated fats, and 40 dietary 
variables. A cholesterol–saturated fat index was significantly and positively related to 
cardiovascular mortality in these 40 countries at various levels of economic development. 
Intake of milk and other dairy products was associated with increased cardiovascular mortality, 
whereas intake of vegetables and other plant-based foods was associated with reduced 
cardiovascular mortality.  
 
Participants from London were much healthier than those from other English regions. 
According to the Office for National Statistics (2011), London’s population is young compared 
with the rest of the country, and young people tend to be healthier than older people. The 
average age of a Londoner is 37 years, compared with 40 years for the UK as a whole. This is 
because young people tend to work and live in world metropolitan cities such as London. 
However, the health inequality gap is increasing (Marmot 2010). People in the top 10% of 
households earn around five and half times more than those in the bottom 10%. The population 
of London is now over 8·2 million, and is expected to continue to grow to more than 9·5 million 
over the next 20 years. London therefore faces a unique set of complex challenges in protecting 
and improving the cardiovascular health of its inhabitants.  
 
Remaining variation could be explained by geographical variation in access to or quality of 
health services, or both. The geographical variations in CHD mortality rates suggest that 
dramatic improvements in CHD mortality in the UK are still attainable. For example, if every 
local authority in the UK had the same CHD mortality rate as Kensington and Chelsea, there 
would be approximately 32,500 fewer deaths every year in England, almost 5,500 fewer deaths 
in Scotland, 3,000 fewer deaths in Wales, and 1,300 fewer deaths in Northern Ireland; i.e. a 
total of over 42,000 fewer deaths in the United Kingdom, including 15,000 fewer premature 
deaths before age 75 years (Scarborough et al. 2008). There is also some geographical variation 
in the prevalence of cardiovascular disease. The HSE 2003 suggested that 20% of men in 
Yorkshire and the Humber and 19% in the West Midlands report ever having had some form 
of diagnosed cardiovascular disease, compared with 15% of men in the South West and 16% 
in London and the East of England. Furthermore, the prevalence of CHD in men is nearly twice 
as high in Yorkshire and the Humber (12%) as in the South West (7%) and East of England 
(7%). Correspondingly, prevalence of cardiovascular disease for women ranges from 14% in 
London to 20% in the West Midlands. CHD varies even more dramatically; only 4% of women 
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in the South West and East of England report a doctor’s diagnosis of CHD, compared with 




Geographical region has an effect on modifiable cardiovascular risk factors. Several risk factors 
have different effects on men and women, so it is essential that studies present results by sex. 
Although geographical variations in death rates from coronary heart disease have been 
observed in the UK for many years, few studies here looked at the effect of geographical 
variations in cardiovascular risk factors, and most are from different phases of the British 
Regional Heart Study. These studies investigated the effect of geographical region on 
cardiovascular mortality, but even less available data in cardiovascular risk factor profile.  
 
Several environmental factors—water hardness, rainfall, and temperature—and certain social 
factors might substantially explain the geographical variations in cardiovascular mortality in 
the UK, but further research into the underlying reasons for the observed differences in 
cardiovascular risk factors in the UK both between and within regions is needed. As seen in 
the Health and Lifestyles in the North West (2007)—populations in more affluent areas could 
benefit from health promotion (diet, behavior change, lifestyle and physical activity mainly) 
and campaigns than those in less affluent areas. Therefore, deprivation (include the access to 
health service or quality) could be a good marker for cardiovascular risks in geographical 
varitions. Ethnic groups such as south Asians living in the UK—Indians, Bangladeshis, 
Pakistanis, and Sri Lankans—have much higher premature death rate from cardiovascular 
disease compared with the white population. Strategies in preventive and treatment targeted 
white population might not be applicable to ethnic minorities. Therefore, strategies targeted on 
ethnic groups should be specifically developed, validated, and assessed to consider both 
cultural acceptability and underlying susceptibility.  
 
Multilevel analyses combining individual patient data with aggregate data could be a feasible 
approach to identify the risk factors that contribute the most to regional variations. Such 
research would allow prevention strategies that target specific risk factors. In addition, the 
monitoring of cardiovascular disease and risk factors in the UK could become more 
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manageable. These actions will require the involvement of both primary care health 
professionals (prevention and detection) and secondary health care settings (appropriate 
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COMPARISONS BETWEEN PREVALENCE OF MODIFIABLE 
CARDIOVASCULAR RISK FACTORS IN PEOPLE ATTENDING PRIVATE 
MEDICAL SCREENING AND NATIONAL HEALTH SERVICES FROM SOUTH 





Aim: In chapter 4, the prevalence rate of various modifiable cardiovascular risk factors for 
clients who attended private health centres across the UK by age and sex was examined. This 
chapter aimed to compare the prevalence of various cardiovascular risk factors between the 
people who attended Nuffield Health and individuals who attended local general practitioner 
clinics in south England. 
 
Methods: Data are provided by Hampshire Health Record (HHR), NHS Hampshire. Seven 
risk factors were analysed: body-mass index (BMI), waist size, systolic and diastolic blood 
pressure, and total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) 
cholesterol. Age was divided into six groups: 18–24, 25–34, 35–44, 45–54, 55–64, and 65–75 
years. Prevalence was calculated for each modifiable risk factor proportionately. Comparison 
outcomes were analysed by chi-square test to see the difference between people who attended 
Nuffield Health and those who attended general practice in south England. All baseline data 
were analysed at a 0·05 α level to determine statistical significance. 
 
Results: In the overall population, participants aged 65–75 years had the highest prevalence of 
overweight (39·8%); participants aged 55-64 and 65–75 years both had the highest prevalence 
obesity (23·5%); participants aged 45–54 years had the highest prevalence of morbid obesity 
(3·3%). The general pattern of high waist circumference in the overall population, men and 
women, is directly proportional to age, with the exception of men aged 65-75 years. Men aged 
55–64 years had the highest prevalence of very high waist circumference, at 50·5%. Women 
who were aged 65–75 years had the highest prevalence of very high waist circumference of 
65·7%. In overall population, participants aged 65–75 years (group 6) had the highest 
prevalence of high systolic and diastolic blood pressure. Men were more likely to have a higher 
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prevalence of higher systolic blood pressure and diastolic blood pressure than were women. 
48·6% of men and 33·7% of women, respectively, had high systolic blood pressure; and 12·3% 
of men and 7·1% of women, respectively, had high diastolic blood pressure. In the overall 
population, the highest prevalence of elevated total cholesterol and LDL were found in group 
5 (aged 55–64 years), but the highest prevalence of  low HDL was found in group 3 (aged 35-
44 years). When data were compared between Hampshire Health Record and Nuffield Health, 
significant differences were found between individual cardiovascular risk factors, and within 
different age groups, mostly because of sample size—the dataset from the NHS trust is at least 
ten times larger than the Nuffield dataset (with a maximum that could be up to 100 times). 
 
Discussion: Overall, about one in two people were overweight or obese in HHR. Participants 
tend to have higher systolic blood pressure, but lower diastolic blood pressure. About 60% and 
45% of participants have elevated total cholesterol and LDL, respectively, and 16% 
participants have lower HDL. It was hypothesised that the population from the NHS trust 
dataset has a lower BMI than the one from the Nuffield Health dataset. However, women had 
a lower BMI in the Nuffield Health dataset. Also, although many risk factors contribute to 
cardiovascular diseases in both men and women, the cardiovascular risk factors for women are 
the same as those in men, such as cigarette smoking, elevated serum cholesterol, elevated blood 
pressure and a sedentary lifestyle. Difference in cardiovascular risk factors is not only because 
of the gender difference. Many other aspects could have an effect on the contribution to 
cardiovascular disease. These include: the effect of adult lifestyle, potential genetic differences, 
developmental conditions throughout the life course, per se and operating through social 
determinants, rapid urbanisation, androgen level, low birthweight, limited living conditions in 
childhood, low-carbohydrate high-protein diet, collectivist society, and psychological stress.  
 
Conclusion: Based upon data from Nuffield Health and Hampshire Health Record, participants 
aged 55–75 years who signed up to private medical insurance and in south England need to 
pay more attention to their cardiovascular health.  They may need to care more about their 
lifestyle and diet, and exercise more. Structured exercise and school sport can make an 
important contribution to an individual’s physical activity. A physically active lifestyle can 
reduce the risk of many chronic conditions including coronary heart disease, stroke, obesity, 
and mental health problems. There is evidence that action at multiple levels is effective in 
increasing physical activity, from primary care professionals encouraging individuals to lead 
253 
 
active lives, to local authorities investing in community-level activity programmes and 






Cardiovascular disease is the leading cause of premature death and a major cause of disability 
in the UK (BHF 2007). In 2010, cardiovascular disease was responsible for around one in three 
premature deaths (under age 75 years) in men and one in five premature deaths in women. 
Coronary heart disease and stroke are the main causes of cardiovascular disease mortality. The 
World Health Organization (WHO 2009) toolkit estimates that the top ten risk factors for early 
death and disability in the UK are, in order of impact: tobacco use, harmful alcohol 
consumption, high blood pressure, high blood cholesterol, overweight and obesity, physical 
inactivity, illicit drug use, low fruit and vegetable intake, occupational risks, and poor sexual 
health. Approximately 25% of people aged 16 years and over report one lifestyle risk factor, 
33% two risk factors, 23% three risk factors, and 12% four or more risk factors. Only 7% of 
adults have no risk factors (HSE 2010). This chapter looks at various cardiovascular risk factors 
in the datasets from Nuffield Health and Hampshire Health Record, and compares the 
prevalence of these risk factors by different age groups and sex, which are relevant to two 
databases analysed in the study. 
 
These results show that the majority of adults in England have multiple lifestyle risks to their 
health. Among males, the percentage with four or more risk factors increases from 3·5% of 
16–24 year olds, to 21·4% of those aged 55–64 years, before declining to 11% of those aged 
75 years and over. Among females, the percentage with four or more risks rises from 5·5% of 
16–24 year olds, to 16·2% of those aged 65–74 years, before falling to 12·7% of the group 
aged 75 years and over. For both sexes, the increase between the first two age groups is mainly 
due to the rise with age in the prevalence of raised cholesterol, hypertension, obesity, and 
diabetes. There is evidence that the percentage of adults with multiple risk factors is decreasing. 
For example, 47·9% of males had three or more risk factors in 2003 compared with 37·5% in 
2010. Among females, the figure fell from 39·1% to 33·7% over the same period. These 
improvements are mainly due to the reduced prevalence of raised cholesterol, hypertension, 
and smoking, although over the same period, there has been a less positive decline in healthy 
eating levels, an increase in binge drinking, and increases in the prevalence of obesity and 
diabetes. Understanding the way these factors interact is central to increasing the effectiveness 




Hypertension is the most important modifiable risk factor for cardiovascular disease. The 
percentage of the population with high blood pressure increases progressively with age. In 
2008–10, 4·1% of 14–24 year olds had high blood pressure, compared with 25·9% of 45–54 
year olds and 72·8% of people aged 75 years and over. There is evidence that the prevalence 
of high blood pressure is increasing in older age groups, although the percentage whose 
hypertension is not controlled by medication is decreasing. The estimated prevalence of high 
blood pressure varies across England. More than 35% of adults in parts of south west and south 
east England have high blood pressure, compared with less than 25% in several London 
boroughs and elsewhere. A controlled trial reporting on the effects of screening, the South-East 
London Screening Study (SELSS), was conducted in 1967 and involved 7229 participants aged 
between 40 and 64 years from two local group general practices. No significant differences 
were found between the screened and the non-screened groups in any of the outcome measures 
such as raised diastolic blood pressure (≥105 mm Hg) (The South-East London Screening 
Study Group 1977).  
 
There is evidence that cholesterol levels have been falling over time, largely as a result of an 
increase in the prescribing of statins and other lipid-lowering drugs; between 1994 and 2006, 
the percentage of men with raised cholesterol fell from 74% to 57% and among women from 
77% to 61%. The prevalence of raised cholesterol increased from 31% of females and 20% of 
males aged 16–24 years, peaked at 84% of women aged 55–64 years and 74% of men aged 45–
54 years, and then fell again for both sexes in the oldest age groups. The percentage of adults 
with raised cholesterol is broadly comparable across English regions, although the percentage 
of women in the south west with this risk factor is higher than the English average at 66%, as 
is the percentage of males in Yorkshire and the Humber at 62%.  
 
Patterns of obesity differ substantially by age. Among adults, the prevalence of obesity rises 
from 11·2% of those aged 16–24 years, peaks at 32·4% among those aged 55–64 years, before 
falling to 25·2% of people aged 75 years and over. There are also differences in prevalence 
between the sexes, with females having higher levels of obesity in the 16–24 years and 65 years 
and over age groups, and men having higher levels between the ages of 45 and 64 years. 
Common to both sexes and all age groups has been a progressive increase in levels of obesity. 
Geographic variation exists. The modelled distribution of obesity differs, with the highest 
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estimated percentages found in parts of the north west, Yorkshire and the Humber, west 
Midlands, and the south east.  
 
There is clear evidence that dietary control and physical activity are effective in reducing 
obesity and overweight at an individual level, although creating environments that promote and 
enable healthy eating and active lives requires action across industry, Local Government, and 
the NHS. 
 
The data sources available to quantify the prevalence of the different behavioural risks provide 
a strong basis for understanding the varying health burden that these factors place on different 
groups in the population and across the life course. For example, alongside the age, sex, 
socioeconomic, and ethnic group differences in smoking rates, there are similar variations in 
alcohol consumption patterns and the distribution of alcohol-related harm. 
 
South England is a more affluent region in the UK compared with other regions. Nuffield 
Health is a private medical insurance company, so people who attended Nuffield Health were 
more likely to be from a higher socioeconomic class. It is therefore reasonable to compare the 
population who attended Nuffield Health with those located in south England in terms of 
different age groups (and socioeconomic status in the following chapter), but not regional 
variation. This chapter compares the prevalence of various cardiovascular risk factors between 
the people who attended Nuffield Health and individuals who attended local general 
practitioner (GP) clinics in south England, and to identify the similarities and differences of 
two datasets in relation to the cardiovascular risk factors. 
 
7.2 DESIGN AND METHODS 
 
7.2.1 Study setting and data collection 
 
Data are provided by Hampshire Health Record, NHS Hampshire. The Hampshire Health 
Record is a joint project supported by Basingstoke and North Hampshire Foundation Trust, 
Hampshire Primary Care Trust, Portsmouth City Teaching Primary Care Trust, Portsmouth 
Hospitals NHS Trust, Southampton City Primary Care Trust, Southampton University 
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Hospitals NHS Trust, and Winchester and Eastleigh Hospital NHS Trust. HHR provides a 
detailed record of care which contains most of the information held in the GP’s record. It is 
stored by using a coding scheme (called READ Codes), which enables the data to be easily 
processed and displayed, whilst ensuring the quality and accuracy of the data is of a suitable 
level. Using this coding system means that only clinical data is shared and any comments GP 
may record for their own use are not shared. The amount of information will vary between 
patients, but will normally include information about allergies, medication, diagnosis, tests, 
and treatments. 
 
7.2.2 Cardiovascular risk factors 
 
Several established cardiovascular risk factors represent the risk profile of the participants:  (1) 
anthropometric characteristics; (2) blood pressure; and (3) plasma serum. We examined BMI 
and waist circumference. BMI is defined as: (1) underweight (below 18·5 kg/m2); (2) normal 
(between 18·5 and 25 kg/m2); (3) overweight (over 25 but less than 30 kg/m2); (4) obese (over 
30 but less than 40 kg/m2); or (5) morbidly obese (over 40 kg/m2) (HSE 2008). Waist 
circumference was measured at the anatomical waist. For men, low waist circumference is 
defined as less than 94 cm, high as 94–102 cm, and very high as greater than 102 cm; for 
women, low waist circumference is less than 80 cm, high is 80–88 cm, and very high is greater 
than 88 cm (NICE 2006a). Blood pressure included systolic blood pressure and diastolic blood 
pressure. Hypertension was classified as greater than 90 mm Hg (diastolic) and greater than 
140 mm Hg (systolic) (NICE 2006b). Plasma serum includes total, HDL, and LDL cholesterol. 
Total cholesterol was classified as raised if higher than 6 mmol/L. HDL was classified as low 
if less than 1·0 mmol/L; LDL was defined as raised if greater than 3·36 mmol/L (Contois et al. 
1996). Age was divided into six groups: 18–24, 25–34, 35–44, 45–54, 55–64, and 65–75 years, 





7.2.3 Statistical analysis 
 
Data from this study were analysed with SPSS version 17.0 (SPSS Inc, Chicago, IL, USA). 
The dependent measures were modifiable risk factors—eg, BMI, waist circumference, blood 
pressure, plasma cholesterol, etc. Prevalence was calculated for each modifiable risk factor 
proportionately. Comparison outcomes were analysed by chi-square test to see the difference 
between people who attended Nuffield Health and those who attended general practices in 





Table 7.1 shows the prevalence of modifiable cardiovascular risk factors in the overall 
population. Tables 7.2 and 7.3 show prevalence of modifiable cardiovascular risk factors in 
different age groups in men and women, respectively. Figures mentioned in the 7.3.1 – 7.3.3 




Table 7.1: Prevalence of modifiable cardiovascular risk factors in different age groups  










age 45–54  
years 
Group 5, 




75  years 
Total 
Body-mass index (n) 46 856 116 538 119 189 121 573 101 216 90 476 595 848 
Underweight (n) 7072 7417 3323 1974 1489 1412 22 687 
% 15·1% 6·4% 2·8% 1·6% 1·5% 1·6% 3·8% 
Normal (n) 28 830 68 650 57 866 48 923 35 185 29 431 268 885 
% 61·5% 58·9% 48·5% 40·2% 34·8% 32·5% 45·1% 
Overweight (n) 6977 25 586 35 820 41 571 37 441 35 988 183 383 
% 14·9% 22·0% 30·1% 34·2% 37·0% 39·8% 30·8% 
Obese (n) 3397 12 744 19 009 25 152 23 819 21 229 105 350 
% 7·2% 10·9% 15·9% 20·7% 23·5% 23·5% 17·7% 
Morbidly obese (n) 580 2141 3171 3953 3282 2416 15 543 
% 1·2% 1·8% 2·7% 3·3% 3·2% 2·7% 2·6% 
Waist circumference 
(n) 
730 2612 3054 4453 5857 7766 24 472 
High (n) 80 347 561 925 1278 1780 4971 
% 11·0% 13·3% 18·4% 20·1% 21·8% 22·9% 20·3% 
Very high (n) 149 611 1097 2204 3271 4424 11 756 
% 20·4% 23·4% 35·9% 49·5% 55·8% 57·0% 48·0% 
Systolic blood 
pressure (n) 
43 713 91 018 117 463 139 715 190 436 210 009 792 354 
n 2573 9887 24 325 50 905 98 254 127 914 313 858 
% 5·9% 10·9% 20·7% 36·4% 51·6% 60·9% 39·6% 
Diastolic blood 
pressure (n) 
50 456 134 567 146 637 152 378 134 234 118 598 736 841 
n 612 4637 10 943 21 207 19 634 17 767 73 809 
% 1·2 % 3·4% 7·5% 13·9% 14·6% 15·0% 10·1% 
Total cholesterol (n) 2857 11 642 36 125 101 601 176 242 279 780 608 247 
n 718 4213 18 715 61 991 112 036 163 714 361 387 
% 25·1% 36·2% 51·8% 61·0% 63·6% 58·5% 59·4% 
High-density 
lipoprotein (n) 
2180 8476 26 548 72 559 123 954 187 582 421 299 
n 403 1757 5933 14 106 19 954 25 958 68 111 
% 18·5% 20·7% 22·3% 19·4% 16·1% 13·8% 16·2% 
Low-density 
lipoprotein (n) 
398 1265 4305 12 501 22 342 35 324 76 135 
n 70 311 1755 5778 10 728 15 319 33 961 
% 17·6% 24·6% 40·8% 46·2% 48·0% 43·4% 44·6% 
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Table 7.2: Prevalence of modifiable cardiovascular risk factors in different age groups in men 





















18 991 47 726 54 847 57 730 49 102 44 189 272 585 
Underweight (n) 3508 2897 1169 568 502 490 9134 
% 18·5% 6·1% 2·1% 1·0% 1·0% 1·1% 3·4% 
Normal (n) 11 871 28 337 24 876 19 451 14 155 12 506 111 196 
% 62·5% 59·4% 45·4% 33·7% 28·8% 28·3% 40·8% 
Overweight (n) 2470 11 578 19 640 24 066 21 326 20 178 99 258 
% 13·0% 24·3% 35·8% 41·7% 43·4% 45·7% 36·4% 
Obese (n) 973 4370 8316 12 367 12 054 10 247 48 327 
% 5·1% 9·2% 15·2% 21·4% 24·5% 23·2% 17·7% 
Morbidly obese (n) 169 544 846 1278 1065 768 4670 
% 0·9% 1·2% 1·5% 2·2% 2·2% 1·7% 1·7% 
Waist 
circumference (n) 
297 1139 1539 2390 3296 4229 12 890 
High (n) 24 129 301 578 820 1139 2991 
% 8·1% 11·3% 19·6% 24·2% 24·9% 26·9% 23·2% 
Very high (n) 18 142 386 978 1665 2101 5290 
% 6·1% 12·5% 25·1% 41·0% 50·5% 49·7% 41·0% 
Systolic blood 
pressure (n) 
7686 19 687 36 815 60 364 89 040 100 042 313 634 
n 974 4486 12 166 26 214 48 488 60 114 152 442 
% 12·7% 22·8% 33·0% 43·4% 54·5% 60·1% 48·6% 
Diastolic blood 
pressure (n) 
16 451 51 146 64 004 72 355 61 767 57 480 323 203 
n 236 2545 6821 11 975 10 943 7353 39 873 
% 1·4% 5·0% 10·7% 16·6% 17·7% 12·8% 12·3% 
Total cholesterol 
(n) 
1379 5472 19 124 57 379 99 395 151 962 334 711 
n 296 1963 10 737 36 346 58 632 77 515 185 489 
% 21·5% 35·9% 56·1% 63·3% 59·0% 51·0% 55·4% 
High-density 
lipoprotein (n) 
1060 3932 14 020 40 484 68 789 99 871 228 156 
n 255 1082 4180 10 484 15 909 20 556 52 466 
% 24·1% 27·5% 29·8% 25·9% 23·1% 20·6% 23·0% 
Low-density 
lipoprotein (n) 
210 636 2348 7172 12 675 19 172 42 213 
n 35 159 1065 3641 5833 7243 17 976 




























Body-mass index (n) 27 865 68 812 64 342 63 843 52 114 46 287 323 263 
Underweight (n) 3564 4520 2154 1406 987 922 13 553 
% 12·8% 6·6% 3·3% 2·2% 1·9% 2·0% 4·2% 
Normal (n) 16 959 40 313 32 990 29 472 21 030 16 925 157 689 
% 60·9% 58·6% 51·3% 46·2% 40·4% 36·6% 48·8% 
Overweight (n) 4507 14 008 16 180 17 505 16 115 15 810 84 125 
% 16·2% 20·4% 25·1% 27·4% 30·9% 34·2% 26·0% 
Obese (n) 2424 8374 10 693 12 785 11 765 10 982 57 023 
% 8·7% 12·2% 16·6% 20·0% 22·6% 23·7% 17·6% 
Morbidly obese (n) 411 1597 2325 2675 2217 1648 10 873 
% 1·5% 2·3% 3·6% 4·2% 4·3% 3·6% 3·4% 
Waist circumference (n) 433 1473 1515 2063 2561 3537 11 582 
High (n) 56 218 260 347 458 641 1980 
% 12·9% 14·8% 17·2% 16·8% 17·9% 18·1% 17·1% 
Very high (n) 131 469 711 1226 1606 2323 6466 
% 30·3% 31·8% 46·9% 59·4% 62·7% 65·7% 55·8% 
Systolic blood pressure (n) 36 027 71 331      80648 79 351 101 396 109 967 478 720 
n 1599 5401 12 159 24 691 49 766 67 800 161 416 
% 4·4% 7·6% 15·1% 31·1% 49·1% 61·7% 33·7% 
Diastolic blood pressure (n) 33 973 79 100 74 634 76 816 63 081 59 206 386 810 
n 361 1887 3991 7229 7695 6412 27 575 
% 1·2% 2·4% 5·3% 9·4% 12·2% 10·8% 7·1% 
Total cholesterol (n) 1478 6170 17 001 44 222 76 847 127 818 273 536 
n 422 2250 7978 25 645 53 404 86 199 175 898 
% 28·6% 36·5% 46·9% 58·0% 69·5% 67·4% 64·3% 
High-density lipoprotein (n) 1120 4544 12 528 32 075 55 165 87 711 193 143 
n 148 675 1753 3622 4045 5402 15 645 
% 13·2% 14·9% 14·0% 11·3% 7·3% 6·2% 8·1% 
Low-density lipoprotein (n) 188 629 1957 5329 9667 16 152 33 922 
n 35 152 690 2137 4895 8076 15 985 
% 18·6% 24·2% 35·3% 40·1% 50·6% 50·0% 47·1% 





7.3.1.1 Body-mass index 
 
In the overall population (table 7.1), participants aged between 65 and 75 years (group 6) had 
the highest prevalence of being overweight (39·8%). Both group 5 and 6 (ages 55-64 and 65-
75 years, respectively) had the highest prevalence of obesity (23·5%). The highest prevalence 
of morbid obesity was found in group 4 (ages 45-54 years) and equaled 3.3%. For men, the 
highest prevalence of being overweight occurred in goup 6 (ages 65-75 years) and equaled 
45·7%. Group 5 (ages 55-64 years) was the one with the highest prevalence of obesity, which 
was 24·5%. The highest prevalence of morbid obesity equaled 2·2% and was found in both 
group 4 (ages 45-54 years) and group 5 (ages 55-64 years). For women, gourp 6 (ages 65-75 
years) was the one with the highest prevalence o overweight and obesity (34·2% and 23·7%, 
respectively). Group 4 (ages 35-44 years) was the one with the highest prevalence of morbid 
obesity, which equaled 4·2%.  
 
In the overall population (table 7.1), participants aged between 45 and 54 years had the highest 
prevalence of being overweight, obese, and morbidly obese (22·7%, 23·9%, and 25·4%, 
respectively). For men (table 7.2), those aged 45–54 years had the highest prevalence of being 
overweight, obese, and morbidly obese compared with other age groups (24·2%, 25·6%, and 
27·4%, respectively). For women (table 7.3), those aged 65–75 years had the highest 
prevalence of being overweight and obese (34·2% and 23·7%, respectively). Women aged 45–
54 years had the highest prevalence of morbid obesity (24·6%). 
 
In the overall population (table 7.1), the prevalence of overweight gradually increased with age 
up to 75 years; the prevalence of obesity increased with age up to 64 years and then stayed at 
the same level and the prevalence of morbid obesity increased with age up to 54 years and then 
sarted to decrease afterwards. In terms of prevalence of overweight, men shared the same 
pattern as the overall population (table 7.2). The prevalence of obesity in men increased with 
age up to 64 years and started to decrease afterwards. 54 years was the age up to which the 
prevalence of morbid obesity in men increased to stay at the same level up to age of 64 years 
and then decrease afterwards. For women (table 7.3), the pattern shows that the prevalence of 
becoming overweight or obese is proportional to increase in age and thus rises from age 18 
263 
 
years all the way through to 75 years of age. Prevalence of morbid obesity in women increases 
up to age of 54 years and decreases afterwards to slightly increase closer to age of 75 years. 
The lowest prevalence is in 18–24 year olds in the overall population (table 7.1), men (table 
7.2), and women (table 7.3).  
 
7.3.1.2 Waist circumference 
 
The general pattern of high waist circumference in the overall population (table 7.1), men (table 
7.2), and women (table 7.3) is directly proportional to age. Men had a higher prevalence of 
high waist circumference than women (23·2% to 17·1%). Women had a higher prevalence of 
very high waist circumference than men (55·8% to 41·0%). 
 
Men (table 7.2) aged 65–75 years had the highest prevalence of high waist circumference, at 
26·9%. The second highest prevalence was found in men aged 55—64 years, in whom the rate 
was 24·9%. The lowest prevalence of high waist circumference was found in men aged 18–24 
years and equaled 8.1%. For women (table 7.3), those aged 65—75 years had the highest 
prevalence of high waist circumference, at 18·1%. The second highest prevalence was in 
women aged 55—65 years, in whom the rate was 17·9%. The lowest prevalence of high waist 
circumference in women was also found in those aged 18–24 years and equaled 12·9%.  
 
The highest prevalence of very high waist circumference was 50·5% in men (table 7.2) and 
65·7% in women (table 7.3), at age 55-64 years for men and 65—75 years for women. The 
lowest prevalence of very high waist circumference was 6·1% in men and 30·3% in women, 
both at age 18–24 years.  
 
7.3.2 Blood pressure 
 
7.3.2.1 Systolic blood pressure 
 
In the overall population (table 7.1), participants aged 65–75 years (group 6) had the highest 
prevalence of high systolic blood pressure; those aged 55–64 (group 5) had the second highest 
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prevalence of high systolic blood pressure. Participants aged 18–24 (group 1) had the lowest 
prevalence of high systolic blood pressure.  
 
Men were more likely to have a higher prevalence of higher systolic blood pressure than were 
women. The figures were 48·6% in men (table 7.2) and 33·7% in women (table 7.3), 
respectively. 
 
For men (table 7.2) and women (table 7.3), the highest prevalence of higher systolic blood 
pressure was both found in group 6; the figures were 60·1% and 61·7%, respectively. The 
second highest prevalence of higher systolic blood pressure was also both found in group 5; 
the figures were 54·5% and 49·1%, respectively. The lowest prevalence was found in group 1 
for both men and women; the figures were 12·7% and 4·4%, respectively.  
 
7.3.2.2 Diastolic blood pressure 
 
In the overall population (table 7.1), participants aged 65-75 years (group 6) had the highest 
prevalence of high diastolic blood pressure. Those aged 55–64 years (group 5) had the second 
highest prevalence of high diastolic blood pressure. Participants aged 18–24 years (group 1) 
had the lowest prevalence of high diastolic blood pressure.  
 
The prevalence of high diastolic blood pressure shared the same pattern as that of high systolic 
blood pressure in men (table 7.2) and women (table 7.3). The figures were 12·3% in men and 
7·1% in women. The highest prevalences of higher diastolic blood pressure were found in 
group 5 (age 55-64 years) for both men and women and equaled 17·7% and 12·2%, 
respectively. The second highest prevalence of higher diastolic blood pressure was found in 
men in group 4 (16·6%) and in women in group 6 (10·8%). For men and women, the lowest 
prevalence of higher diastolic blood pressure was both found in group 1 (age 18–24 years); the 





7.3.3 Serum lipids 
 
7.3.3.1 Total cholesterol 
 
In the overall population (table 7.1), the highest prevalence of high total cholesterol was found 
in group 5 (age 55-64 years) and the second highest prevalence was found in group 4 (age 45-
54 years). The lowest prevalence was found in group 1 (age 18–24 years). 
 
The prevalence of high total cholesterol in men (table 7.2) and women (table 7.3) was 55·4% 
and 64·3%, respectively. For men, the highest (63·3%) and the second highest (59·0%) 
prevalence of high total cholesterol was found in group 5 and group 4, respectively. For women, 
the highest prevalence of high total cholesterol was found in group 5 and equaled 69·5%. The 
second highest prevalence of 67·4% was found in group 6. The lowest prevalence of high total 
cholesterol for both men and women was in group 1 and equaled 21·5% and 28·6%, 
respectively.  
 
7.3.3.2 High-density lipoprotein cholesterol 
 
In the overall population (table 7.1), the highest prevalence of low HDL was found in group 3 
(age 35-44 years) and the second highest prevalence was found in group 2 (age 25-34 years). 
The lowest prevalence of HDL was found in group 6 (age 65-75 years). 
 
The prevalence of low HDL in men (table 7.2) was almost three times higher than in women 
(table 7.3), at 23·0% and 8·1%, respectively. Men shared the same pattern as the overall 
population. The highest prevalence of low HDL in men was 29·8%, the second highest 
prevalence equaled 27·5% and the lowest one was 20·6%. In women, the highest prevalence of 
low HDL was found in group 2 (ages 25-34 years) and equaled 14·9%. Group 3 (ages 35-44 
years) was the one with the second highest prevalence at 14%. The lowest prevalence occurred 





7.3.3.3 Low-density lipoprotein cholesterol 
  
In the overall population (table 7.1), the highest prevalence of high LDL was found in group 5 
(age 55-64 years), and the second highest prevalence was found in group 4 (age 45-54 years). 
The lowest prevalence was found in group 1 (age 18–24 years). 
 
The prevalence of high LDL in men (table 7.2) and women (table 7.3) was 42·6% and 47·1%, 
respectively. For men, the highest prevalence of high LDL was found in group 4 (45-54 years 
old) at 50·8%. The second highest prevalence equaled 46·0% and occurred in group 5 (ages 
55-64 years). For women, the highest prevalence was found in group 5 (ages 55-64 years) and 
equaled 50·6%. The second highest prevalence at 50% occurred in group 6 (ages 65-75 years). 
The lowest prevalence of high LDL for both men and women was found in group 1 (ages 18-
24 years) and equaled 16·7% and 18·6%, respectively.  
 
7.3.4 Comparison of outcomes 
 
Significant differences exist between datasets in individual cardiovascular risk factors, and 
within different age groups, mostly due to sample size—the dataset from the NHS trust is at 
least ten times larger than the Nuffield Health dataset. The maximum could be up to 100 times. 
However, in terms of age and sex structures, the patterns are not similar.  
 
In table 7.4, according to measurement of BMI, participants were more likely to be underweight 
in the Hampshire Health Record than in the Nuffield Health dataset (15·1% vs 3·4%). Men 
(table 7.5) had much higher likelihood than women (table 7.6) of being underweight in the 
Hampshire Health Record. Compared with participants aged 45–54 years (group 4) in 
Hampshire Health Record (table 7.4), those from Nuffield Health were more likely to be 
overweight, but less likely to be obese and morbidly obese. Men (table 7.5) and women (table 
7.6) followed a similar pattern to that of the overall population (table 7.4) in terms of mordidly 
obese in Nuffield Health compared with those from the Hampshire Health Record. However, 
compared with participants aged 65–75 (group 6) in Hampshire Health Record (table 7.4), 





According to measurement of waist circumference, compared with individuals in the 
Hampshire Health Record (table 7.7), those from Nuffield Health were more likely to have 
high, but less likely to have very high waist circumference. Men (table 7.8) and women (table 
7.9) followed a similar pattern to that of the overall population (table 7.7).  
 
In terms of high blood pressure, compared with individuals in the Hampshire Health Record 
(table 7.10), those from Nuffield Health are less likely to have high systolic blood pressure. 
The pattern of high diastolic blood pressures is different in the Hampshire Health Record and 
Nuffield Health. Men (table 7.11) and women (table 7.12) followed a similar pattern to that of 
the overall population (table 7.10).  
 
In terms of measurement of lipids (cholesterol, HDL and LDL), compared with participants 
aged 35–44 years (group 3) in the Hampshire Health Record (table 7.13), those from the 
Nuffield Health were less likely to have elevated total cholesterol, lower HDL, and elevated 
LDL. However, compared with participants aged 45–54 years (group 4), 55–64 years (group 
5) and 65–75 years (group 6) in the Hampshire Health Record (table 7.13), those from Nuffield 
Health were more likely to have elevated total cholesterol and lower HDL, but less likely to 
have elevated LDL. Men aged 35-75 in the Hampshire Health Record (table 7.14) are less 
likely to have elevated total cholesterol and LDL, but more likely to have low HDL than those 
in Nuffileld Health. Women (table 7.15) aged 35–44 years (group 3) in the Hampshire Health 
Record are more likely to have elevated total cholesterol, lower HDL, and elevated LDL than 
those in Nuffileld Health; women aged 55–64 years (group 5) and 65–75 years (group 6) in the 
Hampshire Health Record are less likely to have elevated total cholesterol and LDL, but more 




Table 7.4: Comparison of prevalence of different body-mass index ranges between private dataset and public dataset in different age groups 
 Underweight (%) Overweight (%) Obese (%)  Morbidly obese (%) 
 Public Private p value Public Private p value Public Private p value Public Private p value 















































































































































 Underweight (%) Overweight (%) Obese (%)  Morbidly obese (%) 













































































































































Table 7.6: Comparison of prevalence of different body-mass index ranges between private dataset and public dataset in different age groups in 
women 
 
 Underweight (%) Overweight (%) Obese (%)  Morbidly Obese (%) 
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Table 7.8: Comparison of prevalence of high and very high waist circumference between private dataset and public dataset in different age 
groups in men 
 High (%) Very high (%) 




























































































Table 7.9: Comparison of prevalence of high and very high waist circumference between private dataset and public dataset in different age 




 High (%) Very high (%) 




































































































 high systolic blood pressure high diastolic blood pressure 





















































































Table 7.11: Comparison of prevalence of high blood pressure between private dataset and public dataset in different age groups in men 
 
 
   high systolic blood pressure high diastolic blood pressure 
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Table 7.13: Comparison of prevalence of raised total cholesterol, lower HDL cholesterol, and elevated LDL cholesterol between private dataset 
and public dataset in different age groups 
HDL=high-density lipoprotein. LDL=low-density lipoprotein. 
  
 Raised high cholesterol (%) Lower HDL (%) Elevated LDL (%)  
















































































































 Table 7.14: Comparison of prevalence of raised total cholesterol, lower HDL cholesterol, and elevated LDL cholesterol between private dataset 
and public dataset in different age groups in men 
HDL=high-density lipoprotein. LDL=low-density lipoprotein. 
  
 Raised total cholesterol (%) Lower HDL (%) Elevated LDL (%)  
















































































































Table 7.15: Comparison of prevalence of raised total cholesterol, lower HDL cholesterol, and elevated LDL cholesterol between private dataset 
and public dataset in different age groups in women 
HDL=high-density lipoprotein. LDL=low-density lipoprotein. 
 Raised total cholesterol (%) Lower HDL (%) Elevated LDL (%)  


















































































































Overall (table 7.1), about one in two people are overweight or obese in the Hampshire Health 
Record. Nearly 40% of individuals had high systolic blood pressure, but only 10% had high 
diastolic blood pressure. About 60% and 45% of participants had elevated total cholesterol and 
LDL, respectively, and about 16% of participants had lower HDL. 
 
Although overweight and obesity gained more attention, underweight among adolescents might 
also be a problem in developed countries. In individuals aged 18–24 years in this study (Hampshire 
Health Record), about one in seven was likely to be underweight. Although the prevalence of 
underweight is higher and participants are much older compared with the East of England Healthy 
Heart Study (5·9%), in which Ogunleye and colleagues (2013) examined BMI data for 9614 
schoolchildren aged 9–16 years, much attention is needed on the issue of underweight in children 
and adolescents; this is a problem not only in the developing world, but is also happening in 
developed countries, and girls need more attention than boys because they are more likely to be 
underweight. Much attention has been focused on the rapid rise in the percentages of children who 
are overweight and obese, and their associated health problems. Factors responsible for a child 
being underweight could include rising food prices, a poor diet, and fear of being overweight or 
obese (Save the Children 2012; Treasure et al. 2010). Low muscle mass due to lack of exercise 
could also contribute to being underweight (Luder and Alton 2005). Ogunleye and colleagues 
noted that recent findings suggest that half of doctors in England and Wales lack knowledge on 
how to measure for underweight in children, and there is a need for more training for GPs and 
policies supporting parents and educating them about healthy diet and levels of exercise for their 
children.  
 
Individuals in Nuffield Health were more likely to be overweight, but less likely to be obese than 
were those from the Hampshire Health Record. However, participants aged 18–24 years in the 
Hampshire Health Record were more likely to be underweight than were those from Nuffield 
Health. This is different from what we already know—ie, that people from higher socioeconomic 
groups have better cardiovascular health in developed countries. Several factors—genetics, 
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behaviour and lifestyle change, social determinants, low birthweight, urbanisation, diet, physical 
activity, psychological stress—could contribute to this effect in this study. 
 
Individuals aged between 55 and 75 years had more cardiovascular risk factors than those younger 
than 55 years. Age is a non-modifiable cardiovascular risk factor. Ageing is an inevitable part of 
life and unfortunately poses the largest risk factor for cardiovascular disease. Over 80% of all 
cardiovascular deaths occur in this age group (age 55–75 years). It is estimated that almost one in 
four individuals will be older than 65 years by the year 2035 in the USA. About 10 million people 
in the UK are older than 65 years. The latest projections are for 5·5 million more elderly people in 
20 years’ time, and the number will have nearly doubled to around 19 million by 2050. In this 
regard, quantitative information about age-associated changes in cardiovascular structure and 
function in health is essential in order to define and target the specific characteristics of the 
cardiovascular ageing process. 
 
Clinical manifestations and prognosis of cardiovascular diseases are likely to become altered with 
advanced age because interactions occur between age-associated cardiovascular changes in health 
and specific pathophysiological mechanisms that underlie disease. A fundamental understanding 
of age-associated changes in cardiovascular structure and function, ranging in scope from human 
beings to molecules, is needed for effective and efficient prevention and treatment of 
cardiovascular disease in older individuals. Although numerous studies in the cardiovascular field 
have considered both young and old individuals, there are still many unanswered questions as to 
how the genetic pathways that regulate ageing in model organisms affect cardiovascular ageing. 
Likewise, in the field of molecular biology of ageing, few studies fully assess the role of these 
ageing pathways in cardiovascular health. Fortunately, this gap is beginning to close, and these 
two fields are merging together. 
 
It was anticipated that the population from the NHS dataset would have a lower or much the same 
BMI than those from the Nuffield Health dataset. However, women had a lower BMI in the 
Nuffield Health dataset. Also, although many risk factors contribute to cardiovascular diseases in 
both men and women, the cardiovascular risk factors for women are the same as those in men, 
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such as cigarette smoking, elevated serum cholesterol, elevated blood pressure, and a sedentary 
lifestyle (Johnson 1977; Kannel 1987; Pajak et al. 1988; Petitti 1979; Waters et al. 1978). 
However, the effect of individual risk factors might different between men and women, and 
women were more likely to have cardiovascular risk factors than men (Jousilahti et al. 1999; 
Njolstad et al. 1996).  
 
Most deaths due to cardiovascular disease could be prevented through lifestyle changes. 
Identification of people with medical risks (eg, diabetes, high blood pressure, high cholesterol, 
familial hypercholesterolaemia, previous cardiovascular disease event) and ensuring they receive 
effective treatment will help to reduce mortality due to cardiovascular disease. Fair Society, Healthy 
Lives notes that only 4% of NHS funding is currently spent on prevention. In view of the health 
burden attributable to risk factors, there is a clear case for arguing for this proportion to be 
increased. This is not new: the final report of the review led by Sir Derek Wanless (2007) looking 
at the resources needed to provide high-quality health services in the future projected that a 
substantial reduction in costs could be achieved by an increased emphasis on prevention, coupled 
with higher levels of public engagement in relation to their health.  
 
Although this study did not include assessment of vegetable and fruit intake for the effect on 
cardiovascular disease and its associated risk factors, several prospective studies have directly 
related fruit and vegetable intake to cardiovascular disease and showed a causal effect. In a 5-year 
follow-up study of 1273 Massachusetts residents aged no less than 65 years, Gaziano and 
colleagues (1995) used a 43-item semiquantitative food-frequency questionnaire (SFFQ) to assess 
participants’ average dietary intakes in the previous year and related vegetable intake to subsequent 
cardiovascular death. The authors found that residents whose reported intake of carotene-
containing fruit or vegetables was in the highest quartile had a 46% lower risk of death from 
cardiovascular disease than did residents whose reported intake was in the lowest quartile. In a 14-
year follow-up study of 5133 Finnish adults, Knekt and colleagues (1994) assessed vegetable 
intake with a dietary history method and found a relative risk of 0·66 (p=0·02) for coronary 
mortality when comparing the highest and lowest tertiles of vegetable intake. As pointed out by 
Ness and Powles (1997), the causal link between fruit and vegetable intake and risk of 
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cardiovascular disease has been more assumed than actually shown. In future study, data for fruit 
and vegetable intake should be collected through a standard questionnaire, such as the SFFQ. 
 
Social, economic, and political determinants as well as lifestyle and behaviours have been widely 
accepted as the major drivers of the current global epidemic of cardiovascular disease. After the 
UN High Level meeting in September, 2011, the whole world is now working hard to implement 
the Political Declaration by promoting the “whole government strategy” and “whole society 
strategy” to reduce the key risk factors and promote a healthy lifestyle. Eating plenty of fruit and 
vegetables reduces the chance of developing a range of health problems. Modelled estimates 
indicate that the highest percentages of adults eating healthy diets are found in several London 
boroughs and in parts of the south east and east of England. Recent estimates suggest that fruit and 
vegetable consumption increases with age, but that even among those aged 65 years and over, the 
average “5 A Day” portions consumed is 4·4. Only 10% of those aged 11–18 years achieve the 
recommended number of “5 A Day” portions, compared with 30% of those aged 19–64 years, and 
37% of those aged 65 years and over.  
 
However, it is also necessary to avoid high levels of energy intake without sufficient physical 
activity. Physical activity includes all forms of exercise such as walking, cycling, active play, 
work-related activity, active recreation and organised sport, dancing, gardening, or playing active 
games. A physically active lifestyle can reduce the risk of many chronic conditions including 
coronary heart disease, stroke, type 2 diabetes, some cancers, obesity, mental health problems, and 
musculoskeletal conditions. Excessive sugar intake is a particular concern, but is often only one 
source of unhealthy energy intake. High levels of salt consumption are associated with an increase 
in blood pressure, which is a risk factor for heart disease and stroke. Diets high in saturated fat 
also increase cholesterol levels, another heart disease risk factor. The benefits of being active are 
present across the life course.  
 
For adults, the corresponding recommendation is for 150 minutes of moderate intensity activity 
over a week, or the equivalent of vigorous activity. Structured exercise and school sport can make 
an important contribution to an individual’s physical activity. The direct cost of physical inactivity 
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to the NHS across the UK is estimated to be £1·06 billion. There is evidence that action at multiple 
levels is effective in increasing physical activity levels, from primary care professionals 
encouraging individuals to lead active lives, to local authorities investing in community-level 
activity programmes and employers promoting active workplaces. All age groups should aim to 
be active daily and minimise the amount of time spent being sedentary for extended periods. There 
is a marked reduction in the percentage meeting the appropriate activity level as age increases. In 
2008, an average of 39·2% of men and 28·7% of women reported they were active to at least the 
recommended level, with the percentage falling progressively from 44·5% of 16–24 year olds to 
7·3% of those aged 75 years and over. The percentage of active adults has increased from 26·1% 
in 1997 to 33·8% in 2008, but this rise should be seen in the context of a long-term decline in 
walking and cycling for travel purposes.  
 
Ethnicity is an issue. White Caucasians mainly dominated Nuffield Health’s dataset, which 
indicates a greater genetic risk of cardiovascular diseases. A higher risk of premature death and 
poor health attributed to cardiovascular disease has been reported in Irish, Scottish, and South 
Asian groups, particularly Pakistani and Bangladeshi populations (Aspinall and Jacobson 2004; 
Bardsley et al. 2000; Britton et al. 2004; Harding and Balarajan 1996; Harding and Maxwell 1997). 
The mortality rate from coronary heart disease is 50% higher in people born in Bangladesh, India, 
and Pakistan than among the general population (Healthcare Commissioning 2005). The Black 
Caribbean population has lower premature death rates from coronary heart disease than the general 
population (Abbotts et al. 2004). It was speculated that more Africans are likely to work in the 
public sector, and access NHS services, and a larger proportion of South Asian (mainly Indian) 
people are more affluent, therefore, the results might be different from previous studies. 
 
Private hospitals now receive 28% of their income from treating NHS patients (CHPI 2014). They 
also rely on NHS hospitals to treat many of those who develop complications whilst being treated 
in private hospitals. Also, around 6,000 patients a year are admitted to the NHS from private 
hospitals (CHPI 2014). However, the standards of confidentiality applied in accordance with data 
protection law and confidentiality, anonymous or aggregated data are provided by Nuffield Health 
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and Hampshire Health Record for my research, this was not able to be checked. It should be noted 




Two datasets (from Nuffield Health and Hampshire Health Record) seem to be comparable. One 
would assume that many aspects—the effect of adult lifestyle, potential genetic differences, 
developmental conditions throughout the lifecourse, per se and operating through social 
determinants, rapid urbanisation, androgen level, low birthweight, limited childhood living 
condition, low-carbohydrate high-protein diet, collectivist society, psychological stress—could 
have an effect on the similarities and the outcomes in this study. However, according to the 
findings from these two datasets, people aged 55-64 and 65–75 years who have signed up to private 
medical insurance (Nuffield Health) and in south England (from the Hampshire Health Record) 
were more likely to be overweight and obese; to have hypertension, elevated total cholesterol and 
LDL, and low HDL.  
 
These people may have to care more about their lifestyle and diet, and exercise more. Structured 
exercise and school sport can make an important contribution to an individual’s physical activity. 
A physically active lifestyle can reduce the risk of many chronic conditions including coronary 
heart disease, stroke, obesity, and mental health problems. There is evidence that action at multiple 
levels is effective in increasing physical activity levels, from primary care professionals 
encouraging individuals to lead active lives, to local authorities investing in community-level 
activity programmes and employers promoting active workplaces. Policy makers should also act 
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CHAPTER 8:  
 
COMPARISON OF EFFECT OF CARDIOVASCULAR RISK FACTORS IN DIFFERENT 





Aim: This chapter aims to examine the association between area-level deprivation and objectively 
measured, modifiable cardiovascular risk factors in a socioeconomic affluent population who 
attended the public NHS, and then to compare the findings with those of Chapter 5. 
 
Methods: Data were provided by Hampshire Health Record, NHS Hampshire. Seven risk factors 
were analysed: body-mass index (BMI), waist size, systolic and diastolic blood pressure, total, 
high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol. The Index of 
Multiple Deprivation 2007 was used as a proxy indicator of socioeconomic circumstances of 
residents in neighbourhoods. This was used to compare the different risk factors from the least 
deprived to the most deprived areas in the region. Linear regressions were done to investigate the 
impact of deprivation on different modifiable cardiovascular risk factors, as measured in people 
attending Hampshire Health Record. The association between deprivation (groups) and 
cardiovascular risk factors was evaluated by the odds ratios for deprivation alone, and after 
adjustment for age and sex. Both results are compared in the statistical analysis 
 
Results: Age-corrected and sex-corrected odds for obesity, both BMI and waist circumference, 
decreased significantly with socioeconomic index, and the least deprived groups had the lowest 
likelihood of being obese (group 5 [BMI]: odds ratio 0·60, 95% CI 0·59–0·62, p<0·001; [waist 
circumference]: odds ratio 0·64, 95% CI 0·59–0·69, p<0·001), compared with the most deprived 
groups. Adjusted odds ratio for high systolic blood pressure was significantly higher in participants 
from group 2 (odds ratio 1·04, 95% CI 1·01–1·65, p=0·002) and group 3 (odds ratio 1·02, 95% CI 
1·00–1·05, p=0·041), and lowest in group 4 (odds ratio 0·98, 95% CI 0·96–1·01). Adjusted odds 
ratio for high diastolic blood pressure was significantly lower in the two least deprived groups 
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(group 4: odds ratio 0·95, 95% CI 0·92–0·98, p=0·004; group 5: odds ratio 0·95, 95% CI 0·92–0·98, 
p=0·002), compared with the most deprived groups. There was a general trend towards a general 
higher likelihood of plasma cholesterol in the least deprived groups, and there is significant 
between-group differences in the likelihood of having elevated total cholesterol and LDL, as well 
as low HDL. Greater adiposity was found in people from more deprived groups in data from both 
Hampshire Health Record and Nuffield Health estimated by two measures: BMI and waist 
circumference. Findings also showed that the likelihood of having high blood pressure, however, 
was lower in the two most deprived areas than the other least deprived area. The likelihood of 
having high total cholesterol and LDL, and low HDL, was significantly higher in the least deprived 
groups. Compared with data from Nuffield Health, adiposity (BMI and waist circumference), 
blood pressure (systolic and diastolic), and total cholesterol shared the same trend with Hampshire 
Health Record data, and the likelihood of having high LDL and lower HDL were lower in two 
more deprived groups between two datasets.  
 
Discussion: This is the first study to compare participants both from a private health-care company 
and the public-funded NHS. It provides a unique opportunity to open the research arena and note 
the outcomes from these comparable groups. This research also confirmed the previous findings 
from Chapter 5 that the two datasets are comparable. Our results might not only be generalisable 
to other commercially insured populations, but also to some affluent areas in the UK. Although 
many studies have assessed the association between socioeconomic status and cardiovascular risk 
factors, those studies were on the basis of a much smaller sample size than was used in this study, 
so the results are not as reliable and generalisable as those of this study.  
 
Conclusion: These findings showed that socioeconomic deprivation is a strong and independent 
predictor, and it has an effect in the development of cardiovascular risk factors in people living in 
the south central England region. Although two datasets are comparable, those living in the south 
central England region were more likely to develop obesity and hypertension, but less likely to 
have elevated cholesterol and LDL, as well as low HDL, compared with those from Nuffield 
Health. The south central England region has a higher proportion of ageing population, and the 
area is more affluent than national average, this could explain the above findings. Therefore, 
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regional preventive policy should focus on these higher prevalent cardiovascular risk factors, 
especially the high risk population in the region. Simple diet policy initiatives in the region could 
achieve corresponding falls in cardiovascular deaths. Evidence-based population-wide policy 
interventions exist, and these interventions should now be urgently implemented to effectively 





Non-communicable diseases (NCDs)—cardiovascular diseases, diabetes, chronic respiratory 
diseases, and cancer—kill more than 36 million people per year worldwide. Cardiovascular 
diseases alone are responsible for most NCD deaths, causing an estimated 17·3 million annual 
deaths (Lim et al. 2012). In England in 2007, cardiovascular disease contributed to more than 150 
000 deaths, accounting for nearly 34% of all deaths in England (British Heart Foundation 2009). 
In a recent paper in The Lancet, Chris Murray and colleagues (2013) assessed the UK’s health 
performance and reported that the first ranked cause of years-of-life-lost due to premature 
mortality (YLLs) in the UK in 2010 was ischaemic heart disease and the third ranked was stroke. 
Hypertension has been identified as the major risk factor for this large burden, exceeding that for 
alcohol and high body-mass index (BMI).  
 
Cooney and colleagues (2009) re-evaluated the Rose approach—population preventive 
measures—and pooled data from six European cohorts involving more than 100 000 participants. 
This analysis compared the estimated effects of population strategies at varying levels of 
population-wide risk factor reduction and high-risk strategies at varying rates of screening uptake 
on cardiovascular disease mortality. The study showed that a 10% reduction in blood pressure, 
cholesterol, and prevalence of smoking would save 9125 lives per million of the population saved 
over 10 years; by contrast, treating 40% of high-risk individuals with a polypill—containing a 
statin, three half-dose anti-hypertensives, and aspirin—about 3720 lives per million would be 
saved, even assuming complete, long-term adherence. Also, Unal and colleagues (2005) used the 
cell-based IMPACT model to synthesise data for the adult population of England and Wales to 
estimate the proportions attributable to changes in major cardiovascular risk factors in apparently 
healthy people (primary prevention) and in patients with coronary heart disease (secondary 
prevention). Between 1981 and 2000, total cholesterol concentrations fell by 4·2%, resulting in 
approximately 5770 fewer deaths attributable to dietary changes (1205 in patients with coronary 
heart disease and 4565 in healthy people), whereas mean blood pressure fell by 7·7%, resulting in 
approximately 5870 fewer deaths attributable to secular falls in blood pressure (520 in patients 
with coronary heart disease and 5345 in healthy people). Approximately 45 370 fewer deaths were 
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thus attributable to reductions in the three major risk factors—smoking, cholesterol, and blood 
pressure—in the population. 
 
Reducing the risks—such as by quitting smoking or changing diet—could reduce cholesterol or 
blood pressure, which would therefore lead to reduction of development of cardiovascular disease. 
Some population-based prevention programmes have been accompanied by a substantial reduction 
in the rate of cardiovascular disease mortality. Evidence found that 45–75% of the reduction in 
cardiovascular deaths in Westernised industrialised countries was on the basis of the reduction in 
major risk factors—smoking, salt intake, and saturated fat (NICE 2010). Intervention programmes 
targeted at reduction of major cardiovascular risk factors, such as blood pressure and cholesterol, 
by use of a healthy diet, have been shown to be highly effective (Appel et al. 1997; de Lorgeril et 
al. 1999).  Population-based interventions aim to change the risks from the social, economic, 
material, and environmental factors that affect the entire population. This could be achieved 
through regulation, legislation, subsidy, and taxation or rearranging the physical layout of 
communities.  
 
In 2010, 35% of deaths in men, and 16% in women, from cardiovascular disease occurred in people 
younger than 75 years, although the premature mortality rate from cardiovascular disease fell by 
36% between 2001 and 2010 in the UK. The key risk factors for cardiovascular disease that can 
be modified are smoking, unhealthy diet, obesity, physical inactivity, and high alcohol 
consumption (Emberson et al. 2004; Yusuf et al. 2004). Cardiovascular risk factors tend to cluster 
together—ie, people who have hypertension are more likely to have a poor diet and physical 
inactivity—and have an uneven effect in socially disadvantaged groups, which further increases 
health inequalities. For instance, premature death rates are up to six times higher in lower 
socioeconomic groups than in more affluent groups in Scotland (O’Flaherty et al. 2009). In 
addition, South Asian groups have approximately 50% higher likelihood of death rates from 
cardiovascular disease than do the white population (Allender et al. 2007). Cardiovascular 
mortality varies geographically by local authority, with the highest rate 2·5 times that of the lowest. 
There is a clear north–south divide, and rates are 1·4 times higher in the most deprived areas than 




The prevalence of obesity and overweight continues to rise in the UK (National Heart Forum 
2010). An overweight person of average height will increase their risk of death by appropriately 
30% for every 15 additional kilograms of weight. In ten European countries, the odds of disability, 
defined as a limitation in activities of daily living (ADL), are almost twice as large among the 
obese as in normal weight people (Sassi 2010). The disease burden associated with overweight 
and obesity is considerable: the cost to the UK’s National Health Service has been estimated to be 
£3·2 billion per year (Allender and Rayner 2007). The association between socioeconomic status 
and obesity is complex. When economies become more developed, socially disadvantaged groups 
are more likely to be affected in these economies. A particularly important socioeconomic factor 
linked to obesity is education, which showed some extent of association between higher education 
and a lower likelihood of obesity. This might help in tackling the obesity epidemic by increasing 
general school education and supporting the delivery of health and lifestyle education, or both 
(Sassi 2010).  
 
At present, several area-based indices have sought to measure socioeconomic deprivation as 
distinct from individual socioeconomic position (Payne et al. 2009; Stewart et al. 2009; Townsend 
1987). Deprivation indices are easier to apply in clinical practice than are most other measurements 
of socioeconomic status (Blakely et al. 2002) and have consequently become popular among 
public health researchers. This is because information about individual measures of socioeconomic 
status may be incomplete and potentially inaccurate. When employed as a dependent measure, 
deprivation indices provide a way by which routine population-based primary care data can be 
used to examine the effects of socioeconomic deprivation in determining cardiovascular risk 
factors.  
 
Cardiovascular risk factors and the prevalence of cardiovascular disease itself are both associated 
with deprivation or analogous measures such as socioeconomic status. In Chapter 5, the association 
between area-level deprivation and objectively measured, modifiable cardiovascular risk factors 
in a non-clinical UK population who attended Nuffield Health, a private health-care insurance 
company, was examined. People who attended Nuffield Health are more likely to be of higher 
296 
 
socioeconomic class due to the requirement to pay for this service. The south central England 
region is relatively affluent compared with the national average. It is possible to compare the 
population who attended Nuffield Health with those located in the south central England region in 
terms of socioeconomic status, and validate the findings from Chapter 5. The aim of this Chapter 
is, therefore, to examine the association between area-level deprivation and objectively measured, 
modifiable cardiovascular risk factors in a socioeconomic affluent population who attended the 
public NHS, and then to compare the findings with those of Chapter 5. 
 
8.2 DESIGN AND METHODS 
 
8.2.1 Study setting and data collection 
 
Data were provided by Hampshire Health Record, NHS Hampshire. The Hampshire Health 
Record is a joint project supported by Basingstoke and North Hampshire Foundation Trust, 
Hampshire Primary Care Trust, Portsmouth City Teaching Primary Care Trust, Portsmouth 
Hospitals NHS Trust, Southampton City Primary Care Trust, Southampton University Hospitals 
NHS Trust and Winchester and Eastleigh Hospital NHS Trust. Hampshire Health Record provides 
a detailed record of care that contains most of the information held in the general practitioner’s 
(GP) record. It is stored by using a coding scheme (called READ Codes), which enables the data 
to be easily processed and displayed, whilst ensuring the quality and accuracy of the data is of a 
suitable level. Using this coding system means that only clinical data is shared and any comments 
the GP may record for their own use are not shared. The amount of information varies between 






8.2.2 Individual-level cardiovascular risk factors 
 
Several established cardiovascular risk factors represent the risk profile of the participants:  (1) 
anthropometric characteristics; (2) blood pressure; and (3) plasma serum. Obesity was examined 
by BMI and waist circumference, separately. BMI was classified as obese if over 30 kg/m2. Waist 
circumference was measured at the anatomical waist, central obesity was defined as greater than 
102 cm in men and greater than 88 cm in women. Hypertension was classified as greater than 90 
mm Hg (diastolic) and greater than 140 mm Hg (systolic; NICE 2011). Plasma serum includes 
total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol. Arterial 
blood was drawn and analysed. Total cholesterol, LDL subfraction, and HDL subfraction were 
measured. Total cholesterol was classified as raised if higher than 6·0 mmol/L. HDL was classified 
as low if less than 1·0 mmol/L; LDL was defined as raised if greater than 3·36 mmol/L (Contois 
et al. 1996). 
 
8.2.3 Individual-level covariates 
 
Age and sex were adjusted in all multivariate analyses. Age was defined as a continuous variable.  
 
8.2.4 Area-level socioeconomic status 
 
The Index of Multiple Deprivation 2007 (Noble et al. 2008), using postal code of residence to 
transfer to a deprivation score, was used as a proxy indicator of socioeconomic circumstances of 
residents in neighbourhoods. This was used to compare the different risk factors from the least 
deprived to the most deprived areas in the region. These area-level indices can be used to contrast 
disadvantaged areas or populations (Carstairs et al. 1995; DETR Indices of Deprivation 2000; 
Morris et al. 1991). The Indices were established to capture the multidimensional concept of 
socioeconomic deprivation and are based on various indicators within seven distinct domains—
income, employment, health and disability, living environment, crime, barriers to housing and 
services, and education, skills, and training. A total of 38 indicators are distributed across these 
seven domains, with the aim of measuring both financial resources and consequent outcomes. The 
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English Indices of Deprivation 2007 scale was used to allocate deprivation scores on the basis of 
postcode, and the cohort was divided by quintile (group 1 being the least deprived and group 5 
being the most deprived). This was used to compare the different risk factors from the least 
deprived to the most deprived areas.  
 
8.2.5 Statistical analysis 
 
Descriptive statistics were generated. Binary logistic regressions were performed to investigate the 
impact of deprivation on different modifiable cardiovascular risk factors, as measured in people 
attending Hampshire Health Record. The association between deprivation (groups) and 
cardiovascular risk factors was evaluated by the odds ratios after adjustment for age, sex and 
deprivation. Both results are compared in the statistical analysis. Data from this study were 
analysed using SPSS Version 17.0 (SPSS, Inc., Chicago, IL, USA). All baseline data were 




8.3.1 Descriptive statistics for the Nuffield dataset in different measures 
 
Seven datasets contain various variables—BMI, waist circumference, total cholesterol, HDL, 
LDL, systolic blood pressure, and diastolic blood pressure—have been provided and analysed 
separately. Record numbers in each dataset are different, ranging from over 40 000 to around 1 
million. Participants who accessed local GP centres in the south central England region were 
selected for analyses. Demographic and clinical characteristics of the population in different 
deprivation groups in the format of mean and standard deviation (SD) values are shown in Table 
8.1. 
 
Table 8.1: Demographic and clinical characteristics of the population in different deprivation 
groups (mean and SD) in public dataset 
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Group 3  
 
Group 4  
 






BMI (kg/m2) 26.23 (6.62) 26.26 (6.30) 25.94 (6.01) 25.86 (5.73) 25.76 (5.44) 




SBP 134 (21.42) 135 (21.53) 136 (21.54) 137 (21.43) 137 (21.25) 
DBP 75 (10.21) 75 (10.047) 75 (10.09) 76 (9.98) 76 (9.97) 
Cholesterol 
(mmol/l) 
     
Total 4.9 (1.12) 4.9 (1.10) 5.0 (1.10) 5.0 (1.08) 5.1 (1.08) 
HDL 1.3 (0.39) 1.3 (0.40) 1.4 (0.41) 1.4 (0.43) 1.4 (0.43) 





8.3.2 Anthropometric characteristics 
 
Socioeconomic deprivation was significantly associated with BMI and waist circumference. 
Multiple logistic regression models were constructed to assess the effects of socioeconomic 
deprivation on the effect of BMI and waist circumference. Table 8.2 shows the odds ratio for 
socioeconomic deprivation in relation to BMI and waist circumference after adjusting for age and 
sex.  
 
In multivariate models, females were more likely to be obese (odds ratio 1·16, 95% CI 1·15–1·18, 
p<0·001) and centrally obese (odds ratio 1·88, 95% CI 1·79–1·96, p<0·001) than were men. 
Compared with the most deprived group, all other groups had a lower likelihood of high age-




Table 8.2: Anthropometric characteristics (BMI and waist circumference) after adjusted for age 
and sex and deprivation groups (odds ratio and 95% CI) in public dataset 
 
Risk factors Number of 
people 
Model 
  Odds ratio (95% CI) p value 
BMI (obese)    
Deprivation 
groups 
602 605   
Group 1 (most 
deprived) 
40 980 1·00  
Group 2 77 306 0·94 (0·91–0·96) 0·000 
Group 3 116 360 0·79 (0·77–0·81) 0·000 
Group 4 131 066 0·68 (0·66–0·70) 0·000 
Group 5 least 
deprived) 
236 893 0·60 (0·59–0·62) 0·000 
Sex    
Male  1·00  
Female  1·16 (1·15–1·18) 0·000 




   
Deprivation 
groups 
41 981   
Group 1 (most 
deprived) 
4304 1·00  
Group 2 7185 0·86 (0·79–0·94) 0·000 
Group 3 8077 0·76 (0·70–0·84) 0·000 
Group 4 8999 0·69 (0·64–0·76) 0·000 
Group 5 (least 
deprived) 
13 416 0·64 (0·59–0·69) 0·000 
Sex    
Male  1·00  
Female  1·88 (1·79–1·96) 0·000 
Age  1·023 (1·022–1·023) 0·000 
 







8.3.3 Blood pressure measurements 
 
Table 8.3 shows the odds for hypertension according to level of deprivation after adjusting for age 
and sex. Adjusted odds ratios for high systolic blood pressure were statistically highest in 
participants from group 2 (odds ratio 1·04, 95% CI 1·01–1·65, p=0·002) and lowest in group 4 
(odds ratio 0·98, 95% CI 0·96–1·01). Adjusted odds ratios for high diastolic blood pressure were 
significant lower in participants from the two least deprived quintiles (group 4: odds ratio 0·95, 
95% CI 0·92–0·98, p=0·004; and group 5: odds ratio 0·95, 95% CI 0·92–0·98, p=0·002). 
 
In multivariate models, females were less likely to have elevated systolic blood pressure but more 
likely to have elevated diastolic blood pressure than were males (odds ratio 0·62, 95% CI 0·61–




Table 8.3: Blood pressure (systolic and diastolic) after adjusted for age, sex and deprivation 
groups (odds ratio and 95% CI) in public dataset 
 
Risk factors Number of 
people 
Model 




   
Deprivation 
groups 




51 849 1·00  
Group 2 97 097 0·98 (0.95–1.02) 0·375 
Group 3 163 075 1·00 (0.96–1.03) 0·866 
Group 4 189 180 0·95 (0.92–0.98) 0·004 
Group 5 (least 
deprived) 
342 363 0·95 (0.92–0.98) 0·002 
Sex    
Male  1·00  
Female  0·62 (0·61–0·63) 0·000 




   
Deprivation 
groups 




46 307 1·00  
Group 2 107 041 1·04 (1·01–1·65) 0·002 
Group 3 203 418 1·02 (1·00–1·05) 0·041 
Group 4 225 591 0·98 (0·96–1·01) 0·150 
Group 5 (least 
deprived) 
462 924 0·99 (0·97–1·01) 0·275 
Sex    
Male  1·00  
Female  1·29 (1·28–1·30) 0·000 
Age  1·051 (1·051–1·051) 0·000 
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8.3.4 Plasma cholesterol measurements 
 
Table 8.4 shows the odds ratios for raised total and LDL cholesterol or low HDL cholesterol 
according to deprivation after adjusting for age and sex. Compared with the most deprived group, 
all other groups had a greater likelihood of age-adjusted and sex-adjusted raised total cholesterol 
and LDL cholesterol and low HDL cholesterol. 
 
In multivariate models, females were more likely to have raised total cholesterol and LDL than 
were males (odds ratio 1·68, 95% CI 1·67–1·69, p<0·001; and odds ratio 1·37, 95% CI 1·34–1·41, 




Table 8.4: Plasma cholesterol (total cholesterol, HDL, and LDL) after adjusted for age sex and 
deprivation groups (odds ratio and 95% CI) in public dataset 
 
Risk factors Number of 
people 
Model 
  Odds ratio (95% CI) p value 
High total 
cholesterol  
   
Deprivation 
groups 




45 140 1·00  
Group 2 98 825 1·08 (1·06–1·11) 0·000 
Group 3 176 798 1·20 (1·18–1·23) 0·000 
Group 4 235 484 1·38 (1·35–1·41) 0·000 
Group 5 (least 
deprived) 
446 371 1·46 (1·43–1·49) 0·000 
Sex    
Male  1·00  
Female  1·68 (1·67–1·69) 0·000 
Age  0·993 (0·992–0·993) 0·000 
Low HDL     
Deprivation 
groups 




28 212 1·00  
Group 2 60 007 1·26 (1·21–1·30) 0·000 
Group 3 112 502 1·55 (1·50–1·60) 0·000 
Group 4 147 689 1·94 (1·88–2·00) 0·000 
Group 5 (least 
deprived) 
282 379 2·33 (2·26–2·40) 0·000 
Sex    
Male  1·00  
Female  3·56 (3·50–3·61) 0·000 
Age  1·016 (1·015–1·016) 0·000 




125 948   
Group 1 4558 1·00  
Group 2 9996 1·16 (1·08–1·25) 0·000 
Group 3 22 162 1·20 (1·12–1·29) 0·000 
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Group 4 28 971 1·25 (1·16–1·34) 0·000 
Group 5 (least 
deprived) 
60 261 1·29 (1·21–1·38) 0·000 
Sex    
Male  1·00  
Female  1·37 (1·34–1·41) 0·000 
Age  0·992 (0·992–0·993) 0·000 
HDL=high-density lipoprotein. LDL=low-density lipoprotein. 
 
8.3.5 Comparison between the Nuffield Health dataset and Hampshire Health Record 
 
From previous study in Chapter 5, evidence from Nuffield Health showed that greater adiposity 
was found in people from more deprived groups estimated by all three measures: BMI, waist 
circumference, and waist-to-hip ratio. Previous findings also showed that the likelihood of having 
high blood pressure, however, was lower in the most deprived area than in the least deprived area. 
The likelihood of having low HDL was similar between groups, but the likelihood of having high 
total cholesterol and LDL was significantly lower in more deprived groups. 
 
The odds ratios can differ significantly between the two datasets for individual cardiovascular risk 
factors and within different deprivation groups, mostly due to sample size—the dataset from 
Hampshire Health Record is at least ten times larger than that for Nuffield Health (and to a 
maximum of up to 100 times). Therefore, the following tables of odds ratios were compared in 
terms of value of odds ratios. 
 
Table 8.5 shows the comparison of odds ratios for socioeconomic deprivation in relation to BMI 
and waist circumference after adjusting for age and sex between datasets from Nuffield Health and 
Hampshire Health Record. Compared with the least deprived groups, other groups in model 2 have 
higher a likelihood of being obese than do those in model 1 in relation to BMI and waist 
circumference. However, in multivariate models, females in model 1 were less likely to be obese 
but in model 2 were more likely to be obese than were males (odds ratio 0·71, 95% CI 0·67–0·74, 
p<0·001; and odds ratio 1·16, 95% CI 1·15–1·18, p<0·001). Females in model 1 and model 2 were 
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more likely to be centrally obese than were males (odds ratio 1·37, 95% CI 1·31–1·42, p<0·001; 
and odds ratio 1·88, 95% CI 1·79–1·96, p<0·001).  
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Table 8.5: Comparison of anthropometric characteristics (BMI and waist circumference) 
between private dataset and public dataset adjusted for age, sex, and deprivation (odds ratio and 
95% CI) 
 
Risk factors Model 1* Model 2# 
 Odds ratio (95% 
CI) 
p value Odds ratio (95% CI) p value 
BMI (obese)     
Deprivation 
groups 
    
Group 1 (least 
deprived) 
1·00  1·00 0·000 
Group 2 1·02 (0·95–1·10) 0·581 1·14 (1·12–1·16) 0·000 
Group 3 1·04 (0·96–1·12) 0·335 1·31 (1·29–1·34) 0·000 
Group 4 1·13 (1·05–1·22) 0·001 1·56 (1·53–1·59) 0·000 
Group 5 (most 
deprived) 
1·16 (1·07–1·25) 0·000 1·67 (1·62–1·71) 0·000 
Sex     
Male 1·00  1·00  
Female 0·71 (0·67–0·74) 0·000 1·16 (1·15–1·18) 0·000 
Age 1·024 (1·022–
1·026) 




    
Deprivation 
groups 
    
Group 1 (least 
deprived) 
1·00  1·00  
Group 2 1·07 (1·00–1·15) 0·063 1·09 (1·03–1·16) 0·006 
Group 3 1·14 (1·06–1·22) 0·000 1·20 (1·12–1·29) 0·000 
Group 4 1·14 (1·06–1·22) 0·000 1·35 (1·26–1·45) 0·000 
Group 5 (most 
deprived) 
1·14 (1·06–1·22) 0·001 1·57 (1·45–1·71) 0·000 
Sex     
Male 1·00   1·00  
Female 1·37 (1·31–1·42) 0·000 1·88 (1·79–1·96) 0·000 
Age 1·038 (1·036–
1·040) 
0·000 1·023 (1·022–1·025) 0·000 
BMI=body-mass index. * Model 1 – dataset from Nuffield Health (Chapter 5), adjusted for age, sex, and 




Table 8.6 shows the odds for hypertension according to level of deprivation after adjusting for age 
and sex between datasets from Nuffield Health and Hampshire Health Record. Compared with the 
least deprived groups, other groups in model 2 had greater likelihood of having elevated systolic 
and diastolic blood pressure than did those in model 1. Adjusted odds ratio for high diastolic blood 
pressure was statistically highest in participants from group 3 (odds ratio 1·05, 95% CI 1·03–1·07, 
p<0·001), group 4 (odds ratio 1·03, 95% CI 1·01–1·06, p=0·009), and group 5 (odds ratio 1·05, 
95% CI 1·02–1·09, p=0·002; vs odds ratio 0·86, 95% CI 0·78–0·94, p=0·002, for group 5 in model 
1). Adjusted odds ratios for high systolic blood pressure was significant higher in participants from 
group 3 (odds ratio 1·04, 95% CI 1·02–1·05, p<0·001) and group 4 (odds ratio 1·05, 95% CI 1·04–
1·07, p<0·001). In multivariate models, females in model 1 were less likely to have elevated 
diastolic and systolic blood pressure than were males (odds ratio 0·40, 95% CI 0·37–0·44, 
p<0·001and odds ratio 0·54, 95% CI 0·51–0·58, p<0·001), but in model 2 were more likely to 
have elevated diastolic and systolic blood pressure than were males (odds ratio 1·62, 95% CI 1·59–
1·64, p<0·001and odds ratio 1·29, 95% CI 1·28–1·30, p<0·001).  
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Table 8.6: Comparison of blood pressure (systolic and diastolic) between private dataset and 
public dataset adjusted for age, sex, and deprivation (odds ratio and 95% CI) 
 
Risk factors Model 1* Model 2# 




    
Deprivation 
groups 
    
Group 1 (least 
deprived) 
1·00  1·00  
Group 2 0·95 (0·87–1·04) 0·251 1·00 (0·98–1·02) 0·979 
Group 3 1·02 (0·94–1·12) 0·603 1·05 (1·03–1·07) 0·000 




0·86 (0·78–0·94) 0·002 1·05 (1·02–1·09) 0·002 
Sex     
Male 1·00  1·00  
Female 0·40 (0·37–0·43) 0·000 1·62 (1·59–1·64) 0·000 




    
Deprivation 
groups 
    
Group 1 (least 
deprived) 
1·00  1·00  
Group 2 0·96 (0·88–1·05) 0·363 1·00 (0·98–1·01) 0·422 
Group 3 0·99 (0·91–1·08) 0·776 1·04 (1·02–1·05) 0·000 




0·92 (0·84–1·01) 0·078 1·01 (0·99–1·03) 0·275 
Sex     
Male 1·00  1·00  
Female 0·54 (0·51–0·58) 0·000 1·29 (1·28–1·30) 0·000 
Age 1·073 (1·071–1·076) 0·000 1·051 (1·051–1·051) 0·000 
* Model 1 – dataset from Nuffield Health (Chapter 5), adjusted for age, sex, and deprivation. # Model 2 – dataset 




Table 8.7 shows the odds ratios for raised total and LDL cholesterol or low HDL cholesterol 
according to deprivation after adjusting for age and sex between datasets from Nuffield Health and 
Hampshire Health Record. Compared with the least deprived groups, all other groups in model 1 
generally had a greater likelihood of age-adjusted and sex-adjusted raised total cholesterol and 
LDL cholesterol and low HDL cholesterol than did those in model 2. In multivariate models, in 
model 1, females were less likely to have raised total cholesterol and LDL (odds ratio 0·69, 95% 
CI 0·67–0·72, p<0·001; and odds ratio 0·49, 95% CI 0·47–0·51, p<0·001) and low HDL (odds 
ratio 0·17, 95% CI 0·16–0·19, p<0·001) than were males; but in model 2, females were more likely 
to have raised total cholesterol and LDL (odds ratio 1·68, 95% CI 1·67–1·69, p<0·001; and odds 





Table 8.7: Comparison of plasma cholesterol (total cholesterol, HDL, and LDL) between private 
dataset and public dataset adjusted for age, sex, and deprivation (odds ratio and 95% CI) 
 
Risk factors Model 1* Model 2# 
 Odds ratio (95% CI) p value Odds ratio (95% CI) p value 
High total 
cholesterol 
    
Deprivation 
groups 
    
Group 1 (least 
deprived) 
1·00  1·00  
Group 2 0·95 (0·89–1·01) 0·075 0·95 (0·94–0·96) 0·000 
Group 3 0·94 (0·88–0·999) 0·046 0·82 (0·81–0·83) 0·000 




0·82 (0·77–0·88) 0·000 0·68 (0·67–0·70) 0·000 
Sex     
Male 1·00  1·00  
Female 0·69 (0·67–0·72) 0·000 1·68 (1·67–1·69) 0·000 
Age 1·047 (1·045–1·049) 0·000 0·993 (0·992–0·993) 0·000 
Low HDL     
Deprivation 
groups 
    
Group 1 (least 
deprived) 
1·00  1·00  
Group 2 0·97 (0·89–1·07) 0·580 0·83 (0·82–0·85) 0·000 
Group 3 1·06 (0·96–1·16) 0·271 0·67 (0·65–0·68) 0·000 




0·95 (0·86–1·06) 0·365 0·43 (0·42–0·44) 0·000 
Sex     
Male 1·00  1·00  
Female 0·17 (0·16–0·19) 0·000 3·56 (3·50–3·61) 0·000 
Age 0·996 (0·993–0·999) 0·006 1·016 (1·015–1·016) 0·000 
High LDL     
Deprivation 
groups 
    
Group 1 (least 
deprived) 
1·00  1·00  
Group 2 1·01 (0·96–1·08) 0·653 0·96 (0·94–0·99) 0·012 
Group 3 1·02 (0·96–1·08) 0·596 0·93 (0·90–0·96) 0·000 






0·81 (0·76–0·86) 0·000 0·77 (0·72–0·83) 0·000 
Sex     
Male 1·00  1·00  
Female 0·49 (0·47–0·51) 0·000 1·37 (1·34–1·41) 0·000 
Age 1·038 (1·036–1·040) 0·000 0·992 (0·992–0·993) 0·000 
HDL=high-density lipoprotein. LDL=low-density lipoprotein. * Model 1 – dataset from Nuffield Health (Chapter 





8.4.1 Overall findings of this study 
 
This is the first study to compare participants both from a private medical insurance scheme and 
the public-funded NHS, and provides a unique opportunity to note the outcomes from these 
comparable groups. In some published literature, risk factors were usually clustered; those findings 
are contrasting to my research, which showed that greater adiposity was found in people from 
more deprived groups in data from both Hampshire Health Record and Nuffield Health estimated 
by two measures: BMI and waist circumference. Findings also showed that the likelihood of 
having high blood pressure, however, was lower in the two most deprived areas than the other least 
deprived area. The likelihood of having high total cholesterol and LDL, and low HDL, was 
significantly higher in the least deprived groups. 
 
Compared with data from Nuffield Health, adiposity (BMI and waist circumference), blood 
pressure (systolic and diastolic), and total cholesterol shared the same trend with Hampshire Health 
Record data, and the likelihood of having high LDL and lower HDL were lower in two more 








Current NICE guidance (2006) suggests that assessment of the health risk associated with 
overweight and obesity should be based on both BMI and waist circumference. The findings of 
the current study agree with those from existing studies showing that people in the most deprived 
areas are more likely to be obese (measured by BMI). Using professional classification, Emberson 
et al. (2004) found that BMI was higher in manual than non-manual UK workers. Puslaw (2008) 
found higher BMI values with decreasing professional occupation. Stafford and colleagues (2010) 
found that residence in a more deprived neighbourhood contributed to a higher initial BMI when 
the study started. There was also a note that in this longitudinal, multilevel Whitehall II study of 
13 years follow-up using Townsend index of multiple deprivation at census-ward level, 
participants from the most-deprived neighbourhoods experienced relatively greater weight gain 
over time, an increase of 1·5 kg/m2 in men and 1·4 kg/m2 in women.  
 
A similar pattern has been found in other developed countries. Wang et al. (2007) gathered five 
cross-sectional surveys conducted by the Stanford Heart Disease Prevention Programme between 
1979 and 1990 and found that participants from neighbourhoods with low socioeconomic status 
had a higher mean BMI than did those from neighbourhoods with high socioeconomic status, after 
adjusting for age, sex, ethnicity, individual-level socioeconomic status, smoking, physical activity, 
and nutrition knowledge. Similar findings were noted in the GLOBE study (van Lenthe and 
Mackenbach 2002), with odds ratios of high BMI increasing significantly with increasing 
neighbourhood deprivation, after adjusting for sex. Dragano et al. (2005) found that people with 
the least education were twice as likely to be obese than were the most educated people in the 
Czech Republic. This ratio was 1·6 in Germany. A Dutch study conducted by Han et al. (1998) 
suggested that large waist circumference was significantly associated with unemployment and 
lower educational level.  
 
However, findings from the current research are inconsistent with findings from some developed 
countries, but similar to most developing countries. The Puerto Rico Heart Health Programme is 
an epidemiological study of coronary heart disease conducted in Puerto Rican men aged 45–64 
years. In this study, Sorlie and Garcia-Palmieri (1990) reported that urban men with more 
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education are more likely to be obese. Gregory and colleagues (2007) found that the prevalence of 
overweight status measured by BMI was highest among Guatemalan urban men than agricultural-
rural and non-agricultural rural men by using residence or occupation as a classification of 
socioeconomic status.  
 
A few studies have examined the contribution of area-based socioeconomic deprivation 
characteristics to the distribution of health-related behaviour. Ellaway and colleagues (1996, 1997) 
investigated health-related behaviour and physical measurements in relation to social 
characteristics of area of residence in Glasgow. They found that poorer areas contained people 
who were less likely to consume (and had less access to) healthy food, less likely to participate in 
sport, and more likely to be smokers, be shorter, and have higher BMI and greater waist-to-hip 
ratio. According to the report “Food Matters” (Cabinet Office 2008), more than 70 000 lives could 
be saved each year in the UK with a healthy diet. In 2009, the UK Food Standards Agency 
suggested that about 150 000 deaths from cardiovascular disease annually were due to poor dietary 
health (Food Standards Agency 2009). Some studies have found that there are more fast-food 
outlets per capita and fewer health food stores per capita in the most deprived compared with least 
deprived areas, although the evidence is not consistent across all countries (Cummins and 
Macintyre 2002; Li et al. 2008; Li et al. 2009; Li et al. 2009; Mehta et al. 2008; Mujahid et al. 
2008; Rundle et al. 2009).  
 
In 2009, the Cardio and Vascular Coalition published “Destination 2020”—the voluntary sector’s 
plan for cardiac and vascular health in England (Cardio and Vascular Coalition 2009). Government 
policy in many areas influences cardiovascular disease. The “Choosing Health” white paper (DH 
2004) set priorities for action on nutrition, physical activity, obesity, and tobacco control, including 
the provision of NHS Stop Smoking Services. To tackle the substantial burden of ill health from 
cardiovascular disease and associated risk factors, the UK Royal College of Physicians 
recommended establishing a subspecialty of obesity medicine for physicians. The terms “bariatric 
medicine” and “bariatric physicians” were also proposed (Royal College of Physicians 2013). 
Also, for the government’s consideration, the next stage of policy development should focus on 
effective local and regional, population-level programmes to prevent cardiovascular disease, 
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obesity, and hypertension. There is a need to focus on interventions targeting specific 
cardiovascular risk factors, such as salt intake, saturated fats, and trans fatty acids. Policies to 
promote physical activity and increase the consumption of fruit and vegetables should be 
implemented, with a special focus on socially disadvantaged groups.  
 
8.4.3 Blood pressure 
 
Given the confirmatory nature of the present data regarding the association between obesity and 
deprivation, it was expected that the consequent risk factor, blood pressure, would be elevated in 
a similar graded manner with deprivation. The data are not all, but in part, supportive of this 
hypothesis, with systolic and diastolic blood pressure both lower in participants from the two least 
deprived quintiles.  
 
Our data are in agreement with much of the previous work conducted in developed countries. In a 
review of published literature to assess the association between socioeconomic status and blood 
pressure, high mean blood pressure or prevalence of hypertension was associated with low 
socioeconomic status in almost all studies from North America and most from Europe, regardless 
of the measure of socioeconomic status used (Colham et al. 1998). In the Whitehall study of 
London-based civil servants, mean blood pressure and prevalence of hypertension were higher 
among men in the lower grades of employment (Marmot 1985). Hart and colleagues (2000) also 
found that adults from the most deprived areas were at a higher risk of high blood pressure than 
were those in the least deprived areas. In a study from developing countries, Cubbin et al. (2001) 
noted that blood pressure was higher in the most deprived areas than in the least deprived areas 
among African women.  
 
This association is in contrast to the findings in most developing countries. Fernald and Adler 
(2008) conducted a house-to-house cross-sectional survey in women aged 18–65 years in Mexico. 
They found that two indicators of socioeconomic deprivation—educational attainment and 
working outside the home—showed an inverse association with systolic blood pressure. Similar 
findings have also been found in a multicentre collaborative study of risk factors for cardiovascular 
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disease in the International Clinical Epidemiology Network (INCLEN). Nogueira et al. (1994) 
examined the relationship between risk factors for cardiovascular disease and socioeconomic 
variables in 12 centres in seven countries—three in Thailand, two each in China, Chile, and Brazil, 
and one each in the Philippines, Indonesia, and Colombia. They investigated approximately 200 
men aged 35–65 years drawn at random from a population within their locality and found that 
among the five Latin America countries, three showed a negative association between 
socioeconomic status and systolic blood pressure, and others showed no association. A study of 
hypertension in an urban working population in Ghana showed a lower prevalence of hypertension 
in participants of lower socioeconomic status and the highest prevalence in those of the highest 
socioeconomic status (Addo 2009). There were suggestions of a negative association between the 
level of education and hypertension after adjusting for the other measures of socioeconomic status.  
 
In the UK, nearly complete registration with the NHS provides a potential vehicle for systematic 
identification of patients with hypertension, applying best practice guidelines and ensuring regular 
review. The NHS Health Check programme (NHS Choices 2009), launched in 2009, is aimed at 
the population aged 40–74 years. It is intended to progressively reduce the number of undiagnosed 
individuals with hypertension and other cardiovascular risk factors in the next five years. The 
options for enhanced hypertension control are cost effective and well described in the NICE 
guidance (2011). An analysis done by Murray and colleagues (2013) also emphasises that there 
could be important opportunities for primary prevention through reduced alcohol and salt intake, 
reduced BMI, increased physical activity, and increased intake of specific dietary components, 
such as fruit. Improved early detection and long-term management of high blood pressure could 
be one clear route to accelerate progress for the leading causes of avoidable cardiovascular 
mortality. Data from examination surveys in England and Scotland confirm that existing 
approaches have not adequately identified and treated hypertension (Falaschetti et al 2009; Mohan 
and Campbell 2009; The Scottish Government 2010). In Scotland in 2009, one in five men and 
one in seven women younger than 75 years had untreated hypertension (The Scottish Government 
2010). Although there is evidence of some improvements in hypertension control in England 
(Falaschetti et al 2009; Mohan and Campbell 2009), only a third of men with hypertension were 
controlled in 2006 (Falaschetti et al 2009). This represents a pool of potentially preventable 
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mortality and morbidity. Changes to the wider determinants of health have often been as a 
consequence of public health policy. Preventive services are unlikely to tackle these wider 
determinants unless supported by national policies and systems (Capewell and O’Flaherty 2008). 
 
8.4.4 Plasma cholesterol 
 
Like blood pressure, plasma cholesterol is a risk factor often associated with increased adiposity. 
In this study, participants from the least deprived areas had less favourable serum lipids compared 
with individuals from the most deprived areas. Elevated total cholesterol and LDL cholesterol, as 
well as low HDL cholesterol measures, were significantly higher in the most deprived groups. 
 
Smith and colleague (1998) in the Renfrew and Paisley study reported that plasma cholesterol was 
lower for men and women in manual social class groups than for those in non-manual workers. 
This finding is in line with several studies in the UK (Pocock et al. 1987; Smith et al. 1990). 
Although from developing countries, several studies including from China have also confirmed 
this finding (Bunker et al. 1996; Pereira et al. 1998; Siegrist et al. 1990; Sorlie et al. 1990; Tian et 
al. 1995; Yu et al. 2001).  
 
Our data are in contrast to those of a study of 2682 Finnish men in the Kuopio ischaemic heart 
disease risk factor study (KIHD). Using educational levels as a measure of socioeconomic status, 
Lynch et al. (2006) found that total cholesterol was significantly higher for those who attended 
primary school only than for those who were high school graduates in Finland. In the Puerto Rico 
Heart Programme, Sorlie and Garcia-Palmieri (1990) found that mean values for serum cholesterol 
increased steadily with educational level, indicating a cholesterol level that was approximately 29 
mg/dL (0·75 mmol/L) lower for those with no education compared with those at the highest level 
in urban areas. 
 
In terms of low HDL cholesterol, our findings agree with reports by Winkleby and colleagues 
(1992) that low HDL was found more often in the highest socioeconomic groups. Lynch et al. 
(2006) found that HDL was higher in people who had primary education only than for those who 
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were high school graduates. Pereira et al. (1998) also conducted a study in a population aged 25–
74 years in Mauritius. Using occupation as a measure of socioeconomic status, they found that 
HDL was higher in unskilled workers than in professional or skilled workers. They also noted that 
females were five times less likely than males to have lower HDL. In two Chinese studies, 
however, the authors found that men in lower socioeconomic status were significantly more likely 
to have low HDL compared with men of higher socioeconomic status (Siegrist et al. 1990; Yu et 
al. 2001).  
 
LDL cholesterol had a similar pattern to that for total cholesterol. Our findings agree with those of 
several Chinese studies (Siegrist et al. 1990; Tian et al. 1995; Yu et al. 2001), which found that 
men of higher socioeconomic status had significantly higher LDL compared with men in low 
socioeconomic status. Pereira et al. (1998) also reported that LDL was lower in unskilled workers 
than in professional or skilled workers. By contrast, Larranaga et al. (2005) found that adults of 
lower socioeconomic status attending primary care clinics in the Basque region of Spain had higher 
LDL compared with those of a higher socioeconomic status. Using educational levels as a measure 
of socioeconomic status, Lynch et al. (2006) found that LDL was significantly higher for those 
who attended primary school only than for those who were high school graduates. 
 
A few studies have also reported that elevated cholesterol is associated with lower socioeconomic 
status due to the reduced intake of saturated fats, lower alcohol consumption, and consumption of 
more fruit, vegetables, and whole grains (Briefel and Johnson 2004; Kanjilal et al. 2006; Marmot 





8.4.5 Strengths and limitations of this study 
 
The study is one of the largest datasets on deprivation indices with this number of risk factors in 
the primary care setting. The south central England region spends £5·5 billion a year on the health 
and wellbeing of the million people in their communities, which is a relatively low funding 
allocation per head of population, owing to the fact that the region is relatively affluent compared 
with the national average. Although many more affluent areas such as Winchester and Wokingham 
are located in this territory, there are also some socially more deprived areas—in parts of 
Portsmouth, Southampton, and Slough. This region received less than the average of the national 
funding allocation. The relative wealth of the population included in the region is not matched by 
lower demands on the health system and this has placed local commissioners in a difficult financial 
situation historically. Local residents are typically very informed and influential and demand the 
very best from the NHS. However, because South Central PCTs receive the lowest per capita 
allocation in the NHS, as finances tighten, a significant funding gap will need to be addressed and 
the health system will need to be re-sized to meet the challenge and identify the biggest 
opportunities for improvement in quality, outcomes, and productivity.  
 
This research also confirmed the previous findings from Chapter 5 that the two datasets are 
comparable. The number of people covered by private medical insurance in the UK rose to over 6 
million in 2008, according to figures from the Association of British Insurers (2009), and an 
increasing number of those included in our dataset will be those employed in all sectors of the 
workforce from manual to management. Our results might not only be generalisable to other 
commercially insured populations, but also to some affluent areas in the UK. Although many 
studies have assessed the association between socioeconomic status and cardiovascular risk 
factors, those studies were on the basis of a much smaller sample size than was used in this study, 
so the results are not as reliable and generalisable as those of this study.  
 
When using area-based indicators of socioeconomic position, two forms of bias could be 
introduced (Davey et al. 1996; Geronimus et al. 1996). It could be considered that the area-based 
measure serves as a proxy indicator of individual socioeconomic circumstances. In this instance 
the associations between area-based socioeconomic measures and health outcomes would be 
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underestimates of underlying associations between individual socioeconomic position and health, 
as considerable misclassification of individual socioeconomic circumstances by the area-based 
measure could occur. Technically, the residuals from analyses using individual-level data will be 
correlated with the area-based indicator (Firebaugh 1978; Geronimus et al. 1996). Therefore, to 
fully reflect the socioeconomic circumstances, it would be ideal if individual socioeconomic 
characteristics could be collected and used in addition to area-based measurements. 
 
The empirical findings with respect to these questions have been variable and have depended on 
the context of studies and the health outcomes under examination. The contextual effects of areas, 
and the size of areas that determine these effects, will differ in different places and for different 
health outcomes, so this inconsistency in the literature is not unexpected. The particular aspects of 
different areas that may influence health independently of individual social class are currently 
under investigation.  
 
Another limitation of this study is that the dataset does not include a history of medication. Use of 
lipid-lowering drugs, primarily statin therapy, is recommended for patients with clinical evidence 
of cardiovascular disease. However, as this is a private medical insurance company, it only has 
limited data resources because participants are still seeing their GPs to prescribe medication. 
Therefore, it is hard to know if participants’ blood pressure and cholesterol level were drug 
controlled. Also, the present study did not measure habitual physical activity, but it may be that 
more deprived participants were more active than those in the least deprived groups. 
Socioeconomic groups, but not postcode, were provided by datasets from Hampshire Health 
Record. Therefore, a direct comparison of socioeconomic status is not able to be compared with 
the general population in terms of IMD rank, as well as Nuffield quintiles. In the NHS data, the 
IMD “quintiles” were of very different size, because datasets of variables are provided in 
individual files. Therefore, it is possible that the #1 patient in BMI file is not the same patient in 
the blood pressure file. Therefore, the NHS datasets calculated the estimates of different variables, 
although from the population living in the same region, not equally-sized quintiles. This should 




The English Indices of Deprivation 2007 have been used not only by health researchers, but also 
by government for the past 10 years to identify and target areas of concentrated deprivation—
important in directing significant levels of government funding, both for regeneration and other 
programmes. It is argued that the English Indices of Deprivation might not be an adequate tool for 
understanding and addressing the challenges of rural deprivation, mainly because it fails to 
adequately detect the many deprived individuals and households that live outside of the most 
deprived areas, and rural deprivation has some particular characteristics that are not picked up by 
the indicators and the methodology. In addition, previous research (Smith et al. 1998) has called 
for a range of characteristics, including environmental effects, housing conditions, social 
disorganisation, transport, insecurity about personal safety, the availability of retail and leisure 
facilities, socially determined health-related behaviours, and access to health care. These should 





In summary, these findings show that socioeconomic deprivation is a strong and independent 
predictor, and that it has an effect in the development of cardiovascular risk factors in people living 
in the south England region. Although the two datasets are comparable, people living in the south 
England region were more likely to develop obesity and hypertension, but less likely to have 
elevated cholesterol and LDL, as well as low HDL, compared with those from Nuffield Health. 
The south England region has a higher proportion of ageing population, and the area is more 
affluent than the national average, which could explain the above findings. Therefore, regional 
preventive policy should focus on these higher prevalent cardiovascular risk factors, especially for 
the high-risk population in the region. Simple diet policy initiatives, such as reduction of salt 
intake, and lifestyle change in the region could achieve corresponding decreases in cardiovascular 
deaths. Extra care is needed when designing appropriate exercise programmes for different age 
groups. For example, falls and related fractures are a major health problem for elderly. Exercise 
can modify intrinsic fall risk factors and thus prevent falls in this age group. It is important to 
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The final chapter of this thesis presents an opportunity to review the whole thesis and to emphasise 
the main conclusions. Instead of summarising in the conventional prose style, this summary 
follows the model used in the British Medical Journal and others. It is presented in the form of 
brief bullet points relating to what is known on the topic and what the current research adds to the 
topic. This will provide a clear and concise summary of the work undertaken. 
 
CHAPTER 3: SOCIOECONOMIC STATUS, CARDIOVASCULAR DISEASE, AND 
ASSOCIATED RISK FACTORS—A LITERATURE REVIEW 
 
WHAT IS ALREADY KNOWN 
 
 The burden of cardiovascular disease is large, costly and increasing, both in the UK and 
worldwide. According to the World Health Organization (WHO), 17·3 million people 
died from cardiovascular disease worldwide in 2008 and more than 23 million people 
will die annually from cardiovascular disease by 2030. Yet, 80–90% of premature 
cardiovascular disease is preventable. 
 
 Tobacco use, an unhealthy diet, and physical inactivity increase the risk of heart attacks 
and strokes. 
 
 The health effect of physical activity goes well beyond preventing overweight and 
obesity; they can also benefit physical and mental wellbeing—heart disease and type 2 
diabetes could be reduced up to 50% and hypertension significantly reduced. 
 
 In the UK, the prevalence of cardiovascular disease is high—over 3 million people 




 The most important modifiable factors contributing to cardiovascular disease are: 
smoking, elevated cholesterol, elevated blood pressure, diabetes, obesity, and 
socioeconomic deprivation. 
 
 A better understanding of the most effective interventions for reducing this large and 
costly disease burden is vital in order to inform strategies to combat cardiovascular 
disease in the UK and elsewhere. 
 
WHAT THIS CHAPTER ADDS 
 
 Research focusing on cardiovascular health in ageing populations, different 
socioeconomic groups, and various ethnic groups, especially south Asian people in 
the UK, is needed.  
 
 Given that very little research has been undertaken in the growing population who pay 
for private medical insurance, priority should be given to this emerging area.  
 
 Research data are scarce for serum lipids, specifically for low-density lipoprotein 









CHAPTER 4: PREVALENCE OF MODIFIABLE CARDIOVASCULAR RISK 
FACTORS IN PEOPLE ATTENDING PRIVATE MEDICAL SCREENING 
 
WHAT IS ALREADY KNOWN 
 
 Cardiovascular mortality, incidence, and prevalence rates increase steeply with age, 
approximately doubling with each decade. Cardiovascular disease is rare in people 
younger than 30 years, but increasingly common above the age of 60 years. 
 
 According to the European Health Interview Survey in 2011, the highest proportions 
of obese women were recorded in the UK (23·9%), Malta (21·1%), Latvia (20·9%), 
and Estonia (20·5% in 2006/07), and of men in Malta (24·7%), the UK (22·1%), 
Hungary (21·4%), and the Czech Republic (18·4%).  
 
 It has been estimated that at present at least 1·1 billion adults are overweight, including 
312 million who are obese.  
 
 The UK’s Observatory estimates that the number of people with high blood pressure 
increased by 2·7% from 332 767 in 2004–05 to more than 12 million in 2007–08.  
 
 In 2008, the global prevalence of raised total cholesterol among adults was 39% (37% 
in men and 40% in women).  
 
WHAT THIS CHAPTER ADDS 
 
 In the analysis from the dataset provided by Nuffield Health, men and women who 
were aged 35–44 years (group 3) and 45–54 years (group 4) had the highest 
prevalence of obesity and overweight compared with other age groups. By 
comparison with the Health Survey for England 2006, our data showed that men in 
Nuffield Health were more likely to be overweight, but less likely to be obese, and 
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women were less likely to be overweight, but more likely to be obese, when using 
body-mass index (BMI) as a measurement for overweight and obesity. 
 
 Men and women aged 45–54 years (group 4) had the highest prevalence of high 
systolic and diastolic blood pressures, which was a different pattern to that shown by 
the Health Survey for England 2006—the prevalence rate of hypertension was going 
up with increasing age both in men and women. Men aged between 16 and 24 years 
had the lowest prevalence rate (6%), and aged over 75 years had the highest 
prevalence rate (75%). Women aged between 16 and 24 years had the lowest 
prevalence rate (1%), and aged over 75 had the highest prevalence rate (77%). 
Women were likely to have lower prevalence than in men at ages less than 65 years, 
but higher prevalence older than 65 years. 
 
 Men and women aged 45–54 years (group 4) had the highest prevalence of high total 
cholesterol and LDL. Men in group 4 had the highest prevalence of low high-density 
lipoprotein (HDL), while women aged 35–44 years (group 3) had the highest 
prevalence of low HDL. In the Health Survey for England 2006, in men, the 
prevalence of high total cholesterol went up with increasing age up to 55 years, but 
decreased at ages 55 years and over. The pattern was slightly different in women, in 
whom prevalence went up with increasing age up to 65 years, and decreased at age 65 
years and over. 
 
 Our findings showed some similarity with existing studies, especially in the UK 
population. Our dataset is one of the largest UK datasets especially in a commercial 









CHAPTER 5: SOCIOECONOMIC STATUS AND MODIFIABLE 
CARDIOVASCULAR RISK FACTORS IN PEOPLE ATTENDING PRIVATE 
MEDICAL SCREENING: AN OBSERVATIONAL STUDY  
 
WHAT IS ALREADY KNOWN 
 
 Socioeconomic factors play an important part in cardiovascular disease, with 
mortality rates almost twice as high in deprived than in affluent areas. 
 
 Around a third of adults have three or more risk factors such as raised cholesterol, 
diabetes, or being overweight, which increase their chance of poor health. This 
increases to around two-fifths of adults in the most deprived areas. 
 
 Deprivation indices are easier to apply in clinical practice than are most other 
measurements of socioeconomic status, and have consequently become popular 
among public health researchers. 
 
WHAT THIS CHAPTER ADDS 
 
 Some published literature, in which risk factors were usually clustered, shows 
contrasting or paradoxical findings to my research—greater adiposity was found in 
people from more deprived groups estimated by all three measures: BMI, waist 
circumference, and waist-to-hip ratio.  
 
 Our findings also showed that the likelihood of having high blood pressure, however, 
was lower in the most deprived area than in the least deprived area.  
 
 The likelihood of having low HDL was similar between groups, but the likelihood of 




CHAPTER 6: REGIONAL DIFFERENCES IN MODIFIABLE CARDIOVASCULAR 
RISK FACTORS IN PEOPLE ATTENDING PRIVATE MEDICAL SCREENING 
 
WHAT IS ALREADY KNOWN 
 
 Geographical variations in cardiovascular disease and associated risk factors have 
been identified and reported in a range of European countries on the basis of both 
prevalence and incidence. 
 
 Death rates and prevalence of coronary heart disease are persistently higher in 
Scotland, Wales, and Northern Ireland than in southeast England. These geographical 
variations suggest that large improvements in UK coronary heart disease mortality are 
still attainable. 
 
 The Health Survey for England is an annual health examination survey of a new, 
nationally representative sample of the English population living in private 
households. It provides representative data for a broad range of health topics. 
 
 The Health Survey for England 2006 report focused on cardiovascular disease and 
associated risk factors, which covered health status risk factors including total 
cholesterol, HDL cholesterol, blood pressure, diabetes, and anthropometric 
measurements such as BMI and waist circumference. 
 
 Modifiable cardiovascular risk factors vary in prevalence across the UK. In England, 
this is exemplified at a regional level by a north–south gradient in prevalence and 
health outcomes, with higher prevalence in the north.  
 
 Many reasons have been proposed for regional variations in cardiovascular diseases—
differences between populations in cardiovascular risk factors such as smoking, 
hypertension, hyperlipidaemia, diabetes, or overweight as well as socioeconomic 
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factors, lifestyle variables such as diet, alcohol use, physical activity, medical care, 
genetic factors, and environmental conditions. 
 
WHAT THIS CHAPTER ADDS 
 
 This is one of the first studies to show regional differences across the UK with such a 
high number of risk factors and other variables in a primary care setting, but was 
restricted to participants in a private health-care company.  
 
 Overall, the prevalence of various modifiable cardiovascular risk factors was higher in 
Health Survey for England 2006 data than in the Nuffield Health dataset, both in men 
and women across all regions in England. 
 
 This study provided a unique opportunity to study how geographical regions have an 
effect on modifiable cardiovascular risk factors in a large UK population from a private 
health-care company.  
 
 In men, the prevalence of being overweight, having a raised waist circumference, and 
having raised total cholesterol were higher in Nuffield Health data than in Health 
Survey for England data. Men in London were generally healthier than were men 
from other regions in England. Differences in prevalence of several risk factors were 
wider between regions, such as raised waist circumference (up to two times), lower 
HDL (over three times), and hypertension (about two times). 
 
 In women, the prevalence of obesity, raised waist circumference, and hypertension 
were much lower in the Nuffield Health data than in Health Survey for England 2006 
data. Only the difference in prevalence of hypertension was wider between regions 




 Our findings showed that both men and women in south England were less likely to be 
obese than were those in other regions in England. 
 
 Participants in the southeast had the highest risk of being hypertensive, but those from 
York and the Humber had the lowest risk, compared with those from other regions in 
England. Men could have more than twice as great a risk compared with women of 
being hypertensive. 
 
 In term of plasma cholesterol, the distribution varied among regions—participants in 
the northeast had the highest risk of having elevated total cholesterol, but those in the 
northwest had the lowest risk; both men and women in the Midlands were less likely to 
have a lower HDL than were those in other regions of England; participants in the north 
of England were less likely to have lower LDL than were those in other regions of 
England. 
 
 The North-South effect (or Scottish effect) on prevalence of cardiovascular disease and 
associated risk factors was not seen in this affluent population. We could speculate that this 





CHAPTER 7: COMPARISON BETWEEN PREVALENCE OF MODIFIABLE 
CARDIOVASCULAR RISK FACTORS IN PEOPLE ATTENDING PRIVATE 
MEDICAL SCREENING AND NATIONAL HEALTH SERVICES FROM SOUTH 
ENGLAND IN DIFFERENT AGE GROUPS 
 
WHAT IS ALREADY KNOWN 
 
 The WHO toolkit estimates that the top ten risk factors for early death and disability 
in the UK are, in order of impact—tobacco use, harmful alcohol consumption, high 
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blood pressure, high blood cholesterol, overweight and obesity, physical inactivity, 
illicit drug use, low fruit and vegetable intake, occupational risks, and poor sexual 
health. 
 
 Approximately 25% of those aged 16 years and over report one lifestyle risk factor, 
33% two risk factors, 23% three risk factors, and 12% four or more risk factors. Only 
7% of adults have no risk factors. 
 
 Although cardiovascular mortality rates have halved in the past two decades, 
morbidity, particularly in older age groups, appears to be very persistent. 
 
 Death rates from coronary heart disease continue to fall in people older than 55 years, 
but have recently been falling more slowly in younger individuals and may be rising 
in the youngest age groups. 
 
 The percentage of the population with high blood pressure increases progressively 
with age. In 2008–10, 4·1% of 14–24 year olds had high blood pressure, compared 
with 25·9% of 45–54 year olds and 72·8% of those aged 75 years and over. 
 
 Cholesterol levels have been falling over time, largely as a result of increased 
prescription of statins and other lipid-lowering drugs: between 1994 and 2006, the 
percentage of men with raised cholesterol fell from 74% to 57% and among women 
from 77% to 61%. 
 
 Dietary control and physical activity are effective in reducing obesity and overweight 
at an individual level, although creating environments that promote and enable 
healthy eating and active lives requires action across industry, local government, and 
the NHS. 
 




 The south England region is a more affluent region in the UK. Nuffield Health is a 
private health-care company, and people attending this company are more likely to be 
of higher socioeconomic status. Therefore, it is possible to compare the clinical 
outcomes of people who attended Nuffield Health with those located in the south 
central England region. 
 
 Overall, in the south England region, about one in two people is overweight or obese. 
Individuals tend to have higher systolic blood pressure, but lower diastolic blood 
pressure. About 60% and 45% of participants have elevated total cholesterol and LDL, 
respectively, and 16% of participants have lower HDL. 
 
 Individuals aged between 55 and 75 years had more cardiovascular risk factors than did 
those younger than 55 years. 
 
 It was hypothesised that the population from the NHS trust dataset had lower BMI 
than did those from Nuffield Health’s dataset; however, women had a lower BMI in 






CHAPTER 8: COMPARISON OF THE EFFECT OF CARDIOVASCULAR RISK 
FACTORS IN DIFFERENT SOCIOECONOMIC GROUPS PROVIDED BY 
NUFFIELD HEALTH AND HAMPSHIRE HEALTH RECORD  
 
WHAT IS ALREADY KNOWN 
 
 Evidence showed that structural policy and legislative changes at regional, national, 




 A model study estimated that a 10% reduction in blood pressure, cholesterol, and 
prevalence of smoking would save 9125 lives per million of the population over 10 
years; by contrast, treating 40% of high-risk individuals with a polypill—containing a 
statin, three half-dose antihypertensives, and aspirin—would save about 3720 lives 
per million, even assuming complete, long-term adherence.   
 
 Reducing the risks—such as quitting smoking or changes to the diet—could reduce 
cholesterol or blood pressure, which could therefore lead to a reduction of the 
development of cardiovascular disease. Some population-based prevention 
programmes have been accompanied by a substantial reduction in the rate of 
cardiovascular disease mortality. 
 
 The prevalence of obesity and overweight continues to rise in the UK. The disease 
burden associated with overweight and obesity is considerable: the cost to the UK’s 
NHS has been estimated to be £3·2 billion per year.  
  
 A particularly important socioeconomic factor linked to obesity is education, with 
some extent of an association shown between higher education and a lower likelihood 
of obesity. This might help to resolve the obesity epidemic by increasing general 
school education and supporting the delivery of health and lifestyle education, or 
both.  
 
WHAT THIS CHAPTER ADDS 
 
 This is the first study to compare participants both from a private health-care 
company and the public-funded NHS. It provides a unique opportunity to open the 




 In some published literature, in which risk factors were usually clustered, there are 
contrasting or paradoxical findings to those of my research—greater adiposity was 
found in people from more deprived groups estimated by two measures: BMI and 
waist circumference.  
 
 Findings also showed that the likelihood of having high blood pressure, however, was 
lower in the two most deprived areas than in the other least deprived area. The 
likelihood of having high total cholesterol and LDL and low HDL were significantly 
higher in the least deprived groups. 
 
 By comparison with data from Nuffield Health, adiposity (BMI and waist 
circumference), blood pressure (systolic and diastolic), and total cholesterol shared the 
same trend with Hampshire Health Record data, and the likelihood of having high LDL 
and lower HDL was lower in the two most deprived groups between the two datasets.  
 
 Evidence-based population-wide policy interventions exist, and these interventions 










9.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
 
 Individual socioeconomic characteristics should be collected and used in addition to 
area-based measurements to reflect socioeconomic circumstances fully. Educational 
level has been noted to be better associated with cardiovascular risk factors as a 
measurement of individual socioeconomic status. 
 
 Smoking is the single largest cause of death, disability, preventable illness, and 
unnecessary health expense in the UK. It has caused approximately 17–30% of all 
cardiovascular deaths. It has been estimated that a lifespan is shortened by smoking by 
up to 10 years. About 50% of smokers die of a smoking-related illness. Therefore, it 
would be useful to have data for smoking from the south central England region, and 
compare the outcome with the data from Nuffield Health. 
 
 Blood pressure measurement is a measure that needs considerable improvement, as it 
is influenced by many factors such as instruments, the researcher, subjects, and the 
environment where the measure is taken.  
 
 Non-white populations, such as south Asians living in the UK—Indians, Bangladeshis, 
Pakistanis, and Sri Lankans—have a roughly 50% higher premature death rate from 
cardiovascular disease compared with those who were born and live in the UK. Also, 
south Asian immigrants are more likely to die prematurely from cardiovascular disease. 
Therefore, data for ethnicity should be collected and analysed in the future.  
 
9.3 PUBLIC HEALTH IMPLICATIONS OF THE THESIS 
 
On the basis of the Hampshire Health Record, the population aged 65–75 years are at a much 
higher risk of developing cardiovascular disease than are those aged 18–24 years. For certain 
cardiovascular risk factors, this could be up to 100 times higher. Between 2006 and 2020, the UK 
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population is expected to increase by 10% to almost 65 million, an additional 3·2 million men and 
2·7 million women. The older age groups will experience much larger increases in numbers. 
Cardiovascular death rates are much higher in the oldest groups. Because of population ageing, 
the total numbers of deaths are therefore likely to increase substantially. The future continuing 
burden of cardiovascular disease will increasingly affect older groups and will stretch health-care 
systems, even in the UK and other wealthy countries. 
 
Ethnicity and gender, especially south Asian and Chinese groups in the UK. South Asians living 
in the UK—Indians, Bangladeshis, Pakistanis, and Sri Lankans—have a roughly 50% higher 
premature death rate from cardiovascular disease compared with the white population. Mortality 
rates for coronary heart disease and stroke vary by ethnic group in the UK. Premature death rates 
from coronary heart disease for men born in the Caribbean and west Africa and for women born 
in Italy but living in the UK were lower than average. However, there is a higher premature death 
rate from coronary heart disease than average among men and women living in the UK but born 
in south Asia and eastern Europe. In 2003, the death rate among Bangladeshi men was 112% 
higher and the death rate among Pakistani women living in England was 146% higher than the 
average for England and Wales. Men living in England but born in Bangladesh have more than 
twice the average chance of suffering premature death from stroke. Women born in Jamaica and 
living in England were 76% more likely to die prematurely from stroke than those born in England 
and Wales (Harding et al, 2008). 
 
The difference in the death rates between those born in south Asia and the general population 
increased in the 1970s and 1980s. This is because the death rate from coronary heart disease was 
not falling as fast in south Asian groups as it was in the rest of the population. For example, from 
1971 to 1991, the mortality rate of coronary heart disease for 20–70 year olds for the whole 
population fell by 29% for men and 17% for women, whereas in people born in south Asia it fell 
by only 20% for men and 7% for women (McKeigue et al, 1996). Furthermore, inequalities in 
mortality rates between the general population and south Asians are continuing to increase 




Regional-level and national-level clinical outcome data should be collected. Action and advocacy 
could be an important step forward in dealing with increasing weight status. Governmental actions, 
such as taxation and subsidies, are favourable for public health measures for changing consumers’ 
behaviour. Prevention at a population level requires co-ordination. In the UK, the national level is 
addressed by the National Heart Forum (NHF). The NHF was established in 1984 as an "active 
authoritative body at the national level to speak out for policies directed at the prevention of 
coronary heart disease" and to maximise the contributions of not-for-profit sector organisations. 
Since its launch, NHF has been instrumental in driving the national prevention policy agenda for 
coronary heart disease, developing consensus and evidence-based recommendations for action 
across a diverse range of issues and settings, and coordinating advocacy for their implementation. 
NHF’s mission is to work with and through their members to contribute to the prevention of 
avoidable coronary heart disease and related conditions in the UK. 
 
Regional programmes also energetically address prevention, such as Heart of Mersey (HoM). 
HoM was launched as a non-governmental organisation in 2003 and became a registered charity 
in 2005. HoM is an excellent working example of a regional health regeneration partnership. HoM 
aims to add value to local initiatives and programmes by working at local, regional, national, and 
European levels to prevent cardiovascular disease in the population through integrated, evidence-
based interventions. The programme targets the major risk factors associated with achieving these 
aims, mainly poor diet (dietary fat, salt, and sugar), and smoking (including second-hand smoke).  
 
9.4 GENERALISABILITY  
 
Although the population who attended Nuffield Health were all over the UK, this study can only 
be generalised to the UK healthy and wealthy population and caution must be taken in comparing 
these data to the whole of the UK population, especially those from poorer socioeconomic 
backgrounds and the high-risk disease population. The south central England region is one of the 




There is a great chance of bias owing to the retrospective data collection. It might be difficult to 
establish the correct temporal relationship between socioeconomic deprivation and cardiovascular 
risk factors. However, there are advantages of a retrospective design. It was easy to conduct, 
cheaper, faster when there are time constraints, and provided good prevalence estimates in the 
population. It was also possible to compare different variables (such as age and sex) and carry out 
subgroup analyses, and more efficient for studying disease risk factors with long induction and 
latent periods. When it is not statistically definitive it can help refine questions, generate 
hypotheses, identify potential recruits for experimental studies, complement experimental studies, 
and generally inform the design of other research. And often it can proceed without the participants 
having to be involved or affected, especially if it uses anonymised data.  
 
Data quality is one of the common issues to ensure the robustness of secondary research. Data 
quality is important because accurate and timely information are needed to manage health services 
and improve quality of patient care; provide good information to manage health service 
effectiveness; prioritise and locate the health resources; and make judgements about the 
performance and governance in the organisation. Obtaining good-quality data is only a starting 
point, ultimately achieving data quality should be able to help to ensure that high-quality evidence 
is used to guide the allocation of health-care resources efficiently and improve the patient care. 
 
9.5 INTEGRATED SUMMARY OF THE THESIS 
 
This thesis has mainly focused on a cluster of cardiovascular risk factors in a large UK population 
whose backgrounds were relatively affluent and wealthy. From the Nuffield Health dataset, it has 
shown that men and women aged 45–54 years were more likely to have higher cluster of 
cardiovascular risk factors. Participants from the most deprived groups were less likely to have 
higher blood pressure, but more likely to be obese and have elevated cholesterol and LDL, than 
were those from the least deprived groups. Intervention strategies seem to work for high blood 
pressure, but for women only. No intervention strategy has shown an association between physical 
activity and LDL and total cholesterol ratio, as well as HDL. Little is known about the effect of 
physical activity on novel risk factors, such as inflammatory and haemostatic markers and glucose 
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metabolism, so more research in this area is urgently needed. The opportunity to analyse 
participants by English regions, has shown that both men and women in south England were less 
likely to be obese than were those in other regions in England. 
 
The south central England region, where the Hampshire Health Record collected its data, spends 
£5·5 billion a year on the health and wellbeing of the million people in their communities, which 
is a relatively low funding allocation per head of population, because the region is relatively 
affluent compared with the national average. This was the first opportunity to compare participants 
both from a private health-care company and NHS services in more affluent areas. It provided a 
unique opportunity to open the research arena and note the outcomes from these comparable 
groups. From this comparable design, it showed that ageing is a serious problem in the south 
central England region: individuals aged between 55 and 75 years had more cardiovascular risk 
factors than those younger than 55 years. Participants were more likely to be obese, had higher 
systolic blood pressure, and elevated total cholesterol, and LDL cholesterol. Lower socioeconomic 
groups should be a target for policy makers to tackle obesity, hypertension, and elevated 
cholesterol, especially with limited health services and funding shortages. Evidence-based 
population-wide policy interventions exist, but these interventions should now be urgently 
implemented to tackle persistent health inequalities effectively.  
 
Challenges remain in the area of policy evaluation. Health policy makers need to allow flexibility 
in programme evaluation designs to allow them to adapt to local needs, rather than requiring fixed 
plans prior to funding. In addition, programmes and evaluations should allow sufficient time for 
outcomes to be achieved. A better understanding of the most effective interventions for reducing 
this large and costly disease burden is vital, in order to inform strategies to combat cardiovascular 
disease in the UK. Approaches that change the physical and social environment (eg, smoke-free 
workplaces, healthier default food options, infrastructure that facilitate physical activity) mean that 
people are more likely to make healthier choices. Prevention of cardiovascular diseases is not 
necessarily costly. Many health-promotion policies (eg, bans on smoking and trans-fat use) cost 
government very little in public funds, and some initiatives (eg, cigarette taxes) generate revenue 
for government that can be used to pay for prevention programmes. Effective interventions require 
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support from the highest levels of government. Local government support is crucial in the 
implementation of the policies. Political commitment is fundamental to success in the fight against 
cardiovascular diseases. As New York City Mayor Michael Bloomberg has noted, “while 
government action is not sufficient alone, it is nevertheless absolutely essential. There are powers 
only governments can exercise, policies only governments can mandate and enforce, and results 
only governments can achieve. To halt the worldwide epidemic of non-communicable diseases, 
governments at all levels must make healthy solutions the default social option. That is, ultimately, 
government’s highest duty.” 
9.6 REFERENCES 
 
Harding S, Teyhan A, Maynard MJ, Cruikshank JK. (2008) Ethnic differences in overweight and 
obesity in early adolescence in the MRC DASH study: the role of adolescent and parental lifestyle. 
International Journal of Epidemiology 37: 162–72. 
 
McKeigue PM, Chaturvedi N. (1996) Epidemiology and control of cardiovascular disease in South 
Asians and Afro-Caribbeans. In Ahmed W, Sheddon T, Stuart O. (eds.), Ethnicity and Health: 
review of literature and guidance for purchasers in the areas of cardiovascular disease, mental 
health and haemoglobinopathies. CRD Report 5. York: NHS Centre for Review and 
Dissemination. 
 
 
 
 
 
 
 
